Form 10-Q

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

0001193125-13-213107.txt : 20130510 0001193125-13-213107.hdr.sgml : 20130510 20130510115813 ACCESSION NUMBER: 0001193125-13-213107 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20130331 FILED AS OF DATE: 20130510 DATE AS OF CHANGE: 20130510 FILER: COMPANY DATA: COMPANY CONFORMED NAME: GALECTIN THERAPEUTICS INC CENTRAL INDEX KEY: 0001133416 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 043562325 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-31791 FILM NUMBER: 13831935 BUSINESS ADDRESS: STREET 1: 4960 PEACHTREE INDUSTRIAL BOULEVARD CITY: NORCROSS STATE: GA ZIP: 30071 BUSINESS PHONE: 678-620-3186 MAIL ADDRESS: STREET 1: 4960 PEACHTREE INDUSTRIAL BOULEVARD CITY: NORCROSS STATE: GA ZIP: 30071 FORMER COMPANY: FORMER CONFORMED NAME: PRO PHARMACEUTICALS INC DATE OF NAME CHANGE: 20010612 10-Q 1 d515969d10q.htm FORM 10-Q Form 10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

x	Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

For the quarterly period ended March 31, 2013

¨	Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

For the transition period from to

Commission File No. 001-31791

GALECTIN THERAPEUTICS INC.


Nevada		04-3562325
(State or other jurisdiction of incorporation)		(I.R.S. Employer Identification No.)

4960 Peachtree Industrial Blvd., Suite 240, Norcross, GA		30071
(Address of Principal Executive Offices)		(Zip Code)

(678) 620-3186

(Registrant’s Telephone Number, Including Area Code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. xYes ¨ No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.05 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). xYes ¨ No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.


Large Accelerated Filer ¨		Accelerated Filer ¨

Non-Accelerated Filer ¨		Smaller reporting company x
(Do not check if a smaller reporting company)

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). ¨Yes x No

The number of shares outstanding of the registrant’s common stock as of May 9, 2013 was 16,251,469.

GALECTIN THERAPEUTICS INC.

INDEX TO FORM 10-Q

FOR THE QUARTER ENDED MARCH 31, 2013


		PAGE
PART I – FINANCIAL INFORMATION

ITEM 1.	Unaudited Condensed Consolidated Financial Statements
	Condensed Consolidated Balance Sheets as of March 31, 2013 and December 31, 2012 (unaudited)		3
	Condensed Consolidated Statements of Operations for the Three Months Ended March 31, 2013 and 2012, and for the Cumulative Period From Inception (July 10, 2000) to March 31, 2013 (unaudited)		4
	Condensed Consolidated Statement of Changes in Redeemable Convertible Preferred Stock and Stockholders’ Equity (Deficit) for the Three Months Ended March 31, 2013 (unaudited)		5
	Condensed Consolidated Statements of Cash Flows for the Three Months Ended March 31, 2013 and 2012, and for the Cumulative Period From Inception (July 10, 2000) to March 31, 2013 (unaudited)		6
	Notes to Unaudited Condensed Consolidated Financial Statements		7

ITEM 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations		12

ITEM 3.	Quantitative and Qualitative Disclosures about Market Risk		18

ITEM 4.	Controls and Procedures		19

PART II – OTHER INFORMATION

ITEM 1.	Legal Proceedings		19

ITEM 1A.	Risk Factors		19

ITEM 2.	Unregistered Sales of Equity Securities and Use of Proceeds		19

ITEM 3.	Defaults Upon Senior Securities		19

ITEM 4.	Mine Safety Disclosures		19

ITEM 5.	Other Information		19

ITEM 6.	Exhibits		20

SIGNATURES			20

GALECTIN THERAPEUTICS INC.

(A Development-Stage Company)

CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED)


	March 31, 2013		December 31, 2012
	(in thousands)
ASSETS
Current assets:
Cash and cash equivalents		$7,018		$9,364
Prepaid expenses and other current assets		137		153

Total current assets		7,155		9,517

Property and equipment, net		7		8
Other long term assets		6		6
Intangible assets, net		28		30

Total assets		$7,196		$9,561


LIABILITIES, REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ (DEFICIT) EQUITY
Current liabilities:
Accounts payable		$316		$397
Accrued expenses		1,152		1,161
Accrued dividends payable		-		80

Total current liabilities		1,468		1,638

Other long-term liabilities		5		6
Total liabilities		1,473		1,644


Commitments and contingencies (Note 8)

Series B-1 12% redeemable convertible preferred stock; 900,000 shares authorized, issued and outstanding at March 31, 2013 and December 31, 2012, redemption value: $1,800,000, liquidation value: $1,800,000 at March 31, 2013		1,702		1,698
Series B-2 12% redeemable convertible preferred stock; 2,100,000 shares authorized, issued and outstanding at March 31, 2013 and December 31, 2012, redemption value: $4,200,000, liquidation value: $4,200,000 at March 31, 2013		2,952		2,900
Series C super dividend convertible preferred stock; 1,000 shares authorized, 215 and 220 shares issued and outstanding at March 31, 2013 and December 31, 2012, respectively, redemption value: $5,078,000, liquidation value: $2,150,000 at March 31, 2013		2,105		2,154

Stockholders’ equity (deficit):
Undesignated stock, $0.01 par value; 20,000,000 shares authorized, 8,001,000 designated at March 31, 2013 and December 31, 2012
Series A 12% convertible preferred stock; 5,000,000 shares authorized, 1,562,500 issued and outstanding at March 31, 2013 and December 31, 2012		632		632
Common stock, $0.001 par value; 50,000,000 shares authorized at March 31, 2013 and December 31, 2012, 16,190,429 and 16,060,853 issued and outstanding at March 31, 2013 and December 31, 2012, respectively		16		16
Additional paid-in capital		81,806		80,535
Deficit accumulated during the development stage		(83,490)		(80,018)

Total stockholders’ (deficit) equity		(1,036)		1,165

Total liabilities, redeemable convertible preferred stock and stockholders’ (deficit) equity		$7,196		$9,561

See notes to unaudited condensed consolidated financial statements.

GALECTIN THERAPEUTICS INC.

(A Development-Stage Company)

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)


	Three Months Ended March 31,				Cumulative Period from Inception (July 10, 2000) to March 31,
	2013		2012		2013
	(in thousands except per share data)
Operating expenses:
Research and development	$	1,752	$	901	$	29,362
General and administrative		1,456		1,052		48,492

Total operating expenses		3,208		1,953		77,854

Total operating loss		(3,208)		(1,953)		(77,854)

Other income (expense):
Interest income		5		3		823
Interest expense		-		-		(4,451)
Change in fair value of convertible debt instrument		-		-		(3,426)
Change in fair value of warrant liabilities		-		-		9,022
Other income		-		-		691

Total other income (expense)		5		3		2,659

Net loss	$	(3,203)	$	(1,950)	$	(75,195)

Preferred stock dividends		(213)		(197)		(4,448)
Preferred stock accretion		(56)		(57)		(4,101)

Net loss applicable to common stockholders	$	(3,472)	$	(2,204)	$	(83,744)

Net loss per common share – basic and diluted	$	(0.22)	$	(0.17)
Weighted average common shares outstanding – basic and diluted		16,079		13,010

See notes to unaudited condensed consolidated financial statements.

GALECTIN THERAPEUTICS INC.

(A Development-Stage Company)

CONSOLIDATED STATEMENT OF CHANGES IN REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ (DEFICIT) EQUITY

THREE MONTHS ENDED MARCH 31, 2013 (UNAUDITED)

(in thousands except share data)


														Stockholders’ Equity (Deficit)
	Series B-1 12% Redeemable Convertible Preferred Stock				Series B-2 12% Redeemable Convertible Preferred Stock				Series C Super Dividend Convertible Preferred Stock					Series A 12% Convertible Preferred Stock				Common Stock
	Number of Shares		Amount		Number of Shares		Amount		Number of Shares			Amount		Number of Shares		Amount		Number of Shares		Amount		Additional Paid-In Capital		Deficit Accumulated During the Development Stage		Total Stockholders’ Equity (Deficit)
Balance at December 31, 2012		900,000	$	1,698		2,100,000	$	2,900		220		$	2,154		1,562,500	$	632		16,060,853	$	16	$	80,535	$	(80,018)	$	1,165
Accretion of Series B redeemable convertible preferred stock				4				39																	(43)		(43)
Accretion of beneficial conversion feature for Series B-2								13																	(13)		(13)
Series A 12% convertible preferred stock dividend																			15,625				57		(10)		47
Series B-1 redeemable convertible preferred stock dividend																			14,580				52		(52)		-
Series B-2 redeemable convertible preferred stock dividend																			34,020				122		(122)		-
Series C super dividend convertible preferred stock dividend																			17,114				62		(29)		33
Conversion of Series C to common stock										(5	)		(49)						8,475				49				49
Issuance of common stock upon exercise of options																			39,762				77				77
Stock-based compensation expense																							852				852
Net loss																									(3,203)		(3,203)

Balance at March 31, 2013		900,000	$	1,702		2,100,000	$	2,952		215		$	2,105		1,562,500	$	632		16,190,429	$	16	$	81,806	$	(83,490)	$	(1,036)

See notes to unaudited condensed consolidated financial statements.

GALECTIN THERAPEUTICS INC.

(A Development-Stage Company)

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)


	Three Months Ended March 31,				Cumulative Period from Inception (July 10, 2000) to March 31,
	2013		2012		2013
	(in thousands)
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$	(3,203)	$	(1,950)	$	(75,195)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization		3		2		558
Stock-based compensation expense		852		473		13,226
Non-cash interest expense		-		-		4,279
Change in fair value of convertible debt instrument		-		-		3,426
Change in fair value of warrant liabilities		-		-		(9,022)
Write off of intangible assets		-		-		351
Changes in operating assets and liabilities:
Prepaid expenses and other assets		16		(11)		(140)
Accounts payable and accrued expenses		(90)		-		1,536
Other long-term liabilities		(1)		-		5

Net cash used in operating activities		(2,423)		(1,486)		(60,976)

CASH FLOWS FROM INVESTING ACTIVITIES:
Purchases of property and equipment		-		-		(431)
Increase in patents costs and other assets		-		-		(404)

Net cash provided by (used in) investing activities		-		-		(835)

CASH FLOWS FROM FINANCING ACTIVITIES:
Net proceeds from issuance of common stock and warrants		-		10,403		39,093
Net proceeds from issuance of Series A preferred stock and related warrants		-		-		1,691
Net proceeds from issuance of Series B-1 preferred stock and related warrants		-		-		1,548
Net proceeds from issuance of Series B-2 preferred stock and related warrants		-		-		3,935
Net proceeds from issuance of Series C preferred stock		-		-		2,203
Net proceeds from issuance of convertible debt instruments		-		-		10,621
Repayment of convertible debt instruments		-		-		(1,641)
Proceeds from exercise of common stock warrants and options		77		-		11,370
Proceeds from shareholder advances		-		-		9

Net cash provided by financing activities		77		10,403		68,829

NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS		(2,346)		8,917		7,018
CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD		9,364		6,397		-

CASH AND CASH EQUIVALENTS, END OF PERIOD	$	7,018	$	15,314	$	7,018


SUPPLEMENTAL DISCLOSURE – Cash paid for interest	$	-	$	-	$	114
NONCASH FINANCING ACTIVITIES:
Issuance of equity warrants in connection with equity offerings	$	-	$	4,445	$	9,482
Conversion of accrued expenses into common stock		-		-		329
Cashless exercise of common stock options and warrants		38		8		712
Conversion and redemption of convertible notes and accrued interest into common stock		-		-		12,243
Conversion of extension costs related to convertible notes into common stock		-		-		171
Payment of preferred stock dividends in common stock		293		277		4,448
Issuance of warrants to induce conversion of notes payable		-		-		503
Issuance of stock to acquire Pro-Pharmaceuticals-NV		-		-		107

See notes to unaudited condensed consolidated financial statements.

GALECTIN THERAPEUTICS INC.

(A DEVELOPMENT-STAGE COMPANY)

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

1.	Basis of Presentation

Galectin Therapeutics Inc. (the “Company”) is a development-stage company that is applying its leadership in galectin science and drug development to create new therapies for fibrotic disease and cancer. These candidates are based on the Company’s targeting of galectin proteins which are key mediators of biologic and pathologic function. These compounds also may have application for drugs to treat other diseases and chronic health conditions.

The unaudited condensed consolidated financial statements as reported in this Quarterly Report on Form 10-Q reflect all adjustments which are, in the opinion of management, necessary to present fairly the financial position of the Company as of March 31, 2013 and the results of its operations for the three months ended March 31, 2013 and 2012 and the cumulative period from inception (July 10, 2000) through March 31, 2013 and its cash flows for the three months ended March 31, 2013 and 2012, and for the cumulative period from inception (July 10, 2000) to March 31, 2013. All adjustments made to the interim financial statements include all those of a normal and recurring nature. The Company considers events or transactions that occur after the balance sheet date but before the financial statements are issued to provide additional evidence relative to certain estimates or to identify matters that require additional disclosure. Subsequent events have been evaluated through the date these financial statements are available to be issued. The results for interim periods are not necessarily indicative of results which may be expected for any other interim period or for the full year. The unaudited condensed consolidated financial statements of the Company should be read in conjunction with its Annual Report on Form 10-K for the year ended December 31, 2012.

The Company has operated at a loss since its inception and has had no significant revenues. The Company anticipates that losses will continue for the foreseeable future. At March 31, 2013, the Company had $7,018,000 of unrestricted cash and cash equivalents available to fund future operations. The Company believes that with the cash on hand at March 31, 2013, there is sufficient cash to fund operations through the first quarter of 2014. The Company’s ability to fund operations after its current cash resources are exhausted depends on its ability to obtain additional financing or achieve profitable operations, as to which no assurances can be given. The Company has developed several plans, including cost containment efforts and potential strategic alternatives in the event that such financing cannot be realized by the Company. Accordingly, based on the forecasts and estimates underlying the Company’s current operating plan, the financial statements do not currently include any adjustments that might be necessary if the Company is unable to continue as a going concern.

As shown in the condensed consolidated financial statements, the Company incurred cumulative net losses applicable to common stockholders of $83.7 million for the cumulative period from inception (July 10, 2000) through March 31, 2013. The Company’s net losses have resulted principally from costs associated with (i) research and development expenses, including clinical trial costs, (ii) general and administrative activities and (iii) the Company’s financing transactions including interest, dividend payments, and the costs related to fair value accounting for the Company’s convertible debt instruments. As a result of planned expenditures for future research, discovery, development and commercialization activities and potential legal cost to protect its intellectual property, the Company expects to incur additional losses and use additional cash in its operations for the foreseeable future. Through March 31, 2013, the Company had raised a net total of $68.8 million in capital through sale and issuance of common stock, common stock purchase warrants, convertible preferred stock and debt securities in public and private offerings. From inception (July 10, 2000) through March 31, 2013, the Company used cash of $61.0 million in its operations.

The Company was founded in July 2000, was incorporated in the State of Nevada in January 2001 under the name “Pro-Pharmaceuticals, Inc.,” and changed its name to “Galectin Therapeutics Inc.” on May 26, 2011. On March 23, 2012, the Company began trading on The NASDAQ Capital Market under the symbol GALT. Immediately prior to March 23, 2012, the Company was traded on the Over-the Counter Bulletin Board (“OTCBB”) under the symbol GALT.OB.

The Company is subject to a number of risks similar to those of other development-stage companies, including dependence on key individuals, uncertainty of product development and generation of revenues, dependence on outside sources of capital, risks associated with clinical trials of products, dependence on third-party collaborators for research operations, need for regulatory approval of products, risks associated with protection of intellectual property, and competition with larger, better-capitalized companies. Successful completion of the Company’s development program and, ultimately, the attainment of profitable operations is dependent upon future events, including obtaining adequate financing to fulfill its development activities and achieving a level of revenues adequate to support the Company’s cost structure. There are no assurances that the Company will be able to obtain additional financing on favorable terms, or at all, or successfully market its products.

2.	Accrued Expenses

Accrued expenses consist of the following:


	March 31, 2013		December 31, 2012
	(in thousands)
Legal and accounting fees	$	80	$	109
Accrued compensation		61		42
Severance agreement (Note 8)		1,000		1,000
Other		11		10

Total	$	1,152	$	1,161

3.	Stock-Based Compensation

Following is the stock-based compensation expense related to common stock options, common stock, restricted common stock and common stock warrants:


	Three Months Ended March 31,
	2013		2012
Research and development	$	319	$	149
General and administrative		533		324

Total stock-based compensation expense	$	852	$	473

The following table summarizes the stock option activity in the Company’s equity incentive plans, including non-plan grants to Company executives, from December 31, 2012 through March 31, 2013:


	Shares		Weighted Average Exercise Price
Outstanding, December 31, 2012		3,539,961	$	5.66
Granted		200,426		3.36
Exercised		(39,762)		2.77
Options forfeited/cancelled		(44,408)		9.50

Outstanding, March 31, 2013		3,656,217	$	5.52

As of March 31, 2013, there was $5,427,000 of unrecognized compensation related to 1,466,586 unvested options, which is expected to be recognized over a weighted–average period of approximately 3.9 years. The weighted-average grant date fair value for options granted during the three months ended March 31, 2013 was $2.73. There were no grants during the three months ended March 31, 2012.

The fair value of all other options granted is determined using the Black-Scholes option-pricing model. The following weighted average assumptions were used (there were no option grants to employees or consultants during the three months ended March 31, 2013):


	Three Months Ended March 31,	Cumulative Period from Inception (July 10, 2000) to March 31,
	2013	2013
Risk-free interest rate	0.80%	1.76%
Expected life of the options	5.0 years	5.2 years
Expected volatility of the underlying stock	117%	119%
Expected dividend rate	0%	0%

4.	Common Stock Warrants

The following table summarizes the common stock warrant activity from December 31, 2012 through March 31, 2013:


	Shares		Weighted Average Exercise Price
Outstanding, December 31, 2012		7,424,241	$	3.71
Granted		5,000		2.65
Exercised		-		-
Forfeited/cancelled		-		-

Outstanding, March 31, 2013		7,429,241	$	3.71

Consultant Warrants

In January 2013, the Company entered into an agreement with a consultant that provided for the grant of warrants for the purchase of 5,000 shares of common stock at an exercise price of $2.65 per share. The following assumptions were used to value the warrants: an expected life of 3 years, volatility of 87%, risk free interest rate of 0.42% and zero dividends. The Company recognized an expense of $7,000 related to these warrants during the three months ended March 31, 2013.

5.	Fair Value of Financial Instruments

The Company has certain financial assets and liabilities recorded at fair value. Fair values determined by Level 1 inputs utilize observable data such as quoted prices in active markets. Fair values determined by Level 2 inputs utilize data points other than quoted prices in active markets that are observable either directly or indirectly. Fair values determined by Level 3 inputs utilize unobservable data points in which there is little or no market data, which require the reporting entity to develop its own assumptions. The carrying amounts reflected in the consolidated balance sheets for cash equivalents, accounts payable and accrued expenses approximates their carrying value due to their short-term nature. Included in cash and cash equivalents, as of March 31, 2013 and December 31, 2012, the Company had $192,000 and $583,000, respectively invested in money market funds which had calculated net asset values and were therefore classified as Level 2. There were no level 3 assets held at fair value at March 31, 2013 or December 31, 2012.

6.	Loss Per Share

Basic net loss per common share is computed by dividing the net loss available to common stockholders by the weighted average number of common shares outstanding during the period. Diluted net loss per common share is computed by dividing the net loss available to common stockholders by the weighted average number of common shares and other potential common shares then outstanding. Potential common shares consist of common shares issuable upon the assumed exercise of in-the-money stock options and warrants and potential common shares related to the conversion of the preferred stock. The computation of diluted net loss per share does not assume the issuance of common shares that have an anti-dilutive effect on net loss per share.


	Three Months Ended March 31,
	2013		2012
	(in thousands, except share and per share amounts)
Basic and diluted net loss per common share:
Net loss applicable to common stockholders		$(3,472)		$(2,204)
Weighted average common shares outstanding – basic and diluted		16,079		13,010
Net loss per common share – basic and diluted		$ (0.22)		$ (0.17)

Dilutive shares which could exist pursuant to the exercise of outstanding stock instruments and which were not included in the calculation because their affect would have been anti-dilutive are as follows:


	March 31, 2013 (shares)		March 31, 2012 (shares)
Warrants to purchase shares of common stock		7,429,241		7,424,241
Options to purchase shares of common stock		3,656,217		2,997,468
Shares of common stock issuable upon conversion of preferred stock		2,618,772		2,627,110

		13,704,230		13,048,819

7.	Common Stock and Warrant Offering and Reverse Split

On March 22, 2012, the Company entered into an underwriting agreement, relating to the offer and sale of 1,159,445 units (the “Units”) of the Company, each unit consisted of two shares of Common Stock and one warrant to purchase one share of Common Stock. Pursuant to the underwriting agreement, the Company granted the underwriters a 45-day option to purchase up to an additional 173,916 Units to cover over-allotments, which they exercised on March 26, 2012. The public offering price for each Unit was $9.00. Each warrant has an initial exercise price of $5.63 per share, is exercisable upon separation of the Units and expires on March 28, 2017.

On March 28, 2012, the Company sold and issued 1,333,361 Units (2,666,722 shares of common stock and related $5.63 warrants to purchase 1,333,361 shares of common stock) for gross proceeds of $12.0 million (net cash proceeds of $10,403,000 after the underwriting discount and offering costs). The warrants were valued at $4,445,000 as of the issuance date of March 28, 2012, using the closing price of $4.20, a life of 5 years, a volatility of 119% and a risk free interest rate of 1.05%. Based upon the Company’s analysis of the criteria contained in ASC Topic 815-40, “Derivatives and Hedging—Contracts in Entity’s Own Equity” the Company has determined that warrants issued in connection with this financing transaction were not derivative liabilities and therefore, were recorded as additional paid-in capital.

On March 28, 2012, in connection with this underwritten financing as per the underwriting agreement, the Company issued a total of 46,378 common stock purchase warrants to the underwriters. These warrants expire May 2, 2016, have an exercise price of $5.63 per share, and are exercisable beginning 1 year from March 22, 2012 (the date of the underwriting agreement). These warrants were valued at $143,000 as of the date of issuance (March 28, 2012), using the closing price of $4.20, life of 4.1 years, volatility of 117% and risk free interest rate of 0.78. Based upon the Company’s analysis of the criteria contained in ASC Topic 815-40, “Derivatives and Hedging—Contracts in Entity’s Own Equity”, the Company has determined that these warrants issued in connection with this financing transaction were not derivative liabilities and therefore, were recorded as additional paid-in capital.

Effective as of March 23, 2012, and in connection with the pricing of the offering of Units, the Company effected a one-for-six reverse split of its Common Stock. Per the terms of the reverse split, all fractional shares were rounded up.

8.	Commitments, Contingencies and Legal Proceedings

Agreement with CTI for Phase I Clinical Trial

On February 1, 2013, the Company entered into an Amended and Restated Master Services Agreement (the “Agreement”) with CTI Clinical Trial Services, Inc. and CTI Clinical Consulting Services, Inc. (individually and collectively, “CTI”), whereby CTI is assisting the Company in the design, development and conduct of one or more clinical research studies from time to time. All work performed by CTI for the Company is being conducted pursuant to the terms of work orders that describe the specific obligations undertaken by CTI with respect to any particular clinical research study sponsored or conducted by the Company. Unless otherwise terminated sooner in accordance with the terms of the Agreement, the Agreement will be effective until January 31, 2018.

On February 1, 2013, the Company entered into a work order (the “Work Order”) with CTI in accordance with the terms of the Agreement. The Work Order provides that CTI will provide services with respect to the Company’s Phase I Clinical Trial to evaluate the safety of the Company’s drug GR-MD-02 in subjects with Non-Alcoholic Steatohepatitis (“NASH”) with advanced hepatic fibrosis. CTI is providing the following services, amongst others, with respect to the Work Order: reviewing and providing notices regarding IND safety reports, selecting investigators and monitors for the study, informing investigators of new observations, monitoring the progress of the study and reviewing ongoing investigations, keeping certain records, inspecting the Company’s records and reports, and disposing of any unused supply of the investigational drug.

The Work Order provides for CTI’s anticipated involvement in the study from February 1, 2013 until March 31, 2014. The estimated budget for the Work Order is $2,155,000, which is subject to change as necessary, with payments made throughout the term of the project as the work is performed. During the three months ended March 31, 2013, the Company recognized $728,000 of expenses related to this agreement for services performed during the period.

The Agreement or any work order may be terminated for any reason by any party upon ninety (90) days prior written notice to the other party. In addition, the Agreement may be terminated by either party immediately if the other party becomes insolvent, is dissolved or liquidated, makes a general assignment for the benefit of its creditors, files or has filed against it (and does not obtain a dismissal within ninety (90) days) a petition of bankruptcy, or has a receiver appointed for it or a substantial part of its assets, among other reasons. Further, the Agreement or any relevant work order may be terminated immediately by written notice from the Company, in the following circumstances: (1) the FDA withdraws authorization and approval to conduct a study; or (2) the Company reasonably determines that for medical, clinical or patient safety reasons, a study should terminate immediately. In addition, either party may terminate the Agreement or any work order for material breach upon thirty (30) days’ written notice specifying the nature of the breach, if such breach has not been substantially cured within the thirty (30) day period.

Drug Discovery Program with the University of Georgia

In February 2013, the Company established a collaborative drug discovery program at the Complex Carbohydrate Research Center at the University of Georgia. This program is focused on the discovery of new carbohydrate molecules that can be used in the therapy of diseases where galectin proteins play a major role, including cancer and inflammatory and fibrotic disorders. The term of the agreement is effective through December 31, 2013, for which the Company will provide funding of $154,000 during the period as work is performed. This agreement may be terminated by either party upon 90 days notice.

Separation Agreement

In February 2009, the Company entered into a Separation Agreement in connection with the resignation of David Platt, Ph.D., the Company’s former Chief Executive Officer and Chairman of the Board of Directors. The Separation Agreement provides for the deferral of a $1.0 million separation payment due to Dr. Platt upon the earlier occurrence of any of the following milestone events: (i) the approval by the Food and Drug Administration for a new drug application (“NDA”) for any drug candidate or drug delivery candidate based on the Company’s GM-CT-01 technology (whether or not such technology is patented), in which case Dr. Platt is also entitled to a fully vested 10-year cashless-exercise stock option to purchase at least 83,334 shares of common stock at an exercise price not less than the fair market value of the common stock determined as of the date of grant; (ii) consummation of a transaction with a pharmaceutical company expected to result in at least $10.0 million of equity investment or $50 million of royalty revenue to the Company, in which case Dr. Platt is also entitled to stock options on the same terms to purchase at least 50,000 shares of common stock; or (iii) the renewed listing of the Company’s securities on a national securities exchange and the achievement of a market capitalization of $100 million. Payment upon the events (i) and (iii) may be deferred up to six months, and if the Company has insufficient cash at the time of any of such events, it may issue Dr. Platt a secured promissory note for such amount. If the Company files a voluntary or involuntary petition for bankruptcy, whether or not a milestone event has occurred, such event shall trigger the obligation to pay the $1.0 million with the result that Dr. Platt may assert a claim for such obligation against the bankruptcy estate. During 2011, when it became probable that the Company could be relisted on a national securities exchange and eventually reach a market capitalization of $100 million, the Company recognized the $1.0 million severance payment due to Dr. Platt and it is included in accrued expenses at March 31, 2013 and December 31, 2012.

On May 2, 2012, Dr. Platt instituted arbitration before the American Arbitration Association, seeking a $1.0 million separation payment based on a claim that a milestone event in the Separation Agreement has occurred (see clause (iii) above). On March 22, 2012, the Company’s common stock was listed on the NASDAQ Capital Markets, but since that date, the stock has not achieved the required market capitalization. Therefore, it is the Company’s position that a milestone event has not yet occurred. The arbitration hearing was held on October 16 - 17, 2012 and on November 1, 2012, the arbitrator denied Dr. Platt’s demand in all respects. Insofar as the Company does not dispute its obligations under the Separation Agreement to pay Dr. Platt upon the occurrence of a milestone event, it has recorded the payment as an accrued expense payable if and when the milestone event occurs.

On October 12, 2012, Dr. Platt commenced a lawsuit under the Massachusetts Wage Act against Dr. Traber and Mr. McGauley who in their capacities as the Company’s Chief Executive Officer and Chief Financial Officer respectively can be held individually liable under the Wage Act for non-payment of wages. The lawsuit is based on the facts and issues raised in the arbitration regarding the payment of the $1.0 million separation payment under the Separation Agreement, and other unspecified “wages”. The statute provides that a successful claimant may be entitled to multiple damages, interest and attorneys fees. Although the Company is not a party to the lawsuit, it plans to indemnify Dr. Traber and Mr. McGauley consistent with its obligations under the by-laws and applicable law, believes the lawsuit is without merit, and intends a vigorous defense on their behalf. On April 29, 2013, the Court allowed Dr. Traber’s and Mr. McGauley’s motion to dismiss.

On March 29, 2013, the Company instituted arbitration before the American Arbitration Association, seeking to rescind or reform the Separation Agreement discussed above. The Company claims that Dr. Platt fraudulently induced the Company to enter into the Separation Agreement, breached his fiduciary duty to the Company, and was unduly enriched from his conduct. Along with removal of the $1.0 million milestone payment provided for under the Separation Agreement, the Company is seeking repayment of all separation benefits paid to Dr. Platt to date. Depending on the outcome of the arbitration, the previously accrued $1.0 million could be reversed. The timing and ultimate outcome of this arbitration, though, is uncertain and there is no guarantee that the Company will be successful in this demand.

Series C Post Conversion Dividend Rights

In January 2013, 5 shares of the Company’s Series C Super Dividend Convertible Preferred Stock (“Series C”) were converted into 8,475 shares of common stock (consisting of 8,334 shares of common stock for principal and 141 shares for accrued interest at the time of the conversion) which also resulted in the issuance of 5 Series C post-conversion dividend rights (“Dividend Rights”). Under the terms of the Series C, the Dividend Rights entitle the holder only to dividend payments based on actual sales of GM-CT-01 and will not participate in the 6% dividend payable on outstanding shares of Series C following a conversion to common stock. At March 31, 2013, there are a total of 10 outstanding Dividend Rights which were determined to have a de minimis value, because payment of a dividend for the Dividend Rights is considered improbable at this time and the Company has not recorded a liability related to the Dividend Rights. The Company will continue to evaluate and assess the Dividend Rights for each reporting period. At March 31, 2013, the Dividend Rights had a liquidation value of $241,000.

Other Legal Proceedings

The Company records accruals for such contingencies to the extent that the Company concludes that their occurrence is probable and the related damages are estimable, except as noted above. There has been no change in the matters reported in our Annual Report on Form 10-K for the year ended December 31, 2012.

9.	Subsequent Events

The Company has evaluated all events or transactions that occurred through the date on which the financial statements were issued, noting the following:

On May 6, 2013, the Company modified the terms of the Class A-2 and Class B warrants that were originally issued with the Series B Preferred Stock offering. The Class B warrants were modified to allow for the cashless exercise of all 4,000,000 outstanding Class B warrants. Previously, only half of the Class B warrants allowed for cashless exercise. The Class A-2 warrants for the purchase of 1,000,000 shares of common and all of the Class B warrants had their exercisable life extended by an additional five years. In exchange for these modifications, the 10X Fund agreed that the Series B Preferred Stock will no longer be mandatorily redeemable, if and when the Company will no longer be required to issue Dr. Platt a promissory note as may currently be required under the separation agreement (see Note 8).

Item 2.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

In addition to historical information, the following Management’s Discussion and Analysis of Financial Condition and Results of Operations contains forward-looking statements as defined under Section 21E of the Securities Exchange Act of 1934, as amended, and is subject to the safe harbor created therein for forward-looking statements. Such statements include, but are not limited to, statements concerning our anticipated operating results, research and development, clinical trials, regulatory proceedings, and financial resources, and can be identified by use of words such as, for example, “anticipate,” “estimate,” “expect,” “project,” “intend,” “plan,” “believe” and “would,” “should,” “could” or “may.” All statements, other than statements of historical facts, included herein that address activities, events, or developments that the Company expects or anticipates will or may occur in the future, are forward-looking statements, including statements regarding:

•

plans and expectations regarding clinical trials;

•

plans and expectations regarding regulatory approvals;

•

plans regarding lawsuits, arbitration, and any related indemnification of Company employees;

•

our strategy and expectations for clinical development and commercialization of our products;

•

potential strategic partnerships;

•

expectations regarding the effectiveness of our products;

•

plans for research and development and related costs;

•

statements about accounting assumptions and estimates;

•

expectations regarding liquidity and the sufficiency of cash to fund operations through the first quarter of 2014;

•

our commitments and contingencies; and

•

our market risk exposure.

Forward-looking statements are based on current expectations, estimates and projections about the industry and markets in which Galectin Therapeutics operates, and management’s beliefs and assumptions. These statements are not guarantees of future performance and involve certain known and unknown risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Such risks and uncertainties are related to, without limitation: our early stage of development; our dependence on outside capital; uncertainties related to our technology and clinical trials, intellectual property protection, uncertainties of regulatory approval requirements for our products; competition and stock price volatility in the biotechnology industry, limited trading volume for our stock, concentration of ownership of our stock, and other risks detailed herein and from time to time in our SEC reports, including our Annual Report on Form 10-K filed with the SEC for the fiscal year ended December 31, 2012, and our subsequent SEC filings. The following discussion should be read in conjunction with the accompanying consolidated financial statements and notes thereto of Galectin Therapeutics appearing elsewhere herein.

Overview

We are a development-stage company engaged in drug research and development to create new therapies for fibrotic disease and cancer. Galectins are a class of proteins that are made by many cells in the body. As a group, these proteins are able to bind to sugar molecules that are part of other proteins in and on the cells of our body. Galectin proteins act as a kind of glue, bringing together molecules that have sugars on them. Galectin proteins are known to be markedly increased in a number of important diseases including scaring of organs (e.g. liver, lung, kidney, and heart) and cancers of many kinds. The increase in galectin protein promotes the disease and is detrimental to the patient.

Our drug candidates are based on our method of targeting galectin proteins, which are key mediators of biologic and pathologic functions. We use naturally occurring, readily-available plant materials as starting material in manufacturing processes to create proprietary complex carbohydrates with specific molecular weights and other pharmaceutical properties. These complex carbohydrate molecules are appropriately formulated into acceptable pharmaceutical formulations. Using these unique carbohydrate-based candidate compounds that bind and inhibit galectin proteins, we are undertaking the focused pursuit of therapies for indications where galectins have a demonstrated role in the pathogenesis of a given disease. We focus on diseases with serious, life-threatening consequences to patients and those where current treatment options are limited. Our strategy is to establish and implement clinical development programs that add value to our business in the shortest period of time possible and to seek strategic partners when a program becomes advanced and requires additional resources.

We endeavor to leverage our scientific and product development expertise as well as established relationships with outside sources to achieve cost-effective and efficient development. These outside sources, amongst others, provide us with expertise in preclinical models, pharmaceutical development, toxicology, clinical development, pharmaceutical manufacturing, sophisticated physical and chemical characterization, and commercial development. We also have established a collaborative scientific discovery program with leading experts in carbohydrate chemistry and characterization. This discovery program is aimed at the targeted development of new molecules which bind galectin proteins and offer alternative options to larger market segments in our primary disease targets. We are pursuing a development pathway to clinical enhancement and commercialization for our lead compounds in liver fibrosis and fatty liver disease as well as in immune enhancement for cancer therapy. All of our proposed products are presently in development, including pre-clinical and clinical trials.

Our Drug Development Programs

We have two compounds in development, one intended to be used in the treatment of liver fibrosis and fatty liver disease and the other intended to be used in cancer therapy. These two compounds are produced from completely different, natural, readily available, starting materials, which, following chemical processing, both exhibit the property of binding to and inhibiting galectin proteins.

Our product pipeline is shown below:


Indication	Drug	Status

Fibrosis
NASH with Advanced Fibrosis	GR-MD-02	IND submitted January 2013, FDA indicated on March 1, 2013 that we could proceed with a Phase 1 US clinical trial. Phase I clinical trial expected to start Q2-2013

Cancer Immunotherapy
Melanoma	GM-CT-01	Phase I/II study in process in Europe

We believe the mechanism of action for GR-MD-02 and GM-CT-01 is based upon interaction with, and inhibition of, galectin proteins, which are expressed at high levels in certain pathological states including inflammation, fibrosis and cancer. While GR-MD-02 and GM-CT-01 are capable of binding to multiple galectin proteins, we believe that they have the greatest affinity for galectin-3, the most prominent galectin implicated in pathological processes. Blocking galectin in cancer and liver fibrosis has specific salutary effects on the disease process.

GR-MD-02. The main initiative in our development strategy is the application of galectin inhibition in connection with liver fibrosis, a condition that leads to cirrhosis. We believe that GR-MD-02 has the potential to treat nonalcoholic steatohepatitis (NASH) and other forms of liver fibrosis. The driving factor for our commitment to galectin inhibition for fibrosis is scientific evidence that strongly suggests that galectin-3 is essential for the development of liver fibrosis in animals. Published data show that mice lacking the galectin-3 gene are incapable of developing liver fibrosis in response to toxin insult to the liver and in fatty liver disease. Moreover, mice that do not have the galectin-3 gene are resistant to lung and kidney fibrosis. Our preclinical data show that GR-MD-02 has a powerful therapeutic effect on liver fibrosis as shown in several relevant animal models. Therefore, we chose GR-MD-02 as the lead candidate in a development program targeted initially at fibrotic liver disease associated with non-alcoholic steatohepatitis (NASH, or fatty liver disease). Pre-clinical studies also show promise for the combination of GR-MD-02 with other approved immunotherapies and this additional use will be explored for possible advancement into clinical trials.

In January 2013, an Investigational New Drug (“IND”) was submitted to the FDA with the goal of initiating a Phase I study in patients with NASH and advanced liver fibrosis to primarily evaluate the human safety of GR-MD-02 and pharmacodynamics biomarkers of disease are also included in the trial design. On March 1, 2013, the FDA indicated we could proceed with a U.S. Phase 1 clinical trial for GR-MD-02 with a development program aimed at obtaining support for a proposed indication of GR-MD-02 for treatment of NASH with advanced fibrosis. In February 2013 we entered into an agreement with Clinical Trial Services Inc. (“CTI”) to conduct a Phase I clinical trial of GR-MD-02 to assess safety and preliminary evidence of efficacy in humans. We expect to begin enrolling patients in this trial late in the second quarter of 2013 and we expect top line results by late 2013 or early 2014. In mid-2014, depending on the results of the Phase I study and available funding, we may initiate a Phase II clinical trial to assess the efficacy of GR-MD-02 in patients with NASH and advanced liver fibrosis and based on that timing we would expect top-line clinical results by mid to late 2015.

GM-CT-01. We believe the potential exists for galectin inhibition to play an important role in cancer therapy. Galectin proteins, particularly galectin-1 and galectin-3, have been shown to be highly expressed in the majority of cancers and have multiple roles in promoting cancer progression, including tumor cell invasion, metastasis, angiogenesis, and tumor evasion of the immune system. GM-CT-01 has progressed in development for the therapy of colorectal cancer and is currently in a Phase I/II clinical trial in Europe as a combination therapy with a tumor vaccine in patients with advanced melanoma. The current developmental approach for GM-CT-01 is to enhance the activity of the immune system against the cancer.

In May 2012, we initiated a Phase I/II clinical trial of GM-CT-01 in Belgium in combination with a tumor vaccine in patients with advanced melanoma, a deadly skin cancer. The Belgian Federal Agency of Medicine and Health Products, or FAMHP, granted approval for this clinical trial, which is being conducted at three centers in Belgium and one in Luxembourg. There are two primary cohorts of patients in this study, one where GM-CT-01 is given intravenously (Cohort 1) and a second cohort where GM-CT-01 is given both intravenously and directly injected into a cutaneous metastasis (Cohort 2). Because of patient availability, Cohort 1 is expected to be enrolled faster than Cohort 2. For each cohort, 6 patients will be enrolled in stage one of the study, and if at least one out of six patients has a response (PR or CR by RECIST criteria), the remaining patients will be enrolled up to a total of 23 per cohort. We expect the first stage of Cohort 1 of this trial (involving 6 evaluable patients) to be completed in the second quarter of 2013 and that it will provide data that could deliver an indication of efficacy. Depending on the results of Stage 1, which is defined as a partial or complete response by RECIST criteria in at least one out of six patients, the study could continue enrollment to complete Stage 2 (46 total patients), initiate a new Phase II trial based on positive results or be halted because of lack of efficacy. Stage 1 of the trial is being funded by the Cancer Centre at the Cliniques Universitaires Saint-Luc and Stage 2 may require funding from the Company, beyond the provision of material, however, we have no commitment to fund Stage 2 of the trial. We do not control this Phase I/II clinical trial in Belgium which is being conducted under an EMA-approved IMPD. We are the sponsor of an open IND application under the FDA for GM-CT-01; no trials are currently being conducted in the U.S.

Results of Operations

Three Months Ended March 31, 2013 Compared to Three Months Ended March 31, 2012

Research and Development Expense.


	Three Months				2013 as Compared to 2012
	Ended March 31,				Three Months
	2013		2012		$ Change		% Change
	(In thousands, except %)
Research and development	$	1,752	$	901	$	851		94%

We generally categorize research and development expenses as either direct external expenses, comprised of amounts paid to third party vendors for services, or all other research and development expenses, comprised of employee payroll and general overhead allocable to research and development. We consider a clinical program to have begun upon acceptance by the FDA, or similar agency outside of the United States, to commence a clinical trial in humans, at which time we begin tracking expenditures by the product candidate. Clinical program expenses comprise payments to vendors related to preparation for, and conduct of, all phases of the clinical trial, including costs for drug manufacture, patient dosing and monitoring, data collection and management, oversight of the trials and reports of results. Pre-clinical expenses comprise all research and development amounts incurred before human trials begin, including payments to vendors for services related to product experiments and discovery, toxicology, pharmacology, metabolism and efficacy studies, as well as manufacturing process development for a drug candidate.

We have two product candidates, GR-MD-02 and GM-CT-01. We filed for an IND for GR-MD-02 in January 2013 and in February 2013 we entered into an agreement with CTI to conduct a Phase I clinical trial of GR-MD-02 which we expect will begin enrolling patients late in the second quarter of 2013. GM-CT-01 is in a Phase I/II clinical trial in Europe at this time, which is being conducted in collaboration with the Cancer Centre at the Cliniques Universitaires Saint-Luc and the Ludwig Institute for Cancer Research in Belgium.

Our research and development expenses were as follows:


	Three Months Ended March 31,
	2013		2012
	(in thousands)
Direct external expenses:
Clinical activities	$	743	$	248
Pre-clinical activities		553		320
All other research and development expenses		456		333

	$	1,752	$	901

Clinical programs expenses increased primarily due to the startup costs related to our Phase I clinical trial agreement with CTI during the three months ended March 31, 2013 versus primarily compound manufacturing costs during the three months ended March 31, 2012 for GM-CT-01. As we begin enrolling patients in the Phase I trial we expect our clinical activities costs will increase and may fluctuate from quarter to quarter as the trial progresses. Pre-clinical activities increased primarily due to pre-clinical work related to fibrosis prior to the IND approval as well as our agreement with the University of Georgia. Other research and development expense increased primarily due to increased stock-based compensation ($170,000).

Both the time required and costs we may incur in order to commercialize a drug candidate that would result in material net cash inflow are subject to numerous variables, and therefore we are unable at this stage of our development to forecast useful estimates. Variables that make estimates difficult include the number of clinical trials we may undertake, the number of patients needed to participate in the clinical trial, patient recruitment uncertainties, trial results as to the safety and efficacy of our product, and uncertainties as to the regulatory agency response to our trial data prior to receipt of marketing approval. Moreover, the FDA or other regulatory agencies may suspend clinical trials if we or an agency believes patients in the trial are subject to unacceptable risks, or find deficiencies in the conduct of the clinical trial. Delays or rejections may also occur if governmental regulation or policy changes during our clinical trials or in the course of review of our clinical data. Due to these uncertainties, accurate and meaningful estimates of the ultimate cost to bring a product to market, the timing of costs and completion of our program and the period during which material net cash inflows will commence are unavailable at this time.

General and Administrative Expense.


	Three Months				2013 as Compared to 2012
	Ended March 31,				Three Months
	2013		2012		$ Change		% Change
	(In thousands, except %)
General and administrative	$	1,456	$	1,052	$	404		38%

General and administrative expenses consist primarily of salaries including stock based compensation, legal and accounting fees, insurance, investor relations, business development and other office related expenses. The primary reason for the increase for the three-months ended March 31, 2013 as compared to the same period in 2012 is due to increased stock-based compensation ($209,000), increased legal expenses ($125,000) related to ongoing litigation with the Company’s former CEO, Dr. Platt, as well as increased investor relations, insurance and public company related costs (altogether an increase of $90,000), offset by decreased rent ($62,000) due to our relocation in October 2012.

Liquidity and Capital Resources

As described above in the Overview and elsewhere in this Quarterly Report on Form 10-Q, we are in the development stage and have not generated any revenues.

Since our inception on July 10, 2000, we have financed our operations from proceeds of public and private offerings of debt and equity. As of March 31, 2013, we raised a net total of $68.8 million from these offerings. We have operated at a loss since our inception and have had no significant revenues. We anticipate that losses will continue for the foreseeable future. At March 31, 2013, we had $7.0 million of unrestricted cash and cash equivalents available to fund future operations. We believe that with the cash on hand at March 31, 2013, there is sufficient cash to fund operations through the first quarter of 2014. Our ability to fund operations after our current cash resources are exhausted depends on our ability to obtain additional financing or achieve profitable operations, as to which no assurances can be given. We have developed several plans, including cost containment efforts and potential strategic alternatives in the event that such financing cannot be realized by us. Accordingly, based on the forecasts and estimates underlying our current operating plan, the financial statements do not currently include any adjustments that might be necessary if we are unable to continue as a going concern.

Net cash used in operations increased by $937,000 to $2,423,000 for the three months ended March 31, 2013, as compared to $1,486,000 for the three months ended March 31, 2012. Cash operating expenses increased principally due to increased research and development activities related to our clinical trial activity with GR-MD-02.

Net cash provided by financing activities was $77,000 during the three months ended March 31, 2013 from cash paid for option exercises as compared to $10,403,000 during the three months ended March 31, 2012, due to a public offering we completed in the first quarter of 2012.

Payments Due Under Contractual Obligations

The following table summarizes the payments due under our contractual obligations at March 31, 2013, and the effect such obligations are expected to have on liquidity and cash flow in future periods:


	Payments due by period (in thousands)
Contractual Obligations	Total		Less than 1 year		1-3 years		3-5 years		More than 5 years
Operating leases	$	72	$	46	$	26	$	-	$	-

Total payments due under contractual obligations	$	72	$	46	$	26	$	-	$	-

Operating leases.

In September 2012, we entered into an operating lease for office space in Norcross, GA for a term of twenty-six months, beginning on October 1, 2012 and ending November 30, 2014 at a rate of $3,000 per month. The lease provided for free rent for the first two months of the lease and required a security deposit of $6,000. In addition to base rental payments included in the contractual obligations table above, we are responsible for our pro-rata share of increases in the operating expenses for the building.

In October 2012, we entered into an operating lease for office space collocated with lab space for research and development activities. The lease is for a period of one year, beginning on October 1, 2012, for a rate of $15,000 for the term, payable in monthly increments.

Agreement with CTI for Phase I Clinical Trial

On February 1, 2013, the Company entered into an Amended and Restated Master Services Agreement (the “Agreement”) with CTI Clinical Trial Services, Inc. and CTI Clinical Consulting Services, Inc. (individually and collectively, “CTI”), whereby CTI will assist the Company in the design, development and conduct of one or more clinical research studies from time to time. All work performed by CTI for the Company will be conducted pursuant to the terms of work orders that describe the specific obligations undertaken by CTI with respect to any particular clinical research study sponsored or conducted by the Company. Unless otherwise terminated sooner in accordance with the terms of the Agreement, the Agreement will be effective until January 31, 2018.

On February 1, 2013, the Company entered into a work order (the “Work Order”) with CTI in accordance with the terms of the Agreement. The Work Order provides that CTI will provide services with respect to the Company’s Phase I Clinical Trial to evaluate the safety of the Company’s drug GR-MD-02 in subjects with Non-Alcoholic Steatohepatitis (“NASH”) with advanced hepatic fibrosis. CTI will provide the following services, amongst others, with respect to the Work Order: reviewing and providing notices regarding IND safety reports, selecting investigators and monitors for the study, informing investigators of new observations, monitoring the progress of the study and reviewing ongoing investigations, keeping certain records, inspecting the Company’s records and reports, and disposing of any unused supply of the investigational drug.

Drug Discovery Program with the University of Georgia

Separation agreement.

In February 2009, we entered into a Separation Agreement in connection with the resignation of David Platt, Ph.D., the Company’s former Chief Executive Officer and Chairman of the Board of Directors. The Separation Agreement provides for the deferral of a $1.0 million separation payment due to Dr. Platt upon the earlier occurrence of any of the following milestone events: (i) the approval by the Food and Drug Administration for a new drug application (“NDA”) for any drug candidate or drug delivery candidate based on the GM-CT-01 technology (whether or not such technology is patented), in which case Dr. Platt is also entitled to a fully vested 10-year cashless-exercise stock option to purchase at least 83,334 shares of common stock at an exercise price not less than the fair market value of the common stock determined as of the date of grant; (ii) consummation of a transaction with a pharmaceutical company expected to result in at least $10.0 million of equity investment or $50 million of royalty revenue to the Company, in which case Dr. Platt is also entitled to stock options on the same terms to purchase at least 50,000 shares of common stock; or (iii) the renewed listing of our securities on a national securities exchange and the achievement of a market capitalization of $100 million. Payment upon the events (i) and (iii) may be deferred up to six months, and if we have insufficient cash at the time of any of such events, we may issue Dr. Platt a secured promissory note for such amount. If we file a voluntary or involuntary petition for bankruptcy, whether or not a milestone event has occurred, such event shall trigger our obligation to pay the $1.0 million with the result that Dr. Platt may assert a claim for such obligation against the bankruptcy estate. During 2011, when it

became probable that our common stock could be relisted on a national securities exchange and eventually reach a market capitalization of $100 million, we recognized the $1.0 million severance payment due to Dr. Platt and it is included in accrued expenses at March 31, 2013 and December 31, 2012.

On May 2, 2012, Dr. Platt instituted arbitration before the American Arbitration Association, seeking a $1.0 million separation payment based on a claim that a milestone event in the Separation Agreement has occurred (see clause (iii) above). On March 22, 2012, the Company’s common stock was listed on the NASDAQ Capital Markets, but since that date, the stock has not achieved the required market capitalization. Therefore, it is the Company’s position that a milestone event has not yet occurred. The arbitration hearing was held on October 16 – 17, 2012 and on November 1, 2012, the arbitrator denied Dr. Platt’s demand in all respects. Insofar as the Company does not dispute its obligations under the Separation Agreement to pay Dr. Platt upon the occurrence of a milestone event, it has recorded the payment as an accrued expense payable if and when the milestone event occurs.

On October 12, 2012, Dr. Platt commenced a lawsuit under the Massachusetts Wage Act against Dr. Traber and Mr. McGauley who in their capacities as the Company’s Chief Executive Officer and Chief Financial Officer respectively can be held individually liable under the Wage Act for non-payment of wages. The lawsuit was based on the facts and issues raised in the arbitration regarding the payment of the $1.0 million separation payment under the Separation Agreement, and other unspecified “wages”. The statute provides that a successful claimant may be entitled to multiple damages, interest and attorneys fees. Although the Company is not a party to the lawsuit, it plans to indemnify Dr. Traber and Mr. McGauley consistent with its obligations under the by-laws and applicable law, believes the lawsuit is without merit, and intends a vigorous defense on their behalf. On April 29, 2013, the Court allowed Dr. Traber’s and Mr. McGauley’s motion to dismiss.

Other.

We have engaged outside vendors for certain services associated with our clinical trials. These services are generally available from several providers and, accordingly, our arrangements are typically cancellable on 30 days notice.

Off-Balance Sheet Arrangements

We have not created, and are not a party to, any special-purpose or off-balance sheet entities for the purpose of raising capital, incurring debt or operating parts of our business that are not consolidated into our financial statements. We do not have any arrangements or relationships with entities that are not consolidated into our financial statements that are reasonably likely to materially affect our liquidity or the availability of capital resources.

Application of Critical Accounting Policies and Estimates

The preparation of condensed consolidated financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, expenses, and related disclosure of contingent assets and liabilities. On an ongoing basis, we evaluate our estimates, including those related to intangible assets, accrued expenses, stock-based compensation, contingencies and litigation. We base our estimates on historical experience, terms of existing contracts, our observance of trends in the industry, information available from other outside sources and on various other factors that we believe to be appropriate under the circumstances. Actual results may differ from these estimates under different assumptions or conditions.

Critical accounting policies are those policies that affect our more significant judgments and estimates used in preparation of our consolidated financial statements. We believe our critical accounting policies include our policies regarding stock-based compensation, accrued expenses and income taxes. For a more detailed discussion of our critical accounting policies, please refer to our 2012 Annual Report on Form 10-K.

Item 3.

Quantitative and Qualitative Disclosures about Market Risk

Market risk represents the risk of loss that may impact our financial position, operating results or cash flows due to changes in the U.S. interest rates. The primary objective of our investment activities is to preserve cash until it is required to fund operations. To minimize risk, we maintain our portfolio of cash and cash equivalents in operating bank accounts and money market funds. Since our investments are short-term in duration, we believe that we are not subject to any material market risk exposure.

Item 4.

Controls and Procedures

Our management, with the participation of the Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures (as defined in Rule 13a-15(e) promulgated under the Securities Exchange Act of 1934) and concluded that, as of March 31, 2013, our disclosure controls and procedures were effective at a reasonable assurance level. During the quarter ended March 31, 2013, no change in our internal control over financial reporting has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

PART II – OTHER INFORMATION

Item 1.

Legal Proceedings

As previously disclosed in the Company’s Form 10-K for the year ended December 31, 2012, David Platt, Ph.D., the Company’s former Chief Executive Officer and Chairman of the Board of Directors, commenced a lawsuit on October 12, 2012, under the Massachusetts Wage Act against Peter G. Traber, M.D. and Mr. Thomas A. McGauley, who in their capacities as the Company’s Chief Executive Officer and Chief Financial Officer respectively can be held individually liable under the Wage Act for non-payment of wages.

On April 29, 2013, the Court allowed Dr. Traber’s and Mr. McGauley’s motion to dismiss.

On March 29, 2013, the Company instituted arbitration before the American Arbitration Association, seeking to rescind or reform Dr. Platt’s Separation Agreement with the Company. The Company claims that Dr. Platt fraudulently induced the Company to enter into the Separation Agreement, breached his fiduciary duty to the Company, and was unduly enriched from his conduct. Along with removal of the $1.0 million milestone payment provided for under the Separation Agreement, the Company is seeking repayment of all separation benefits paid to Dr. Platt to date.

Item 1A.

Risk Factors

The information set forth in this report should be read in conjunction with the risk factors set forth in Item 1A, “Risk Factors,” of Part I of our Annual Report on Form 10-K for the year ended December 31, 2012, which could materially impact our business, financial condition or future results.

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds

None

Item 3.

Defaults Upon Senior Securities

None

Item 4.

Mine Safety Disclosures

Not Applicable

Item 5.

Other Information

Item 6.

Exhibits


Exhibit Number	Description of Document	Note Reference

3.1	Amended and Restated Bylaws of Galectin Therapeutics Inc.	1
3.2	Restated Articles of Incorporation of Galectin Therapeutics Inc.	1
10.1*	Amended and Restated Master Services Agreement dated February 1, 2013 between Galectin Therapeutics Inc. and CTI Clinical Trial Services, Inc. and CTI Clinical Consulting Services Inc.
31.1*	Certification Pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934
31.2*	Certification Pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934
32.1**	Certification Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
32.2**	Certification Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
101.INS	XBRL Instance Document*
101.SCH	XBRL Taxonomy Extension Schema Document*
101.CAL	XBRL Taxonomy Calculation Linkbase Document*
101.DEF	XBRL Taxonomy Extension Definition Linkbase Document*
101.LAB	XBRL Taxonomy Label Linkbase Document*
101.PRE	XBRL Taxonomy Presentation Linkbase Document*

*	Filed herewith.

**	Furnished herewith and not “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended.

1.	Incorporated by reference to the Company’s Current Report on Form 8-K filed with the Commission on May 30, 2012.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized, on May 10, 2013.


GALECTIN THERAPEUTICS INC.

By:		/s/ Peter G. Traber
Name:		Peter G. Traber, M.D.
Title:		Chief Executive Officer and President

		/s/ Thomas A. McGauley
Name:		Thomas A. McGauley
Title:		Chief Financial Officer

EX-10.1 2 d515969dex101.htm EX-10.1 EX-10.1

Exhibit 10.1

AMENDED AND RESTATED MASTER SERVICES AGREEMENT

This Amended and Restated Master Services Agreement (the “Agreement”) is made as of the 31st day of January, 2013 (“Effective Date”) by and between Galectin Therapeutics (“Sponsor”) with offices located at 7 Wells Avenue, Suite 34, Newton, MA 02459 and CTI Clinical Trial Services, Inc. and CTI Clinical Consulting Services, Inc. (individually and collectively, “CTI”) with offices located at 10123 Alliance Road, Cincinnati, OH 45242.

Introduction

Sponsor and CTI entered into that certain Master Services Agreement dated as of August 30, 2012 (the “Original Agreement”), and desire to amend and restate the Original Agreement in its entirety as provided in this Agreement. Sponsor has sponsored and/or conducted pursuant to the Original Agreement, and may sponsor and/or conduct pursuant to this Agreement, one or more clinical research studies from time to time. CTI is knowledgeable and experienced in the design, management and conduct of such studies. Sponsor wishes to retain CTI to assist Sponsor in the design, development and conduct of these studies and CTI desires to provide such assistance, on the terms and conditions set forth in this Agreement.

To that end, Sponsor and CTI now agree as follows:

1. Services. From time to time, CTI will provide Sponsor certain clinical research or design and development services pursuant to the terms of this Agreement. Prior to the commencement of such services, CTI and Sponsor shall agree upon and execute and deliver a work order or work orders (each a “Work Order”) that will describe the specific obligations transferred by Sponsor to CTI (the “Services”) in the performance of a particular clinical research study sponsored or conducted by Sponsor (each a “Study”). Each Work Order will be a separate agreement and will incorporate the terms of this Agreement by reference. In the event of any conflict between the terms and conditions of this Agreement and the terms and conditions of any Work Order, terms and conditions of this Agreement shall control unless expressly specified otherwise in a Work Order, A sample form of Work Order is attached to this Agreement as Exhibit A.

CTI represents to Sponsor that it is not a party to any agreement which would prevent it from fulfilling its obligations under this Agreement and, that during the term, CTI agrees it will not enter into any agreement to provide services which would in any way prevent it from providing the Services as contemplated under this Agreement.

CTI will ensure that the Services are carried out by qualified and experienced staff. CTI covenants that it will render the Services in accordance with its applicable standard operating procedures and to the highest professional standards and will make all efforts to maintain consistently high levels of accuracy and expertise. CTI will comply with all applicable laws, rules, regulations and guidelines relating to the conduct of clinical investigations, including, without limitation, 21 C.F.R. Parts 50, 54, 56 and 312, the International Conference on Harmonization Guidelines for Good Clinical Practices

(collectively, “Applicable Law”) and other good clinical practice requirements (collectively, “Applicable Requirements”). The parties agree to comply with the Health Insurance Portability and Accountability Act (45 C.F.R. Parts 160, 162 and 164, as well as the regulations thereunder) and any state, municipal or local law, ordinance or regulation protecting the privacy of individual health information (collectively “Privacy Laws and Regulations”).

2. Personnel. CTI shall ensure that appropriately trained and qualified employees and contractors of CTI deliver the Services outlined in each Work Order. CTI must obtain the prior written consent of Sponsor regarding any contractor which CTI proposes to engage to deliver the Services outlined in any Work Order. CTI also must obtain the prior written consent of Sponsor with respect to a decision by CTI to utilize any CTI employee that CTI proposes to have a substantive role in the delivery of the Services with respect to any Work Order that is not so engaged as of the Effective Date. However, such prior written consent shall not be required with respect to those employees whose involvement in the Study is limited to only non-substantive activities (e.g., monitors, etc.).

If CTI contracts with investigators or investigative sites (collectively, “Investigators”), any such contract shall be on a form mutually acceptable to CTI and Sponsor. If an Investigator requests any material changes to such form, CTI shall submit the proposed change to Sponsor, and Sponsor shall promptly review, comment on and/or approve such proposed changes. The parties acknowledge and agree that Investigators shall not be considered the employees, agents, or subcontractors of CTI or Sponsor, and that Investigators shall exercise their own independent medical judgment with respect to the applicable Study. CTI’s responsibilities with respect to Investigators shall be limited to those responsibilities specifically set forth in this Agreement and applicable Work Orders.

If CTI will be paying Investigators on behalf of Sponsor, the parties will agree to a schedule of amounts to be paid to Investigators. Sponsor acknowledges and agrees CTI will only pay Investigators from advances or pre-payments received from Sponsor for Investigators’ services, and that CTI will not make payments to Investigators prior to receipt of sufficient funds from Sponsor. Sponsor acknowledges and agrees that CTI will not be responsible for delays in a Study to the extent that such delays are caused by Sponsor’s failure to make adequate pre-payment for Investigators’ services. Sponsor further acknowledges and agrees that payments for Investigator’s services are pass-through payments to third parties and are separate from payments for CTI Services. Sponsor agrees that it will not withhold Investigator payments except to the extent that it has reasonable questions about the services performed by a particular Investigator.

CTI shall have Investigators complete and return to Sponsor such financial disclosure forms as may be required to comply with Applicable Regulations pertaining to financial disclosures of clinical investigators.

The parties agree that any payments to Investigators are not intended to encourage, and are not being given in exchange for any explicit or implicit agreement to: (i) order,

purchase, prescribe or recommend any Sponsor product; or (ii) influence or provide favorable formulary status for any Sponsor product. Payments have not been determined in a manner that would take into account the volume or value of referrals or business, if any, generated between Sponsor and any investigator, sub-investigator or their practice.

By entering into this Agreement, each party attests that it understands what is required of it for the Study under Applicable Law and Applicable Requirements, and commits to complying with such law and requirements. CTI hereby certifies to Sponsor that it is not, has not been, or has not used, nor will it use the services of any person, debarred under 21 U.S.C, 335a, as amended, or disqualified by any regulatory authority, or otherwise found by any regulatory authority to have violated any Applicable Law or Applicable Requirements concerning the conduct of clinical investigations or excluded from participation in any state or federal healthcare program (collectively, “Debarred” or “Debarment”) in any capacity in connection with any of the services or work provided hereunder. In the event that during the term of this Agreement, CTI or any of its Investigators or any of their employees or agents (i) becomes Debarred or (ii) receives notice of an action or threat of an action with respect to its Debarment, CTI shall notify Sponsor immediately.

3. Transfer of Obligations; Regulatory Compliance; Inspection. The specific obligations transferred by Sponsor to CTI in any particular Study will be detailed in the relevant Work Order or Transfer of Obligations Form. Sponsor will retain those responsibilities not specifically listed in that Work Order. Sponsor shall at all times be the “Sponsor” of each Study pursuant to the terms of the U.S. Food, Drug and Cosmetic Act, as from time to time amended (the “Act”). Sponsor will maintain all direct communication, whether oral, electronic or hard copy, with the U.S. Food and Drug Administration (the “FDA”) at all times with respect to the Study, and CTI will not engage in any such communications regarding the Study without the prior written consent of Sponsor. Sponsor will cooperate with CTI in taking any action that CTI reasonably believes is necessary to comply with the regulatory obligations that have been transferred to CTI.

Each party acknowledges that the other party may respond independently to any regulatory correspondence or inquiry in which such party or its affiliates is named and which does not relate to the Services provided under this Agreement. Each party however, shall: (a) notify the other party promptly of any FDA or other U.S. or non-US. governmental or regulatory inspection or inquiry relating to the Services provided by CTI under this Agreement including, but not limited to, inspections of investigational sites; (b) forward to the other party copies (within five (5) business days) of any correspondence from any regulatory or governmental agency relating to a Study, including, but not limited to, Form FD-483 notices, and FDA refusal to file, rejection or warning letters, even if they do not specifically mention the other party; (c) give the other party the opportunity to review and comment upon any response to a regulatory authority relative to the Services or a Study under this Agreement before such response is submitted, such review and comment to be conducted promptly and without delay; and (d) obtain the written consent of the other party, which will not unreasonably be withheld, before referring to the other party or any of its affiliates in any regulatory correspondence

relative to the Services or a Study under this Agreement. Where reasonably practicable, each party will be given the opportunity to have a representative present during a FDA or regulatory inspection. Each party however, acknowledges that it may not direct the manner in which the other party fulfills its obligations to permit inspection by governmental entities. Notwithstanding the foregoing, CTI will promptly notify Sponsor of any FDA or other U.S. or non-US. governmental or regulatory inspection or inquiry with respect to CTI not relating to the Services or the Study but which is reasonably likely to have an impact on CTI’s performance of the Services and/or its other obligations under this Agreement and, to the extent legally permissible, discuss with Sponsor such potential impact.

Each party agrees that, during an inspection by the FDA or other regulatory authority concerning any Study for which CTI is providing the Services, it will not disclose information and materials that are not required to be disclosed to such authority, without the prior written consent of the other party, which shall not unreasonably be withheld. Such information and materials includes, but are not limited to (i) financial data and pricing data (including, but not limited to, the Budget); (ii) sales data (other than shipment data); and (iii) personnel data (other than data as to qualification of technical and professional persons performing functions subject to regulatory requirements).

During the term of this Agreement, CTI will permit Sponsor’s representatives (unless such representatives are competitors of CTI) to examine and review, without any additional cost to Sponsor, the work performed hereunder and any facilities at which the work is conducted, upon reasonable advance notice and at mutually agreeable times during regular business hours to determine that the Services are being performed in accordance with this Agreement and the Work Orders. In the event of a more format audit, unless the costs of governmental or Sponsor audits are specifically included in the Budget, or a governmental “for cause” audit is conducted as a result of CTI activities, Sponsor shall reimburse CTI for its time and expenses, including reasonable attorney fees, associated with such audits, including the costs of responding to the findings of any such audit.

4. Scope of Work and Payment. The Work Order or Work Orders for each Study will include a scope of work statement that details CTI’s Services for that Study (the “Scope of “Work”). The Work Order will also include a budget and payment schedule for CTI’s Services for each Study (the “Budget”), and Sponsor will pay CTI for the Services accordingly. The aggregate fees and expenses set forth in that schedule will not change or be modified unless authorized by both parties in writing. CTI will invoice Sponsor in accordance with the relevant Work Order. Each invoice will describe the Services performed, and any expenses billed will be supported by appropriate documentation. Sponsor will pay all uncontested amounts reflected on each invoice within 30 days of the date of its receipt thereof. If all or any portion of an invoice is contested, Sponsor will provide written notice and a summary of the contested items to CTI within ten (10) days of Sponsor’s receipt of invoice. The parties shall work in good faith toward resolution of such items.

All changes to a Work Order will be in writing signed by both Sponsor and CTI and treated as amendments to the original Work Order. Any material changes in the details of this Agreement or a Work Order or the assumptions upon which the Agreement is based (including, but not limited to, changes in an agreed starting date for a Study, change in Scope of Work, or suspension of the Study) shall require a written amendment to this Agreement or the relevant Work Order(s) (a “Change Order”). Each Change Order shall detail the requested changes to the applicable task, responsibility, duty, budget, timeline or other matter. A Change Order will become effective upon execution of the Change Order by both parties, and CTI will be given a reasonable period of time within which to implement the changes. Both parties agree to act in good faith and promptly when considering a Change Order requested by the other party. CTI reserves the right to postpone effecting changes in a Work Order until such time as the parties agree to and execute the corresponding Change Order. Unless a Change Order is made in writing, Sponsor shall have no obligation to pay for charges not otherwise set forth in the Budget (Out of Scope Charges). For any Change Order that affects the scope of the regulatory obligations that have been transferred to CTI, CTI and Sponsor shall execute a corresponding amendment to the Transfer of Obligations Form. Such amendment shall be filed by Sponsor where appropriate, or as required by Applicable Law or Applicable Regulation.

5. Term and Termination. This Agreement will begin as of its stated Effective Date and will continue for a five (5) year period unless otherwise terminated under this Section 5. Each Work Order shall be effective as of, and remain in effect for the term specified in, each specific Work Order; provided, however, that if any Work Order does not specify an effective date or term, the effective date shall be the date that such Work Order is signed and dated by Sponsor and the term of such Work Order shall be the same as this Agreement. This Agreement or any Work Order may be terminated for any reason by any party upon ninety (90) days prior written notice to the other party. In addition, this Agreement may be terminated by either party immediately if the other party becomes insolvent, is dissolved or liquidated, makes a general assignment for the benefit of its creditors, files or has filed against it (and does not obtain a dismissal within ninety (90) days) a petition of bankruptcy, or has a receiver appointed for it or a substantial part of its assets. If a court order or Applicable Law or Applicable Regulation, including any applicable rules and regulations of the Securities and Exchange Commission, requires the termination of this Agreement or adversely impacts the continuation of the Study or the Study itself, then this Agreement may be terminated by either party immediately upon delivery of notice to the other party. Further, this Agreement or any relevant Work Order may be terminated immediately by written notice from Sponsor, in the following circumstances:

(1)

The FDA withdraws authorization and approval to conduct a Study; or

(2)

Sponsor reasonably determines that for medical, clinical or patient safety reasons, a Study should terminate immediately.

In addition, either party may terminate this Agreement or any Task Order for material breach upon thirty (30) days’ written notice specifying the nature of the breach, if such breach has not been substantially cured within the thirty (30) day period.

Termination of a Work Order shall not affect any other Work Order; each Work Order shall continue in full force and effect until its expiration date or completion of the Services, unless specifically earlier terminated in accordance with the terms of this Agreement or the terms of that Work Order. Any termination of this Agreement will not affect the Services being performed under any particular Work Order, and the terms and conditions of this Agreement in its entirety shall remain incorporated by reference in that: Work Order except to the extent that the Work Order is also terminated in accordance with its terms or this Article 5. For any termination of this Agreement or any Work Order, both parties recognize that such an event will require discussion, cooperation and coordination between them to ensure patient safety, compliance with all Applicable Laws and Applicable Regulations and continuity of treatment (if appropriate). To that end, upon any termination of this Agreement or any Work Order, CTI will cooperate with Sponsor to provide for an orderly cessation of CTI Services. Additionally, unless otherwise stipulated by Sponsor, CTI will perform such Services as are reasonably necessary for an orderly termination and shall transfer to Sponsor all Study data, reports, and all related Study documents prepared but not yet submitted to Sponsor. Upon any termination of this Agreement or any Work Order, Sponsor shall promptly pay CTI for Services performed under this Agreement or such Work Order prior to the effective date of termination or in connection with the process of an orderly termination; provided, however, that the total of such payments shall not exceed the total amount remaining under the Budget. Sponsor’s final payment to CTI will include reimbursement to CTI for all non-cancelable obligations and all pass-through expenses incurred prior to the effective date of termination or in connection with the process of an orderly termination. In the orderly cessation of activities, CTI will use its best efforts, consistent with good clinical practice, to minimize costs to be incurred by Sponsor for the Services.

6. Confidentiality; Records. In the course of fulfilling the mutual responsibilities under this Agreement and the Work Orders, there will be a sharing of confidential or proprietary information (“Confidential Information”), which will remain the property of the party disclosing such Confidential Information. Both parties expressly agree that all materials, documents and information concerning a Study (whether or not confidential), including, without limitation, the protocol, case report forms, all papers, records, clinical data and other data provided to or possessed or developed by CTI for use in a Study, except CTI Intellectual Property as defined in Section 9.D. below (“Records”), are the sole and exclusive Confidential Information and/or property of Sponsor. The parties agree that each will maintain the other party’s Confidential Information in strict confidence, including, without limitation, methods, trade secrets, unpublished pending patents, ideas, products, services, processes, unpublished pre-clinical or clinical data, techniques and other proprietary information, and will use the same reasonable efforts to protect such information from unauthorized disclosures as are used to protect its own Confidential Information. The Confidential Information shall be used only for the purpose of performing the receiving party’s obligations hereunder. Such Confidential Information shall not be disclosed to any other person without prior written permission of the disclosing party. This obligation of confidentiality shall extend to the parties’ employees, officers, directors, agents and affiliates.

Confidential Information shall not include information that: (a) was already known to the receiving party, other than under an obligation of confidentiality, at the time of disclosure of the same, as demonstrated by competent written records; (b) was generally available to the public or otherwise part of the public domain at the time of its disclosure to the receiving party; (c) became generally available to the public or otherwise part of the public domain after its disclosure, other than through any act or omission of the receiving party in breach of this Agreement; (d) was disclosed to the receiving party, other than under an obligation of confidentiality, by a third party, who had no obligation not to disclose such information to others; or (e) was subsequently developed by the receiving party without use of the disclosing party’s Confidential Information as demonstrated by competent written records.

The parties may disclose Confidential Information to the extent such disclosure is required to comply with applicable governmental regulations or to the extent ordered by a court exercising its right of authority over the disclosing party (subject to entry of an appropriate protective order), provided that if a party is required by such law, regulation or order to make any such disclosure of Confidential Information, such party shall give reasonable notice to the other party of such disclosure requirement and will use its reasonable efforts to secure confidential treatment of such Confidential Information required to be disclosed. The confidentiality provisions of this Agreement shall remain in full force and effect during the term of this Agreement and for ten (10) years thereafter.

CTI shall maintain all Records in a safe and secure manner and in compliance with all Applicable Laws and Applicable Requirements. CTI shall store all Records in compliance with the appropriate record retention regulations, Thereafter, prior to disposal of any Records, CTI shall give Sponsor not less than sixty (60) days written notice, and, if Sponsor so requests prior to such disposal, CTI shall transfer such Records to Sponsor at Sponsor’s cost and expense. CTI shall make any and all Records available for inspection or duplication by Sponsor’s authorized representatives during normal business hours. At any time and at Sponsor’s cost and expense, Sponsor may request that CTI (i) deliver any or all Records to Sponsor or to a location specified by Sponsor, or (ii) dispose of Records as directed by Sponsor, unless such Records are required by Applicable Laws and Applicable Requirements to be stored or maintained.

7. Non Exclusivity.

The understanding contemplated herein is not exclusive and both parties shall be free to enter into similar arrangements with any third party, so long as such arrangements do not conflict with the terms of this Agreement or the interest of either party; provided, however, that the foregoing shall not serve to relieve either party from any other obligations hereunder including, without limitation, obligations of confidentiality, and with respect to ownership of information.

8. Assignment.

Neither party shall assign any or all of its rights and obligations under this Agreement without the prior written consent of the other, except that Sponsor and CTI may assign this Agreement in whole or in part to any of their affiliates.

9. Intellectual Property.

A.	Ownership. All materials, documents and information obtained by, developed by or provided to CTI by or on behalf of Sponsor as part of the Services under this Agreement or any Work Order will be the exclusive property of Sponsor.

Inventions. CTI will disclose to Sponsor any and all inventions or discoveries that incorporate Sponsor Confidential Information and that are made by CTI as part of the Services under this Agreement or any Work Order (“Intellectual Property”). Further, CTI will assign all rights it may have in any such Intellectual Property to Sponsor.

Assistance. CTI will cooperate with Sponsor in executing any and all applications, assignments or other instruments reasonably necessary to apply for and obtain patent or other protection in the United States or any foreign country, or to otherwise protect Sponsor’s interest in such Intellectual Property, Sponsor shall compensate CTI for its time and reasonable expenses required by this assistance.

Notwithstanding subsections A, B, and C above, all computer programs, software, applications, databases, proposals and other documentation generally used or developed by CTI, and any improvement, alteration or enhancement to these (that does not use Sponsor’s Intellectual Property or unless specifically requested and paid for by Sponsor as part of the Services under this Agreement or any Work Order), are the exclusive and confidential property of CTI or the third parties from whom CTI has secured the right of use (“CTI Intellectual Property”). Any data sets in the format in which they are collected or any derivative thereof or other format to which such data sets may be converted are the property of Sponsor and will be transferred to Sponsor upon written request,

10. Indemnification.

CTI will hold harmless and indemnify Sponsor, its affiliates, employees, agents, representatives, officers, directors, shareholders, successors and assigns from and against all losses, damages, claims, costs, expenses, complaints, lawsuits or other liabilities, including reasonable attorney’s fees and court costs, that arise as a result of the negligence or intentional misconduct of CTI or its affiliates, employees, agents, representatives, and assigns in its performance under this Agreement or any Work Order. This CTI indemnification does not apply to the extent any loss, damage, cost or expense is caused by or attributable to the negligence or intentional misconduct of Sponsor or any of its employees, agents, representatives or assigns. For purposes of this Section 10, intentional misconduct shall mean intentional falsification or destruction of data or records, intentional disclosure of confidential information, intentional mistreatment of Study subjects, intentional misuse of clinical trial materials, data or records, and/or similar intentional misconduct. Notwithstanding the

foregoing, CTI will indemnify and hold harmless Sponsor from any and all damages flowing from its, or any of its employees, violation of the Privacy Laws and Regulations.

Sponsor will hold harmless and indemnify CTI, its affiliates, employees, agents, representatives, officers, directors, shareholders, successors and assigns from and against all losses, damages, claims, costs, expenses, complaints, lawsuits or other liabilities, including reasonable attorney’s fees and court costs, that arise as a result of (i) the negligence or intentional misconduct of Sponsor or its employees, agents, representatives and assigns, or (ii) personal injury or death alleged to have been caused by or attributed to any Study substance provided by Sponsor and dispensed or administered in the Study pursuant to the provisions of the Study protocol. This Sponsor indemnification does not apply to the extent any loss, damage, cost or expense is caused by or attributable to the negligence or intentional misconduct of CTI or any of its affiliates, employees, agents, representatives or assigns.

The indemnifying party shall be entitled, at its option, to control the defense and settlement of any claim for which it may be liable, provided that it shall act reasonably and in good faith with respect to all matters related to the settlement or disposition of the claim as the disposition or settlement relates to the indemnified party. The indemnified party shall reasonably cooperate in the investigation, defense and settlement of any claim for which indemnification is sought hereunder and shall provide prompt notice of any such claim or reasonably expected claim to the indemnifying party. Notwithstanding the foregoing, the indemnifying party shall not agree to any settlement of claim, liability or action without the consent of the indemnified party, which consent shall not be unreasonably withheld.

11. Independent Contractor Relationship. The parties to this Agreement and the applicable Work Orders are independent contractors. Neither party may offer or agree to incur or assume any obligations or commitments in the name of or on behalf of the other, except as specifically stated in this Agreement or in a Work Order.

12. Miscellaneous.

Delegation and Subcontracts. CTI may delegate part of its Services under a Work. Order to its affiliated companies or other subcontractors as it may require, and with prior written approval of Sponsor of such delegation. However, CTI remains principally responsible to Sponsor for the performance of all its Services and obligations under this Agreement, whether delegated, subcontracted or otherwise.

B.	Non-Solicitation. During the term of this Master Agreement and for a period of twelve (12) months thereafter, neither Sponsor nor CTI shall recruit or otherwise induce any employee of the other party to terminate his/her employment or violate any agreement with, or duty to, CTI or Sponsor.

C.	Force Majeure. Either party shall be excused from performing its obligations under this Agreement or any Work Order if its performance is delayed or prevented by a

cause beyond that party’s reasonable control, including, but not limited to, acts of God, fire, explosion, weather, disease, war, insurrection, civil strife, riots, government action, or power failure. Performance will be excused only to the extent of and during the reasonable continuance of such disability. Any deadline or time for performance specified in a Work Order which falls due during or subsequent to the occurrence of any force majeure under this section will be extended for a period of time equal to the period of such disability, CTI will promptly notify Sponsor if, by reason of any force majeure, CTI is unable to meet any deadline or time for performance specified in a Work Order.

D.	Binding Agreement. This Agreement is binding on and inures to the benefit of its parties and their respective legal representatives, successors and assigns. However, neither party can transfer or assign this Agreement without the prior written consent of the other party.

E.	Amendments. This Agreement may be modified or amended only by a writing executed by the parties hereto.

F.	Notices. All notices shall be in writing and shall be personally delivered or sent by certified mail, return receipt requested to the parties, Federal Express or another nationally recognized overnight courier service, at the addresses each party will furnish to the other.

G.	Waiver. The waiver or breach of any term or condition of this Agreement does not constitute a waiver of any other of its terms or conditions or any subsequent breach of the same term or condition.

Entire Agreement. This Agreement and the Work Orders constitute the entire agreement between its parties with respect to its subject matter. There are no representations, warranties, covenants or undertakings as to that subject matter other than those expressly set forth in this Agreement and the Work Orders. This Agreement and the Work Orders supersede all prior agreements between the parties with respect to its subject matter, including without limitation, the Original Agreement.

I.	Severability. The invalidity or unenforceability of any Agreement or Work Order provision shall in no way affect the validity or enforceability of any other provision.

J.	Governing Law. The laws of the State of Delaware (without regard to any provision or rule applying the law of another state or jurisdiction) shall govern this Agreement and the Work Orders.

K.	Counterparts. This Agreement and its Work Orders may be executed in two (2) counterparts and by facsimile or electronic means, each of which shall be considered an original, but are one and the same document.

As witness to this Agreement, the authorized representatives of its parties have signed this Agreement below as of its Effective Date.


CTI Clinical Trial Services, Inc.
CTI Clinical Consulting Services, Inc.
By:	/s/ Timothy J. Schroeder	Date:	2/1/13
Name:	Timothy J. Schroeder
Title:	President & CEO
Galectin Therapeutics Inc.
By:	/s/ Peter G. Traber, MD	Date:	2/1/13
Name:	Peter G. Traber, MD
Title:	President, CEO and CMO

EXHIBIT A

Sample Work Order

This is Work Order No. dated this day of , 201 , between Galectin Therapeutics (“Sponsor”) and CTI Clinical Trial Services, Inc. (“CTI”) and arises from and is now part of their Master Services Agreement dated , 201 (“Agreement”) which is incorporated in this Work Order by reference. In the Agreement, CTI agreed to perform certain services under written Work Orders, such as this one, that will describe such services and the payment terms associated therewith. Accordingly, the parties enter into this Work Order as to the Sponsor’s Protocol No. , entitled: (“Study”), and agree as follows:

1. The specific services contemplated by this Work Order (“Services”) and the related payment terms and obligations are set forth in the following attachments which are jointly and severally an integral part of this Work Order:


Study Protocol		Attachment 1
Transfer of Obligations		Attachment 2
Study Scope of Work and Budget		Attachment 3
Payment Schedule		Attachment 4

2. This Work Order begins on the date set forth above and will continue until the Services described in Attachment 3 are completed, unless this Work Order is terminated as provided in the Agreement.

3. CTI may use the services of its corporate affiliates or subcontractors to fulfill its obligations under this Work Order, subject to Section 12.A of the Agreement. Any affiliates or subcontractors will be bound by all the terms of the Agreement and this Work Order. The affiliates and subcontractors that CTI will use for the Services under this Work Order will be listed in Attachment 5 to this Work Order.

4. No change to or amendment of this Work Order is effective unless it is in writing and duly executed by, and delivered to, each party.

Acknowledged, Accepted and Agreed To:


Galectin Therapeutics Inc.		CTI Clinical Trial Services, Inc.

By:		By:
Name:	Harold H. Shlevin, PhD	Name:
Title:	Chief Operating Officer	Title:

EX-31.1 3 d515969dex311.htm EX-31.1 EX-31.1

Exhibit 31.1

Certification Pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934

I, Peter G. Traber, certify that:

1.	I have reviewed this quarterly report on Form 10-Q of Galectin Therapeutics Inc;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.	The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:

(a)

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b)

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c)

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d)

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.	The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a)

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

EX-31.2 4 d515969dex312.htm EX-31.2 EX-31.2

Exhibit 31.2

Certification Pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934

I, Thomas A. McGauley, certify that:

1.	I have reviewed this quarterly report on Form 10-Q of Galectin Therapeutics Inc;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.	The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:

(a)

(b)

(c)

(d)

5.	The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a)

(b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

EX-32.1 5 d515969dex321.htm EX-32.1 EX-32.1

Exhibit 32.1

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED

PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Galectin Therapeutics Inc. (the “Company”) on Form 10-Q for the period ended March 31, 2013 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Peter G. Traber, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:

(1)

The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement required by Section 906, has been provided to Galectin Therapeutics Inc. and will be retained by Galectin Therapeutics Inc. and furnished to the Securities and Exchange Commission or its staff upon request.

EX-32.2 6 d515969dex322.htm EX-32.2 EX-32.2

Exhibit 32.2

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED

PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Galectin Therapeutics Inc. (the “Company”) on Form 10-Q for the period ended March 31, 2013 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Thomas A. McGauley, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:

(1)

The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

EX-101.INS 7 galt-20130331.xml XBRL INSTANCE DOCUMENT

1000000

100000000

10000000

50000

5000

2.65

2155000 154000

4000000

1000000 16251469

5.63

1 2017-03-28 9.00

1333361

46378

5.63

2016-05-02

15314000

137000

6000

-1036000

5427000

11000

50000000

61000

16190429

80000

1473000

316000

83490000

5000

5000000

7196000

5.52

7196000

7018000

16190429

28000

7429241

1152000

1468000

3656217

16000

0.001

7155000

1562500

632000

7000

81806000

241000

20000000 8001000 1466586 0.01 3.71 10 1000000

632000

1562500

-83490000

2105000

215

16000

16190429

81806000

1702000

900000

2952000

2100000

192000

2150000

215

1000

5078000

2105000

1800000

900000

1800000

1702000

4200000

2100000

4200000

2952000

6397000

153000

6000

1165000

10000

50000000

42000

16060853

109000

1644000

397000

80018000

6000

5000000

9561000

5.66

9561000

9364000

16060853

30000

7424241

1161000

1638000

3539961

16000

0.001

9517000

1562500

632000

80000

8000

80535000

20000000 8001000 0.01 3.71 1000000

632000

1562500

-80018000

2154000

220

16000

16060853

80535000

1698000

900000

2900000

2100000

583000

220

1000

2154000

900000

1698000

2100000

2900000

1159445

173916 P45D

0.1667

10403000

1333361

12000000 2666722

0.0105

1.19

P5Y

4445000 5.63 4.20

0.0078

1.17

P4Y1M6D

143000 4.20

50000000

83334 P6M

P10Y

1000000 1000000

0.06

8475

8334

141

P30D P90D P90D P5Y

0.0176

-77854000

39093000

9000

0.00

13226000

1536000

404000

5000

171000

107000

558000

P5Y2M12D

-60976000

12243000

-835000

823000

68800000

431000

7018000

48492000

140000

691000

1641000

29362000

68829000

77854000

4279000

1.19

351000

114000

4448000

-75195000

2659000

4101000

10621000

-83744000

4451000

11370000 4448000 9022000 -3426000 329000 9482000 503000 712000

1691000

2203000

1548000

3935000

GALT GALECTIN THERAPEUTICS INC false Smaller Reporting Company Q1 2013 10-Q 2013-03-31 0001133416 --12-31

0.0080

-3208000

13000

852000

5000

0.00

852000

3.36

9.50

-90000

-1000

-0.22

39762

3000

P5Y

-2423000

5000

2.77

-2346000

1456000

49000

-16000

200426

P3Y10M24D

<div> The following table summarizes the stock option activity in the Company’s equity incentive plans, including non-plan grants to Company executives, from December 31, 2012 through March 31, 2013: <table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="95%" align="center">  <tr> <td width="95%"></td> <td valign="bottom" width="1%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="1%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2">             Shares           </td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">  Weighted Average   Exercise Price</td> <td valign="bottom"> </td> </tr>  <tr bgcolor="#CCEEFF"> <td valign="top"> Outstanding, December 31, 2012 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3,539,961</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> $</td> <td valign="bottom" align="right">                    5.66    </td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr> <td valign="top"> Granted </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">200,426</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3.36    </td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> Exercised </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(39,762)</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2.77    </td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr> <td valign="top"> Options forfeited/cancelled </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(44,408)</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">9.50    </td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> Outstanding, March 31, 2013 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3,656,217</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> $</td> <td valign="bottom" align="right">5.52    </td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> </table> </div>

77000

1752000

77000

<div> Dilutive shares which could exist pursuant to the exercise of outstanding stock instruments and which were not included in the calculation because their affect would have been anti-dilutive are as follows:   <table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="97%" align="center">  <tr> <td width="95%"></td> <td valign="bottom" width="1%"></td> <td></td> <td valign="bottom" width="1%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="1%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">      March 31, 2013       (shares)</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">      March 31, 2012       (shares)</td> <td valign="bottom"> </td> </tr>  <tr bgcolor="#CCEEFF"> <td valign="top"> Warrants to purchase shares of common stock </td> <td valign="bottom"> </td> <td valign="top"></td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">7,429,241     </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">7,424,241            </td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr> <td valign="top"> Options to purchase shares of common stock </td> <td valign="bottom"> </td> <td valign="top"></td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3,656,217     </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,997,468            </td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> Shares of common stock issuable upon conversion of preferred stock </td> <td valign="bottom"> </td> <td valign="top"></td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,618,772     </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,627,110            </td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom" colspan="5">   </td> <td> </td> </tr> <tr> <td valign="top"></td> <td valign="bottom"> </td> <td valign="top"></td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">13,704,230     </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">13,048,819            </td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom" colspan="8">   </td> <td> </td> </tr> </table> </div>

44408

3208000

1.17

<div> Accrued expenses consist of the following:   <table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="95%" align="center">  <tr> <td width="92%"></td> <td valign="bottom" width="1%"></td> <td></td> <td valign="bottom" width="1%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="1%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">    March 31,     2013</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"> December 31,  2012</td> <td valign="bottom"> </td> </tr> <tr> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="6" align="center">(in thousands)</td> <td valign="bottom"> </td> </tr>  <tr bgcolor="#CCEEFF"> <td valign="top"> Legal and accounting fees </td> <td valign="bottom"> </td> <td valign="top"></td> <td valign="bottom"> </td> <td valign="bottom">    $</td> <td valign="bottom" align="right">80 </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> $</td> <td valign="bottom" align="right">109 </td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr> <td valign="top"> Accrued compensation </td> <td valign="bottom"> </td> <td valign="top"></td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">61 </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">42 </td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> Severance agreement (Note 8) </td> <td valign="bottom"> </td> <td valign="top"></td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,000 </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,000 </td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr> <td valign="top"> Other </td> <td valign="bottom"> </td> <td valign="top"></td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">11 </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">10 </td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> Total </td> <td valign="bottom"> </td> <td valign="top"></td> <td valign="bottom"> </td> <td valign="bottom">    $</td> <td valign="bottom" align="right">        1,152 </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> $</td> <td valign="bottom" align="right">        1,161 </td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom" colspan="8">   </td> <td> </td> </tr> </table> </div>

<div> <table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td valign="top" width="4%" align="left">8.</td> <td valign="top" align="left">Commitments, Contingencies and Legal Proceedings</td> </tr> </table> Agreement with CTI for Phase I Clinical Trial On February 1, 2013, the Company entered into an Amended and Restated Master Services Agreement (the “Agreement”) with CTI Clinical Trial Services, Inc. and CTI Clinical Consulting Services, Inc. (individually and collectively, “CTI”), whereby CTI is assisting the Company in the design, development and conduct of one or more clinical research studies from time to time. All work performed by CTI for the Company is being conducted pursuant to the terms of work orders that describe the specific obligations undertaken by CTI with respect to any particular clinical research study sponsored or conducted by the Company. Unless otherwise terminated sooner in accordance with the terms of the Agreement, the Agreement will be effective until January 31, 2018. On February 1, 2013, the Company entered into a work order (the “Work Order”) with CTI in accordance with the terms of the Agreement. The Work Order provides that CTI will provide services with respect to the Company’s Phase I Clinical Trial to evaluate the safety of the Company’s drug GR-MD-02 in subjects with Non-Alcoholic Steatohepatitis (“NASH”) with advanced hepatic fibrosis. CTI is providing the following services, amongst others, with respect to the Work Order: reviewing and providing notices regarding IND safety reports, selecting investigators and monitors for the study, informing investigators of new observations, monitoring the progress of the study and reviewing ongoing investigations, keeping certain records, inspecting the Company’s records and reports, and disposing of any unused supply of the investigational drug.   The Work Order provides for CTI’s anticipated involvement in the study from February 1, 2013 until March 31, 2014. The estimated budget for the Work Order is $2,155,000, which is subject to change as necessary, with payments made throughout the term of the project as the work is performed. During the three months ended March 31, 2013, the Company recognized $728,000 of expenses related to this agreement for services performed during the period. The Agreement or any work order may be terminated for any reason by any party upon ninety (90) days prior written notice to the other party. In addition, the Agreement may be terminated by either party immediately if the other party becomes insolvent, is dissolved or liquidated, makes a general assignment for the benefit of its creditors, files or has filed against it (and does not obtain a dismissal within ninety (90) days) a petition of bankruptcy, or has a receiver appointed for it or a substantial part of its assets, among other reasons. Further, the Agreement or any relevant work order may be terminated immediately by written notice from the Company, in the following circumstances: (1) the FDA withdraws authorization and approval to conduct a study; or (2) the Company reasonably determines that for medical, clinical or patient safety reasons, a study should terminate immediately. In addition, either party may terminate the Agreement or any work order for material breach upon thirty (30) days’ written notice specifying the nature of the breach, if such breach has not been substantially cured within the thirty (30) day period. Drug Discovery Program with the University of Georgia In February 2013, the Company established a collaborative drug discovery program at the Complex Carbohydrate Research Center at the University of Georgia. This program is focused on the discovery of new carbohydrate molecules that can be used in the therapy of diseases where galectin proteins play a major role, including cancer and inflammatory and fibrotic disorders. The term of the agreement is effective through December 31, 2013, for which the Company will provide funding of $154,000 during the period as work is performed. This agreement may be terminated by either party upon 90 days notice. Separation Agreement In February 2009, the Company entered into a Separation Agreement in connection with the resignation of David Platt, Ph.D., the Company’s former Chief Executive Officer and Chairman of the Board of Directors. The Separation Agreement provides for the deferral of a $1.0 million separation payment due to Dr. Platt upon the earlier occurrence of any of the following milestone events: (i) the approval by the Food and Drug Administration for a new drug application (“NDA”) for any drug candidate or drug delivery candidate based on the Company’s GM-CT-01 technology (whether or not such technology is patented), in which case Dr. Platt is also entitled to a fully vested 10-year cashless-exercise stock option to purchase at least 83,334 shares of common stock at an exercise price not less than the fair market value of the common stock determined as of the date of grant; (ii) consummation of a transaction with a pharmaceutical company expected to result in at least $10.0 million of equity investment or $50 million of royalty revenue to the Company, in which case Dr. Platt is also entitled to stock options on the same terms to purchase at least 50,000 shares of common stock; or (iii) the renewed listing of the Company’s securities on a national securities exchange and the achievement of a market capitalization of $100 million. Payment upon the events (i) and (iii) may be deferred up to six months, and if the Company has insufficient cash at the time of any of such events, it may issue Dr. Platt a secured promissory note for such amount. If the Company files a voluntary or involuntary petition for bankruptcy, whether or not a milestone event has occurred, such event shall trigger the obligation to pay the $1.0 million with the result that Dr. Platt may assert a claim for such obligation against the bankruptcy estate. During 2011, when it became probable that the Company could be relisted on a national securities exchange and eventually reach a market capitalization of $100 million, the Company recognized the $1.0 million severance payment due to Dr. Platt and it is included in accrued expenses at March 31, 2013 and December 31, 2012. On May 2, 2012, Dr. Platt instituted arbitration before the American Arbitration Association, seeking a $1.0 million separation payment based on a claim that a milestone event in the Separation Agreement has occurred (see clause (iii) above). On March 22, 2012, the Company’s common stock was listed on the NASDAQ Capital Markets, but since that date, the stock has not achieved the required market capitalization. Therefore, it is the Company’s position that a milestone event has not yet occurred. The arbitration hearing was held on October 16 - 17, 2012 and on November 1, 2012, the arbitrator denied Dr. Platt’s demand in all respects. Insofar as the Company does not dispute its obligations under the Separation Agreement to pay Dr. Platt upon the occurrence of a milestone event, it has recorded the payment as an accrued expense payable if and when the milestone event occurs. On October 12, 2012, Dr. Platt commenced a lawsuit under the Massachusetts Wage Act against Dr. Traber and Mr. McGauley who in their capacities as the Company’s Chief Executive Officer and Chief Financial Officer respectively can be held individually liable under the Wage Act for non-payment of wages. The lawsuit is based on the facts and issues raised in the arbitration regarding the payment of the $1.0 million separation payment under the Separation Agreement, and other unspecified “wages”. The statute provides that a successful claimant may be entitled to multiple damages, interest and attorneys fees. Although the Company is not a party to the lawsuit, it plans to indemnify Dr. Traber and Mr. McGauley consistent with its obligations under the by-laws and applicable law, believes the lawsuit is without merit, and intends a vigorous defense on their behalf. On April 29, 2013, the Court allowed Dr. Traber’s and Mr. McGauley’s motion to dismiss.   On March 29, 2013, the Company instituted arbitration before the American Arbitration Association, seeking to rescind or reform the Separation Agreement discussed above. The Company claims that Dr. Platt fraudulently induced the Company to enter into the Separation Agreement, breached his fiduciary duty to the Company, and was unduly enriched from his conduct. Along with removal of the $1.0 million milestone payment provided for under the Separation Agreement, the Company is seeking repayment of all separation benefits paid to Dr. Platt to date. Depending on the outcome of the arbitration, the previously accrued $1.0 million could be reversed. The timing and ultimate outcome of this arbitration, though, is uncertain and there is no guarantee that the Company will be successful in this demand. Series C Post Conversion Dividend Rights In January 2013 5 shares of the Company’s Series C Super Dividend Convertible Preferred Stock (“Series C”) were converted into 8,475 shares of common stock (consisting of 8,334 shares of common stock for principal and 141 shares for accrued interest at the time of the conversion) which also resulted in the issuance of 5 Series C post-conversion dividend rights (“Dividend Rights”). Under the terms of the Series C, the Dividend Rights entitle the holder only to dividend payments based on actual sales of GM-CT-01 and will not participate in the 6% dividend payable on outstanding shares of Series C following a conversion to common stock. At March 31, 2013, there are a total of 10 outstanding Dividend Rights which were determined to have a de minimis value, because payment of a dividend for the Dividend Rights is considered improbable at this time and the Company has not recorded a liability related to the Dividend Rights. The Company will continue to evaluate and assess the Dividend Rights for each reporting period. At March 31, 2013, the Dividend Rights had a liquidation value of $241,000. Other Legal Proceedings The Company records accruals for such contingencies to the extent that the Company concludes that their occurrence is probable and the related damages are estimable, except as noted above. There has been no change in the matters reported in our Annual Report on Form 10-K for the year ended December 31, 2012. </div>

16079000

213000

13704230

-3203000

5000

56000

<div> Following is the stock-based compensation expense related to common stock options, common stock, restricted common stock and common stock warrants:   <table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="95%" align="center">  <tr> <td width="94%"></td> <td valign="bottom" width="1%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="1%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="6" align="center">Three Months Ended March  31,</td> <td valign="bottom"> </td> </tr> <tr> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">      2013      </td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">      2012      </td> <td valign="bottom"> </td> </tr>  <tr bgcolor="#CCEEFF"> <td valign="top"> Research and development </td> <td valign="bottom">  </td> <td valign="bottom">   $</td> <td valign="bottom" align="right">319 </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">   $</td> <td valign="bottom" align="right">149 </td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr> <td valign="top"> General and administrative </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">533 </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">324 </td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> Total stock-based compensation expense </td> <td valign="bottom">  </td> <td valign="bottom">   $</td> <td valign="bottom" align="right">      852 </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">   $</td> <td valign="bottom" align="right">      473 </td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

-3472000

<div> The fair value of all other options granted is determined using the Black-Scholes option-pricing model. The following weighted average assumptions were used (there were no option grants to employees or consultants during the three months ended March 31, 2013):   <table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="87%" align="center">  <tr> <td width="92%"></td> <td valign="bottom" width="1%"></td> <td></td> <td valign="bottom" width="1%"></td> <td></td> <td valign="bottom" width="1%"></td> <td></td> </tr> <tr> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" nowrap="nowrap" align="center">Three     Months Ended      March 31,</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap" align="center"> Cumulative Period from Inception  (July 10, 2000) to    March 31, </td> </tr> <tr> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" align="center">2013</td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" align="center">2013</td> </tr>  <tr bgcolor="#CCEEFF"> <td valign="top"> Risk-free interest rate </td> <td valign="bottom">  </td> <td valign="bottom" align="center">0.80%</td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom" align="center">1.76%</td> </tr> <tr> <td valign="top"> Expected life of the options </td> <td valign="bottom">  </td> <td valign="bottom" align="center">5.0 years</td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom" align="center">5.2 years</td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> Expected volatility of the underlying stock </td> <td valign="bottom">  </td> <td valign="bottom" align="center">117%</td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom" align="center">119%</td> </tr> <tr> <td valign="top"> Expected dividend rate </td> <td valign="bottom">  </td> <td valign="bottom" align="center">0%</td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom" align="center">0%</td> </tr> </table> </div>

<div> <table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td valign="top" width="4%" align="left">3.</td> <td valign="top" align="left">Stock-Based Compensation</td> </tr> </table> Following is the stock-based compensation expense related to common stock options, common stock, restricted common stock and common stock warrants:   <table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="95%" align="center">  <tr> <td width="94%"></td> <td valign="bottom" width="1%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="1%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="6" align="center">Three Months Ended March  31,</td> <td valign="bottom"> </td> </tr> <tr> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">      2013      </td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">      2012      </td> <td valign="bottom"> </td> </tr>  <tr bgcolor="#CCEEFF"> <td valign="top"> Research and development </td> <td valign="bottom">  </td> <td valign="bottom">   $</td> <td valign="bottom" align="right">319 </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">   $</td> <td valign="bottom" align="right">149 </td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr> <td valign="top"> General and administrative </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">533 </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">324 </td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> Total stock-based compensation expense </td> <td valign="bottom">  </td> <td valign="bottom">   $</td> <td valign="bottom" align="right">      852 </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">   $</td> <td valign="bottom" align="right">      473 </td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table>   The following table summarizes the stock option activity in the Company’s equity incentive plans, including non-plan grants to Company executives, from December 31, 2012 through March 31, 2013: <table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="95%" align="center">  <tr> <td width="95%"></td> <td valign="bottom" width="1%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="1%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2">             Shares           </td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">  Weighted Average   Exercise Price</td> <td valign="bottom"> </td> </tr>  <tr bgcolor="#CCEEFF"> <td valign="top"> Outstanding, December 31, 2012 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3,539,961</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> $</td> <td valign="bottom" align="right">                    5.66    </td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr> <td valign="top"> Granted </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">200,426</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3.36    </td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> Exercised </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(39,762)</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2.77    </td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr> <td valign="top"> Options forfeited/cancelled </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(44,408)</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">9.50    </td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> Outstanding, March 31, 2013 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3,656,217</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> $</td> <td valign="bottom" align="right">5.52    </td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> </table> As of March 31, 2013, there was $5,427,000 of unrecognized compensation related to 1,466,586 unvested options, which is expected to be recognized over a weighted–average period of approximately 3.9 years. The weighted-average grant date fair value for options granted during the three months ended March 31, 2013 was $2.73. There were no grants during the three months ended March 31, 2012. The fair value of all other options granted is determined using the Black-Scholes option-pricing model. The following weighted average assumptions were used (there were no option grants to employees or consultants during the three months ended March 31, 2013):  <table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="87%" align="center">  <tr> <td width="92%"></td> <td valign="bottom" width="1%"></td> <td></td> <td valign="bottom" width="1%"></td> <td></td> <td valign="bottom" width="1%"></td> <td></td> </tr> <tr> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" nowrap="nowrap" align="center">Three     Months Ended      March 31,</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap" align="center"> Cumulative Period from Inception  (July 10, 2000) to    March 31, </td> </tr> <tr> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" align="center">2013</td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" align="center">2013</td> </tr>  <tr bgcolor="#CCEEFF"> <td valign="top"> Risk-free interest rate </td> <td valign="bottom">  </td> <td valign="bottom" align="center">0.80%</td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom" align="center">1.76%</td> </tr> <tr> <td valign="top"> Expected life of the options </td> <td valign="bottom">  </td> <td valign="bottom" align="center">5.0 years</td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom" align="center">5.2 years</td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> Expected volatility of the underlying stock </td> <td valign="bottom">  </td> <td valign="bottom" align="center">117%</td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom" align="center">119%</td> </tr> <tr> <td valign="top"> Expected dividend rate </td> <td valign="bottom">  </td> <td valign="bottom" align="center">0%</td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom" align="center">0%</td> </tr> </table> </div>

2.73

77000 43000 293000 2018-01-31 <div> <table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td valign="top" width="4%" align="left">7.</td> <td valign="top" align="left">Common Stock and Warrant Offering and Reverse Split</td> </tr> </table> On March 22, 2012, the Company entered into an underwriting agreement, relating to the offer and sale of 1,159,445 units (the “Units”) of the Company, each unit consisted of two shares of Common Stock and one warrant to purchase one share of Common Stock. Pursuant to the underwriting agreement, the Company granted the underwriters a 45-day option to purchase up to an additional 173,916 Units to cover over-allotments, which they exercised on March 26, 2012. The public offering price for each Unit was $9.00. Each warrant has an initial exercise price of $5.63 per share, is exercisable upon separation of the Units and expires on March 28, 2017. On March 28, 2012, the Company sold and issued 1,333,361 Units (2,666,722 shares of common stock and related $5.63 warrants to purchase 1,333,361 shares of common stock) for gross proceeds of $12.0 million (net cash proceeds of $10,403,000 after the underwriting discount and offering costs). The warrants were valued at $4,445,000 as of the issuance date of March 28, 2012, using the closing price of $4.20, a life of 5 years, a volatility of 119% and a risk free interest rate of 1.05%. Based upon the Company’s analysis of the criteria contained in ASC Topic 815-40, “Derivatives and Hedging—Contracts in Entity’s Own Equity” the Company has determined that warrants issued in connection with this financing transaction were not derivative liabilities and therefore, were recorded as additional paid-in capital. On March 28, 2012, in connection with this underwritten financing as per the underwriting agreement, the Company issued a total of 46,378 common stock purchase warrants to the underwriters. These warrants expire May 2, 2016, have an exercise price of $5.63 per share, and are exercisable beginning 1 year from March 22, 2012 (the date of the underwriting agreement). These warrants were valued at $143,000 as of the date of issuance (March 28, 2012), using the closing price of $4.20, life of 4.1 years, volatility of 117% and risk free interest rate of 0.78. Based upon the Company’s analysis of the criteria contained in ASC Topic 815-40, “Derivatives and Hedging—Contracts in Entity’s Own Equity”, the Company has determined that these warrants issued in connection with this financing transaction were not derivative liabilities and therefore, were recorded as additional paid-in capital. Effective as of March 23, 2012, and in connection with the pricing of the offering of Units, the Company effected a one-for-six reverse split of its Common Stock. Per the terms of the reverse split, all fractional shares were rounded up. </div> <div> The following table summarizes the common stock warrant activity from December 31, 2012 through March 31, 2013:   <table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="95%" align="center">  <tr> <td width="95%"></td> <td valign="bottom" width="1%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="1%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2">             Shares           </td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">  Weighted Average   Exercise Price</td> <td valign="bottom"> </td> </tr>  <tr bgcolor="#CCEEFF"> <td valign="top"> Outstanding, December 31, 2012 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">7,424,241 </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> $</td> <td valign="bottom" align="right">3.71    </td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr> <td valign="top"> Granted </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5,000 </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2.65    </td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> Exercised </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">-</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">-    </td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr> <td valign="top"> Forfeited/cancelled </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">-</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">-    </td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> Outstanding, March 31, 2013 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">7,429,241 </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> $</td> <td valign="bottom" align="right">                3.71    </td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> </table> </div> 2.65 38000 <div> The computation of diluted net loss per share does not assume the issuance of common shares that have an anti-dilutive effect on net loss per share.   <table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="76%"> <tr> <td width="76%"></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom" colspan="6" align="center">Three Months Ended March 31,</td> <td valign="bottom"> </td> </tr> <tr> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center">2013</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center">2012</td> <td valign="bottom"> </td> </tr> <tr> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="6" align="center">(in thousands, except share and per share amounts)</td> <td valign="bottom"> </td> </tr>  <tr bgcolor="#CCEEFF"> <td valign="top"> Basic and diluted net loss per common share: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr> <td valign="top"> Net loss applicable to common stockholders </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">$(3,472)</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">$(2,204)</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> Weighted average common shares outstanding – basic and diluted </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">16,079</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">13,010</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr> <td valign="top"> Net loss per common share – basic and diluted </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">$  (0.22)</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">$  (0.17)</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> </table> </div> 728000

319000

533000

13000

-3203000

43000

10000

29000

52000

122000

-5

-49000

8475

39762

15625

17114

14580

34020

852000

49000

77000

-57000

-62000

-52000

-122000

-4000

-13000

-39000

0.0042

0.00

7000

P3Y

0.87

-47000

-33000

2618772

7429241

3656217

-1953000

10403000

473000

-0.17

2000

-1486000

3000

8917000

1052000

11000

901000

10403000

1953000

13010000

197000

13048819

-1950000

3000

57000

-2204000

277000 4445000 8000

149000

324000

2627110

7424241

2997468

0001133416 us-gaap:StockOptionsMember 2012-01-01 2012-03-31 0001133416 us-gaap:WarrantMember 2012-01-01 2012-03-31 0001133416 us-gaap:ContingentlyIssuableSharesMember 2012-01-01 2012-03-31 0001133416 us-gaap:GeneralAndAdministrativeExpenseMember 2012-01-01 2012-03-31 0001133416 us-gaap:ResearchAndDevelopmentExpenseMember 2012-01-01 2012-03-31 0001133416 2012-01-01 2012-03-31 0001133416 us-gaap:StockOptionsMember 2013-01-01 2013-03-31 0001133416 us-gaap:WarrantMember 2013-01-01 2013-03-31 0001133416 us-gaap:ContingentlyIssuableSharesMember 2013-01-01 2013-03-31 0001133416 us-gaap:SeriesCPreferredStockMember 2013-01-01 2013-03-31 0001133416 us-gaap:SeriesAPreferredStockMember 2013-01-01 2013-03-31 0001133416 us-gaap:WarrantMember 2013-01-01 2013-03-31 0001133416 galt:SeriesBTwoPreferredStockMember 2013-01-01 2013-03-31 0001133416 galt:SeriesBOnePreferredStockMember 2013-01-01 2013-03-31 0001133416 galt:SeriesBTwoPreferredStockMemberus-gaap:AdditionalPaidInCapitalMember 2013-01-01 2013-03-31 0001133416 galt:SeriesBOnePreferredStockMemberus-gaap:AdditionalPaidInCapitalMember 2013-01-01 2013-03-31 0001133416 us-gaap:SeriesCPreferredStockMemberus-gaap:AdditionalPaidInCapitalMember 2013-01-01 2013-03-31 0001133416 us-gaap:SeriesAPreferredStockMemberus-gaap:AdditionalPaidInCapitalMember 2013-01-01 2013-03-31 0001133416 us-gaap:AdditionalPaidInCapitalMember 2013-01-01 2013-03-31 0001133416 galt:SeriesBTwoPreferredStockMemberus-gaap:CommonStockMember 2013-01-01 2013-03-31 0001133416 galt:SeriesBOnePreferredStockMemberus-gaap:CommonStockMember 2013-01-01 2013-03-31 0001133416 us-gaap:SeriesCPreferredStockMemberus-gaap:CommonStockMember 2013-01-01 2013-03-31 0001133416 us-gaap:SeriesAPreferredStockMemberus-gaap:CommonStockMember 2013-01-01 2013-03-31 0001133416 us-gaap:CommonStockMember 2013-01-01 2013-03-31 0001133416 us-gaap:SeriesCPreferredStockMember 2013-01-01 2013-03-31 0001133416 galt:SeriesBTwoPreferredStockMemberus-gaap:AccumulatedDeficitDuringDevelopmentStageMember 2013-01-01 2013-03-31 0001133416 galt:SeriesBOnePreferredStockMemberus-gaap:AccumulatedDeficitDuringDevelopmentStageMember 2013-01-01 2013-03-31 0001133416 us-gaap:SeriesCPreferredStockMemberus-gaap:AccumulatedDeficitDuringDevelopmentStageMember 2013-01-01 2013-03-31 0001133416 us-gaap:SeriesAPreferredStockMemberus-gaap:AccumulatedDeficitDuringDevelopmentStageMember 2013-01-01 2013-03-31 0001133416 us-gaap:AccumulatedDeficitDuringDevelopmentStageMember 2013-01-01 2013-03-31 0001133416 us-gaap:GeneralAndAdministrativeExpenseMember 2013-01-01 2013-03-31 0001133416 us-gaap:ResearchAndDevelopmentExpenseMember 2013-01-01 2013-03-31 0001133416 2013-01-01 2013-03-31 0001133416 galt:SeriesBTwoPreferredStockMember 2000-07-11 2013-03-31 0001133416 galt:SeriesBOnePreferredStockMember 2000-07-11 2013-03-31 0001133416 us-gaap:SeriesCPreferredStockMember 2000-07-11 2013-03-31 0001133416 us-gaap:SeriesAPreferredStockMember 2000-07-11 2013-03-31 0001133416 2000-07-11 2013-03-31 0001133416 galt:ClassATwoWarrantsMemberus-gaap:SubsequentEventMember 2013-04-01 2013-05-06 0001133416 galt:DrugDiscoveryProgramMember 2013-01-02 2013-02-01 0001133416 2013-01-02 2013-02-01 0001133416 galt:AccruedInterestMemberus-gaap:CommonStockMember 2013-01-01 2013-01-31 0001133416 galt:PrincipalSharesMemberus-gaap:CommonStockMember 2013-01-01 2013-01-31 0001133416 us-gaap:CommonStockMember 2013-01-01 2013-01-31 0001133416 us-gaap:SeriesCPreferredStockMember 2013-01-01 2013-01-31 0001133416 2013-01-01 2013-01-31 0001133416 2012-10-01 2012-10-31 0001133416 us-gaap:MinimumMember 2009-02-01 2009-02-28 0001133416 2009-02-01 2009-02-28 0001133416 galt:WarrantTwoMember 2012-03-02 2012-03-28 0001133416 galt:WarrantOneMember 2012-03-02 2012-03-28 0001133416 2012-03-02 2012-03-28 0001133416 2012-03-02 2012-03-23 0001133416 2012-03-02 2012-03-22 0001133416 galt:SeriesBTwoPreferredStockMember 2012-12-31 0001133416 galt:SeriesBOnePreferredStockMember 2012-12-31 0001133416 us-gaap:SeriesCPreferredStockMember 2012-12-31 0001133416 us-gaap:FairValueInputsLevel2Memberus-gaap:MoneyMarketFundsMember 2012-12-31 0001133416 galt:SeriesBTwoPreferredStockMember 2012-12-31 0001133416 galt:SeriesBOnePreferredStockMember 2012-12-31 0001133416 us-gaap:AdditionalPaidInCapitalMember 2012-12-31 0001133416 us-gaap:CommonStockMember 2012-12-31 0001133416 us-gaap:SeriesCPreferredStockMember 2012-12-31 0001133416 us-gaap:AccumulatedDeficitDuringDevelopmentStageMember 2012-12-31 0001133416 us-gaap:SeriesAPreferredStockMember 2012-12-31 0001133416 2012-12-31 0001133416 2011-12-31 0001133416 galt:SeriesBTwoPreferredStockMember 2013-03-31 0001133416 galt:SeriesBOnePreferredStockMember 2013-03-31 0001133416 us-gaap:SeriesCPreferredStockMember 2013-03-31 0001133416 us-gaap:FairValueInputsLevel2Memberus-gaap:MoneyMarketFundsMember 2013-03-31 0001133416 galt:SeriesBTwoPreferredStockMember 2013-03-31 0001133416 galt:SeriesBOnePreferredStockMember 2013-03-31 0001133416 us-gaap:AdditionalPaidInCapitalMember 2013-03-31 0001133416 us-gaap:CommonStockMember 2013-03-31 0001133416 us-gaap:SeriesCPreferredStockMember 2013-03-31 0001133416 us-gaap:AccumulatedDeficitDuringDevelopmentStageMember 2013-03-31 0001133416 us-gaap:SeriesAPreferredStockMember 2013-03-31 0001133416 2013-03-31 0001133416 2012-03-31 0001133416 galt:WarrantTwoMember 2012-03-28 0001133416 galt:WarrantOneMember 2012-03-28 0001133416 2012-03-22 0001133416 2013-05-09 0001133416 galt:ClassATwoWarrantsMemberus-gaap:SubsequentEventMember 2013-05-06 0001133416 galt:ClassBWarrantsMemberus-gaap:SubsequentEventMember 2013-05-06 0001133416 galt:DrugDiscoveryProgramMember 2013-02-01 0001133416 2013-02-01 0001133416 us-gaap:WarrantMember 2013-01-31 0001133416 us-gaap:MinimumMember 2009-02-28 0001133416 2009-02-28 iso4217:USD shares iso4217:USD galt:Right iso4217:USD shares galt:Right pure

EX-101.SCH 8 galt-20130331.xsd XBRL TAXONOMY EXTENSION SCHEMA 101 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink 103 - Statement - Condensed Consolidated Balance Sheets link:calculationLink link:presentationLink link:definitionLink 104 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:calculationLink link:presentationLink link:definitionLink 105 - Statement - Condensed Consolidated Statements Of Operations link:calculationLink link:presentationLink link:definitionLink 106 - Statement - Consolidated Statement Of Changes In Redeemable Convertible Preferred Stock And Stockholders' (Deficit) Equity link:calculationLink link:presentationLink link:definitionLink 107 - Statement - Condensed Consolidated Statements Of Cash Flows link:calculationLink link:presentationLink link:definitionLink 108 - Disclosure - Basis of Presentation link:calculationLink link:presentationLink link:definitionLink 109 - Disclosure - Accrued Expenses link:calculationLink link:presentationLink link:definitionLink 110 - Disclosure - Stock-Based Compensation link:calculationLink link:presentationLink link:definitionLink 111 - Disclosure - Common Stock Warrants link:calculationLink link:presentationLink link:definitionLink 112 - Disclosure - Fair Value of Financial Instruments link:calculationLink link:presentationLink link:definitionLink 113 - Disclosure - Loss Per Share link:calculationLink link:presentationLink link:definitionLink 114 - Disclosure - Common Stock and Warrant Offering and Reverse Split link:calculationLink link:presentationLink link:definitionLink 115 - Disclosure - Commitments, Contingencies and Legal Proceedings link:calculationLink link:presentationLink link:definitionLink 116 - Disclosure - Subsequent Events link:calculationLink link:presentationLink link:definitionLink 117 - Disclosure - Accrued Expenses (Tables) link:calculationLink link:presentationLink link:definitionLink 118 - Disclosure - Stock-Based Compensation (Tables) link:calculationLink link:presentationLink link:definitionLink 119 - Disclosure - Common Stock Warrants (Tables) link:calculationLink link:presentationLink link:definitionLink 120 - Disclosure - Loss Per Share (Tables) link:calculationLink link:presentationLink link:definitionLink 121 - Disclosure - Basis of Presentation - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 122 - Disclosure - Accrued Expenses (Detail) link:calculationLink link:presentationLink link:definitionLink 123 - Disclosure - Stock-Based Compensation Expense Related to Common Stock Options, Common Stock, Restricted Common Stock and Common Stock Warrants (Detail) link:calculationLink link:presentationLink link:definitionLink 124 - Disclosure - Summary of Stock Option Activity (Detail) link:calculationLink link:presentationLink link:definitionLink 125 - Disclosure - Stock-Based Compensation - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 126 - Disclosure - Weighted Average Assumptions Used to Determine Fair Value of Options Granted (Detail) link:calculationLink link:presentationLink link:definitionLink 127 - Disclosure - Common Stock Warrant Activity (Detail) link:calculationLink link:presentationLink link:definitionLink 128 - Disclosure - Common Stock Warrants - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 129 - Disclosure - Fair Value of Financial Instruments - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 130 - Disclosure - Computation of Diluted Net Loss Per Share (Detail) link:calculationLink link:presentationLink link:definitionLink 131 - Disclosure - Dilutive Shares Which Could Exist Pursuant to Exercise of Outstanding Stock Instruments and Which were not Included in Calculation (Detail) link:calculationLink link:presentationLink link:definitionLink 132 - Disclosure - Common Stock and Warrant Offering and Reverse Split - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 133 - Disclosure - Commitments, Contingencies and Legal Proceedings - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 134 - Disclosure - Subsequent Events - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink EX-101.CAL 9 galt-20130331_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 10 galt-20130331_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 11 galt-20130331_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Accounting Policies [Abstract] Accounting Policies [Abstract] Accounts Payable And Accrued Liabilities Disclosure [Text Block] Accrued Expenses Accounts Payable Current Accounts payable Accretion on redeemable convertible preferred stock. Accretion Of Redeemable Convertible Preferred Stock Accretion of Series B redeemable convertible preferred stock Accrued Interest [Member] Accrued Interest [Member] Accrued Interest Accrued Liabilities Current Accrued expenses Total Accrued Professional Fees Current Legal and accounting fees Accrued Separation Agreement Accrued Separation Agreement Severance agreement (Note 8) Accumulated Deficit During Development Stage [Member] Deficit Accumulated During the Development Stage Additional Paid In Capital Additional paid-in capital Additional Paid In Capital [Member] Additional Paid-In Capital Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value Stock-based compensation expense Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract] Adjustments to reconcile net loss to net cash used in operating activities: Amendment Flag Amendment Flag Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount Dilutive shares not included in calculation Antidilutive Securities Excluded From Computation Of Earnings Per Share By Antidilutive Securities [Axis] Antidilutive Securities [Axis] Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Name [Domain] Antidilutive Securities, Name [Domain] Assets Total assets Assets [Abstract] ASSETS Assets Current Total current assets Assets Current [Abstract] Current assets: Assets Fair Value Disclosure Fair value of cash and cash equivalents invested in money market funds Award Type [Axis] Award Type [Axis] Basis Of Accounting Basis of Presentation Basis of Presentation [Line Items] Basis Of Presentation [Line Items] Basis of Presentation [Line Items] Basis of Presentation [Table] Basis Of Presentation [Table] Basis of Presentation [Table] Cash And Cash Equivalents At Carrying Value CASH AND CASH EQUIVALENTS, END OF PERIOD CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD Cash and cash equivalents Unrestricted cash and cash equivalents Cash And Cash Equivalents Period Increase Decrease NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS Cash Flow Noncash Investing And Financing Activities Disclosure [Abstract] NONCASH FINANCING ACTIVITIES: Cashless Exercise of Stock Options and Warrants Cashless Exercise Of Stock Options And Warrants Cashless exercise of common stock options and warrants Change in fair value of warrant Change In Fair Value Of Warrant Change in fair value of warrant liabilities Change in fair value of warrant liabilities Class A Two Warrants [Member] Class A Two Warrants [Member] Class A-2 Warrants Class B Warrants [Member] Class B Warrants [Member] Class B Warrants Class Of Stock [Domain] Class of Stock [Domain] Class Of Warrant Or Right Exercise Price Of Warrants Or Rights Exercise price of warrant Class Of Warrant or Right Expiration Date, Extension Period Class Of Warrant Or Right Expiration Date Extension Period Warrants exercisable life extended period Class Of Warrant Or Right Issuable With Each New Share Of Common Stock Class Of Warrant Or Right Issuable With Each New Share Of Common Stock Warrant to purchase common stock Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights Warrants to purchase shares of common stock Class Of Warrant Or Right Outstanding Outstanding Class B warrants having cashless exercise rights Collaboration Agreement, Research And Development That Will Be Funded Collaboration Agreement Research And Development That Will Be Funded Collaborative funding agreement Commitments And Contingencies Commitments and contingencies (Note 8) Commitments And Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Commitments And Contingencies Disclosure [Text Block] Commitments, Contingencies and Legal Proceedings Commitments and Contingencies [Line Items] Commitments And Contingencies [Line Items] Commitments and Contingencies [Line Items] Commitments and Contingencies [Table] Commitments And Contingencies [Table] Commitments and Contingencies [Table] Common Stock [Member] Common Stock Common Stock Par Or Stated Value Per Share Common stock, par value Common Stock Shares Authorized Common stock, shares authorized Common Stock Shares Issued Common share issued Common stock, issued Common Stock Shares Outstanding Common stock, outstanding Common Stock Value Common stock, $0.001 par value; 50,000,000 shares authorized at March 31, 2013 and December 31, 2012, 16,190,429 and 16,060,853 issued and outstanding at March 31, 2013 and December 31, 2012, respectively Components Of Common Stock [Axis] Components Of Common Stock [Axis] Components Of Common Stock [Axis] Components Of Common Stock By Type [Domain] Components Of Common Stock By Type [Domain] Components Of Common Stock By Type [Domain] Contingently Issuable Shares [Member] Contingently Issuable Shares Conversion Of Accrued Liabilities To Common Stock Conversion Of Accrued Liabilities To Common Stock Conversion of accrued expenses into common stock Conversion Of Stock Shares Converted 1 Series C prefer stock converted to common stock Conversion Of Stock Shares Issued 1 Conversion of share, common stock issued Current Fiscal Year End Date Current Fiscal Year End Date Debt Conversion Converted Instrument Amount 1 Conversion of extension costs related to convertible notes into common stock Debt Conversion Original Debt Amount 1 Conversion and redemption of convertible notes and accrued interest into common stock Depreciation And Amortization Depreciation and amortization Development Stage Enterprise Deficit Accumulated During Development Stage Deficit accumulated during the development stage Disclosure Of Compensation Related Costs Sharebased Payments [Abstract] Disclosure of Compensation Related Costs, Share-based Payments [Abstract] Disclosure Of Compensation Related Costs Share Based Payments [Text Block] Stock-Based Compensation Dividend Equivalent Rights Dividend Equivalent Rights Dividend rights issued Dividends Payable Current Accrued dividends payable Dividends Preferred Stock Convertible preferred stock dividend Document Documentand Entity Information [Abstract] Document Documentand Entity Information [Abstract] Document Documentand Entity Information [Abstract] Document Fiscal Period Focus Document Fiscal Period Focus Document Fiscal Year Focus Document Fiscal Year Focus Document Information [Line Items] Document Information [Line Items] Document Period End Date Document Period End Date Document Type Document Type Drug Discovery Program [Member] Drug Discovery Program [Member] Drug Discovery Program with the University of Georgia Earnings Per Share [Abstract] Earnings Per Share [Abstract] Earnings Per Share Basic And Diluted Net loss per common share - basic and diluted Earnings Per Share Basic And Diluted [Abstract] Basic and diluted net loss per common share: Earnings Per Share [Text Block] Loss Per Share Employee Related Liabilities Current Accrued compensation Severance payment due to Dr. Platt Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items] Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items] Employee Service Share Based Compensation Allocation Of Recognized Period Costs Report Line [Domain] Employee Service Share-based Compensation, Allocation of Recognized Period Costs, Report Line [Domain] Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Unrecognized compensation cost Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition 1 Unrecognized compensation cost, recognition period Entities [Table] Entities [Table] Entity Central Index Key Entity Central Index Key Entity Common Stock Shares Outstanding Entity Common Stock, Shares Outstanding Entity [Domain] Entity [Domain] Entity Filer Category Entity Filer Category Entity Registrant Name Entity Registrant Name Equity [Abstract] Equity [Abstract] Equity Component [Domain] Equity Component [Domain] Equity Method Investments Equity investment Expiration Period of Agreements Expiration Period Of Agreements Option to purchase additional units to cover over-allotments Fair Value Assumptions Expected Term Warrant, expected life Fair Value Assumptions Risk Free Interest Rate Warrant, risk free interest rate Fair Value Assumptions Weighted Average Volatility Rate Warrant, volatility rate Fair Value By Fair Value Hierarchy Level [Axis] Fair Value, Hierarchy [Axis] Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Fair Value Disclosures [Text Block] Fair Value of Financial Instruments Fair Value Inputs Level 2 [Member] Fair Value, Inputs, Level 2 Fair Value Measurements Fair Value Hierarchy [Domain] Fair Value, Measurements, Fair Value Hierarchy [Domain] Fair Value of Financial Instruments [Line Items] Fair Value Of Financial Instruments [Line Items] Fair Value of Financial Instruments [Line Items] Fair Value of Financial Instruments [Table] Fair Value Of Financial Instruments [Table] Fair Value of Financial Instruments [Table] General And Administrative Expense General and administrative General And Administrative Expense [Member] General and administrative Gross Proceeds from Issuance of Common Stock and Warrants Gross Proceeds From Issuance Of Common Stock And Warrants Gross proceeds from issuance of stock and warrants Impairment Of Intangible Assets Excluding Goodwill Write off of intangible assets Income Statement [Abstract] Income Statement [Abstract] Increase Decrease In Accounts Payable And Accrued Liabilities Accounts payable and accrued expenses Increase Decrease In Operating Capital [Abstract] Changes in operating assets and liabilities: Increase Decrease In Other Noncurrent Liabilities Other long-term liabilities Increase Decrease In Prepaid Deferred Expense And Other Assets Prepaid expenses and other assets Intangible Assets Net Excluding Goodwill Intangible assets, net Interest Expense Interest expense Interest Paid SUPPLEMENTAL DISCLOSURE - Cash paid for interest Investment Income Interest Interest income Investment Type [Axis] Investment Type [Axis] Investment Type Categorization [Member] Investment Type Categorization [Domain] Issuance Of Common Stock And Warrants, Shares Issuance Of Common Stock And Warrants Shares Issuance of common stock and warrants Issuance of equity warrants in connection with equity offerings Issuance Of Equity Warrants In Connection With Equity Offerings Issuance of equity warrants in connection with equity offerings Issuance Of Warrants Price Per Share Issuance Of Warrants Price Per Share Closing price of warrant issued Issuance of warrants to induce conversion of notes payable Issuance Of Warrants To Induce Conversion Of Notes Payable Issuance of warrants to induce conversion of notes payable Issuance Of Warrants, Value Issuance Of Warrants Value Value of warrants Lawsuit Damage Claim Lawsuit Damage Claim Lawsuit payment Legal Entity [Axis] Legal Entity [Axis] Liabilities Total liabilities Liabilities And Stockholders Equity Total liabilities, redeemable convertible preferred stock and stockholders' (deficit) equity Liabilities And Stockholders Equity [Abstract] LIABILITIES, REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' (DEFICIT) EQUITY Liabilities Current Total current liabilities Liabilities Current [Abstract] Current liabilities: Maximum Development Budget Maximum Development Budget Estimated budget for work order Minimum Company Market Capitalization Minimum Company Market Capitalization Market capitalization Minimum [Member] Minimum Money Market Funds [Member] Money market funds Net Cash Provided By Used In Financing Activities Net cash provided by financing activities Net Cash Provided By Used In Financing Activities [Abstract] CASH FLOWS FROM FINANCING ACTIVITIES: Net Cash Provided By Used In Investing Activities Net cash provided by (used in) investing activities Net Cash Provided By Used In Investing Activities [Abstract] CASH FLOWS FROM INVESTING ACTIVITIES: Net Cash Provided By Used In Operating Activities Net cash used in operating activities Net cash used in operating activities Net Cash Provided By Used In Operating Activities [Abstract] CASH FLOWS FROM OPERATING ACTIVITIES: Net Income Loss Net loss Net loss Net Income Loss Available To Common Stockholders Basic Net loss applicable to common stockholders Net loss applicable to common stockholders Net losses applicable to common stockholders New Contract [Axis] New Contract [Axis] New Contract [Domain] New Contract [Domain] Nonoperating Income Expense Total other income (expense) Nonoperating Income Expense [Abstract] Other income (expense): Notice Period For Termination Of Agreement Notice Period For Termination Of Agreement Agreement termination notice period Notice Period To Cure Breach Of Agreement Notice Period To Cure Breach Of Agreement Breach of contract termination notice period Number Of Right Declared As Dividend Distribution For Each Outstanding Share Of Common Stock Number Of Right Declared As Dividend Distribution For Each Outstanding Share Of Common Stock Outstanding Dividend Rights Operating Expenses Total operating expenses Operating Expenses [Abstract] Operating expenses: Operating Income Loss Total operating loss Organizational and Separation Related Charges Organizational And Separation Related Charges Separation based payments Organization Consolidation And Presentation Of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Other Accrued Liabilities Current Other Other Assets Noncurrent Other long term assets Other Liabilities Noncurrent Other long-term liabilities Other Nonoperating Income Other income Paid In Kind Interest Non-cash interest expense Payables And Accruals [Abstract] Payables and Accruals [Abstract] Payments To Acquire Productive Assets Increase in patents costs and other assets Payments To Acquire Property Plant And Equipment Purchases of property and equipment Preferred Stock Accretion Of Redemption Discount Preferred stock accretion Preferred Stock Dividend Rate Percentage Rate of dividend Preferred Stock Dividends Income Statement Impact Preferred stock dividends Preferred Stock Dividends Shares Convertible preferred stock dividend (in shares) Preferred Stock Liquidation Preference Value Liquidation value of dividend rights Preferred Stock Shares Authorized Series A 12% convertible preferred stock, shares authorized Preferred Stock Shares Issued Series A 12% convertible preferred stock, issued Preferred Stock Shares Outstanding Series A 12% convertible preferred stock, outstanding Preferred Stock Value Series A 12% convertible preferred stock; 5,000,000 shares authorized, 1,562,500 issued and outstanding at March 31, 2013 and December 31, 2012 Prepaid Expense And Other Assets Current Prepaid expenses and other current assets Principal shares [Member] Principal Shares [Member] Principal shares Proceeds From Convertible Debt Net proceeds from issuance of convertible debt instruments Proceeds From Issuance Of Common Stock Net proceeds from issuance of common stock and warrants Proceeds From Issuance Of Convertible Preferred Stock Net proceeds from issuance of convertible preferred stock and related warrants Proceeds From Issuance Of Redeemable Convertible Preferred Stock Net proceeds from issuance of redeemable convertible preferred stock and related warrants Proceeds From Issuance Or Sale Of Equity Net proceeds from issuance of stock and warrants Proceeds From Payments For Other Financing Activities Proceeds from shareholder advances The cash inflow associated with the amount received from holders exercising their stock options and warrants. Proceeds From Stock Option And Warrant Exercises Proceeds from exercise of common stock warrants and options Property Plant And Equipment Net Property and equipment, net Public offering, net price per share Public Offering Net Price Per Share Public Offering price Range [Axis] Range [Axis] Range [Member] Range [Domain] Recognized Expenses Related To Agreement For Services Performed Recognized Expenses Related To Agreement For Services Performed Recognized expenses related to agreement for services performed Repayments Of Convertible Debt Repayment of convertible debt instruments Research And Development Expense Research and development Research And Development Expense [Member] Research and development Royalty Revenue Royalty revenue Schedule of Accrued Liabilities [Line Items] Schedule Of Accrued Liabilities [Line Items] Schedule of Accrued Liabilities [Line Items] Schedule of Accrued Liabilities [Table] Schedule Of Accrued Liabilities [Table] Schedule of Accrued Liabilities [Table] Schedule Of Accrued Liabilities Table [Text Block] Accrued Expenses Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] EX-101.PRE 12 galt-20130331_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 13 g515969ex10_1pg11.jpg GRAPHIC begin 644 g515969ex10_1pg11.jpg M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$! M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$" M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,# M`P,#`P,#`P,#_\``$0@`8`!A`P$1``(1`0,1`?_$`',```$%``,!`0`````` M``````D`!08'"`,$"@(!`0$`````````````````````$``!!0$!``$$`@`$ M`PD!```$`@,%!@O:F:Q%CG,YRT"5V_ M6H=;H+E,I+9'8L"8XQ6G1P;-<$`GQL`,0Y_9_ M(2(:`D*1&[].=)=ZC[_@12YX'DM%@'!;UZ8U&H"SII`4$?H6V1@\>B0)ANB" M18$=;&6X.:;9'B6BG`WVB/WW1''"N/\`'B_S!/2,[WV'`7+95Z!CK;]W)4^$ MA->JX=AK9Z982),0(5:J83!6/@29Z->Z&0G]K^/`E'VDM$<8%2@/GGH"TYN] M+#>B6(N)Y(7&H2ZED=?.C)VO2@,U#2++;KC"W0).-?)"+:0^RM M'5-K5SBT]Y_GSOP'GX"^`O@+X$8NESK&>52?N]TF!H"K5B,(EYN6*2^XV($, MG[E]0.*T08:4\OJ6V!V&W2"7EH::0MQ:4]`7\&?O_P#8-,G'?R=@\_>1`I`Q M5?[`+3&ZSJ+D418ZVVJ=D"GY(6.#9LT6\0?"$1(S`HP\:2+(3+XE!,S.+M5@K1;?J=G.C8*/@I6/B[2^&>K5E6I0$@SVX1\=+Q14>7'M/* M_E%ID`UAYXB*-L_LOWA:]#D(70+UC>@Y_BU6I,K!**B-='`%_>;!`[^@*WUL+(Q3TD[2?$OF MG5-FFK/J.CZ-FN>?J1U1K7[VDZW?+)6VYI4;6*5P*L*(L+P+;Y9C2F`AP6!G MWGU-,-+,I:X=CE[95^1F8D&:4P4,)3M` M>BR%-M2,,2"P24,(HYLIH?B%!=&9:U7=/%.;`C[+6K1`-0Z+E2+A7Y*`LE0E M9B%CYM$3(\*8_BI;H[,AQKIL64?&//M.H9)=ZTY]H6E\!?`^''&V6UNNK0TT MTA3CCCBDH;;;0GJEK6M7>)0A">=[WO>_3G/@">@@^_V+;I)W&3DI?_9G@4X' M$T"!AY&0'@/1VF1Y0\O+7:SJ>$BVI7.8AK]86-!92>%(L\63TSK1K@;09YU7 MTW<=[IWH'2K+MVB>,ZQAU-L`-6R6NP]\KVTVJR/B_P`1+G6Y)3=<588(6XM! MQ8A=898VU9-` MU7%G90@FQ5MX^CKI$S*-AV0]TQ80C@@*0)DYLT5;#:V>`2CGG[*9;SQ/>>`H M"1K^57G-IS/9")%=*BK&'5K=67ZX2UR0,0[*!S\;"%I88?(_(2*IAOG>]ZWS MX$#U+GD:/RH#S_Z`M&:6:DP-7K77ZGJDO7I"0FQ;^/ZE3?27I8Q5ZVRJ5J`Q#)XD.8&G&ZUUMD(5F=BWFPW[4V[=>9^B^YZ_-DW^L^:K3>GF?.=\PT M6+=!J-4HQ8-86+8J&^[+EHD;@P&Y:XBY<4N093&M"0ZPU_J>3W:;:AO06.Q$ M50/3D16H-R1K4[(BM5?48@`,\E[#]CGZV+(.RD/%N6"11"3`G2/X";=1(,ME MB_L`EA=V1Z=7-DSBJ:35G>*B[-'*>=#4M2BX.;`)?BK+5Y5"VF'1IRJ6,$J- M/9<;;<8,%<;4E*D]YP+'^`._^P>^6)VOY5YNHCTDSC142+J$H$`>-*XI"17'F0:[IZDJ7C.7J?F6%Q;2 M;DQ4,KK-BBI:LIJ[(U@CC3K%"&,U6L-RRK'.2X]DBQD$@1<F@]&ILH`@6K5.]95J4I!L"2U3$UXVL2=PC*Y M9J[;Z<171+6W&3!M<(CRFELD1[XCW0-SL/HNH><,IK6@;DZW$S4^77*@#4ZD MOLX;:M4G8@N09H-&>E/X$:2+->BC>BD'KCAN##*?)<&;2M2`"Z;?O['/4^2V M3T;A!S'7T,=*'2.&HZEYO\R9IFDYH#VM&9RJA:LS6H^`MDSGYYPN:& M/TMF`-F%F4.P`'S4,>6@Z>EIDD8^0Z6:3QQQ#Z@B6/U'.=WVW`)36M0NWE&SO=?/CQL_)>D\G7/)1%_QLC-8W)&-U$QD)<7]JV!4 MALE-%/I)0_\`5O\`$$?C+S&[G*6WQS['JL15=7;(BK+4W*?,VFMUG58:'>1; M8#1<+MZ#XVUBSM*-B.?R3#;[$C%G".I4AP)3;Y(,R[GH'GUJKYIJ*X;U[Z9[ M+:2;Y:D45F(I]^E&<9(2R\L,@-V8JT MJ\*SR1C'7$M/_B:?;4R8,(4.%?>+`[3F'G-JJZSFPF,GY,79J_*+X_'/1%BK MM-=?CQM(1*QQ!;9P$_%17[;1!#G37`.,.EMC$+=$'#+/D^CF^W]"A_[$=.D; M/'5W\,G&^2,Q[*/DUFFYK.T0BJ6>YR-?GZO$C2/#V.4+5[.V?#8%O_I"G:1"PXK)"=CTC(?3.DQ2+;/6A M/G MZY<*FJRQ4O&==8DXIELX-]E8DK'J>")2MAY:?@9SR]V4]88O#@6D^9RSU7YC MNK=.G;H5!0DG9,YW>N4P.,L=H`A'UJ@YRH:?2+BZ^V.]Q("6>GH>9*R64M55%<*NF52L+K-0;'CCY8YZ1HIJ M9.8BHZ,C%I.D#;33NR<.EEOBE.IXE7U^G0]=_BA@R=D]!;)H:Y7L1V,FK$).VE\P.3L3AG!9YV7YUYQ#H\ MB!#E1SG%"=CQ4L\1T">_`&;_`&RVF?#\F$935@T%37I?2\Z\[K>4Y')5%UK0 M)OB[O)<3*_;'-_DI\2:"@E];3`#QK92U_1G[5`1>M0`-4KE?J\7TA496X2*@ M(Y1;W[!:@8OZ<^Y7U[].?7X`F?&47H_BZ$]+9%J4 M4J$A+[_9YJ"?*+LDY6&("M[QP77'IA!`;ZE M-_K\3]@%'SK-:1DU:[3\]@FZY6^SUJLW\6R9(G-)F[M9I:XV8!0Q_[`=UA*D1(TZOTC*(C7UB4R_&!V%[6O M8NR7&X;3)2C8#_9:O5^RO^?H0MN+4ZT&26?(E\94M]+B`(J9(4+%:+)3EJM@ M=6IE<:>E;#<=`MB^"C=+)3^Q)3MGL\@I+:RS2$I3Q;J6^+6EMI*>?8CX$PAI MF(L41%V"ORD=.04W'ART-,Q!@\C%2T7(#ME`2,:>(X\*:":*ZEQIUM:D.(5Q M2>]YWG?@#EDFRL5_M!K3\("RU3_:>!3S=W;%A'/L1K'FLF,37[=(S@\D,`"7 M,Y[=6852"0R#))(`B&WTM`?BX!+/@1RX0L99*C::[-1P\O#3U=^!X5/^?OL_\`Z*'?_P`*[%_YOX'J MP_JV+4#YC>SM^NRU=*R75-3H?69*.D66BHT2Y2DG7G6)GKLA5K":)7I(460> MA)"0!;/8=;6ZDGC[:`(]\`9_]C4,M^5\2V8I\P6O5;V-G[DZ9'+#;(B6Y6NV MP4.=.4X7`R3M;BWFN_R;(DN'UX9SJ7A99CKD64%Z;SZ,MF!V7%G[32HI>*(T)\F)DTE/%-L_4)3;RNF+X*$ M5]HD$#6WPBMM8[0J_8J1&]/B""+$9*Q#,?">= M*<^]'1D`\G\%:)&E9I,_;;<5SB_N^HJ?)=4MD$/E,/J>FT M.O:F/`7&"?N=2A#IRP'/U*^2%!=LW+#R#DC:PZ=$<>,'>04+].J0\.\V@&K& MH.1\MZUBGC^JVB6O60G8!=YJJ@V=FLL6;)H[#R<5I$*&W)UV`A'[3"7E=Y,? M(?E/S'LR+'_=.K84IM@&OT,(*5[[_KR=;'EE3$="^NSFRHR+X<*S!+SZBQLL M)/']AI!N"B##CP74OJ("4^:*..A:E.];6!"O@+X&;/\`;R]_U'G?_CM0_P#2 M/@4%YE>%I7LGW)DCSC/"9*6S';JXTZ^([,DU[1(B8T'C1K MQG>GK_"0-WBAPQWG@(A\#&_OO")OT5Y4T_/J>M]G0PQH>]9F2*^".\W?\_FP M+97@U.R<'9H_@,\[%KC#..1Y?W!&O<0W^3J%)#-N1.2"\`@5YC\Z_J@)[ M[_A>T_RZ!=+5HER--RGU!YXU^%F8ZJ5V=L)QB?3E(5"9T'"M_P`*#T`QBS?Z M?#,2M)H3"V25+?>95^4&ZW^KO/N9Z+I&\7S,MOSC3*ABF;P]D9N5=5$3^D]%\UUO+FK5=ZQ':%8M;FZ%8Q1F+C8&>@ MS%YMDH9:+H9!M3,Q/1M6[9)=PB2'J,#)3Q:X^+:6V"%^=?XFD]4KO0R3CZ)7 M:_:^Z;B\##ISS`Z]_M4S*14/-B6D^\)DP;EOA+S,B*R$BLL2J8*/8?!><'E2 M(_O7V^.1HSO0(%\!?`7P!U^V8Z?R*Z8I[1IBBN-X]..4;=H6/DA`"KM@VAOL M1S\>.%+S5?KDW.UZ_?Q3\*4]SHZ$+`@T7(BS$9'2P+B70I0$21 M#=0XR\AP4T=LD=Q+HSKX[J5M.\[Q3:UH5SOU2KO/IWX'>^`-^R-M^%]6;NO(*6]3>.;Q"^?).&N,C;BM M3-2B2AW!%OAO$MO\:2ZRIQ+J0JW<_`\1)85I@&9M2%EW&P4?.ZM7INY6Z9.C MXD*B6RKV=^"J#$_*%#U6&E'X1Y21$$,I^QQ`:2AA$H_"$GWWQJ)-YGG5"QRN M!"L*]/\`G_3M4[-76T&2A-(I5DB&;H77+1:S['98V7BZN)WL:T"8`2UU"^BO MCD+_`"*">>>?-9OG#9=NY2H>KJQ'6NPVAA2YDF:1I]?TE/.0D_23WBHTLFVT M!46(U(QDA(2JY"->?=C4-*!9$ZR#AO>OV.>GBO,6`$D$;A;81I5JO`+*2:[Y MNH4V0W'GZ5;C_P`B1TWKL2Z4]3Z]S[RIB58:>-9!1<%S*H9)F MT0W"T^EQ:8Z-'YQ'22WW'73)2:E7T-M_NS<]*DO&G$=3Q3Y3[B^\Y]WT^!9W MP(E(N6$JUP0`"2P*^"*9,SLHVN.ZS*/J2Y'1=7X.7'&E*;6X\X<0^P$ZQT1 MAOBG$$.)2$M^`U3T%#6B$EZW8HP*:@)^,.AIJ(D6$%`2D5)C.!GQYH[G%-OB MEBO*;6GO/HI*N\^`.+R=*73RA:H[Q'MMA+M,<03;IOR[KLL?8Y(W1J`F19DD M9O+].BI%`M]S,8Y]!J7YI_\`-&I'(&:9%5Q@4"9?`;)J%A['$2=?L$5'3D%- M@%Q4Q#2X8\C%RL8>PL8V/D0"VW13`BQW%-N-.)4A:%=YWG>=^!C(KR]?,HL, MU;_+.H'U%BWS<&;>LHT+_P![Y_+#C+3&GS-2E9AD^X4:TQEFY0Q+K]EL0<+;XRF MV2!J44"/U327OW#G#WFA/Q]:_(<@)(]Z)W*5YT"F^,=9>G4?K./+T*ZY=0*@ MTT@J%'EF.64*RW.3*DF695U$#$4Z*8T`1Q9([OX6W@9R*?[,V3^8!N]YJ/E MZEOF]1$!X@;S4VJ;5YH=A<62SR*B3D,F<(0H@EA"./AH MS'LAH^&9]6\VS^+1'0-*\3P+.^!UB"6F>M,](&:*+ZZT"T0XE'22&V'".MM-__Y<[WX#+48^PQ5;B`+98&[396!>?S<^Q%CP@LC(.N+>?6%$BK=;CP&5 M.?B';ZXZXEE"?R...?FSA.L2`%@JEJA'DB66 MD7"%(;.K]KKIJDK2S)1$@RVZE#B5LN?9SBT]_P`.\"IZCMEVQZSUO'/4#@3I MMB!EGASGPNM,#J:0& MR6G6WVFWV5I<9>;0ZTXCOU0XVXGBT+3WG^'4J3WG>=_[/@<$&ZMV&K'#6/UN'$<0PLI26 MD=4OZ\X'FPGXZ8@YR/%E8B5`) M1UL@*1CCFGQ#!7T=^BFW$*2KG^?/@9:(P+2),.2K]MIS3P+HXJ"1>EJ':$9XIDAIM+'`?AMWT"J-R3VV8-;Z M=&QL9%F.6C,"3MVKCQSP(;TQ'CQM1KQ!$/.D,QS97>1RHM:74/?\` M`YQQ'$=4I:.*!](F%(8<=$B9@]Q!Q$?^LT(D-U3P[;ROV.*E70&51[KC7$(( M2I32NK3WG>I^JN!`GXC3K;^1F9FH_.X9$H]S]&GK3/6:8B`;0*;'?MV>8`&C MZ\BQ5<)0_2DT.,,%*">1E D\20"`=.R#A4S(#"D&O.(2^^Y]KCRU?\`$M7>@]_`7P%\#__9 ` end XML 14 R33.htm IDEA: XBRL DOCUMENT

Subsequent Events - Additional Information (Detail) (Subsequent Event)	1 Months Ended
	May 06, 2013
Class B Warrants
Subsequent Event [Line Items]
Outstanding Class B warrants having cashless exercise rights	4,000,000
Class A-2 Warrants
Subsequent Event [Line Items]
Warrants for purchase common stock shares	1,000,000
Warrants exercisable life extended period	5 years

ZIP 15 0001193125-13-213107-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-13-213107-xbrl.zip M4$L#!!0````(`$M?JD+$2%]Y%VX```&=!``1`!P`9V%L="TR,#$S,#,S,2YX M;6Q55`D``QX9C5$>&8U1=7@+``$$)0X```0Y`0``Y%WK;Z/(EO^^TOX/WGQ8 M[4I;"?4$HNFYXGG5TDPGF^X[_1+1=2=`0R`+N3NY?OZ<`.WY@&S!@]]UH MI-:8*KM^YWU.51U^^LOK)K,POCQP\4\0T$V#<.+ M298'\2R(DEA^N'B3V<5??O[7?_GIWQ":W-U-W"2.913)M\G?IS*2:9#+R<=8 MS9A*>#B=/\LX_Z_)UR"3LTD23_YNW_TR(9=X,GG*\Y?KJZOOW[]?RMECD*(D MCL)87DZ3YZL)0HO?^*UB76O&-3;_9W5T\O*6AH]/^>0_IO\)@V&DFC&YN[R[7$'V[Y// M29S!Z.>7('Z;6%$TN5.SLLF=S&3Z38 M<`;2(`47D,@I?ES(<@^UK,JQ[`?$R0AA'% MBRDS^?Y#Q8HR.;U\3+Y=P8.:X8]!E*\M##Z0TSR,\R>0N1.N M'M8L)HR_R2ROGU4^JYD4SY_KN3[+TRL%^PI&R#2<+B>`N!^>D\1H8]X\3W>* MEWD%3R]`,2:30C6BZZP0H#OY,"GD]%I]ZX>++'Q^B90T%9\%Z31-(ME,(XH9 M3ZE\^'"A9`0MV'_YFLTZ*$QS7;PJ8542?NT!@N1-RCL9@>69_1(&7\,HS$.9 M.?,T!1LXF29Q+E_S.[54F43WMYZA,XT@A##%&OIO3=/(_>QV$YI]+4^[]]=B\F,SD-GX,(I!KQBTDX@\>S>RP$P_`EV/.Y*4P?68;N M(:91`YG4:\RG899\#62G^;/7V7:,[4R]>/9*J$^?O*/ MH!2_^)FODZEW"JP3V(F"++MY^#U07YC?I$6440Z\>?@LI_.TU,,`PI*9_5:- MRZJ!+84/["1\6I#38)R]6Y0MJ M.-AW'6]I:O@:+8\$VX!R%;7E+;@KN7PX%+E6=/7^1:;WQ8^L4H\<03U\\3.Y M%/P`]0X`7C7Q1MO120!-2L/:@Q:J1',:IZ3B@AI;! M`+M@R+1]%UFV<*G+A>T8SCVN)(=@SE=L]8[%K^!SDB@*OB9IJ9^/J2RT4X7K M$%T\6?%L9?*7IR#_/8PB6_J03T":THD&(!<$8_&J:Y0+O0M%#`=0^YJ#A($Y M8MC7D.TQ$U'+(XZK"ZIY[KO;YNR=(,>@;:!'-_.\2`$A+6Q-&ZZ)@C9""`H6 M&U,3_@\,MRE>.<6$T-;VVX(8W/-\()-P+,1T["#+LP@R+$LS,+9!;_B23&S3 MT1T"N")#U9@OR>T!M1@5:F`Z^%.OMP ME?`A![OVXAPB@I5'A6/+CI,%<\U6-..W[V'+M2RL3"-!S-`M9/LF0<3V/(M(HX@8ZX9L?64K*[^=?XW"Z'L7\&U&'B/A M8,_,RZ7-W@_EE%F$HHNQ$A9CW2#[Q7M;##Q/-ZD/.9B-;0TB'TU')D3`""($ MU^66RSW=*%VZ2EXI_`D\9B(Q*O%P2^*9S-)]@P@D+!W"1M,3R#0=C!S/H@3D MC1/,WN,A077CQ\W!#M&K@\]I3C[2L\_IR[#6$*0S1ER865'LF9##9G9)B2!3 M:8;Z1U62O@61JAY9N0-3W\!@_19$\P[0:*/<$M$MP"Y$A3:A&+D^IHAYAH\, ML+S(M`BSF,%LR"Z!9C"2JO`8[`Q;SQ*:X%DGP6TJ7X)P!E22<29A\HW:FK"R M3.;=2L!E';LC`3BQ3@,< MZ\!7GG]*XNFY0H6(4:P!K5WW1L%3A4)/2323:5962$?$1;B/'J*`4SX%M5\@[@0+IE/`6C MWR_4URR\CL/HPT6>SF57'JI]RAW[+I]E^@T,;GV!%OBK2MIR5M1BLR])'D2K MSYTDRS\E^1\2%CY-'N/P'QVJ0`TY71,$,\]G%EV7"-ON]"<*`68,WSIR3M12Z:Y7L--8+IU1[%NOO:O?Q!=RW'8"SX M:X%K->#`AN5.XAQ3TAJ6N::J:6%38\3HWF2IE62VE]$F@QN5:1P?/Y'"& M#-<5JG#B(=-V.<(N\0SX,LO%1KG+5FQ(<-+?49&&9-GI`R&=.VGZVM1LTAHQ M.P1C^.+3,_]\A3$E7U9 ME@2Z',7K+"O"(@2;/D:63PABFNTA6Y@?%)X34-*14^)HQ=WJ(66(^>>%1=L2P(+X2M(<_5 M#,0,UX+@@UA(`P_B^KJO,\J6P0<57`"I!XD_:H^JOMOML?UK4W]3G`C:51?; M[T5O@_0FA?0+#$(QL..9@2Y!:'>\(`7:)8A#+=Y=B.IRD;-5?Z9B1QC7%VS M.4.,JB`-V=E&#:1^^?O$])<0B#$K''#Y0,93.:CLUIPN]RS?(_D[L:RX*?;Z,__%LZ^'H^:O.Z+F$V75 MC4\0X")_$MP0%9%Z!MQ`CCXE$(OV;@@:EW2;ZI)11-/X@"R]@]D4HD'*%.=< M*S=\S;9T2R!'MSS$7),@V_94NDH()*\V^!FQ+.W02QVO2N`IJ;7"N<71U^*L MIBNG$?SNS,K<\%LXD_',#>&WPJ]S]>U^DJK3\RN_S757:Q M,(P]HURA7U5J^BQ?@HW+:.=7*B.;]Z)V+WZ84X$07W)#)Z_,5%9ZR#."&EA_ M7)T1W,Q+#NVN].3V=X)MYN%:`-4JH%LIYH'TN6^VPF]31H=D*R;WF"^.?FZ? M/3C(V=X!8\S(H'+,[\T*+\$:/Z4<;X'M5X[YO;$$RD\HPIBR'7?<>^*H>8_I M0F';'5WNGZ'K6/ME*.`D2YR;FZ"CL]6`)0QJF=16305WNX(RNF'"PB3#&B95 M+*JXJVLG=;!;8/N58Y5HET#-C3-/8PNQPCFH>]7HO;XPPB8_/5/;MTIH#E2\ MN]567"UW7_P@+)-@2!VF49+-N^Z4W7.L@5M5#1*4R81_.,5@KR"V:>"&MI,C MC6+78HPC6W=U]='.U"@;930,K+I7SXK#2+P(-M;9WP3<7G+TI@@[2-%G#;&@`MT(N0[A M:8#^F$VX\8"3)L#KMN1J!QY;(Q\/=]4?Y0#P7:=W-P;?R1E\H/3CB`IG6[W? MMGLMX#-U?%DW]E%@`]1>`BQ.*5K/ZA:`E9>5)'43X(LJE7:N!+6E2>==OX(H M6DV"V1KHZ&ZB89C;65_*6_!J]][0SMQ-=`N"6U`!;P?`Y^(I!L>N-<0^OK,8 M&CIDSZ8@NBL)J:XI$>8XAK!J=?. M0,=PJ]&Y'[)\_\&I.P-M0^TS6SVWSD`C,!97@<8Y=`8:FKE%9R!-:`:G>Y@[ M3F>@$5A;O*?&7-^=&Z4UT`A>L3P2PM8;4`[;&F@,5*HUT$9(=Y:M@4:@1=$: M2-OL\W"VK8'&D`Y>&PJ.W1IH:"M]DM9`([`/4GKX>'W7],=I#;270/VV!EHT MY.>70OQSM08:PVS2&C$[?6N@8Y`WJHD8BYJ(2<71;:E[>JO)P(;2:!3.CM0: M:`31AMR,KKN%?Y[60%UEI5%KH$63>IT1]L_4&FB$'*IH#;3IM$=J#31&2*GP M"?ICM0;JJBN-6@,M@@_*J6F*/G1EE-9`(\C*&;0&ZA*$=L=[XM9`8[!4Q8I8 MKTE)1F@--'1X=#ZM@89&>MK60&/(:9?60(N;V>=?]:-;+=QWK'VPWD=C)*8E MR-/U/AH#8]%.A=.-9FO[>A_UWOEGC`W-D3K_#&PWS[OSS]!.HY?./[VWJ^FG MS-A4`/X?M:OIA["-VM4LR@UGVJZFMW8K(Y0?3M=NI0(W5KL5O&RWHM7$>D-? M'#X$ML>+PWC9;J4X^#1VNY4-I$.W6\'+=BL*+=K>SQV\J\$6X&';K>!%NQ6% MEV#.3BG'0[9;P8MV*P50P]LO0JMU*A7-C8VET MM@[;;@4OVZUHN"YI&]TP#=QN!2_:K93<-5N:X9[E>,!V*WC1;D6KN6TZMA`/ MW&X%+]JM%$9X"^P)F#I0NQ6\:+=2NM5V7.VKW]]Z;[-PK"-!]_]`T:Q$,->GR?5]?G]5&EK(8H4LQ2@\K;-K4S#9%82 M]Y/\7CQJ<1>#X((Z&B6DRV%8TS9USS*0(0A#D#SYR*;<0()YOFLRFUN7:R)4/`MG8^4R_IV&NDNMJI^GFX7;^-0JG-P\/4GW'S3>96E&4%!>5 MRZ\Z,U*H,U(Z-;%8V0+M@&J%+M[K2UCN3)44O'E8[E!U!]\-'"2-MXR[%;1] M"SM4!?J4Y++<"W^)PMQ19YM3=7OR3GU?"U1D@8JNL?0%\O5##-4-1C%U*>*N M[B%F6139"CWU;MRR^6>;I1O6<,: MTS;;0QP",K!EVP&^F3HW1*XL&X6_M7/+;2W;7],DRVK)M?K^$BN>_1ZH_?M6 M:MU.`A#O2@AEU\C:QGEK5"L4.32TM6D?0Q94H52`(2"DHD`S%.M:L"PL6C"Y M;#:4W879GSY8SH_JZJW,W_(_]<%?76ZO_"UUI>;2M&7=[]H/5.ZX9Q+GO9G`'E!6P MB\^+8U/M[VFTAMKX[%ESU.7=85I!K@6TE[L_,'0=&'Y)=G.[A@BGL/6XE:TW MF:7[!A%(6#I7M\8%,DT'(\>S*(%D@!/,EO#5E1W=^"%-_3ZJ;`M%XB[EO#EQ=!&*TC;4?P?CMP-S8^#6'S[H;O[OD M#>:\WJ5'(\.9IE-@U)`>[=@"27'7NVO!;K*A&E M,H4@0=6D(XG1#2QXM%OQZP)J[8IJ3O4<\6[BJNRG:KX;+N%./@=A',:/JM]B M&DSS>1`ITXD[D@2L!#.Y_JJ*X-3L2*#JKL$MUO[8.!`T+@U6Y.:7X'LV#W,W M>(8)3A2$+1PB+0N?6&MXLV"[0D)TPCW-=!&QJ4#,\`4R/"94R=`TL<4-9KI5 MJ6BM0+*]ZA5(-^EC$(?_",IK;*J'S/("0M4FT`%Z/K8I@AR/%#/FV-B@R+1< MB(JY;B-+%QQI3*>^C9F!B:A#VAC,OINRBQN:*CH"-9R"!+5JHU;"I_`?WEL+ MKKF#T^3=Q44L`*&P6*V`'E[_"LL7`]Y[YA1O/F[-X6V(S9Q!0Y@JUZOXNFO% MFUT)%N7NFX>5^VWEQ\#[%M9L#>"19Z.:P:U>NK92R3H(IQ'ZLC[<`_0NQ].; MO8R[,O0&TP^CK^",#OV>"\(8?H6\W*0#$8)6&8Y11$#G3@A3",J&(01;I+8, MMZ-#^3KW)"^3`0B@OB0.6%T[E>JE[0\=K@,N*$$*]=Q"H[O")%Q#OF-:X)'! M11F6K2%'TS7L6,!.W9JU>':N M<"1$$'@2C,6KKE$N]&U\#A>VKSE(&!@23NQKR/:8B:CE$$4Q/3:7Z+ULRP?25 M=URT*E6Z/L6V[GK(LYDZS.^";O@61JH(+!RJ&;9%R];,:DM*[Z._9;<"Y\V+ M5)R)'S_&T^19_I)D+2*[W11J?G#)<(2GWG*--&Z;D-X9!-G_Q]Z5/JF-)/OO M1/`_U'J.\$2@-CI`8+_9"$YO[_B8L=G8M^_+A("BT8Z0&!VV>_[ZEYE50@=' M"QIH8?/)#4:ES*RL/*HR?]7`C&6@=OM&L]_6VN;O.NY[**;9RM4];Z"^0-U" M^N#SO,P6@K#4J;(55FB[0.E"FI?MK$L]"<`<4>/\$`R2.\$"KTD(T?)^V-YG M%`26;K:W"J$`5RT M7%/O1OKS"*H3",<0=5S\>^OF<-H[[G0=)[*4,E`)AT#/RN`P_G*&2"[3D=>9 M0$KN%J7R*!=!&UQGODG6<4A$Z75&8[T8HRM+6>L)RL&M1RE\6"3!.=G]6E M#R\5C@1,P<+S0[FE6DKNP"%!BJE;-I;5>L? MX;3D0?ZR_^O`)?-*I8O>4R*,(U*L]XVLYZR.%>[[.)[ MW[Z#*-;!;TMM$$VLK-4,?8=)W,!+(46X)VV#X;CS%(*`Z_G-O-(9OMPE97':^Z"K\"#Z,YT8;LVQ)$6IA;R*M-26@)( M$$`>[2Q,WP.,/)0DR1M<^_*8>N--KJ74!^PP$%!2NQ*F(NQMN)P,4BPON]M9 M2H5`&33;60.QA?Y9"R0Z M.XY<8M+S\0U"F_]BN].GB6`+3B>&,9J9.UI8(_T,IP>'=@^&G4$` MN=A@`9[2QV'>S_)W?#WBHK(SZED+;Q#*^HB]F%J[KXWT$C6UE.PB3IFJ&KD( M*"&Z2"5E(*(#NE.'\DF0UZ2<>3!N!1F&D;_/HCA7:RZRY*?P>""@F`VUO;;I ML>T`?CWL*W600]W2C9R3W\;"+FW&0S$N:GX^\"D71@]A&7$?K)R\8]N,6E=W M*/-.IK97'UQ$.(]'P/6FEF=_*Q<[EF[GDV4[`BPG59TAH3?`.=J3#-/RO_?1!;Z3+..8;!D/S%P>ZJ M"K*46D_@B9J6L+Z=_@S,<2RGYH.MU^5FQKX,;6P;%MA)<8?M+:X8%_([&._?=C@7 M_QLCAY73,NIX"Z;12JV(`[G;V58]\F[=:33A:7DC#E=<3U5*T>`E88WZSH;R MA_A*KQTKF#L\2`'+I;Q.G3RNF1V!X%Q*31F(2./;%RKL?(29,TOB"+@X]G<`.1S4N MMN)(8%2;NK;1\"`'D7$$+-]A$4"!+`/?(F5 MF^X=P],)R[U/BSA#8\)`WYN($-\.)I83M^Q-HCU"CZ-(&]CX317T;B5I&]7_ MX9;_%#2C#X-!-E&](FF=YM']\FC+L""A!/R@_)8E%.E8ITZ(>^!.^WL=QAV% M3$W(4ZGKBI[3A0Q9^>77XXA`XD#XS;_\PL^]`(%J&%!5==U`].BM9"54RSO, M$TTYLK@+$HY5O(JJK62]C:S2MJ?FI'#LYE2)(5VOMT[50?9P<^IFR.KDGJ&U-U1N@X_I0(L?_Z(2OIO:G M'^_"5]4*?B!T?!:$]P[_^5GW_8?^X(/2>__F3>?7CX.70)_C6,L`)F;L^<`. MX;M-N.,$2PL+15:?E]9T&G_^;$_#^<_/()OZX5GJ17[J[RG[9#GVG?OSL]!; MKIXP?GC&Y-<.GX7T,/Y\!E**21R^?S=2AIVWMV_^\Y*-[`4/V#O^F7WP%I;[ MC`7V7QQ+!^(GQ_B'<8-_OAC'7[[`\58?PNEVNDY`C-B08J0BU4J<8QC5XRXX=73/ZD M^WXT>O_V)8,?I:;JW(TYVP&FN9]QC"(N*I68+TM++S;(F#A'.T+R2V@ M#.:SW*"V1)W2/9M!0L#Z?,(78^[_:"V6K[[[TJF_TM5:M8(P33"$[T5W<_86 MR[XR/V"XKEZNBSWS8?F`E$G(ZS)]Q4@('V__;R!FXO%"7I&^/Y'-_34A/>;I M+$6[D2Q\1'+B?HJ$ORD*ZT*FX;(1$?`/;DV9HFPU+*DQ'UKC8R\,O45BL+8^ M<92OG^2U&8.QQ01+>K)KF'1.?5#G=K-89,CB@V=5+U;8[P0X&E.77UC@.?;T MV9J@03=!"]UX#3UR'3>3%9*EO=#ZRPT.5&]7_4>;B)/])6")SO&FG6;N".IW M\1J]07N.JSLQA&3RC023W,;RV&E]SLFP\1U(W0/']EVO-Q@,A\\VTHYQXP8[D'&[BLH7*TOP9C"$K^";1TY= MZA(X"'HVQD(8ZFBG7E!'6EK'#(P>\,/RHX]J_D@JS)JA&37-4!]!CNM]]JWE MS\_$OR=8T$]K\TXTZ]\_Y;3K-Z9ZN$,KMSX4B2`/-'KZHXW>:TP#P35=;=KI ME+M1@V#D`,71]!7$W=*A5(%FPC M[^%'Y=CR$7]]0[O)E^SB=7"Z4R\:._PL/O[0UWW-3CY[IILZ MM!6_+%(>MZDH(ZZ!>L3">-23-O[1\]P@T0GPYCXL5 MEEBL@$]]CQOA;,E]\>0-&\UYM9)4*EI)43#[#(RP*`#*@)5/U$B.1,14O11O M$-A1U8ICS^@-.KOGEA_4V*<5G!1^W3)_J#'?#OY@,Q`(BD=`DOE8:>W-JI7Z MC:']`$-.V5_<]]@T;ODG$E?B]?G$NW.Q1SQ^NQN(Y[\W22"^N"\2209B@X1< M-B5<6&(AG",-(*UP'L",39'^+664-[O#55EXG`.B+5(H?<3+?[;5GQ^Y9Y^: M8Q1=JV>;_QZ\^6?$%TO/A_4BY+&"KAEY"72-J$B?_C<2R,7GY%UK#-5>?=!6 MNH;14XQ6PU3:3;6KM.O-3E/3U?:@W_P=+]&#)]!MX97>V7[1`QC,2BCY'J%[ MIU-;7(0J8/!ZUM(.+66IQ'*F11,QV@DX1$+KJ:&ZYLN/\M<0HV/>JN&V34.RJQF9'T]3V4%4Z0TV# MM=P=*-UFNZ%TA\U6HU]O&V93D]>T9B&TSR2'TEX$5;2-YT`81_7)KX$:6#Y> ME(T0V#3LT9MV5+.OTRVAPWI+5XR^WE?:_?I0:73KPU9#;PW[7>W;;=IIEJEI MAR(,4(1JA52A*&7[=^N<+2X7<&XN#QE$6A`28Y`;Q\3((K,QI%HL(PP/Q_H-)AYD98G[HND@ M=$G6$;U;8=(6I&P@7"B9`_*V0;"JY4]*:=@W$-;SI80P[JA;3F)2,1/X']= MEF+PAOT:_S0W&.8]=A!2K)[]'QMA#Y#N:`E?(H64A0"!J_P%2+-=!?Y+@>^F M8L:JEO`:UPLE#S2F+7$=-N@&IH!L#A-!N2*0K-#@-GS!9S.PYPQ^ MO/Z:W5G)X?UU;6WM8FD?N M88$G(_QC1!L7;VGC@@B*$GKHSP%N9I"37W6LK&]L)$^>0GS[;)9_G;-_Y`ZF MS8>F%]XG=D;A;>@/NFIYZ6S<<]M-J`KG7A1`(!?4DN_XEPE?ALGG(,Y;$E,' M3R3_OTRWBHD?KSY:=`E>\-/3:L;7WK\G,C*,QZ>Y'&<].]L`5U"RLI`G^=FE M./=F5[9=>*R^Y6.G[YWK-,+6]K?!35WQ\*D52MR_RN]%2E%@-G%*S;.N^JKX3OA:E";M;K9 MOK2U<)WH_2=:K]75^J5-]&4$;_D,HEJY6K2G\^^;!/&\?J-=H[MO>/95\^)F M_]C%N(6.W9[XU.T"\#3[\:FH#&0_S^W)',Q_Y$RK%?X%#Y:7D8_'K*$L_+]GU3(*\`Z+6<2.>((>,PG5A30V:[M M,XO.:6$`)$:0%X'76/2O#4?=JP]TBOJ89K:$)-CI\<8V.?"H9W_).K48>ZWI%C:8Q4K MK4M/IA'?U-GDZF8[B!97;55;NJE.O7-0=*)C897!/%QFHKJI/?XK;4N^;F,< M!>KVO']=F(Z=<*/X"&`DLCC\:N"_H26LUYJ-9DU3S:]_\5T-_/[%H+5V&XQ\ MLW4U\"4L?WB\R?\HJQRRUKU:R78899M^<@T_5U?P]2SVIMJJF>8AR?F%+=.K M*SA$.S2SIJKUJRLXS!6<"^:JN#J>8MR<"SLA+F:R[]DX\9L?$,0^2=W5*5Z8 MV5/UFEDW:II^B-V[,(MU]8H'U2L:K5I+;5_=XJ6[Q<2AM(HZE!,!,AY>4[6. MK[85PZ8(K-`Y<;#Z+6W8U715Z0]573$&K:'2:G?;2KNC&1VC972[O9:`5,O# M7VVF?4_8I&`;=-!&3*:X;T!>@QA?T4)W'!Y5:+\ON?_[.H[5.J12SU2':J]A M**U^OZD8[<%`:7?[#47M:X,6#-;IJZW?&_4ZH2KI-WIS#U2EX\GFR),BKY:( M0#I?P\PTGOV]?=/8!^_JR`+*3L^M._$Y#-SGXM];MS.94!\PO`GM3L>=(G9? MQ*=O;&N,T)4V/RL,8T&;H:K/_JZTZQFC<1AS#PF(D-S>>>XD\GV8BI*+10.Q MJ`](93M'N['2J)<99!BC-3W)TBL(TZDV01!8>[_=;>;8R=DQW`B]#0+0E3[A M58F5)G97Z3_?QY!S\BJOIWP/9H':4..M`?FD/3 MT`UA>\"OZFVSJ>606??B*BN5%>9>`N8:'!U!SVQUC$&_-5!:C>%0,3H:_&5J M/8A>-=/LMCH#O3WX=A'T&F5"T$-]8`)>U9NQH>U:[H00TE)(F$7)+3&L7AI] M>6XA$AWW0\MVV2SF&*'.N`1>`K&:?2RAMT(V0V%]0F'=5"O#U8<`UGO( M_87M"F2[-_P3=YC*;'<9P8@1XD?_!?(=!]S_1/H]M4*K6@FBR1S+Z?^,/#3& M!&\=8*F^-:%J^X7E_P$DW;"MKZI6Q+NT_+OP!6SIV5@;)L#OPKGEKKVI6LF^ MBL"\JY0$NK>V'((!B^86"%UBQ&^";O"]+^`J0@&CAYT8,3T2K'P:<=D+ M8B-L'O"GH(B9:V$`><-NDQ8/T&H@A-Y$?V0)HA/%+?C@HGED^]WD673XN35E MWZMMC:#*\6W?-UHZ?JA5*^!.$,`5=`HTQ78_\4#*D2`/XQF<1>XT;G_!T>*^ ME!B.D-9BK%.$BXCJ0$H!\H8)<>`7]LS&91E(-=-H.E$59/L+.G;1+Q_%T"V1=0?:?;S7IH#&J"]S,9^*(B',DK=\UA'P+.CJ*;??#*>D]7 M.OV^JO3:C4Y=;PQ:O7[KV_7*:IF\,ND`@8S^"HH""YA2S*_`#[^VT+*BJ<*U M:BTY^(1)@$;LACU'&R.7&JAQ[Y6T-\E7_5<_H4\`?R&M.H8G2A!*C`@R3N3! M;(&*0V84#;_#+<3!F=M+,I-WD@H63&R.MIP:K/WHCJ7&)0!:R+="1*?]3,;' M6F)$,$/3,+/'O@>T@UL,,">35A<&\\D.!>A8P$NBSPC(HQ+,.Q/8L-7*&F_M M5^!]+?^.TY('4[TB$EQ$R&TWMIZ%*":E++[##%`QP[+`?]/UB M(!@[^Y0;61!87H\WT)C`(LV8A M%_QGXER,N>&K**Q6QB($PY]L7B2^P(H6U]?(>X&8M;H``ZE`:/\)%T#6J`]H M:F5"!@&CB(>)2H_A3T-[AJ%C&")RN;AO2,;]J7'1.,G0ZH9]C"##^#/"I2)Y M7K4TX_LA$A,(VE+!D!GB4-RVLY6O%3HYS(0'HTE&A;SCY3.C!$G,J%`<\3`V M9,>+V7;`@&,6-1$"@!F-'Q>6`>WRF*]N)J)!<3*%'9;#KQ03_C-6VUD$E@8O M+Q)$K2P=VVSHTN8CQ6S.@$#>@6WA8V32(ML'8_Q7NA8(N/%2*%R('=>-8*!U M0_C+BCXD+;ZMZ-#XN@0>)+.9("REV".P!*Y+@&:"9)+8"URJ\'O*>"`]"2!L MA!QF0C>)^:BFD.UDERYVWT_L)2T'6J0X-@('V(Y#:8$-S\2BQ1NPT#UP"M9G MD;`$G:TISEI2)ZZ?4EN4UX$&1"Y>;N7;I(!;4\O<90.8VLF7ISQ(EJTQ=VS@ M5_)$VB/0"6!DU*D2$N$Y&!R1Z+R[_DP&FG*$PE^1^Q#2](`)EYD3\141_".LRMB)+@ M*5_B56"X+/"AU,C>F$Q?RI;)18F1H(^;-'.4%QK3F2URL80.2NUA$&$W0*]P MA\-'TXV.$7$>(.`%&^-FYP`544:[6#7,\>`)(@BP^4%-^AR1>P8A!4E((87% M?`9JMG9#`>@):"D%H`Z(Q26S%L@-%.EXQ'33KE?"'Y"(AE&8%H?N1),W/$A* M;ZH5S(5]),>YKV7B:%1]#E*7Y"2^`Z8*0S)YO<26<#N>-B^^^XO8KVUW;5/0 M;R16/D@['-(YXV)->7?B=(%G>LA9$L+9,Q'KQ;-@(ZG)=1=R0$:WU/:P$Z"#^.RN9GN/F#IKA&QQHH5A>1(LQG"[/`=UNNEZ$+H=L*7?F!#Z M@8V,DYG]PD\1SN%$[0P_MYN--,D8=\2AM=AZ==&B._`J>C\N,,PL`@\D@[\@ M<_C<_BEY(1IU)(&@H3,I:KR1F%FQ#J01$Q`R6&ZZ.@3&AXCZN9T>\HZ[M-[) MT$X7\`0M8,)XP=T[L?>-_PO/I1_J0L0T]MUR9[8RN=M7MG4'!':M,',QV$:*`=<(BXO,2.TQX*KWHVW9:?B M8)Y>(-U8+/\:A9@>C`QF*#4-8EY0&_'(#8V82*-SDDR,ITH^`)8-7M8 M:,Y)-B'I?)(7]"N*@T,("KP/B_M4OJ'#*8A6N';+C8?KIR5@B061>'23ZI$( M9'$&+T:1M)RN(PF)1/.1];\KSN;48R%RGN6RT&8&!;Q3;PU:)$.*CCD=4CO% MKB\DQ+`(#W)"BKX2VQ2,K>0W(0N:X#:`24-]/.%)O&;N2J-G'#XV^Y5M-^OT MH2:DS,9!BJA=I4H1V):JU7+2"K]J1_Q``WB*(246%"$2(7DZ^!42+TZPKV3E M.N5;QL@,P]][$X\"(+P9+3ZILM.;]87R9O68X)>#ZCBEVZ(6X\Q@_ M[%3CA#Q`A8@<%B*@@4!BJF.)8*14C46RP6ICP0;][CV4VZM9M+UJM_SHJE+V M?X$9-)W?H=1/_AO0`1&J2M*-,4U"^NQ^&[K_+?'ND"AV>%M2D*/=2A]F-W$H M_>;^X[HK?9JQ$"!>M0#S,G]YU=NKK`@>&]J,\.[2DKH"T9'9;W)4U%(?'$D, M1DK]V$M`/"ZJI+NZ'O3[]G$8>Q'^"&I4QEFLB3&Z-PMV1]UX2"N36!P= MN3E()O(<7*D'=@5T@V*.\6@\4\2A6?-4(I^%,G#.MVB-Q2#R=`EZSPZ*\F6, MY(OSXT1HC,;Z M-*>N:_/0KP145U@;U>V!2=PFW@RG`-L9,G\DY">XEPDOBF:_U)U#ET`0.F.I MGMP,88&L"CO!(.0X4LOK";CDJ%8K9ABZK.$40P6H`6M,5%@FS'9A#B:-PV]- M*2#%V*H<&T9,\SG%=IZRO5(4Q`2V480B$Y\'P*J^*;E(U6%85`/<)6'?/^D6 M`UF\>V`X%HSSDQE0!F-D%&JG/]-B)\/BXAD)(7ALTSO<1Q>S]7O;H0\V!_(J M@D&CB3M#*,+_G2IB&_'&-9#A$]-?@@]^U+/X<;O7FTW:O5[#!JJ[NNA>LY&M M^N[C%_-?"[C>O2RL3L#/?C8`*_`+BXQ/^@]_P'B?HJ(#N5NZ#:?'-RHPCJP9 M6IUYUE_2(E87`2)(2-9V_1-W$4^P:[RUV&EZU=QWC*87.,Y7@:4WWGW4NK:] M0RS]1N2I;PUR+&@Z_-]E&2J)N6#6NW&11=7+\QD)"J/MK M`:%+%F,Z09'4WGU4#;.^_F=6L19$G'3YH*BO<34=E(&%;V7XX(`$T4P0,.6R M)_<-8R`;CFG+/4OMRSW%T!Y"BZ#WYV>!*D*IEI8S^1:K+.X#77^1IE;OR5XGWARJ0E@ M!VB*8FB;I*QMONX%PA:W^I?D"^T\<4'37,,=:;I\.7`N9<,>&B!QUE#6>Y;6 M`Y74U^TWG+C0.R6(9,D+[1;CAE<`CWR$+"BA*@@@>Q:^DRS!M+1;<055O_QB M\X=?@'8ZB%,I[DU9I7_XY].=+8\3EXZZLL1L!^ESJ%W<,'*^`Q(J3X!8HB:$%#G8J8`S?0'W!7/L$WN67$'3\ M%C<+_.9P<70:N)QEW&YY2/WR!A.,NM"'9ZI-(9`O#`+?$VJCTB*"QF^WRA=T M)9C0?1#G*0:DXBA$)@NG-2I4YT-O)X@0SW&HO;RRB#KIBN?%O,5=#06]U&*N MHIM;<<]#D:@P7#D?NF!BB1!\$J1SPV"*0*F,@?QN$#53CQG=,]11BLD2",A@ M]P)B>JF@^5A$*?'EJO(_T@@!']YMXA//B&B5V%YI<7CC(3C.C6Y"B=':K6%2N7CX$GH9@H[F M23R#[S&>"O)+$`*$D)5(A>I8%*IGUQ$I&#<\E$PKI?#@1>K[TF<Q(WITD`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`EMXRQ1"G"^X,TPY0# M+".5B0J[U8R):HX$0]U6JH.QQ`\V(N\CD(DJ?V4_"-ZN`*&Z-_[8PTI;+"_! MFT[]<08#4+W4HN8L%?*4!=NP4K(IAP2G+P7/;@H,W(L7L=8D3Q+@:Y\GP+=! M"F_MF.W!UWL=0YX%Y'/=OQZ'>,I_4*CG)?BD14J6L-*7*-@+=J!M?*]P)'9J M&&L98ZT?]5A!R2HO'8TCWA0\^<\BOS8:C[8ZA]3J:H>Y`_Y]XP/),`]C'Y@YC2^[8S5]GQF-[A,KLX/)OSDME-`K^ M[8AP>=_XZH6O4?";PQ8[O1XH>L_'2M:T!S%+P>8;=4IV/;VSCG9R:FS5&P#7=H=D=5UT=Z-D=![2@X%`!F M?7;H6\S7OOR5H,SQ.,G]R3\"UE091'\_ MQ4O[E\.AX0P,>3BX!-)<*CVY9_8OY='`[3FVJ1N&HVP"ME3/`&W):5OTFJ6> MOHBQC'DOXZ=JA+\^(.,6Y6;/N%*IU@`9&R#C^0UYMGBSI[!E&_I*NX$D+D^* M;9ABMTRQM")F?6GE=BXOE'E(/&"CN0XU9,E[UFYY[X)26>(\]:))`R_=[TWT M/_Q;+V3=38K>L>W6U/?3)\W/)I:^TZ/UJ-GPCO("'7"6H?,C\N>[ MS2>-W^1!B'9K7`DM-=KSM5PU6>KYRDVSR6O.PM#.=Y//#?OH8Q>,:.Q7F[IA M0[=V:UG5PD9MGJ=$42_%\Q6J9I_?QCZ?M&5)7;P;E?AJ1*6Q)-_`)K\>97A" M&+%]CKL&WNQ-E/`]]OQ/BEIGYE11+^;&4G@C$?M=8YG5CFJ><0#DK-CJM3'. M.8='3]?>>?68^&=`L74P[2">S8*,:F"ZT600TRVU'XWAL6&0CL,XS?=0O72H MF,I`U4>R-G(,(H MH9>A/WVQ!H$G;_`/ITM[?%/L_KJ6P3XF4V&03KM58Q#"-C"4PYM-,`_W")F_B/([J3!]2=I&B?MUAH9JVB-GWH@>)P$54ZC:+ M85\E%P@QP9M7W..O?IIY&7S[NY?"SZ1O?G(?C.&U)VL^`]=(\1.Y;^&VYQ(L@`ET13'(O#!_8$*@0 M?*SN[('XMU)+P,-^QF/D$IFB;Q3,I@&ZEJ,?R_ MLB(W#*4?&2#+O+S\24Z"]A/5@ MSH9$?/,@S;TD"[!,IT+. M6*P9\5JA]%]>A#)3`V@2%)/KZ(W$'I,8#B7W[9:0]ZI)^:S@5QACB4C_B5]> MX9F6'K^'SQ!,,S2H29)?BO]]E7^?2@K&BP9II/?_!LFP*?S M.8YD-QS'=W$((O0M\[TLOO/G($89R.A%E:"?W6__62-ENT5#>)-[I.!$8L^- MI6EPD\2@CBHDXUJ*T81KJ3(IIZ111_)F,9S+&9.?M`(P7D:]6KHC@C\B=P^"?T"3"TH%WBS^.$K(74)]T+7P?1/9PAJ$OBA-D-,*>` M_B'T&*F&#OP2U1RMH/X0;$D$W![?X,*83NJ(4<3R88;`7*D0>*%O\'WE4H`8 M<7U.;*R_?'].^A.U'&YKXB,KIS@G(I%XRU*NX#_F[V(48$?0)`!]E]*;IZ0B M\RC'_AEI/I^'!:O59H./PGJEU?E8S+L!S]@FUR#7^XU0,_-98T%6X53-\7;MUDT]N M_:Q@XXH6`^E\KW54T\1[W`[O5P`?^PRQ)L+)28&Z0J!1FUF%J9,Y2 M)5-IYDU0-R5Q?GL7YUFA407G`&G^3=T'O)3^32H<-8.P&+H2:WG"GKP#[8MR MD]VE$K?QEJ]YX:!`!K^-8(LFTGM;T(:HV"93_J/$]]*8S"9A(CV` M/86%R*(@0IUYT5,^E!LP\1Y0L0?P](\DR#*PN)C&%4J:-#D;I]MN?8)3%[Q9 M5!R=NIVS9$HP!S\H'PV$O`4ZC?Z) M%ER[%0;_FP<3'!XT,AB(L/<2^(A^@OCW%.WD@@UP^!OX:AJ0B1QDP#ACL#_H M+.C`.1=B\;9$NL-&&?"/";"1AXTZX*?2!2K720R_P/8<\0VJ:1,59Z0@-6-@%TCA(QOD,YP_"^(MTH58HA+\<#5VBXB3Q?N"2\NP. MSM?_8UU/*)EACKH8EH[JBSL['E.QO^)J+K3ZB*7GQ$@!COX#N!ML4<+$0_+B MRL`RZY1^0XQ,F`4D;H5Q0>3LB%=*Z1WU7"EH5"515ZJ*1KM597PB;OG4TDVI M;`5%`E#CD[-Z`],`74X2#`R'PUWHB[Q6/:(6=@J60R[6@]#*,(<\\85&9\-W M4!S3'-[#7X?,B8R/K67(Z!1<"`0=YVC$<_9G>G[YM%ZB:IW]!F"&:%ACU#$& MV7O`F-)MXLVX28QK^B,*J&HC,]!_\^/D-O#.(A`#?"@,#]9Q=,$)2S'^%:1W MJ.]8$/,FQIH3X(B2NS$15"%+",DB>60)5/P!&"OT?TH#+[F)[QY`?H&M1<\O M:4!^7OEK+R-GK.IC+Z%M5[J^8SX&O3)`\VM,QBLQOD^JEV\7M\_'U=?/8G`` M\E!(^=C#QDD2#1#P`5`BO3D]#F.!=%-G)VS!=.LQ[P%?G_EP!DCS$&36`\G] M-PAH`F-WT$G`8B^DV5"E):2CP(D(O=D,'0=F_9/_A(X4O(.%/7!I3+52*6C< MC=)@@866D0!N>DE+LS6YH43J@1EXU7VM>JW2-&?-I^!M[U73(`/JL0F$':*6 M6'#7=8MJV;F^H-](.?7@%6A,,+5S@C+_#1SL)(&7K`/](7L*[!^/IRUQUV:Z^JN4+M%G$,^$AW M@3^5+G^"_!$77TVG@1"/P9T7)+`@<=[T8_#B*3XS#,#V05.,BJY>%Y/T1I[KW85:0:)SMVF%1\*EJ<.$]!%D!IA0',-A[# MP9;X&$WBSC.?$0S!'ZKAZ]&;KU.)@P]^FQ,?::0Z,8K0G\!(;SPX!T M9?G=C5=JT^6!A=]^EP?7LJ*"L(_OHCB,;X'?+D!%DJS#V&@2D)E0_H"4!PR/ MINL',@)YLSP/@Z=+*(_*)4QCY-H@"YD3YX'&0M,"XQ+PB:K(#[`M8*Y[Z1W& M8^6BNQYKIQ=3"9]:K7W0^2&H]$QR](ZN&ZMJ[^/O@!N+\<#U&;,6?!3WA;.# M6['`MJ#ZDK]\.+TP:E=83+71"N.2E"G_!=N)J72++5]^11ZI,@D6M\GQP.`B MYTG`#5'JD60R?QP'I)D%VM_KRH5@4"7 M&;PE\KPHY",,SO=F[4=)_."%9/`"5^?^0G"S0W''!RL M^HW_DX5+2'))K,>@Y'BHAS9-\,;8FP>9%PJWA4Y8'CW2+LP`-=[!?GX"SZP&CP@.#XS"(AM0#>:!YEX`O5Z,]= M;4^ZCT/X&B\&T<6-BG^B0<(=9=1K%4]96E`^WJ(.Q@6#D#/=/>DP[<2^`1X" MDRA+@MM;GYT>Y1T3,9_'-#0>(N!P<7FHGHPH7F1-+B$'T@J=\`0G-0Z]8%:A M0^5%(J9`SE:Q,(E=B0':[+#&96R.2D`WU7$2RK$B#6^*0[2[4L\%&0 MY;C;X/D$PHBX\8'Q>%@!S#$X,-#`K?S`!5D=!QX+VJ6^_Q?=LBQNVJ+Q!%PH M#`;!X,2&CT60AP&667#M%BHD(9[2!;P=Q\)VM@OJ#KS0>_]#5R**U#9:TVBC MM4Y-T]65>NU0_@&O+*4"G_GL?ANZ_PW^*K$X1:'_HO#938[(0K3YV-4TR&2' MQ_%Q)!$&X=I_PLZP!$]57,Y2R2%S-J$]Z7#6KH:FZO/&VQJFCY:35DS@`8\: M049F,%=9X`ZL)=Q47/F=']*ZK\"XKDF$:DFRI-J?@>QUR5$YN=FY MQ]^"AJ4?!2B3CSESX=+2GS''6$+]R^_\4@R0I?'42R2O3I`RRHJW5SF&U;*T M"@>0"`VPP&(5%T[H\B>L_$7COJ0S/_]HIY#8[&Z-JS6AOC!26R@E<0V!WY)R MQB,8%TS:&Q];W$1Z>7KB>JC=>LPP0O"6D18ESJ>+8T\*O1\IV)GE1J&$I6#2 MWH&@9[";?WIP_+@8O>6G86W`Z\2[8>XB/%?]XO?Q;UX>^@]`VIAK&;#*0=R\ M,3O:^#74)DP5=`J3"V@R84H'([.@8E4G5%:3]4=96M#BP;%MXZH\,@DPOM& M*54:6JPS!#R-4\1/]IAF]`QP,#&VG&Y`NX+DXB_R&5L+!15W)#+"]U M6P^#!5QA\\B40"-QNI.8ST./]6F#+?5G43!]V)0=>7W2`K^W6F'=/,@AN]Q@ MUQGHW2/GP(=P^(#M!AJ"\7"%,W!,O'W%PSSC-_M(BFA"1G1P&R=QGI)G@'HH M%H)QXX/%.Z4CU`6_-JP/11':(YF*X8U_,FRQ2]>>:^B1/UWLUB8UOR6 M[.UB"E"?+IHQO657W<_:='#0<:-.>M:F8T&!<1`1VHUL$'Y)MS2ZA@'U/$4U M0\87D^+"PT!)93*\-(PS3;P<4>!1AI>Y>#?'#TTQ0!:SP"0+2ZZ<18=?.2$" M"8/^H&)A7>`B3O)"?HM0!#]H/1*Q/,30)Y`&GZ7[2!R`WQ.B>L";48X[FE%( M3D!U:I9O>5H+%RLM0FZ`&IGOZ/.)H)A$S`?XE;2S=YAY&POS'?BP& MHAD:LG)&T$$?"#OR)"\2$C0^!M*7&$R90='?#6/:R#@(8\8TG_1<+AB$CK;@NX%H9)1EM+P;+)HBQI8EJ".]#'2C@FV^`I5J;Z\(%"[Q2G$=I68L1+BAQ?? M>?63_G:=O&E&N3^W60,MFL8!^D MZ=*IXY(HA,@PJ+2)'/`!.[(J7+><(^\\O@2&[L)=+BY=WFL&E:K#.+!.9PS-6?7=HL[?B2L#/8*/^M@`-N?4Q0&KQNJUBK\#B4!44KP M'3CL+-#-M0[8+QEFG3#^9'H9/!_)C2+48U_I8]1#([23547^?^R`P&?Q_I%A M5E>#,9X)+3_.G-PL`[*>/?FGCY+B3UP,KM_ZGW.*/:[SZJEF+W:CUOMEM9G3HN*WN.TWOG;/M#7&B0YYPFY6G_VIZ[[Q)IFAZ[YPE1S6]=W;"3DWOG::2W_Z/ MUJ;W3E-VK^F]._O7GD<4G',N+MEL.Z]+5!I+\@UL\NM1AB=4BWZ?XRZH]=?:3::A5M-[I[$47D7$ M?NU[]S7_:GKO'(ZM7AOCG'-X]'3MG=?9>V=+G',=+%VD95%6EDC%2#]%F.CW M#>O28$CQTVSNC;.7`\B#-#8TU?[^Q[?ACE#D^KN/&KRHBB'?9$D+R/$H"R8( M*0_N_6]%T9S+GZP8S2B)9YC:D&=T)W4UO?22"#,\OO@)`=1=JGBT#YC]I\^C M1Q3JF2.U/U)'\J7JF++AZ'W948!"0U/O#X>&X8XL#2@$!%)U6S$TO4*BG2RT M3KO/?L8H_(\X34^14[1W'V5=4^J\4IOUPH+B*)[[F-T:W;+?<)3X*2Y.???1 MK"]LU>R?$G_4'S[;\J_^Q)]1O3:JC+L3OM[]L@U8MO6$\#^YH#HERDYFE[-Y M&#_X/F_W0QS?Q[S'0>5&V@U!EWIB:%$`ZPNEO`WB-$MWGE=BC32C[[B&#,(] ME$&^>W+?'O5E>V2;NCLT-$@.\8AHM/WE!P"3NA5/(`8BS@6?[[$O-,:44W2]5+ MB0[?P5P6DA#:+02CKWYW`ST_YQP$L>DO"5%0DLA+@AW'8ZYFP[?<<.U,-_Q- M91X4'3=8[[>R.^B3IM]!!>2`-PM'#0OKZAECPQLFV!%PP3AC)CAI&-=OHL,; M*CJOTD/CWG_]NNZ('&WJ^OER=+/?FQ]CFG&^^WVLN\@&_[,=6JJAV_%Q4_IN M<%-2)41?S^(3,?K7?TR?FC7Z$@_>>7M@IH:!=LE`AGW&AN,K,B2VA30=^'4G M:$J\#LKM$GNV-[3$$Z`B]]X+0IS8=3R@BWF">+"2U2E5!#U%B(J)L"/#UE;# MCIY?URJD2DELWEG0_>$E#/ERQ>`._Z3RS;@#:9HS^$M*6[Y[>(KB.O;(=F2] M?PGT&&H]V>VINJP[MF-?CH9.3[U\;?"4:]$<]%[4I\;F#KQCCNAV29T_L>!P M6BT?GJ>B:4\_],!)59])7@7Y<>TZUEW\PT&@,$=:8Y6/UQQ,L]T>1"=4]'AY8&`U75XM M[)R:>-GI7K[LE!F4KJ/\[40$^U415NW:UC.$/6GT$&;!4;)/&$S]H@DHC]6\ M#=DPNY6B.MC;:LFZ&T%Y.96UC:A\9B52"CFZC]$QHE:#0IJH36[X@`%$P@*\ M#;%25;LY-]8O,LCC)U;1Z6_R5 MI7#3Q?"CM^X^L5X9]@>7(V4@6ZYMR(9IF'+/,H:RJUN.:CE]NS=TWV[#1OV4 M&C82M\E]!BT<+#8(6&..K[-Q8U,FX5AWP4V9A!7G75,FX74'X9LR"9N?BDV9 MA'TPX(EFS3=E$M[8AC=E$LX@;-F423B9E)*F3$+#!$V9A*9,PBM+FV_*)+RM M_6[*)*R]TWO-T7L-Z?X-W;:C6U,FX3S5]JE9HR_QX)LR"0T#O8B!FC()IW$@ MOHYD_X9R.S$F-D+/[.2&>.4J=G7_?&AP0CUUG4C6;J7Y;.8E\"O"*]2P!Y(W MSH)[Q),&$7V).`\O$BE8FJ+V?DTE_W]S^$F[%41X"1#<^](\]**T`P]A$QM\ M581I]/!A)>&=#P46EC^FYC<(=,!,.6GHC_W9C9^4]-?5CH1A?4R`C_/;ROU? MD;C%LMY?"G1X6Q@"L\$0/#XO7VJ)'=6XV\6-WC,BLA862-M6B1X\I71_?Q%< M,CW$F_;MG9X]2^_VDGK)*O[D56#*3UQ6#F;5DDM,S.5//QD'J2]]28+QDD!# M<^6\NXN8JSQ+,R_"PQ4,AM5VQKX%ZOC>^A$=<[UCZKU.SU+/S;$^T[T^VRC, M*?UE=BUK^^/XM/EZCW?G+P_0_\9*MC4:>8]"JBE*Q]"L<^/;9J[:R/ MSL/CZ[86%3>5XBFOVOWH]E;O2+S7BI=*[\V.H=D=W/-X*N514G0\6@#Z5XKP MJ!W#LCJF8\'O[_T4/Q6E>*0?=\'X3@K`V?5%,3EXX@:+^(B!I?C>3R2OZ`S# M)X@S^U4TB9E3A7A:A#>?)_'/8`9O#Q\DO=N3J$(EZS,CQI#%@X2?DR;PXTJW M&_*\I<4F-]OUC6%4T[JV3C.HM*SAT+TGAUVU)UKW28OF;*L]-5V'ZMSSX9>G MSJ[-MK]I[;/"ZFA:^[PBE%K3VN<9@[QI[;,/5Z5I[;/=%)O6/GO"83>M?4[L M8-KE0=2T]GE#6_FF$.5-:Y^FK/P>"-NT]CG[+6Q:^QR&RDUKGZ:U3R-(36N? MIK5/(Q%GV]KGA>UWZKU\RA]6AW*Q%2[H,_$'PM])0ZK#$83MSZX79 M+U^2>.S[DW24Q+-*VRHWFOS)6M:([)ATIQ2MDE'6']%QZ&BCOJ:K\G"DZD!' M9R0[O7Y/[KF:X1J.T>\/'.`RS7KWT;;AO?_Q]PT74Z&`.QXG/O[L:OK5G_C^ M#%7$((Z`>%D`?WY)_*F?)#[KZG5(*FCF2!THESVY;QC`38YIRSU+[A6=!$W6Y`R] M!R+6JQ!CTS55R;$W+5ZPXXEJ<;W0XHP0?G(?C'WW-O%IW3#_>9`0-5"][*KU MW&6_;QM]RY%5UQC*AF%>RHYF.+)NFJYM#8:N:NNL]1P,XLB**NNJV.6G9UA= M"VXRUPJ[[YYG:(:EFWU;5DQ'E0US`.?`Y:`OZSU5<1UMX`[4P=OMGF>?4O>\ M`>O3]JUHW,:9HMVZFH(^0*<>/_WJ@YY(?>G;'%S_=:>_>6.]@P'WKJ)'"#%- M8PBQ3K7`G$0&/&*FHBP&2D@4[/B1!!E0IMWRA*1U&&Z/D$HQ#1`C^8AVJ1=2 MZ%'MJ&:O`P)-ZBHE3%0!/(`W#W[]`S\O/QC^^H$'6<1T.I+OC>_H>4))!0P4 M"+_Y$;=;3/GA/Q_M:APA#)%V%B9)ARA/O06"_JK/(YQ)1%YL23`+\V@LE4'.=GFI) M1!36DQ#QC/@?V0O#.",-)Y"0\+X'Q$+R7&98V"(V3+,X`I`@;//\)@S&;)=P M/8AR0V!;`H,@B?&M#(+8ZRI*5[K$#P4%8=+("P'\)H"9BK?R09"2[\VNI2.Z MDE&W@Y@[_C-2%T$S`NXYS(">)I&"],3K5'SC.5DR%PX<.5%">09[N%#Z%_7W(\SMSH:DH'!%3I8&"8 M+LP]\LB.(.!Q2)@([P;)'K`UT/@ M6>!-T"/$%XCQ3A#^ZJ4UE3GW@HF,[_?F`1CZYZL@5M&PD*;,CTJ"`@U2TK5K MGE)BISQ0#UAU'T7"X09A"A&M324HEJE3[V)0A&+1&-D:A'5:3 MYP-?15W_M%M,`4FH?U1#7]`^8MA""UTPB)/8Q@\PB1)K'*5K.Z]$XW2>5SE9?:^V43PB>I'+"X9:"HG`8_@9S,JTK1J\)!)#3_ M%JQPKM>0!0J>K3W8P5P/+%G-=A;;B##SAFU9G%.F1#Y_>E?*NX`G`@35",+X MSI_DH7\UI9_>@1D'4V+L_#G.?/&L&TW8@NAG+J_C3=<3.X\[.(JC]4?N0+[L MF7W9L"V,'3HC>6`[AJ4[QJ7I6"OB#N>=^?-,*?7:J2:NP- M>IZ"$4T]]IG&YGSYM]GQ+:K_6N8;46=-9?.&X;-?Y7/CXF:/M]CCMZ'13DM_ MC9HRYHTF:S19H\FVL%"\_<46*T=I>$ZU]:]':@UQ;ON"O M-Q1-/N_:KB4/;/=2 M-H8]3>[W+UU9,33-<(9]=SA"Y**&F?.6*7;A!,AUG$3AXVS@TTG%:V[A8E+Q MOFMDY,FK()M1)]O`2^]"/RTX@RLBOO2RXL$IEFW0K7>:Q0@?`)<$8GA@&80[[?.DEF"J2PNX3$^T'=7UI&7W-U2S954Q8MF/U9;?G MFK*C.<9PX-J7EYJV">KZ8$G`UPP:+T+9!H;$P]8.@"F=E9?PQ-XMTB>6`M!K34( MZN4(:MLJ0<1;`J:K0ZR)7#:.`YC>ZVNW`$P?M4I7@02U=HP$A2=SIF$P6XTW M'\`)Y>5\Z$_6AR!\5">\%LTJG]Q'/&,3EW.O[SK:[N\8!WQ"1<;/DGA+4+8- MEY^+6>\=A0\>0^4];IH!;.T]*I]NR3I[\0N5X[RLW-=T1YQ,-J+^?*S M<)*\^3P,QB1>6-BEFM;*0Y`GSY7G?.7W_D+O&+:VL18^]KU)L]5;;+76T13C M[+;ZH#"&EVNV/Q?;9S*55I9R*V$.E?(C^J_2S>)1W2B^/4J#:G44NW=NLM!L M].8;K7<453FWC3X/XVW1@VBW&HUVO/-]&2$NE*[66'=O>/=5^^QV?P^0ENUO M5"L7M%_]<7P;P=(FV!$F2OV4M]"XCHORW*,XX16[<;QIG,S\'91`7W%?O:1* MMV'JO<%@)+NN8\@&?"KW^J.A[/:MH3XTK?[`&7S7OJOO/MI:Y;IZVY6MTP]C MR]5_-WJ.;6H_3<6R[=YVS094R['ZHY[L*D9/-@S'E?N#GB&/[.'(WV MOJN*0O?8NMHC>CR]F$,L6%5T;J*7DF%'DB$M@49Z*-/5.IWF&.M68;I9-7D MF'))2>54%,TW?YPGK)SO2ZFU("N/0B4U'%`F M,,7MJ%$ZU^EU[!8-"KYXP>13-&#=">BYF\7@Q5N&(*BP>["N?] MQ01U+'7+`-6:+JGZ7350Q$#A.`O6]KZ)D"&C8(G1X@Z[YDI3+R2$4%GV=A-T/D(=S5[9AH,[Z'' M05A$[*3WML-/VV=U3[R@H11'G-LV7G_-4C_&B6^_XDW??NZ M?;-M6*YCF`8H,+MG5N,B\SSQJ^0T'M^6ZZ/1R+)<&4QK538L79==TS)EUQU9 MNC-01\/!)5X0PR_??52ZX/%KS]V7[I`>>R0_WO)C[S*A9P]!_L<%,M8GO\G( MOR?B+Z/&/B_Z5U%L?93'VH2SP"+?#M;PR%]\3-R;38A[[25GH`X?UGT5+SU,571_%U[#V+;YT>^[69#^8ZZO"$-I$@_%=.^>Z:73"8RHT4Q^V= M=4U2I>W=QXC:FP2=#3[`3GR__O8%;,!OV&%AB%>JFL2&%3//L[,SL[.#;K8& M';T_&!@&G5]8U*VQWE$FZEI6RB\I17"0NLP:J!)UB>,:0,O`-C;0^]WP/R1X2,0Z:88=R1B-6W/WX&W6_K`,< M93[S5,;]Y4]*B:&WFO1QU\SC-L4JF\4\NV9TS7SY;T&1LJH8>@LBTFW"TB49 M#H"&FO7PR\B\Z]FS$C*UL*:H]`?+/2Z<"=N-%1M=]+Z`4'LP(.(G0+@Q-=I= M&V5CBV-DRFKC=^)11DS8]!A/7<\-(\:/!8D/E@"$';-%*[<1YX$(1#GY(QN%]E2H_M3#\]5 MQA0L`GLM;RMWA?2WON=GPW[`:R#*.\,[GW[?],]M.(N,_<`-1^7PNGRQ:5#? MV3?Y]PJTA[]7"\>=\(/E?BKS$7 M/=)1F,V$J!66"S.,SEHM)\HF^74`E>G#I#'U6AE'O@U`2B:TPGX*F.VEH'P% M=17]%+8*++^?`@\9=6P<+7"=[F%%FY18;%)B"R'M76VL[="ES$U*'&]2&N]M MDW*K+N5N4O(YBVW;,LRN%%W&TO/G.UEZ/A0=C+H7=)F,_Z)_,SBZ@>WW;>JB0//%B MV-[KKV`R=C^25]:0UXUN"`O^?QN[]%MVN.7314E*ZB^W#W#UZH87EYF3(_$* M*1ZEU][ZA)>]=B)"K*QV1EN]&<]:IP2.G"`:L!(AIO:6AN@_.L;JT]6%U)-+ M7::W=,2&'J2EX"\LR?GB'[M$YPD]6Y#/%WH:(;`D`WVRR9+' M$>PT'3?^Y\2&K/L*D@WK_GJ?I[.)OR3)6=(=]9V3B3]RDN1)TG%.;"I>^V$4 M]I?W9.8'T5?7(UE*'-B/.T=>B#CNS'FQ=U_NC%@AG0>-T\Z>ND>0<^8].=5Z M,?SURO%73K5LIQHP],JIKMRI!LB&]/D5D&Q8U1-<3YPPC+<**6A51Z_R",D6M:JAUAH&BHI9<:@$GDP+S#>VP84,+VW%.G0)0 M=%+.LJ)3B712#K*B4WET4DZQHE,)=`).(`7@P9>8-1E`M16^Y]6'L(&%'<=< MC4;SZ9R_!'M`'MF0X@4FJ3)3.M*3S"+3!G$-NA&!'>0HKA7E6A,6+-@1D.): M0:ZI\$AQ33;7@+-+H7LLNNK0'HA#>V!YH0[MU7AH#QHK8!W:`Z`=PS2L;:'O$\@S#'+?%Y"@?`@(^M%-H1WJ M:O-HVS1-G2X\2+=7I#>QH1MFXT@O6DFRCZ^H.Y&TC"PMI3/_%9)_Y\P17]#_ M-H^\Y2Z0ZZ<;Q3S13DLSY;`("19A3>1L,$+FJZ7I'=."R9M;\L).>`?.*$JQ M91#,GWASX@4)EM\"_REPIM(#+%P`.,SQE0T<*.,(23LHY\SQJB!J%@WTVK&I MP036*$%8OE4:,O/RL!3;66_N.7LQA7A+3^G)[MU^"+0R$B1M=2U`(!W9.K"J MH(($^A:XWLB=.9-"C3$4@++W&]XDTZ M#T>M_++*P0*:N=X#UITGN2TM*+!`V1T0VL&)=O1&:T>7HYVDI3'&C=8.EJ(= M3?BE6)5&'&,?78\B1J\6?C'F?G'R617@-"\RKK#H;EU]9=6,6M]5%0V\VCT)^ M!2XKT3ST%B2,IENW;V]\CRQOG.`?$GV9>^.2NS[7PA75D+0Y`$&WM+6W&:T3 M(-70"CY$#=@AJZG50KVPP'S+@"F56Q_6$(6.%QE1``M855EM!7#0&$XN8-F;%,"]_1;%@RB]XAMER9 M50.:YC2@V>"&61,W.CK"X#..^[C15\0XG1BJW]!1<(ACI)+A`+9NR98Y;NX0 MNXB:97>`I@9S+F+R<6Q^9-(.R0R4U.'Z?>I?GPJ7K'Y`L_X4F>>>*P1V0]_` MR'KX^7VP$FE*G'`>D,OXNX_TNUX[^5`,QN[/C13RID@;@XB/"]R?>I('^N`/ M]^[3<[0:;NPNJ(K6XK/;;N=3$CB1O^9HD8<7JME^/Q]V0#Q_ZGJ[!N8K&7^X M7>-N#M!KIYZ_D/0Y;<(1?QN>;Q,]"_0A-6\=8D:_W1B!?;CC7F%XZ"__`U!+ M`P04````"`!+7ZI"RJIR^UH+``";E```%0`<`&=A;'0M,C`Q,S`S,S%?8V%L M+GAM;%54"0`#'AF-41X9C5%U>`L``00E#@``!#D!``#M75MOXS86?B_0_Z!U M@4476,=.LM.=!),6'CLS,#:=&$ZF,]B7@2(=VT1ET26E).ZO[Z$D6Y(M2I0E M69+1E\E$X>7[#@_)+L7-,6CK.Z[O5>7E[.P)SKK$MMB]AP9M!E M3^MV-_W]YB.[UGXZN^ACO?`O4^K:YK5V&7DT9.#W;"*F:^VB?W[9[;_I]M\^ M7O2O^V^OSZ_^'RU-5VM&Y@M'^]'X%Q;&DJ*&-CV;GD5(_E-[H#;'TLN5;J^U M@65I4U&+:U/@P)[!/`L:M0*^&HK4YC>=",77)V:=43;O83>7O4W!SO??:7[A MZU=.8A5>+C?%SWM??[U[,!:PU+O$YHYN&[&*HK&DJN=75U<][Z]^:4ZNN=?* M'34\*2D`U*0EQ&_=3;&N>-0]O^A>GI^]1BNG?4*;CJ< M+%<6=()G"P:SF\Y@'6\)&=*M\AF-<"9
L*%0!X24QV6RT1$-#C=_?"\M% M*"XV[XDDZ&D*:.2`^4CQ;TMJ>V7O5Z(`CSQ!"\%AQ'"$C8/<3I$?ONB,Z;; M3EGR.#+H,L7M+II0XK=UXU2+DX6E?=!1LTVO@"S#X1!TT6BW7!'-L1^(<)4GIZ+"K62E$ MU_[LO9_-@"$X?#(%$6&"AY5%G",M(0?B*%DHQ/'&8TAMI#$'G.0@!N<.L.*$ M40-`#%_ERVHA&*7:>$\<_G`1R^USU>NK6E_E^)\XQX`_TNTZOG4;>>!IH9M" M74_XA=CEZ:=J9D%7?**O]2<+4)T"7^R.Z$\$)QCJ6#@:C_#JO+=P7E;$_U`T M#972HRAL"E/5$@M[OI]%G9G`>1U2[G!OC_3<'>3@U:I:OXJB:KC4*M6W M%%5+9>NOA1`J7W72^ZR:\:W.;&$6 M;IRTJMG*^ZN-::4:GM7K4>;Y)M1RE.5MO[.J.4:\'R^$'7&`CK>TYP11^;CO M>$:5#[VTOX"I$48EQ)F1&&,L"[8I`L7^4]%792E_'TYO!\_Q0"IF\CU`"`EE M&(-AB9,=E,75(T#A'=^8Z?S).\/A\NY MX=F$$O1J=6MA%49G4PGL%JL#ZPB>P:(KL1;CHCP'W"N`K1CA,((9,8B#"X6[ M=#T'=N2*\/)N#0F[$AJN11[DF9BXQZEM`++2=2`?B[U^3D2@RYO7G\"Y?17Y M$!3M1TK-%V+)%E2EJG5PBFQ/$NC1$C4C3%>5ANRTW@&U8)2I;:1"3BY;&^J( M!-6@)U>H`_\$VP+LWLS<%))*UH1XA<95<*!J<[)1Q:I0J5D/([H"YJPGECA& M@EX1&@W>9H.KG91*2I4Z..S'"B7($PKFP[OO;(LGWSZC]\?)W/;BV;[9+55I MA0I;3!&G<\#B\'1F;!K&_^YYG/'C^D&)'A[_@;FC24H7QO.A<=S>4(CJY\YZ2I[-(G0DCV M/Z=`5K+?A2S?G`)+-=LO)/U3VTCO;#E1[HH^9$C^_(3(*VW3(?6+]E!/,/VC MQ)/L[BU/'.%3X9EF^89\6Z32GQEH:;PDY M7[6'L]P^%YQ5+.AP3K=HK4ZGG>H$AWQ;9%NK\=T/`X=D6V1;JY&59G!"SBVR MM-4XEQ$[#\43L\F[BO)I?`XW_N)R@S#OOYE<1GQDN$`_#,9VY*67X"Q(4G`D MI70=T:6/8*/T+'%.UEP2FW"'>9()O`M)J"FK5DVY$&#`G73DNZ7J0?J,"(1* M^@JYP22%+"E>!_9/$*`0;SA)`,?+U(YR\*P32]B9L7>#@Y5>O%M@J/!0:*46 MIKC2K<1W:G"G\<&FZ[^\?"TYG@V4\,WYY-3.7KE:T6;.@*22M>70]H<\+8&6 M4+K^[)GPD\%_QW(*)OBO/XOCA2)@H)152V^A?H9;G]B7^=9H&2]7NJ%&,:.) M.CB*KTBA#2YBM1$S.'V%2J]34D:+@6Z1/\'\J!-;S,ZQ/8(G)WS+=&N=)>>W MU*O7ZM(D;M:Q2&/2BM;*;%`FU92-LI4QY`--G)A(XC)K96BY!#'D6X@EP3I5 MY_U4Q)2Q(TM"?$V74I8Q'<^_RKRX5B::93&._\%D,K$U;JLDB+ M=[4R:Y5+]:4N52N35U('/$HYPXIOY2D+)>*9P=%6GK)("6,D^@:AA"2'XMJ5 MN,CW#<\&`=__2&=CWMZ9`(Z]B2+#75)DPOR?$@<_5Q.E^/NMSM",`)72(/X: M@2O1DC*'_!E\32A1P&DU:LEWH.M$V"8%%S^UJ/RZ2JXVZLGJQ%5W;*M\BT:: M\SFHL6;PWIA(P:&U0]BF--$,CL$AS%'@$R<>QE1FJ]1837DTL4Q/&!5!$?/] M6GQQ%%=&/_=OSX,O<\I'-D<##>+GN_8%^"4UT"!^6]/N4'Y)#=2>YVUL-MH_ M'?4_8IL9F?Z$@O7@#;Y210<&&F@,SL[RW-W^4V=U72X6T*:Q>30&JHJ96Q[F+RD)E6 MK7PYO)@HDGR8MAX4.D`,19+`;TY^!C`J*KD MD,%I:].!V856GDHH6U1I"8EBAS]KS`P?<.-A_0+9)M#O?B]K\WB4NB^UN904;N"M6Z\>2Y5;2[60R]`/3E&P>5IS>55 M]"K1DV76^)%3OZ+S!#@T?C32+\=L+F[Y-9`L``00E#@``!#D! M``#M/6MSX[B1WU.5_Z!SJJ[NJL[CL9W-9:=VDI)?]^^K?CX\EL-KD*?!]Y'MI,_F$C M#X56A";/UO?`#U:;R16:N[X;P6"3.]?_]<7"Z+\FY/_.!'[ZQ\7L;G+VX70R M64;1^M/)R=O;VP?D+*SP./`]UT/?_YT^N/_%EL'ZTWH M+I;1Y#_L_X3&T)+TF,P^S#X4>C`HK?7T+O0Q`N3F":\Y-MPZ/?_VZ2-O[T';NE#F_GV^:G M)__X>O=D+]'*.G9]'%F^7>I(!J-U/?WQQQ]/DJ_%U@"'$^V:%\'ZX23]F+;& M[B>S(]:,E;.(UBB/7QLD&C++=?$)ZG0A-<-(4 MC1GT_.4I@IU+YGB8W[@^++5K>8\!3L[3I6=A[,Y=Y#3"1G"*+O%YM$+4;(DD MYH&18!#+4X_A+5R;*S3U(A3ZL"E>D2J4#@=6`[OM'A=F>5H">9:!Y\"5>_VO M&/;WU'<>")3D[H-/R,P&.0W1A81<_S!]#8$!P'9%-/G6<9+-;GK);3WXZA2A.;3N,D7/]?0T; M`&%%F.R/JA#@IRBP?[T@<@[9N#!\0I)LIAGR8&YMF&^T(V4$/!1RD@"LER>%(4;V3.!*VB@=O?_#_,KU8C@$]RBZ"S!^1&$BQ:E;V,J9%"*6S``29C(P M_K9T[>5E$'L@([@X>HQ#',/6>@ZNOZ/0=C&Y".*(*.'$/I+LON(J^$XRP#<4 MHOL@`J'5BQWDW/J7EF?'GLK]T#G8[=P49.KT]#[,YR@$X."7&2+F*/2T]MRH MHRND)AR*B>)&R7I"\8_2L& M6*Y?V[Y?Q>92HW_"&4/X.=C=XSNU$6>:%J@I09P0OQ%V,O.TC5DV%7ZT-M:+ MAV`[9;K8G6N]N'#`8(_EJ_&,OD<7'IS+EO"O"XVA5'HFC9OIA&W!U#;%\ID? MYD5E)E->+P,&$JWN&EDHVJ;*3E_+06C]UN'/V3;&UU;H$[%PJZ2UC2U[/FV8MKK#JV;M MY)QO32V=7&^'D[6-8T'[24S8!06HNZM=$HC6UWU/,VI]Z9GS99A:H2V*+",@ M81OJ0"(1?DAH8'G>T20;N(C1KA<@=.*XJY.LS0GIT"(\,!5Q?`;^L8/F5NQ% M;4*:S'"\0JL7%$J"6>K:(HQ+&"*TXQ=TO*.,'*2T M`3)XG5UL%@G-*L$,APSY#O&PI+^2H5J+E4F@`7C@5)>`\$BL41!2*9?@BY'] M81&\GCC(!>J=GI&_D,OL[/CC:19.]`?XZ9D/?YZ/#[ M2>OP7,8AB3RY@>O;\OZ)K/#:=Z[@PJ.`QFS:/I3;-4OG!CG##9P;^`U3P&2W M[1I.0B,Q*/.6W<%8V/9PYM`M,#D>H-3FW4&;KB-[<]+;=0??,PS+`2OYW#XT MR84&TE@B>%/`*7_O")[-)1`@).9J!WW_&]JPX#IHUQE\N;%>66]J&Y<3T47L*Y6P0A>Y7+K;J";886+HZ(TG9OK9A'8[]9 M^]`EKJMT[NEWEW8![[=H'Z;GT$J3-7"7$%;B\]'9T23&@$>P3IUQ;=%A3S-H0I$R MK]H2Y,/'4T*.7F.V)U7GJ)WU'C6&`)2C>#X8%`^DYAS)/PX,R9(*DZ/Y0^_1 MW.,=.6I_ZCUJ=$$BQ_"_!X+A@;B>H_CGWJ/(MG?D6/[8>RRI\O@.P=./`T&0 MK[CE^&H2<*@&TWVLJ2K[%LT#[2#?I+K6\,"DOH\00Z,IK]Q6<97%YZ>3LJ6X M,^NQ8&YB;=UL;N&7A.`Q/EY8UCI5T)`7X>TO^YI:]O,O>U%0V06WI[95-*ZO M4S:">R]6JQ)T1GLMT.^B,!\M-PE(7KN1M:\M5[76`CG&*-HW-.Q]U`?7](4( M5S9S$Y0;Z8.S8J^6VFB'4HBH^VUU0$UR4TED`?Q!0J5>X6XFL0;1I16&&V#J M20P1`PNQOEJP(OPA2]:C6FPY#;7`RP[S8`'.Z:$+@TPPY&Z9_68Z8+U"K\@+ MUH1X(&0L$`A(*`1!""-2L,1V(V!\\2I.0DRO8I(`LM^#@9V"@;70PWUU'9#9 MQ`0:5NNA>&#JT_&6A#@L7!(8G]SO]RBZ_D[RIV"AOP2!\^9Z+'%%J.NP?"/U MZ5P02!GD++;0#"'%TD*J%Z?@LDH6+UT+'>*4B7`AB(]-""P=;^6M21*5)A=7NMT!\X M-%A@WRF(L50`+RV0D-%(#YR"LJPATJNTO&J8A/J,5NL@M,)-"LO6M#9=$:?" M-(I"]R6.R&YX#M**A@RTY,=1Q%9 M\R+B52#+C;#(D3&*2O*-T>V%_><`++,T*4YT=5^IC*W*7MW!I@:+4>0?2->OI'-U3/$,!-GS#G.FO2+ MRFPIOG/2W)0I!8@)7%T9FF@J]K-H#"DVV%VA,J18F\?B\`VF(JH]C"E6&2/]RYE9&-&6:#BQ*)W$ MW!BQI&/4C=K8E$I)O1_NTMJH;D7Y?O@_:Z-)K\EL8+7T1K@>Z,M]R+2NA2G# MVM&'K&L^OL):81]RL!N@RKF(#4[$;HPPHW:\N0J;V.FM\H#U(:>N/J8'/-;@ M[+GZ6#*V;M^E)J$`E#YDRTFCRSNF?1>$SFGH1"D'\<5^17,@FP_1_N;3\!;KU;RPWE8T?YM^LD+R-1;/UD"3J;."+4[" MI,F.R^KF,.A:U4M3!770;G'$AWR_E1Y(7P&"]/$L*.@KBG]6]]-2?WP+4@8,ZWP\S!NZ:$+C+##X+D>41$]D7T'?(K7?K7Z$7D&C@UD[? MV]YJF_3P,_'N.NCZ#;F+):B5TU>X'Q?H/B:6J8=YHGD6;$IBJFO-P?H0\F.` M[4G`>"@L!Y9+);-4NSYXY6JBO*=W]\$;)X6I_-W5!S>=/`EX!L0^N.QJ;6^F MB-P'SUTMC#GJ>Q_<=Y4Z9!'7"@&T#WX\*7PKS;U]<.M)84PQ@&AWZ8VQJ6H] MN)P-T8=<#DDDB]:E/N1PB*$GP*KT9W(H0[;LL1A.Z+2]B82'-8U?"+T>469=JO" MVKMW"Z)54F0[\&$71>0QL?*=23/X2HZ@P^9;K)B8UE"D%T[DUE&1'$0+GO0J MF7RTN'WT8/%_<6J>Q<\!`[SDH+Q8H#F1@P&G(DF>F2$X,]B-T!,*7UV;A#2[ M@3-#=K!(SS"O\$;KT_:L1*+NDG;<77O83@>T^>,$O%NRJO48WYB]6@-'*O#A M_'$W*KUM+Z$>BPKV+#J0H3BG"0ERX1U9'WTEY*;2)>3H/<:"@6/!P)8Q$*QQ MI;*@[;LO;[C'L+`(!M0^8ZR7";%>JN`\+,+/@/6@H39XTUS(5%=/-;/THDA- M%#@Q7!3,%4_(AJ;IFYELW.H/:AP=DH\/B2T,7W]'H>UB9KQ;C8$,PC=1PQ4O MN^"8IE%!P:)SQC&@,.;.*OD<[-61R>T\#'SKC-2/XGL,F;\/3A"5%2,-KC&C MLF*DP3&L*BM&&AS`RK40#:K2J12FO2YV6HFIW.XU.$I&$M-*YF)NV(PPIA3W M1!_"8X3QJW`@]B$F1AQ72:>P_JB8H:7WO).GI67K%O-,;Z7@)OI.-PE?D75M MA.Y8Q7B`D>+<`E_F2H:BJ\UYR-3@O"R!8J"RL61]2,ZJ5<]7S/C4ASRM1@'E M6[]X'Q*TQ!!E!OST(2-+XGYJX#/1GK?5-B5$O0@[0IR9:VY4L"48GH0<>W.M MD,VW027RYEKLQ)!O/Q8WIU7?)3M6OMB9)J'.E,0*$Q$3U$)EZ]+V`E5F^=WS M/J7*7%IX>>,%;_@65,00.LNEP[20JD#N-M]V/52Z")X#`NEC&!#)T;G8_`SW MY*V_RQ.>`M:OB<10446OE:FTA/@#C%/?(7^00_<**T_.6W1IA>$&P.3E:(CU M-0>KE.G!"H4(^.,52O^40HXQA"X5DFP+X'"0W@GQF479";<`2Q9%9W]^"#)SFI@[7.1\.Y2DEC4 M*^ANQ%(#@OV=:[VX7K*_2GG15')*=->2E(1>HAS&3#DEC&!;`FNZ(AGNIPRJ M"W?7C]M#Z"[@@O#(KS)(T?KIP68-@HN;J$NDV,\J""/WM^2?3#S8/<8T,E*Q MP@VWKS-$<.L1F\P48Q3!S6Q[,?$E?`D"Y\W-/3;[==REQM!3F+XL"MSZ<`N1 M38P?K0T1_LG&.+B76.C6&\P,O'>2;6:(J)`S)`8P!+^LJIT=AV%B?)!?3M`',QJ_> M>O(&,@A?BN%/#D_:`&;C5V\]3;.0]J080N(#_)OK.Q5/8U$:ZH%WL_5CVB"F MA`BV`;!_4EB7*V96]S,%&]C&T>;1`]D&1%XBBJTY66X2`^@IM1'8"#GX)@Q6 MA0`+8K)A(<3IH1N#7/AD&Q?%^YF$C5BAN+JCF(.I?'&\YN/IQGY[1=P$8:)` MBPO\LJ,HT1.+DQ;<+[GW9>N=H:JX$KWU/,*TSNA8.B^<^Y#78RP[-)8=ZF*U M>U]VZ&(_K(T%/+WQ6("H-O1W8^F>EHJ!L)RDI29J;K)XO4X3DRQO%SK_X(M* M4/7&4`*YCD?P.@]K;3-ZK90UP?-S]Z&Z05>$8K&#'4.87, M97+*#Y>\7I^3Z5WR-/'`M9Q0YJ;/MW'BRO:I'17.S'5]*'\EVJ*YU%5E5%2`=!37TH MJ::&#-S8KC[44VM&!NG@O3Y45E-_0(2B,?M0=DT-:622TOI0CZU^TE+9.RZ> M%M"'9U_:H\I>ZDN_,81 M3K[,J:++#/).GEP8*_(K+VW:X`HP5W]KA#V7[^;8FRM<-<*>*Z[OL/^CN=*4 M&/9R=1USO,T5&YK@?5"E,T?87#XOAG"Y1$^.E[F>6?&%;.:LSVFAR9X]%K)6 M4=U9N(BUMNK.^>:[L+`+2#S"@21!1@F]=\7G;_UY$*[2U`@5N3Z4R0Y.5#&Y MA]M>2?81909:>AF_K3E5D,VH[6Q6E MY#C:;"2E1M&<)WKPVLD]>DN^L%-R1?IVI?(+W^T['Q3[VAV@`4"*/'6U`@-S M.FOA+7W^3<[8K$4!P7O!Y$S,NBLO;][5E5!9J4\(29?FZDN:H]8,4(RRX,HL M`!5K>?/F(+[S,HUP9$@%[/8ZY)L,&CC/H(]:Q=1B99I[J3L/DN1WIB5+[)L\(JE[)H6J.T@039<#&ZXZU M,1=@DL:KC?7."4^V,5YCK+W>54Q2N[K8]AGG(ZTI`T1,1Q;FTK?@&$E]J[+`$=,0;*M671J=,UPF*%U$";Q"=R7'EN:;*1;KGE-K%G@>'!ORL7V2%2?K M.=V^(7>QC)`S?04I:8&VU>4>0Q`&VRNR,*.#S!(0&)2';FD%MK:-/CCJ^T-@JKE-OUO?*!+7D!S[$(#3GTU*M:*;G`*DWS2D@0WV MX]7JGBR)2GV_#X]B#V19)$V+?7A&8B`K(VV,E'W5PH1H%&H2HH+JGQWF=]T' M295=6!6R>/@YB"RO^)W$#MT'T3]1E$<5-4GQJC6?L=EQ=;!)#P.C9G`Q%:]"^ M@E;]L]*BH:S/P`";SAY64XSC58H]J:;]'%RA"(4KH/(.S8=YD3P`RZA$CTKT M>U&B=Z>@<%!(TCHIJW;EDCKTOC.#2T&UFB@\KS9JUA$.>%@]P[7#,A.V..%@ M=N/?`P^&\>`.ZGH_[LW<>XK.7/SK38C0]AG"KNA)G;=7U.S2Y#@:A$:#T&@0 M&@U":C5!<7[P_@Q#78A_[]=,U(E0.-J&6M0`>V@-.JP%/E:;&:T\W5MY>`[K M.H>6O(@9;6Y]#))1`FSR`,3STO)9@95,9W9'T_>-7A(IP4:!UBM]NA+W+`J5 M/(/93C6@&A`8OI.;51$P#+AA[>:R_ZWSK;PWO>'[N':%!G/@&M;NY4?'=3__ M0*G;8I6M>D`8?D_4*[1E"%"&TY8'^_2%%#FWJ4\&:X:H5S?#Z%,:?4KF^I3: MM&G`^*PT%V#-O>1?@26!QR+C9-T)<8=:QA-`;F M=1>89^`;Z-KA'M-&Q[31P>S&,6VTW32A]NDYIHWVM5(=DU/G\K[O/'J6?V^M M$%4>:W4J'33+Q-VOB!-"5VZC]15WJO*FILXP;P_H#WL80UL&']JBER:,$R;[ MIOMHSQ[MV75IW]C^,^A@*'G259H+!QVL5.TZ:4DU'G3(43L.J7HI]>:%#_6( MO%5%-OXT$E>UZ?']^4^K[-&#>-FH@56A2*,]35PVY,X`KV^A@NF-ZUN^[1)G M[\[[;8X'&&,4X1VT.0(L;S"S_5!\@_5IN:/*Q6;WU_]Q8<.$]G)SAUZ1QW&S M"W;6BM>MOXXCG`!SQK62\7IHQ>`KLLAF3<[@(9FY9DZY,=X%EK^"]!EER`+/!;PC^Y5Y)`QX'A M(WTZAQLA\S7PT>:K%?Z*HIO8=S"7LHS&[7LST-R*O8@N>R1)R^PY7KV0M.E3^U[74P@ M4(5P7SB^N.)0Q)\E".OWT^D-ZC'`8DPLZG&4K-_#_,KU8E+9!$5W`<:/*$RL MZEH>.K="W_47.Q@N+.S:4]_)(&3H4%6]M#PZSH>)43-+MO=0S.##,@#`0;KU MX?0A M6PQ^\IUD@&\H1/[)"J>)>69\>>OE@H6")GB^PK>#>R0TH;8 MW_?351#[+/51S=@Z!-*&D%]LZ`/P*HZT.&,/*_MSHB5&:ZM&J!C)XT MK>8B':`YHHME4*3+]<%&+"IV"B58F6OSK8,FC5OKM^^V@VNUO*[=_C8TRW:- M*B4JI>L>AR>V3YA.!"/9H$@##+D%=RBQPV9%,N9S%`+:\,L,O:(0HZ>UYT;F M9*F.=8J5UREFA&)09][RDV]NM+RV[.4]>DO]R//"=J+%8#08S9@5[''5Y2;6 MO]U*I$($631FG`FK=9]M?8SSQ5LZ1W'`U@P9Z*H=R.G@@&NV!Q+GCT+BW!E6P_,7C2IJ-7 M)CV[U*T?/EE$84I?5&$<>H&.2M;Z,7[Q7'NK/MRCJ'(+5O08:R7WHU9RSVFF MJG)),:PX/5<'5NE22#JGN39O9@F>^R!"J1Q/#`"7Y.VKD)AO9H3H/%>GQ"@M M49Z=",!HJHWBJ79T%9,;,-4*4KD`%.'D$[,6O5AG)?3]V0=RO8%F2HBVB^HK MW]X/L*Q3SPN2-$2V4%1W*"5X9()%KH9='8K*G(8J87CP$=4/3V^C3`;^ODMJ,0^;Z,Y"F$LK6_:PP-&1!0,S8%E0,E/Q@6Y(\V9><_^ZB!-X?;, M26/*L[JBHG">IL,2W@88[2)#'%DIT>3PE#IX,[T.)@>H2._^)BXVDZ-7I`G! M]Z7H#U=1B&IM=HCIM-\R6EVO;HY_OT4W&9]VWX*8>!Q0CO$PI+$:$34Y"?HMBLD'3.68]UM`J^WJS,UL MI@;1B_A!>YPC((H>PRW1T]A\-]'^\2Z;QR;)!KZ3K%\F>I#\!`6A^0QWW=2V MPYA48TEO`[;/CMY08]AVLE>XH224AFJ"Y@,/9@I2!7=GPYHAC&"W+TG1(%)! M.E@GY7J75O3-];P+1"KP'H14-Q]/$4:[K0C3E7;CP35;AER@7]L0,B-!*OMH M#K6OJ*RQWTX5'=>!3TA2UN$.HR(KF[<)S\6&7.W4TRWTI"%^6S60A/&" M"!T!X+P!F6(16BLVF^>TUE+%>[7V@@U",P2:&G+N7.N%Z&O$!!>'(6(68*ON MU^=D)46T303LKRA:!D[^O@`K&I'56LD>O;/>,`Q_9:U`*P>QS=W/2V*UZG_J M`(,B7ZWO[BI>%22_B]A9H/W]SF^K!A+0B&!TPM$L/WM-XM):NY'E90]04&&J M[J7E:;@4+/Z+<*4V>NK7OQ%IE=11Y:1`[[?2#"E7%3MLURMH5240W`=1:F5V M`^ MR&[.%&^%*!!>HM!]B0EM@%(DN*98G%8HCUWU%$KP?@@7EI_=G98'"NT36ENI MS2"3_0QPMGM\QSLN`3RPM MU`XV`/.&E-OQF6=^KY&6A#7@WZ`CEV\??N533@\UJ7_I`N:QHM7)755=%,%% MG,AP#V>A_JGH0P>'VM+(1%Y6#L/#-F0@B68DUO-42&+M"N7S:*/62S46+]58 M[$4>S!!1*T!:W.H9L>41H9YELM0!B9I3TG`C_!WAB'@=.:=+[0QZTH3A5B)P M%3V6'-F&W5Y?>A3;*UN*R^#QESP&P[R8*SDT*4Z^'#E-L47T/"X9SV^>TE+I MC!UJ9E6CT17"!VP_CLM9HZ%]TZ:WP66RUL)7S#QB>V MU2(`+8#,^(2VNM>?0`BO\9ELBG'?!?P:G\A6:WNSHXFUYZVUM=!B,2$F%PYK M8#Q0'>*DO8A8-[N$%V63DT"3@">6`2F:Y]3W3$\9/"DA/[+IGCW"DN,,S+`^ M'R#6!R'/&:Y_'!"NU0EX&=(_F%#RE%8Q5S2%L`K;UY$+!^(-H>OMQK])841:@OVY`2$5_$:"]U M,-]V1CZO+!Q:2*E^6`INDUTY`PKK/,4O&/TK!J2O7Q/!O+7J.0G!IL]OP;:* M'#MSAM54394*,OB%(!#[[=YG#1]ZK=YB7-XUV9CD@+%CCVN,HI':93`+)D,^ M[=G=AE)#P91:`,9&DW<)??GR/K#^[@//:FX`[/R\*6I;`Z"FE=/B-C4!Y@WW ML7A6:T,@Y[^'R&S?:^A5991N'\P)'N/07EH85:3V<]N;FE;"D?%,#B&618XF M2.L/!QZN,DPS&`IS&Y)0F:53K M*,?:"0"D'O087"4[&PQG!E0>E#`;)] M\3I4:E0<;`^%9#%?A#8;/7F$`3\'-ZYO^;9K>;N#B2\L[,+)G-IV$"37:[2$0=*WVL-UH"37:$EII13QLJ!5>K@VNW&A4>QNJ@\P]0I4@WH$**$00 MRE6I7=L3EQNIYTR9[&\@>\W6"3]:&X+RU'>RX+5"&GKN0'\&@"X\HM=JN`3K M@DJ_+>N.-C+TD:&/#'UDZ.^&H=>^=D>V/SBVG]`'UV?^(PMLD:782^3$Y/GA MPZ5,UJU*(I(88&3Q(XL?6?Q@6+S,U3%R=7.Y>LZQDURU70&D;:F7`$?XH/X1 MUJK4-P69?JTV'754\HV4<$8)8)0`1@F@#0F@\34\B@6#%0M&I=]@EKB3W+=5 MA+,JXHQ*F%X"BTN*I.55R=-(O60;B-L(5,^GEWIT\)-PL*PTZ!2.X"LLM:0I MI?;`IM"C6"6U"#:IGI6N,<;Q*OVM-FT:3#(*HJ,@.@JB@Q%$6V1HVD74%HA4 MGV_U(B^A-C6:<*T>)2R\.U4F6Q4`>/%]_@VL6\D7TW9]^CS;$-)LYZBC<7H*GKLRV]D-0QSBO< MBAC$U(\_BBVCO6=D[+UG["U1R5/SB<]$:P@P&QCZ[<=N M/X;MCBQX9,$C"WXW+)AS=8[LMX?L=S1[&\S&\B0Y`,1Q/5CW5_2$[#A,$N6N MO]M>#-OF!C8W"<:)HRPN25:^:6$BQ6Z"TJRDX(\])8_/`J#(.0!"PCW08-Q1 ML!D%FU&PZ;U@H_"BT2X`M9&>K8SS:`__',5#?I3$UO MZ9N:)@_26XZ2R"B)="Z),#:M=MEBY)Y,[DDB1=PH^6L2-Y(4H470R)A"II(0 MTN]HR4%&U\@H/8P6A)%O#YYOU[UD1Y9N+DO??[=[U(E'KF8*5^L23N8Q8(#, M;#_RY)$GZS!DLS?PR'[9[/>G$S+%BX41_./_`5!+`P04````"`!+7ZI"=$G( ME\)2``"WF@0`%0`<`&=A;'0M,C`Q,S`S,S%?;&%B+GAM;%54"0`#'AF-41X9 MC5%U>`L``00E#@``!#D!``#EO7MSXSB6)_K_1NQWP-;=W:F*L#-%ZF&I9GHF MY$?6.,9E>VU7U+A\OKJ]_^+=_ M_>__[5_^Q^DI>'@`EV$0P.T6OH/_7,$MC+P$@B?O6QB$K^_@QOL"MS&X\8._ M?O%B>`+P_Z]!&(#_/'^X`>X'!X"7)-G]_/'CUZ]?/\#ULQ>=AL'6#^"'5?CZ M$9R>9JQ^IT+]#&8?W!%ZK_C+0[@/UC^#<>E7%Q'T$O0T6"-Q?@;NR!F?CJ:G MH_F3._IY-/_96?R_Y:?#W7OD/[\DX,?53^AA]"1^`SQ\>/A0TN]_@\`?+[18\X+=B\`!C&+W!]8>4Z#;5%R!K!O%??BBI^.U+M/T01L\?$9OQ MQ^S!'_[[?P/TX9^_Q7[EA:_C[''GXW_^>O.X>H&OWJD?Q(D7K"HO8F*L5YW% M8O&1_)4^'?L_QX3*3;@B5I(0$'"?P/]UFCUVBG]UZKBG8^?#MWC]P[]BAO\2 MA5OX`#>`R/!S\KZ#?_DA]E]W6_A#^KN7"&[84FRCZ"-^_V,`G]&W7&,.\U/$ MA'+X?])?_P#P0[\]7.=4"(5]_'$?GSY[WHX2V6)_S$C]\)&*1WZ)7;0B(/R6 MP&"-*=/?XO<%AJ+DL8T)44PV7%4(;K&UPXBI,J&U\>(OA&`F,G)"]R/<)KD2 MV"W=TY&3*9_^^L_E:H4PD""0WH=;?^7#>/DE3B)OE63^_=^[*%RV"-?A/M MX?K&][[X6S]!0E[Z\6H;QOL(/J'`<(ZD^:OXHW>FIA]W7464=%K'G;B3"BAC MD'("B!5(>8$2,U!P`Y\Q/T`8FH7MH.;),$TL50'I$<5R7`\Z4DA6@ZZ.56]%J1PE9A*F:8PD@4]:^ M&R*>O6U")B^C<>KE^#>8?@1QJG^W>8!KB')_S"4,T$PO\=&/]^AEB'BN'Y/F MR-:'@F(\K,/5_A59A$Q7#A=/-E0O)F>S/\=9J";T\=PURCF`5<$"[#(>(,9, M/@P")%9D&-H"3M4"=QM0<``E%B#G`0B3PPP@,8'3:X9YS1$VX!%&.'LYE_0( M$['H`/CC`-77ILJB%DH;K@,T>L`X^16^?H$1[Z,W'S01@QI22'K88C8;3XI0 M@[/"C`[X3"D-DPT+X\EAVCCZM>&F&8I4_IA-O!;I5@`$%\]G#%0H3;SN\0C.LT!/F97@& M(49+;1(A4-P@V.^C<`-CO'OC;3]!2<3S7M(/>XXDLG/3R6Q2&PO+!`&F:$4$ M4*$F"0,W*#O?`B]8`Z]8M-Y`X^M;$J[(@)/(+"JSW$>X\R*26RZ?(Y1C-P'2 M]K2A?)8E,O0UW M6+;'Q'N&S'EP3R)Z1],.DLD..Z-Q"6P9?9`R`)0#*+$`A(>A6:@&4Q!P9NI7 M3$)-D;S`ICD,#\P]O+XV4'>UIA%XK]=^0M*(>\]'T_$+;^>CZ07/13A/ZP0L M6P39:=3$R9&9$P*8$K@.0$K+$/P4*.;6%-LA2J=^`%9\Q;0A2NQH%>@(+&$1 M1L0CGO`=\WCI%L3G,V?1AAK3HYL@PO1.Q='!,(@$HU"K50B`(%(54E.NRJ9,%[O-QBH](*^&.PU?R'C$Q%(%*W\+;V%R':#O M#F_"&/W^PHM?[J/PS5_#]?G[;S'>7KO;X<,/:-ZQ7"7^&UE_;ZO"'H*5J7#`S"4"A4CFZ\=-V]>M MVS<)093;-T#VW6+#HM_BGU?8N'ML4#0/"G.#>KD,/UL3)!7CFAL857ZT_L$P MAJL/S^';QS7T:1Q$/]3#'_K5GTLD]1I+_FGK/==\LOEW#8&FP53.>R>+LS,W M6WO(7@?X?;TX/DQ\5T[\H?'#=0SL]&P-C0S;0>*O_>T>00S[C977A0@J,4H^2!9RO(5;U3RXK`2VCH'9A4"2Y]GF"VR M%8L26U#P!1EC@#F#$FM<2IHQQS,0.E\!E+^A,5>[Z>B*?6:V&%.)01`F:!1- MS4:6%;4W/Q[&384:5O!(?<:2F9I-6&)K5V1KOH&.),3)8%EAX&O]*D<8#F_\`%XG\'6@ MV%>0/YY`E\LLO7`Y=\[41K7/6`9`A#C.`-;/AL)HE=MP4[=AV,N&1Q+C&@!5 M&-"J7\F>Z'7KO<++\-7SZZ60TJ\9CS:%+/(UO=.9.(I@FN`SI6I56.BIK`CN M)^W:F@5PTT?;@5FSDQ'`Q3%,N(,]_:-.\!".LEYS-AMGJQ_D/4-G7KK+7!QP M`1Y7[54M*X_:\K+.^[+.^.IX["\W9(8?HA6))1?5%S?;,6`R*FX&+`D MPG_R_(@44A6=MH0?CO6\=DPPA)"N)QZ/J[C`M&@)8ZF[G$EH'*H<@0?1ZHUH M%6YHQ0T^:$M^P'5UZ$^D4,S:1 MQ;.<$71]]:+U$^(BVIRK/*,3167&TLXUF6;GT_'K`+]O=J.JMQ:NM!;:O)WE M+A4/;RAKPJO/O=B/[S9%K43-U=0IB(?W,;W#Z5AEK=9:+7*4,A_PCT*);\3 M?=8"Q!-!))UEXLRF$R':"37S0.^NE`CD`RK5&=_=-1-AFZ^9*5A7,"2"=&$( M$\DK/DRQ#-;XGZMB"KQ,+KPH>D<9ANB@JMR[&I-<*8%DQY/1:)8>&24'GW#W M??)#B3)8)B"C/>")SQTYY'<5K$5)L7K=)T3WY>._@^7M)2`_7/V?WZY_7]Y< MW3X]GH`K]-N[3^#^ZN'Z[G)`Q1\3+TKTJCYM4?W\ZI?KV]OKVU\&-D#K5$B] MZF[N\:RUL4&T?(/1EU"WG@Y1]+<`MW6-_!5>[N.N")J<&'8*T.7)HKS)[!EW MZ''FZV`502^&EY#^V\DG."2,CT)LN617+J;S^;QM,$J[$&0L0,;#S%[N8%8@ M6[VW5T_@Q\NKBX>KY>/53^#ZEOZ$?@#WR]L+G,0M+YZN?[]^NKYZ-+IG MK@H_]A>KAM';8>M]5]=[.;3> MXO6L891W*\K#TD=?A:^O84`OP@%AZ=M_%=A`R\I79U3G2V'=;*@F!+V@CP"O M@[PFXFZ3,F%^9/[3VH,,5Q3)X0_Q.DNWMR@M7-NRJ=3#I*ZD.8JH4I-<+$D)@"1"I/"BN#KSGDLBM/V<$MN=]W&`Z=EQW7,;LN15X M/4091[\R$D`]1".7I9%9C'*@404H2V\C?U6D MOW'Z5]Y1@%ZD]&.HDWS2A[IFDT4-92DIT68;` M-==_1_07KV%H!FPO_V=`NKL)U:6D3>X[G][W=>DE\.I;`@-\M1_=A>0F(]VH M&$EG.XDH6[,XP_^,F0@."P1GC`#F=`)R7NENOH%T>#ACM(:SBC'TV$(BFQ[. M("2*Y3$[7?#'Y:!@ZV\@^@4BC3MD[;CZZTO">P6#:HK>W9##Q;+K.-YC2__A M)R]7WNKE%GXE+;3N-A=DKX6D4M(N(4?-BM@F):KLFNT<_<")<3FL,X8`[S,@N:<>3>T"V^[Q3H)X$`6JV91Y=B1]H.O%5!8-SOL#J76B6)'4UL35>[V M29QXP9I_BK[U-=-QH22+=&WB^&S>!OP268L@W5=9@MG2RR#;<<@*FL"+]X9_ MOVJ40T7UBYF?X`Q1"KB(O+2USS39":`A]#3/N4Y0%@Y!SX;N>YTGDYZRMQ`SNX$9`Q)G6+YQG#,$V"F MX!P"RE;SG$>7@1R!@J[`8(72*=X@*7A#9V+"%T-VF'86[B0#<4Z,'CPKDS.4 MBRC2SZWK1TY_ELF!'V_#!(+Y3T83CG8_K.0:+=:Q#$KR!\$ZT;`#;GT/+$T6 M\]%H)`%`J\YR#68')E![VL$"U$J>W>IL3FN1_02_)>?;YI9*3R*V83N73/KR M0G<\ZPINS`00+C;#NY\IZO@^J=D!P_T&HDP27T"]@A"GR&;7`'IY?6=T5ZVI M:'V`R_=&U/%/ZCW]\_UVH62WY*=GXZPZ63C0F.L$J%Q;B0ADN#.@#8.L[%D603BWJD'.Y4M'#1&=!I4K*!`UCG0:5:BH3 M*PQW'I3%H$R(,-R)L*AT8!Z!XC^G>39082Z]W#2>S`OD9/4\ADX*J='&K6MC M.A]G>D\]Y6[J:]C9[[WH+GI,\,%JHU!2]8A+\?8H6G>F('P',UV:J4I$!FU"LG#'L MM!5$`83_.?HP&CG%S.R? MP71T,AJ1_S533.`EX%=2XSAV3@!>/">KAY=P158>LM^Z)\"9G3B+TZ@;'W?!":9$B\G[\_(5+,EDS2KUF"_[),DJXT72S<]CAP_I[>_3ID*Z>N M$:&WMFV108NVO6)$;Y7;8H6,RB:C!@ND;=&C82PSF7VZD9ILW[/3W'3>T;*9 MV?*:ULQ?+(OL1/)L.LY/#A04BSX'Z:39]-:G0F7=-F7-)M]RGEE-QB6LHVBP M#M[0MT+C'[G7.$+SG9NBO?-36,(Y.W[*OZY_\):63;95QAA/3=-!/".>WLB- MR8,2??`4FFRM,I#NCCVZMPWLPQC`K1D@W``O-0#\MH-!C+3W@R0TWO&@+[I+ MHWTW"QH:]7,92TN-]-<)7#O\T:?E/;WCOE@8^86S.1.AE;7RG"QPC(W\"M4E M>'R$$6G#`G;(MV"4WM.RRC6U`(Z=/;:6#DB8S"(`TLVRCNC+7C(/O502Z1QT M["Q:<4=I6@:Z/HHR1D"R^'Y2O27)AMU>&=^4P%G92OU!%L/5A^?P[>,:^A1? MZ(C;/R]DI M)4!)`4P+7.%-%41-+V*4Z>7VT6MH;,@X&$9$JQ5,##:7\$M20#0?_:Z#.(G( M5'#Y&NZ#A#?L2+^N<0"2E4FZ`F\Q21&%*8-2F"[ROH(XH-1-#4J#*,\8GF#> MR'@5QDD,(KCU\K20,/7Q4E$0)K9,WOIZ?'DPZV1=\W"^B_QG/_"V^+==<,QZ MSQB`&<)(E_^XV84#=>1F1`'Y@TV0/53=.E9Q&44$U_"5W$%)^T;6\8F?R59< M$%8A4C.Q&;0"O^:CE6=8,S!%L^J53QM'!6LD#OH>?V>MNLJ\H16:7#%DO71\ MYN;#:4&,'+@LDS.%137ZN0W]",9:]-.'IE;WJ^)(;!0S",I;JSTFWC.\PF%K M%_DQO(0;?^4GR]5J_[HG2;49M0L7LDL:VJ6Y`6"=D2/![H'.>"SP!(JM:7[P8KN^]=WH27=SX[4"B.F/, M09+*8F4ZF::]6TK]H6BI3\X1I"P!X0D*IB#C:KQ=G$9CN35CA2)CG5!KG78R ME[:(HP1@E6AS^&>P.M*^_>5O$A7D#C?A9 MW65B/$&DKT]:3-*:L(P2*$@->0D,M_A+B4:.`8W$)5U*U'(K:M&[+`SN54O! M)B_)$EK`3`Y`!8I14,$UJNF6(3?^LY_6.F8S19"^^W8Q7U21$8.4$DA)F1I: M#]>+0".KYESG^NTH1;-CIM#-JF,AWQ!F$4)*TR*X9M52MSUM!"$5$61G>PO' M;2(DHZ2B&KC_4IH"Q>;%AA7=D]KEJM&JIPPV=J"%Z7)LM#1MHB8C3+.O[%\/ M#5Y!XB?OU\$FC%[I,CU[\:G[^]HSQP["R;G9;#293L_2;#*E"DKD`:4/2@R& M7D7B9YE#:>]8I'U+1CJ4"5QU)M"3P?:`>9'5=K7B\#68F2BT]HU>B/T)_:X^ MDQ4_JZD*DRN`=+GBV71:0UU:KTB)`4)-?QFF&L7YWU22CAM3UU(H5=#MK:!.?(A4$]Z\.OF_+BS\*Z4\#I]MNP2=5?-U5.SOA;MG_'V;_@&H_?[ M*'R.O%=FPYNVI[6OG7%%D;W`>3R=92MEB!;(B8&4VK`-;OC+8FH46@D_NXQHWHG@R2/[*^6*+_TMWO^%F/;6P;14Q-%_D8/EP\B0I,<_;Q".7:O*\96+ M$WXZ:;RV7HU^!&(W&$S"&_Y,@4A8!2^V@!&@O.ZVX3N$:1U^J7NBN$ZV_3V= MP&D31OJLN>ND5>49R?S42KEUJ-$R6K7*5@IJ5RWG3PY63N)F+\7?,NV]B!A[ M",JX4)BLP*[W$+?6N8P^@'O$A_DIM44060A6(HF4F4Q&E$<8O?DK6!SJ*1_[ M66Z)!*2+W0-RW&XV&B(94($/R:N37&(@L/$AQ/ MI&U\7%&2!WWUP9+Y3:V-F;?X,%.,EY6^>M$Z?@H3;UO^.U;I-DS^"R:%LH=` MHA<_VR)G'R6DMR%&DVG7X)G+`ZA`@$A4?0;+A!Y,`)*J!'Z+H^?@5B8!]+<@ M*B)A>9).FL5:'_@.P6_GV-?[BWQ7X2\[@!&EO\+/\7K5:A;B>PB43,VD;RAP MLB,<6J)G<8XH`B5Q377GM?B;2,1:?%]R8<(=8?E=QE]A`-$2E/G?<_BZ:7*V M$]\@A=LS,.J`JW_75#E=82I_@B2[Y#1['7PF!`R>O[!0R2R-M>!VOX[3_@.\_^C>=T>F^=N7P-O3LM>?$[2.D`0@@@2H:\ M^2"%W*X*:?-NGC-5O)RINS9O+V[VHQ<@W>V3&!_+]X-G_L<2O:07!P))Y"/C MV;P*BO(MSNF57B6ZQB"B2E>7H^N)I+(:X2/AG34LM1E)%["8NPZ-/VL%2Y=U M9^PJBRHLS"S"'R2^*RF^/H]NKD@S%=3EI9_\+8PNO`0^AQ$_U:D^I=5G*ZSE MO_W8J;@NH0(R,J8='Y$]+KJ?=;=9/D<0LOR]_7G=#5!$PDA&T(D[F4YI"Y2"6K8E M'6Y`05!O"Q1EJCELU>X&5TW=_2RVR0$.R3FBQ=#X*W79$O6VX)] MX"MMMR(]L6KJAR$`O[X?2:B\3X^0GSX]^][9[N(SC/;UP M.$:"PE4"UT\P>N5$]=;7-(Z<;;)(%VA,%NG15DP1$)*@1!-D1`&F:F8T5:HK MP=T?7H2GYR<`9MIM_8W1XZZR+ED>9*7L8@N^'OSXKY\0\J_3>[L?FOTA.[]N M&&\LF613O,5T/!7B#A,'F#K(R(,'[3TF!]6^BL0(Z[O!^N8WNT>&6E#V=>,V M;'(M9@M&_X#X2BFX7N)CO<_P]W"+1NXM7M'L!E8Q'<.H%0HG.Y2,1I,S(7PS M+B!E`PH^EN%8G3VJ@'XK%+81R%*^WH;H=ML9A?;Y>_[CO_M(0C3%>+_!MU4O MO_F\52')ETV`6"B1?/>\B=M`[OD[*/U73AP0ZN`SIF]HE74`Y=VJ\BJE.\R\=EN*:.@+&YL;;MZ7?B*"0`RY)!>TIR,F_/,$CWC^WC*E'1[*ZD= M8P)79"*+9QI;\-36C4S\CF%$=>[:YF4R=GG54A1OPR0^\8.63 MXF[DC'MCJZ*=7+(-6.9;E^5270>[?1*3H=-E-I:7><,$JIIBR"9(SFBT:&"* MDDN30==0"W;52C:R0$KO)%/3"B#Q/9`)(XY)C(+H5^AA7)/@U,Q+A84KW6B8 M`)J,8-(E(F0%[BF:V"&8X2S3P6>9PTMT6VK';Q?&9:)8VJ9*"@IS# MW29/+$IYQ0VG;UZW=W47&L@*)CMRS!=3AQ8=2*1BP_>OXU8A#*)W/3;=&=-; M7*(PB/*R^;?Q!GN]P)R7*W2RG8ZXPSHI+_^>9?&FPP'UZ<193!8=8LV`A^_[ MAIGNZLJ'&!.]!H;163ZRF&M/T!FIL@%%13N#_I.47V"`LJGM,E@OUZ]^0`ZM M)/X;Q$4D0]<>G'5;?AJ-W9$LV@POMJG7^WC!QU]_ MD[>2DHSYERB,X_LH7$&XCC\A%:[C>(]O(;C;E+H](&G24A3FE+T[$=VY=&<) M)?W0G2W0/R2Q)BQ`Q@-@=P`9%YR'51J?8&?-6.E-LX>UA,.PQ*>*)>YJEE@. M;0EQ!CZL.=S"'+N*8_@EQXASC_@JL(.6K+QW-,A3]'[V-)%37+_NT'0"1XV[ MS34*'<&SCZ8/RSB&27SU;;7=XZXVOX3A^JN_Y0UIW6AHS#$Z"28]YLZR,NN" M/,9SP0!0#B!G`3(>9E*.X$0$[)>,F7"LW<'III0Y38 MU2K8$9C"$$HBZ,7P$M)_KX/E:A7NT>![[[WC-3,\V:"WJY6NZ.)_YS[$]&*L MAX32^\D+MX`@H0\R1F@@!!DKD/*BT_'TZKH2.V,@'=HTV5U]U`J[U`IDUZ1VQ(*['<0K#,'SA;?S$V_;/HC*$C"*>9Y4TDV%1O.% M`.9#2MV$`'L($!,\7+^A!&*,<%X2YXC3+)=#>%IYM]++H[MXMAK+0@I;` M-WF!T2TR#;U1L\\`+B!A%L).C9/9(KU9YE6M*&^71WI9 M=5JL;=77DQ%=>]:45>OLUG2FT#P!`33:H*Z+FU;1*&D?0]@CW4+$15GUI_0B MJLQ:UI$F\ZS+6][@1DF)U0%#7'\]YA4](%\/C5!@>4W-ZQOZFG3P>S3\M7P: M\H@!U\9\9?W!=9QYS:_QZ\8B?S\%2(1__.W^_N;JUZO;I^4-N+Q^O+BY>_SM MX0J<@@LO?@$D4=N$4=ZQR0:'+WL1R]MS2YAQ]:P5*MUPR83B?CW.XUHAP)9! M^KIR=S[)X)!1`NF&V;7`;W1@0X%F;@7H/B%D%@9B#ZM"0F``L_!X0JP$38H8 M#QJ!1,9=^N3U-+N(I@0&3,1HCZ$#]7&[Z:,?"75G8F.@HKMY[T^OR/'_3@I$ MA>7B$B\:0P=+&MD`.Y]-YVRT5*D:+A)7K#`33G6%+3CH+>^N?+QQC:6D4+RM MCI->"%C[JEW>U%T2+B>6;+GO?.I.:!VX5*5S=ANDWMKO`51VI%4>4F-QC?<` M:KL5M<,-OH0=JVU1+760-.-E+G(TTE.60=%_\QJH0@Y**27GV1NB4LY5CDW\!6QRQX),X:F M@M-P5FE$J_1*F#Q&70>@X`8PN^R1NT&M(AO`AC--(Z(I14.5`)33Q/38TK3`5J@Y7 ML1&2M*HH&W<.UY/6$6[#&._@[HAJ*,BDT86`N'=YC9,8%9N+/<=6ZF8CQIM(G88W>;-="@?UI(0C6R8 M#Q[=4D;X@0"SRNK738<7I;;@1YRG$%`^H&"$'R"LLA,-5L0AI09II#Z'.X>A MJ"4;'`2!3,JR`\4VTMM'S@'HH^:C%)%#VMMFDS$_ISFA/9M,QYKN&O$#RG`* M=0T8W;4B42'OHF71<@X3+0)$%ZHK@>V-]S5&LY]+[]5[AA=;SZ_?\,=[2C=8 MFR)(?O^SN3M-YQXI#4")`$)%+T`/U,+1JH48E0>JXI9506.OJ1M\6U"0(Y&C M;O_=T!BN/CR';Q_7T*<;H>B'^OXG^M6?-Q#QOPH2?+=\<]N?]82&'4T&6]F; M0,[.QFEE,"$`*`4CN_R':N%VT&)H/Q:X"O9AGJHF=O/;3[49.K36XSC6;.2F M?9(&/VT6)MY6M-G>5_H9EOX)4[?E"%G+"3$;#H"59%@&:[*M]A)NURC2T-7D M]F_$?LV,MS-ED2[-.)N/&A`@F\5EFNG.BYDZ%*6JNDR\G(`(KB%\)0T2Z/I" M0@Z`[*+LW%JQG1R7)/@G\.,:;OR5G_R4;L%8`CVA7W/PR+>NC2!M:8X@_;I% MH.W:%<#)RSXDP&N\*\(@VM,L[GIY?GUS_71]]7@"'JXNKZY^79[?7(&+N]O? MKQZ>KO'/]P]7GZX>T!_!X]/=Q7^`Y6WZT[_?W5Q>/3PB)%]>?;J^N'[Z"5S] MG]^NG_[+9B2+>B=TLK-A9%_04^'M'I,]:`:M*7?I\N'%E#&HID2,YY=]E"FE MF5F#!OO2S9HS<3!15M\.[YHO&$5#QWCMC)SQG(L*FT:G0_2C>^M-B!CM MQ=/N*_XK/5X`NA0(Z%?@VC MOX(P0AF5L37O-OSD*]]"4ZB!LA]@#A?AZ\X+WG_UHK_").W1E9Y_8'ZB]K>T MP[M5)-E-R]'<':5`IS1!2A10JJ!*5C/FU:KIF%6S)1"HU=6ED8[HMFK534\@ MD$9?$1+DC&(B-TY%$YX*K#ZC,0.N,)9-"L>S\:**$;.'^OHKX9:4,)G,,GVD MG+\V533BRF$`4W!]V@?K6.S3[(=U.C=3`NGVI)-%.K4C=++X3RB9=OC#%7,+ MQ5ZI8AM,R2@(A-Y500-??Q.PN,5C3?QR'X5O_AJNS]]_B^'Z.DCO$`R>EZO$ M?Q/M+G<@H!$^\E))[U:-%NG`<4LRJ?@%9-3!^3O`]/$1J9P#*%B8`=I`)G`S M$ZQ(:Y[,!%_>P297W1.JK@N3W5V[C-..YK,;NRTKFCT(68GESEV\G;-)3TP; M7Q\=V"ITW73Y^._@T\W='X_@T\/=K^#3]>WR]N+Z]A>PO'BZ_IUL\!E=2.V/ M@'Y0-[Y5QQ&5=KLX8+AF$3`/<894\DVSSLXDH)US&'RX;ML0',@$,^YP_>,> MV\`/?D+_RXQ@]<`M<'()-/,,:3>*^PW<(D)6HKI[J/3_8/W!((Z`=U6P?N_!:5O@,WBX!YB#.DDAZU1E(#=W')D*7S[$-- M4)UGIV-U^8HA._.50]6>':2VX?`E0+-$V.*9SNYPU2]#$1&R,GQU'8NGT\6T M9QBS-4-1915FAG)W?_6P/((,10(!_:!N0X9"VS/?A+$@"2D]HQ>H!6/I;=+1 MM(3!M!+)NUL\S.'B7:0\\!=?,I-6+,#.82/!4%! ML3$J80-XN]W67Q$S)&&E*6O*P(+`HM@`,PL,\`:C+Z$Y'W`J3@![6L%(B):/ M?=P@+FE,,V'^ZT48D)1/<`%%_2FM8;K"6OY*56>6A>&O(*-@]-Z)0S1Q.VBB M#R5,UZFBH*FR82^G5PFT?Z+T.3.>3IE+>\C,<5F^+K@U0:NW]]"&X>\6W`'! M=2..SY<4-^+U89"O6-+!2'RI(O]YG2C@"2$_VSO+-N5*I+),7,F=B[V33"6Z ME0[=TIN"Z35>Z8N#*[$"SKF5(`4W]T]S9,:']M/UQ_"J,G&+WZ`3DV=+=9/D<0 MOC8;.G1X4?>I/RFI)`^.3F?.Y(P>_*-D`:4+$&%0HHP;L^:T]9[^4Z^N8X&Z MXE.`ZG4FL2-_%20E70-JB1WA9NQ88">0YB<#Y0VE/)(\A1?[")Y'T%N]=(@C MO-=,1A&.3)*#TV(QG4Q9,02O)2.Z@!*V)(2HT)410'3K*A\_5"A,HD>J&KFO M+)WYVAU&6A#*#"(B:ZD)(7M\FNUN\^`_OR27<+7U(KA>QI<^WOX.UI<^RG[\ M+WML4A30KK`8^R1.O&"-$B5R04CER!0`3"( MB0@@DP$L8Y!)`O%._UE!SY#-H2ND,7>[P$`AK8C/`QC=Q`I.7M.4SG1Y6UK-YS2NT#28RRY1+&9N.K4J2O8R M&F;6-`]3I;R6F2L$!0KI6F[ANE%Y>86MNQ5>W[)>R7_>)`JZ+M@MQEGKP"8: MC"]+JM'.K6J70HM9PLYO/9N(Z,P2M/ MI8>*GOHP!PO3Y9P";V+"X*#23LYT]RYZ]H*T29>WQ=V=XMF)B-#;$G"BS"(PZV_)O^!A+U' M?I.A_FZ3=K?PMH_H-V05L#5U54);YS"N0F#IYDCN&0/LH,*7`+_,&:_YY+Q! MP=Q\#JW==&[=="[B6OG>B MY26=(44HB72EY2AKTTWK75*"0-OM%*WP5Z=F4=9C%(U2;E>!6;L)S.$GCF$2 MWR*U)6!3?U8[6FH"R'K/R'6K("%T0$'()#0.T:E4Z+8-T40:;S,#CU`T#Q&. M9S61P;*`,4"4`"J'"O8+NJ'!E$+ZNLG\O"/UI?+@805(#M>NAI13@A1+[CEJ M][L&9O@&,0:<9IVJZ(LRGM8-F:8(LAYU-IXLRGAA5%8;!,N!>C6*IXU#@^]9 M#5QP=#-NV54'1 M&UH1P15#NCG1)-O4SHB1];J,G/$U.54JNA45/7D5]:&FU0FK\!';Q1".R'K; M4[A<_6WO1_`^"M=[W.P)TID3_QNWO*<74V)AY!>"1FZ.++I(^Q2"E"@HJ*9S M_,/@193_39$A0E\+7+.\9IEAX$#*.1+97T:#!WYT)8$O*` MT"=#8<[!(H0J,`&!ZCT2]\7#]6OA!O=)I[ICF$*1UB8Q*G;J-K`*#&<$M8@6 MC")(+TC'`SFDNU@/<`U?=_CG2S]>A7L^;#M0T(E;>;'DNQ%D=Q'EQ.F9`9"3 M)V<2<@8@XV`*N`/98%ZU`6EC!;R,O%&\=G?G"F`[&LP\8K/S"@_(#>XA\J`@ M\9YYJXE2KQK#*%L>Z2[\9\Z$#<[B1`LB#`K*AJ:3JG4F\TJB&AI!URD]>S`H M=E`^^`26L0=U,5TWS0L]KE]W@B6;+B2,HY`ME^PPX4ZS73(>&N.L/COG`"@+ M*\9*A59@#I893LU.0'OX=#M@!2:S"+CD!!]W.4CXCGEH4D&DSQ(X,[<-BY2B M32-B'R5IB_LP>$-S+!^W6MUQ8`=^]`,0$P9&NX=).:<$Y$JV,H^Q&Q_-:FEM M)/T#1';XW=ONY=)2P>O&D,>7278HF,S&G`&Q1!L4Q`&A;@,@%>E.L%G6]0V3 M*.>L(#)VXKRO(_.AV6(U\RBE(6.Y3U["R/^[9%K4>,D8(NN22)=MC.9C-@XI M15"0M`%\!ZF9'@2*<&G:$CCN_\(]=GACXTDZ'@)/:``S2.0Y*Q]_3,/9@KKK M.-YW0ESZ@F&T42FD5PIGCAAIE)P]*.NA7D>$^5R-3<*JZHUMD"I9R18XE1JS M=/CMW6:IHQG[H@-*6OF8MWUZ82=K(-U MZ220^`"GS)MZL=DFCNQRW]EB,<^QBHGFW=EQP4SEY)K1$YVJ57;+*F?-D4I5 M;>GI%ANJV^2]M@8\*8,IZ2-S'_G!RM]Y6SK0_DK"5.U+"A[4W1^&*87D:#!V M%N,Y[063D\EB_&=*:9CZ:E9`4*2-4]7F48,VXGXNAZODLCZ0L98M0GSD[5GX M6IL9+<,5A.OX$U*CM!5T";_P1TG^&UI'1ZX8'=8D9ADJ*#&`J8'REABF9VHL M5*-@?K7B+E,2NRS)23V\<*KQ%]X`=Q$NV--4#JX)S5P5!L,=/XNDY- M+FH>+O^>(:PQA9%-RA;3V8*%N(RHV>[2PZ@KA;_B?E.2G7[UHLBS"'Q"S^5! MD&\ZFX"8AXGJ'+:C:_"H6`!2CFC29P^<[)(O$62+\:.V&&07@E78HN-X6J^I MP?".TE:*-L.\!1Q>^J+YH.$Q5I MI*NXYQ-7'`\B@.GBN$`I6X3[_AI+`/P(\GNFX[8"M&DUTTC,CI)^"B.R(IXV M&0V>E_CL-VEN)>$6,E0,851"-.EV?],%,\//CUOCVZ#H'E'.!11LS*-7M2W< MBBT(C,G*\DNX7>-6".LW[/76@+>#K_.0+&M!1=M(!6,R=M_MTL;`?]"P>/4- M1BN_>3=3U[?U;SC)BB8[LDRGL_1&@J<7E!72QE&;;?@5[UB&*Y\F@7[R`M!7 M`]XK/FF+DL,5]-_0'XCG4J>-`:2\,7;1LWZ4CD8A$3&NC$H?=.]L#6(V1D2C MY2F4/-GY3AF`G(.17;!!U&<$L=0%FDN.V8>G.^/4(PSNHG4-#Z6MM4ZF-)2D ML%M:H-21/]3Q7]&;?G#ED#[;,G+RB,PV2=G1D[Q&]J'?Z$XLG4- MB[/Y(BT\(?10L*8$B=N@V65ZP3--236/U.HT=$H:9@0Q[`$AB=M.T`(5$P.R M.BU=EI;D$YH;7J5@5@RI[<8P,8P^(-O#Y3>?-XLO_JYQ@,R9RLXV)XMI.O,F MKX+/^&5#?3O[">_*"*]K7&LX17D0J^IGS&>919.L)W3[;9?JN\EB/IFZ%<\U M4D5XJ`)E[[T,7ST_,.^_S:I!GI9*LJX'N`J?`WQ@(;N`-;TC[BE0M"3Y M%$:/,'I#<3]&@7\31J^-TYB'T=*=J?455,ZYSO#]*>FR3<&IN'DXNT@1=[', MN)$UUHP?R!GJ3>^TF,6QU2SBI%"+;=R:;?(3"]E^;Q("+[<-8@#BS#8[D6VT M)):'1I(\Y3S(U$8&=IC=%EJI>A'44(O>T#GP\\60[IPPF3@9IC-B]9*PPVNH M>[)UT71`TBR,))ZPBJ-,67'4Z.C::G9TMY-!E>EZK6.?C!)M@1BQI'R/`"]]1,OO^@.0*N-T? M:@_IA%.%LW0IJY-G>_1]D!(PA(_^2KAE)2*^$MH0P'27BK,WE56R`O2X>H'K M/:[?:]XC?.,'\#J!K\Q*'+D7=:_M2$DENY4[G[LCNI"3D<6I/^LB[,^8-B#$ M-1\,5Z^P4U'XSI#"XO48]5J[*CZSEI663HC-EU7D+39X6'G"I?Q=ORI]R:9P M0B22]+&)BZM"Y$()H6M1%.FNIUP$&5#/_L&CN[)R@8.OK/&848&C5+PHC&0B MM6Z5[`E^2\ZW_(-['0AH3,GEI9(=UT9GSID<%@E]Y*2(`R`L#,UX![(!@6BF M=[:K8#+=[^["Y:E`1RL9QFB0^&M_N\=W+C["U3XB8EY]6VWW:[BFO3I>=WLZ M!-]MKKPH$/G."LQ8N4*`S$Q@W4%DLMWEI_-&?&@)`$H1`"9#%E3G%P*#&HA3"F',B66J/MQQQSOYW$45HZ.,>QWS M@-'\;#(=,O99E#F9L"P)@I>Y)6EOP3]>_-4+LMY^B[,N/T[`_3["9X837,ER M53J.5&K:G)[2NBZVT\E.!:7U!T3&O@T3?!L:_4!^`"Z\[6J_]4Q?ICE<"!@F M7AZ0([:N^50XGWNQO$[-%A8N"X)DC:&PN)(+C4?0MCPV@0YS*0W+%NPVZ+"9TFAL MS:;%@3%*21#NN\"@*@`70O#6"-31M3X,,X3N`).S0R,QQ0?A;WD`/M10!\;@ MDJ$,+I*8,5UZOW)EF3%XXK@@U/4/Y;S/:7:Y^.IUMPW?(4R/ M,Q$AD0YPC;6"04S46FZ)+$3!XG@4TLD/T7-Q$I^_/\!=&"5XHB`X%C\X6R-+ MRG%%.-$+%"6"Q2"T4ZY^>D_*AL@PH%S7&J+Q0-D MAFRR4X!5AF]LOK$-?_JE8?B3LN5#KN5/P!=9T^M?:!XV>+"7G0?\Z-]#)):K M5U#)ZXAC;I?-]M'9V8)16:@ZT%I2Q6#*OH/'4[NJ&@;`_)!1TY8:!T7:2)'*F)6S:4P!ATM`T?N(*AE.&+;-CI0]%/X_R=5=I:UJ4X(>CY/(7R647/$XKHNH_.(/"_K*#QXE!@VP%JT,<%3`7_B9-$%!273Q3-K" M>_G5B]9R.>BA](T$T0.%EFYN-YTS*F7Y,;+$'T_5RP^F,@`BA"WII4XS-E)* M7@99->.7]\J#TF;4'^<4`94=UU1\*1OC6*D_=YS>,O#>\?!.;$61:YV::6G M;^X9X^@N-V15$H[L.H]WXSLUANQ&8]3^]=6+WDF(JMP4D-*W.=K(PZE+F)&T MLBWQI1S]RJ+_[FWW-&SBG37ZN]ZQY@`FAN-.?\FEIT"+!:-JAY\-58-0+@`B[?8.0]PXJ1?HOI;/(2(CU>\3;%)\^/B$5I?7WZ MW"]X>FBF2>2PP&V+:@=^*<45/T2"]&8>>FO:;9C`;/:^#-:E&Y.EDB/U],U5 M`!TNO'2/_M',;?9D*//_I_2*0GSF!)[DZRO-E1=1CJ"C&DBST9HQOL2_;+/" M9$N>R8Q'>+.FS*J$&JMX1O/.P0(6HWY'D<&-9*$P\F&\K-Y%*VRK*'I#9W[( M%T.Z_F(VR2:T)R9"<63S^-G"S5(-ZDCGIXZ6^\_YN8,ZOO8<>HP'O#4%3@B-/!J\;5J.!:$114 MJ%4-"HBBA4%!A9[5H.`>45!H05\]*(B,92[WONB<>[/?T)Y[,\60W;1PG$EU MV+VP!%VJ=70K.L9[?//E<`US!8VX:M#H[93,/YIE(UX.*RF/P"G?CJV\Z/ MR/!VZ27LP]PMKQ@89A@Y;0RT* MMHZ]RK1TRUH65V/!0LDU1TE=`ZT,ZLHC;:MI%(4#O(F$A$_W16@)'/MK,9_4 M#WZ6&-)]>IU%=N0WHY/O1%)*NH%^L#:.=FW:4'VP2FY5I>RRK1U7)4T8%D&E M!%VN_D:28V8]!R]98S^L,R5F2B"=*:)_4T!PRIT,)<&':U6J)Z=UD*MR$1?D M7P*F+=D5.EHES^5;0\V8UE8IR2N4I'M.I8:#=\D+C)Y>O"`M$L@Z%<;7@6"@ MU,A>^^BK3S?9]&\^SO?N)-1H7^G$H`WVD+V?":D(" MXZM)@Z@E?5/,9*HYK.>B&ILFV?XYR$PI)_%QA5=OMUO#IV/TQX3V-;KA/I7E M,Z=4Z'UDX]RIJW#?S^RIH^8=R_B_E452?9G?'1F;/0&]^IG*IF4FKK M"0Q_!Q*<;>@KH!GW>J9-C`]C^9RI*K$]TZ4.FE.S>Q6BQF.L-X;F@@$HZ2(BF9?Y7P=K,#.B0CS'!'Z-TA?D)^!4%T1
\5:(7.%(2?3\I MCHRZLFM,\]FB?!).PT#9,CB"SYD*P\P^#>0VRK^7UL3&\/E/^M1K?;B*VS(#3:ENUGP#:KX(M3+M`?D0[-YH3Z^Q["F M*ZN,=,W??'ZF*E27[B@J7V:4B0%* MUFH[?1EC`?-+NV9?NFCV!*-71^3DPS#4'2('T4(6H^-YI0]=RZIJ%AH9BZJM MD1&+!1R#(=&\G:NQ<.MOAADA4$;U)3P*@SA-B^#KS%"J"$)*V_@8,6A0:PP. MPWV2[R:-_CW<(C);-+O0G4C7.!][*EU51Q:WB_E<64U$VY!12/B]I=,'V+X: M,M\*$Z6!CETLKF*;.INF8FGS%W0-@?6Q5L M/[NY2FK<6NUF?2QK@$])L*I^DZ.*1M5&D?BFOF%.MG'Y'$.LX@DOO6"]^V<(XIE/3=)$/P(+P48:J-F0JB5S"CW!4 M>SY-36K%``_PU?,#/WB^"`-2"+#WMH-L!AT@R3'L$O573W8:M3B;+-1L'[&" M9:-()Y<7E`0^SITE3=]&+NH:O+#,@FBB9!?FP.]YC)DHH[W>0)D'B],19:,, M\653I_E\TG)/7/=\E-GY\]@:;2LR+6FHG1EF8T>_3@WX5)F1\C[!,8:T:L>< M7Z(P5K[V)^!T1"&-(;[T^>V1.U,=TAH=NXA$QSG-/M2TICMM:<"BRO#%,_?Q MAZ]:`DK^B._DSC=LM#APNQ1'&_9:59.^VV,^5[9A(M_$D#P!L,"EO>/O(6:J M_2Z5\T*G7FJ\9TST=(V-M\'&>\-T8UR$DU8NTB>^IQ`L'4^&"\]R7U;=N=T# M5@+$_0<'86'D9*TZ^:7OC%V3"G`RY22,^]6K(EDH7<+5T7I0X MC&K(EF2T^"TS`1T+S)XF51_#JL=#%1OZ&//N4E.)0??DFWR.*'=N""^;A;GC M,V4EYZPN04?;(5:)84E_GRMJB7-OBQ<^C[+YJQ)CD"X]Y_#9#X(6>QQ+"L\- M32J3=+;1CSR2#]B/5SFBFK(<**[`?=0]5=18^]EZI4M`<*)P= MUOO4NIC6H2&J;N['&?44]`<]-=AB=0$GDH\_@A_@TMK8S-!]`#(3I M^D'N3_ MGI!\RV!]C[SDUGN%ER$^=M(WM>G#RJ:LN8?\TL>K9J,.>7$LCEKT_[$\``D$ ML$0`BP0^4Z%L7;P>VKXDCI6,(S*'-0GM`?CLE++V-?YQ!;7JP3K8Z8YE9>[< M2XBC"(1]-).=GTX[%6ZTA,C:`6%H[?WL1_!-TAZ"]'6[*Y0'B0MJPFSOSW24 M`9AQS,]$".XJQC$%X8ZZ21+O-!`/^5W<8SZ`/%#,4!J> M^WR\HPS0PI,R6F)S!PF.*2S+JR6-_(G3HJM#J,H"_SH!R`F M5'\R7J#56S%V*56;;EIC$0LHC8C1,(`17"=>0F+4Q=:+X[O-(^YVMOSF$++G5L;%["XC!0@M<+T"MNUTH:/-H>K MX$1H"*-XH9=UX@$_#/`0+X,9YCLF<,,21'HQ=)XO4.?822_C+0C:`9^#U:1K MOAV4TXXBD1LRD<2UB5$TW;3=&M!\T`1N;KIVIS^;CAL#C07=^0_3Q^VFCW9, M-)R)"80;\UWM,U'N-KC;[*=M^#6NWRK-^W*L5TP@@B&';)+BN'DQ2.Y+*/W" M]``A:.QV=N5:UA`3=M!2.WH$SLC$$<\VAA'UR0_0M-#WMO=A[)/U&&ED\5\U M@S"N/-*YS**9LB&DY71!1M@FQ*G1NHF\SEH;0&"K\W*0*+:98422R=M+N%TC M)Z!9J#PD!>^:P21?(%GW=,_<,P8HRX2S>95%J%2D=Q.69<+_)*>X`6"V^S`' MF2UV,PK-)]QYO^W3TX=,@(UPEK[N=;H8-R91H/:O7Q.G?I8XRE5;C&@&%PR^HPA6QK)'"8-O)G_@\/0V'B M;0=49895><),Z'TX^4#]XQIN_)6?_`0@U_7T12<>Z*L1BFD).Z)4:T9L1QI\ M6`XX6EF0[BK1SZWK]T\I1@K0_&P77,2YK,($EG=HN\&#MR_0^KCV MX]1\620#[70^GA@F\]./5-HSW$7R"WY)SQ/^OTD&=][[1D90CE/3`!3MY!!\*L;!RA5-=GXUGA3;H!S(4A\F3$#!!1`V-N%6 MC2T(>A\@?A^FMZ_&1/6(IZ]9!+>Z>#N.Q88;*+=F+?L*'S6?4W=90YVXH^FX MF4\7>PL#K@IWR*6[J\3/HTVL)O_*V\>GM[\8'OIHG-4:ULC$,N_OE/O*#9WJ'H043.0ZB%IA^;X+@.$E&-VB#(]1%5*57%=7\$6%'R- M@W=H6Z5ST=P2N-0!,&9#W._0CS#I` ME)K"*CM(34RRS_V_Y"(?`_CL)0H=N9-=YO9T.^L-?>GXQC>71;&.7-6L>!HC M2=-\!)035-;#9^/1N#48$I;'-X<9P%(=IC`6!HINN)&(&1TL;%OXZ#EGJ;UK M23CHFK>/IG.W?<9"86_IA.4`O6EW>Y@`4BH*5M[.Q_\F+U&X?WX!L8="FA>L MR62&F0OA/WZU91M=UK]EX6SM#(=(IV""(Z!C"9P/REG/QLY<$MK',+M19)!^ MDQM;P7UHKM]B5&.@3Z7Y%99OFF;Y2?5!W;"M<)==*INX\TJFG<'N,R5CLNJL MOSYN0Q_CD&'Z4`,33975E99D%7:\.DS1DT8*2QIB2/K`>#YWIZ6Z$F%MX<"5 M)(?IX#1U,%@2JDJK9O$GSEQ3FF@2OX$D)\"_S(K,2.65V?(2+GRJU25LTQ@9 MNO9?8OBW/>XH]2;3P(GWN,YAC".#]+Z/,\I.[.>4`"%E0T\G%]QB+$ MV'`M=IOCM:"F]P75O)V<_6ZW)>W[O.VE_^:O8;".[X)2@=,]>AU&$5R3Y6CF M$GY7&MIW?SH**.MPB\4H.V]YH8 M^I_@ZRZ,O.@][6FV6D40!XZG\`&NT=_PSZ1P9+G^O_LXP1IQ!JP^E#2F"SW$ MD^X0Z;AI\57.)#NZG[,!3R$H&*6E6`4K0XEU>>GKLG,Y`!%'T[@?/R]=P'R3+)(G\ M+_L$S^>?PGLOD@X$$G3,A8%VX:0KH^83EQ,$,B:`<@%E-C@N4$9FIAG#VJ-T MTH@4@O_'1/VLR5:`)"0RX5WU+O6H.RDQYI(\( M.-F"<@.]);J@(&P%6@]7N1V@VY+ZMH%5Z+T"?/+M9@$D:XF!G"?47S('PYHD MLL.%.YU/.`"LI\U60.\0-=M!%Q4JVX8YCGL*T,8RE04XHT>?E_OD)8S\O\M. MD1IOF4-:711I'W2R*V(:4$L;(!0TK<#:08JV@XWV,0">4&E#:.,YJ0!N3&M9 M@S=Z+*G+=T_?,(TS*H9L!BC]"S"5P\%V['E<[4T"JBJ%[:"J60: M:X!TMT_BQ"-7!77YRN773$.J)(MT&8#KMN"J1-0B8RGK` MV5FVVYZ^#NC[>AWY,/%=.?&']ERN8V"/96NHI.[FMV`-HZ^1CZV;=26XV]SO MOVS]579B]0Z-@G> M%NP#/RDMC)#M^:P_DK':G`-C15ZB(6OM M7_8M$Z%,+))L`X/%[&Q21*V,)DB)TNJX$W!+MLP'W`P0AB>%FCIB38=7M#WD M*-36;6B;3F%W2$=CVQP=H5@)'Q+&&312M&QA='O7EJC1<[7?G9]-Y^VQ0\\. M1^<`; MC60#S)ALTWG2>^M@UZ^F2 M&+OCL[G;'DLLFNETUZXM8M@VN^FN(3F^>C:H#:8*[2!INC;.="58G$W(RJ)S&D#UZMO.Y]<9QY< MHF_,^L3L!W5'6Z84LBZU<,_2%:F4S`DH"`%,26_L/%P9IZ2,%EW$H?!PA5QZ MS5>NR!H1P%A/+_HPAFLA3'($\_4W43652B/L[%I]1F.U5(6Q=(^ZQ;3F\V8; MN/97PBTI8;(DBNDCY7*HIHHJAYV[`#+=D_V,H<$F%T#VG`.:@XXJXPQPAG74 MMA&FGP85H"$2AL!VN")EL($P,+>MR?/Z^@!255,EX.+[R%_!>QB1=42!I6L/ M&H)>50KIW>W%;%+!7Y6,$0@>H$D9AS$@=/`-4F`X9:2P>(!&M`$1462'%"%+ M;Z4LSTC#V7:4U%'*,(!*J#Z%]^B[O7@QI)>'J!\E8H1*!^NFV-,-RED'ZZ@6PE9N$QQEZE8N?+-W`WUTDBKHYYO M'*7@_QJV)L;%,Z9`G@G0(1MSJL!VS2;&_32HPO=K:$%BW$^12F*>7!*Z7;S#RGN'M'DMSMR$I0&E7_MR+_=4R6%_ZVSV_W5M/ M8CJ7:7I)*-T08.)DZ6W*!Z2,`.6$#P`07N4"%D"X@27>=J7\#*W^#&\;MV(; M+[5--H32'>O2@5-P"KX0V^`MZ37?-MI6EPX"2V49JK^M*5I2,]P@PNB_T7^A M'Y"M(/J/_Q]02P,$%`````@`2U^J0G"EH6A[+```/M<#`!4`'`!G86QT+3(P M,3,P,S,Q7W!R92YX;6Q55`D``QX9C5$>&8U1=7@+``$$)0X```0Y`0``[5U; M<^2X=7YW5?Z#,JY*)571:*1Q$N_4KEVMVT1EK:22M!XG+UL4";48L\E>@FQ- M^]<'(-E-LAM7$B30(/S@W54#X,&'VW<.SCGX\<_?%]'1"J0P3.*?/IQ^_/3A M",1^$H3Q_*9EJ+FCVS#^^XL'P;\?X?\/CM"?_G;^>'MT]O'T MZ.@MRY9?3D[>W]\_@F#NI<=)'(4Q^.@GBY.CX^/-!_]:BO;EZ#\_GGU"]>I? M'I,\#KX'TTBZ*C1UP+'CVB MOJ8K$'RL&HVJ_AXA3&/XTX=&%[^_I-''))V?H,]\/MD4_/!/OSLJ"W_Y#L-6 MA??/F^*G)W_[^?;)?P,+[SB,8>;%?JLB;HQ4]?2''WXX*7XM2\/P"RQ:N4W\ M`B4!`8^H)?!_'6^*'>,_'9^>'7\^_?@=!A_^A#_X8YI$X!&\'A4R?,G62_#3 M!Q@NEA'X4/WM+06O/WV8>U%6(/_I)GR_0--K\TXN#JS@+L_5-_)JD MBT+Z#T>X_5\>;UK=0&T!/POC[`U-S"7(L]"'Q93*JAEZ@FN="'W@I&\W'E'- M7Y_08@#X&_>OUV&,!B_THH<$AO@3%Y$'8?@:@J!7;P0_,69_'KP4]!LBB>^@ MEE`C7J2^AS=H*UR`692!-$:38@54=6F_836R^^%QXRM/;PB>MR0*T"9Z]5N. MYOQ$&8(ME5]6N_X=ZR M7X;0CQ*8I^#<@R&\?VT>G[,@*":[%RG;]>0_I["+,]]/QB8SIL6>8-4K+20BT8 MM+N=/JUV=)=Y>?;?OUZ&48X6P1W(;A,('T!:L#AU`\O]DL*.%5]`#+-H&'Y[ M"_VWBR2/$$<(8?:0IS!'4^LYN?H.4C^$>"/(,ZQ68YM',?N:HQ`'10/?0`KN MD@R1UB@/0'`37WB1GT%PD,>K&'*!%#O#@W`)4\2%-?`#P\`V^K?820RG'>X'@MQS) MG\5^Y8:_1.M,0"?D^T^OE4;8:5I(34ER0OP>_5.YCM#]ZSZ%'SPUMY+ M!-!TJG2QV]!["=$"0W.L'HUG\#T[C]"Z'*C_7:4Q%*5G7+B?3CB43$,C5G_Y M_K6IS%3*ZT4",UB#N8 M^/>-06+062,KQ="H;/6U6H3!=QWV-X?N\967QI@6;I2TH7M+_YZVG@XZPWE? M'66=;TPMHVQO^Q\;NH\-[:9!$2+J6$!'VF4C2-O"5#(5C!`3^QWFR.@E` M>(+&X@S_"QZ4L^-/IY5;Q._1GWZ=H4\'^//7D3??-!=Y+R#ZZ#RW.1 MI_@&_1I-0R_Z'^"E5W%PB0:.(!JUJ)R4^],5_^57D>&9O<`L]?"5;DLX^?K# MX[H1HT0+[?!A$ERCOT$"L/2R8\N)1U5,RKKD>#(V1A+M$N`&;2\L08G%QY.V M'$?ZN='DJ^WY M76HLV1[!/,3'59S=>0OJTM@M-KQTQ:5!^>W9]Y"T`>^6&%ZFY]0KKL'6BYL%6)DV7ACGCLOX71EJ^^ILFB"T?9 M2).0-L*C)`U`6CALH_]].$(]>06(G@6W9:>IDA9B9O@2K"B):X9)BD3XZ/XX:7CH-KH:H1\F MC1!1F]N"S,VXGV98%1I9]O.JP=?"G!R>#SWO&5IX`%1!C=_V;7T5'_^ M=<=_K3H>=\P^G,+=;5*]Y-[QLN.*3BFO1?JM_^R#%Q:NY,LP\W:M;;S26B2' M$&2[ALJ='_7)1;G4I!32)R=GKK;*:)=2"-3=LCJDQE'%V"<$_0,[N:W0WHR] M1+(++TW7B)H5WE^47HC5U=(K?#Y489;$&Q]&02WRTAUT:((S:NCJ047OF5-F MMY@.62_!"D3)$H.'2,8<('H%4D2&(+@$KZ$?9NC@RQ=YX1Q\F>/0G=T:E-XI M:%@+'N$J#!!G$R,TM-*VW.!VQ_$&WZC-0QS24.SO=R"[^HXCW]!`?TV2X#V, M:'1%J*I==ZO=<6X04@J-O>D9H@/M MBR&.O@ELLTC#4^UP2>PS(2>7U29U`TDQTD9J:0FB9=(;:_2 MQFSR-XGH@2(U]?0H68(T6S]$.%E&'.#-KZ!]Z*2G=H5118G/\Q-(T>P\OX]! M>^!_!HL7D.Z()5)#I53/[XFD5+0:.L:[%.E"H`K(!%;(+Z]5 M^KUK*9K8MPI\M!7(2[!V<\YXH:I:^T1RKJ84TB.G(#\WA)%+?3+W$`8#B/B]CQ\EJ! M2JP$*NBX9I(='$>3]!F>PA(4,PY34`$K^JV>)W9O/4(X"5D1-BB]=GF_4@`+2HN7?8? M\U<=_888@R)D':D7FIU31QPBJJFFALC.4XP-D9`MJ(;(OM@H0]T:]K=(V;G;8Z11L=Q5&G1L].=9KO4M+2$BFA#S6+M2O\N#-* MM$"+&BCKSP0!H*B>IS5,UN_U`C"Q)U*77=U\5L9U/VC1,((>;KL^2?=PV#?K M$ M$'=QQZ7MS0+'R<;6C&)R2#$=O&W-*M8-HOWX1%N3BG7#AQI=;VMBL6XPJ0@= M%0(J3]AOS+II>)A8= M87>?%C`'Q;9?ORQ*[H!`3+5VD`UD;M0:5CC.?Y>J.("E]M"4KFQOC M(!,B99SKUQ!.3EPR:/_57F>8-DS3UO>#%$!$ M?K_#LI>$>N&TIT;:GC6E$TH4`X+M&5386`DK:;;G4^D!$^/`LS2I2F^P*&\R MV:FUB>U6O(M!V\.ONZ.TQZ$L#;3NCA!EN4V9C0OY[M@>6"T-%6M;FC(AIWH= M]8J)7H'T);$4(,J69#D'=\%/+OAIW."G,P>.KM@G4UR^;V+T,YA%2'BDCH4K M(.?;3;F1O'CSXCFXB:^]L+01W+]^\U+\YC?I"I)16L>=^967QNCD@1NJ=^[! MT)_%P648Y1GUYI]7RQ:/V^ZX?@4QFI41PF06+,*X>`0>S[@J-R8%5UXM/6]L MX46S744<9R]::4VO@P&TPV1LS'=+Z9%TA20HWV+&^&UDHHI,*>Y\RTN`[D"% MS&T":8Z5[3+:I9RMO#`JTV\U5(0J2JO87T7Z(="*EIZB\W@)\%X6STMAV6N2 M7MXHZ3E[(;^>EK>U-B)5PM#6QWXY(Z3E8$XOKU5Z[FY$*JGMY;7]B4N3FE): M?QP+3@@&L%YQ_UI?"E^&L$BF1NF-3`OZ>[C-Y+5#N6X62_KRD&I"1Q\?D4:( M5%^<=K\1Q\T^+=AU7'2'"9$05&_>%'@1-J!_19H:WO5NXDOP@A@-VK5S_+&M MGDSVYQ6OK@/7;R"+9"^^,[HS1X39=?M)'YK";+O'24>X=BPA8IXF!YP110HF^:/(=A\4>?A85G#; M_5$ZK4FJIF6[6THGM!@6I'Z^*>;GY>6:0)HX!HNUAF)(`-:V@_<(O;9D[`F>AK4&8DD"U;_3Z!=+9,GOD M#,(3R((I#QKGGD`LRLYZS*1OJOO%W=FR/KG.5=,.N>MK)9],))YS`G9^KC)^ MKL7*::>#KM[B1ALV$N8-,4RDYU8&)Q7W>#O'*%@4;TLE,5K168C^M7WHDJ[R M)%O0<9O7S#1>YAXG)QQGIE&4;$1+/\F9Z=G=8M;1TXO_R\LK(OB<4,0K%LJ+ M!T&`%P9:%<42?01HS<`P`T\@784^#H,+D^`1^,D\#GDYZ@;_K):,S(>;CYPY M:_?+Z9"V?I./M4OR2CN?^^IA6[2DDABM/^9$)9=U_M.'Y#]-,7^4895R#G!5 M'7V9F&?2F9C)-5S>[7VI7-YMI3T03*NJ\AT&#=+^>N:RFG>7?N=XA2(](-9Q MWKM2N=GY#T'1NL"L:Z=/LBHY]U_3HLBZ5_#`Y-6V)R)!RCPBI:VDU(S++;LT M$<'"<-0P%ST!'Q7%SPVS>M>]4>-P*'Z\+^R1\.H[2/T04CW).S1D4'\+,XCB M81=LTS04%`PZHQT#X1BBXH3?8="BY*=ZW_:'!<1QDG3WL/6M`1>Q[%[+Z0@0ZQJ@Y2A+7I.3P6GOHJ%U MXK/2!'?@C,O2V)=Y:68%/`1[=J^`8TOPZ>27*19[;'V\0R^4WF3SZ75`4O4#;@G@V:?K5X=:U1LY.$WK_Z<<% MSDZ3L1APPX-N:.Z^>M9$YH.AN52H;J*`RO@(7E%-?#I M8%P^-'Q$W`RGF-J1[;GHXG;Y<;MD>Z%[P(?_NM'I".'-QJ-S.^VP[PL/OEU' MR3N\0>=VBBK+A78/$':+B6?LAQ%H,:WG!$OZD";8!A* MKPH5E..[/LBGM(2K(AEG<8#_@7?`%1IYO/EE%UZ:KI&8K'ACL;I6]DJ3.SI9 MME+30C,O!4@INP3E/Z6Z1VE"5Q_Q5G*'UA3ZUS+=,EXP<5"]V]APRBB("S7AJ:G%UM4X"9&NQ">Q/#! M6V-M"$^,O7V)UMUNC9G1[RUCKZS?_%M.N+="C>E\=!1?UE![TRBBA.?@2S;$GA'=*RUH M&PYZ@T_U&)L1DOA;F+V5O]Z_(M!P7DH2Y^G:E.)^;#[[G-S$0>ZWKJOOD@QL M-BUV%X1;<8E_MC=B)(,)03FCS&V)!LSN'^]M3_F&#.IOK7AW'$]2`V;WK]MX MLAHRJ+\$@Z9U.23;EP4KV=2;\22.7=MQ9R>RB>P[M^>[MYOMHCK)"T4 M:''"+]N*$CVQ^='&]4M]^[*YG2&JN!*U]3R!O:QP;*T7QG[(JN%2FKJ4IF., M]L&G-#W?]:6F"4\N[)*%=I;^]N#2;&X]K<2S:^Y7<4DUA9+>T2YZ6T74[,;Y MB;8#>?2S*`KNUH41RJ;>K]X66J:[3%71(W\)6=";KMM[VK%9C@4P[ M=&W/AS46OB2CG>U9M(;&5GZS%^:,-QM*E\M^95-WC@=HIC[G^OV*)M1V0DJ[' M8CFW':R=_9QM3]>M'N`]EUVQE-Y3AY#I]2R6SON`*6,_#*5]XFW/[*U^50L% M2-B>]EL-K#(QYK;G`^\>O]QV]1*/$!1[(]B^K50!I#LAI&)/"4\>29D4!/V> M'DXR+SK(Y2[I,41+6_]Y4J>.)&C#N'/5V$_J?)*?L,)9*VI$NY@QS=\"W..1 MH@#=R''/-5KY.QT:^B%'%/]V2+WARFO5KF4V35F=K+`/ICM MI4^OP>K`0"QYZE0*LM9S/7_H_'[NX3S7PX2LG:ZRQL6N>T_Y:=3/R:W&T<[; M/I%0>/<"%'`O0/'@$-"*W`-'TW[@J-Y?SST8HKGQT!RB[>.8-_%KDB[*&'(5 M*14(']L[-)HY%)CEE21Y('R!E,6#7=:-[(K`<1)I%,VJ9DM;7Q>+;R MP@@OL5:H8_5&)EZ./KV34JWHZ.E].O?B*@/*11+#)`J#37:4YAYS_UH19"_: MGEF\'$EJVM:L[\%[\0L]I)5)7!RT1/OWZ&"NZY,Y9@?0E,97,=4)- M>@/IE1O'/OP$%Z"M66^ZSCGYNSAF\AI[@)NVMBZ,BL"\&U,[=2$46LT72KDA M:WJ-;CLTQ.Q1!7M5T710RZ/.>_%F%V74%(7=TLOKX.F5-.C(>P40%B-\#02[ M0*NDQ*)3?>,)H%56+IEY"@#A)0=>:1VH7BV64;(&X!%$V(M1>&[PZSEKCHG6 MG#*&5W(CX%32])P*/DC@)HS6BW@6"E8--8F'_3<0Y!$@98184$A3T51['-8_P007GO572*IB\. M]97#1>H1+).T<*DC&H(&_I@M1J[NH_@5Q&@/C+#2&2S".,1+#\=75WL;\P4Y ML;K.=+?)K0(!.KJQA\8E6($H*7(!B.`L4E.+Z\V6+ZA9GN?K>H&R'M`;^K,V M8,E\6FZ0;QW\FY$:;'YJ6%?+&V>8>62KIC0P[9-[:LTN4]`X/+&=O4S@A+75 MPCL^W(+4T5;+L+O`V@VA&HD.DFXF5,]V-U8]Z.;D[*VCH3K>4K,_X'.LL5). M+:=H?\\7"R]=MQY%1W7?>)VDKR#,T!8";^+R]%`-$.-+ MAXC8U^HEVK(+7],BF><@B)&^=(B(W><9S+P8OT-]ES-N+=1_QZ$E\9U?SPX= MK\-N?'0<,*VW8+H$JA_* M6S#:C.4:V%US2#L\6C]%UC#DH*JTH=8#:^D+?G8,J>15C]B3U&Y4-8^J],62 MV`/9;EP/XE1M4:4NSW-+4R53',")"5@4/#SD_,%'SPEREQ1O^:$9CA<`?,9I MIIJ_XX[=)=G_@*R.A*!`--SWK$*O/"?0T5']"9<['1M2LA`N:F%7(!>UX*(6 MIA6UP%0^BQ\OT8%W[84IZY&ZL:50D]!Y>WZSA7ZA"+W=B(G.Y8-\PGGT.(\> MY]'C/'J,1=)Y].CW(1E0$;0]@8_:`1F&93AG`Z,6!46_MSVSF)GN;]+:S'A9 M[0TQYNY@,H,P7Y38X6G^M0DNDL79>%W.#V<]FY;U;+L; M-#8,G&L0Y]2_#/%#NG'PB%:-:ON0\'>UH=F%VK%Z]8RV7]K]P(`?M&8V_C5! MNS=^.&,]]GS<^?+!(_H8PK]?IP#\:W"68&<)=I9@ M9PDV#4EG"3Y@)V!5Y>!E^6DUF7KN_HM1\-T$Z/)G!?"%@\\/[]Y,2U&B>K` M-M+G#PTOB6QG1HEV4*8T;M^KH"P0#)5TNX,$AL_D?@D2#1/.KMG<=F`8?2KO M?-[P>=PY^:0Y]D>\>-_WZ$[X/VU>/\&3'[?30C#]^%N6=H-$<,X9PAG#/$(5[A.V<(YPQQ4)>(O2B^DG&2 M5^)<@M]#'])=FYT+T!MJ+,>_$7.YA0]X81*NAEPNX@,>SWT#I-6YBTVP-(RW M^7;(;=PA6:KQA&E:@]XI];%ER52G->)=,R-W2;CJ!MV00>^1.-FNJ()I#7NG MQ,H==&;#>9RAOO$="7^OIR4,7II#IX#2N.#'>S3"V-@&:$RZ\O*"`'V%X&-/ M+J/CMO%!/ZEKOB8.'R(OOO`4@\K%!/Z4#LXKV_PP8D1WM,CIM)$0=5LU3 M>ZPI8+OKH7,E=J[$^F>A<&YJ.24L[>`V[@1DC"Z-S+ND[,&/Z?1B*9@]#8Q/? M'>-<+P?T0W2G:3P%=1W&7NR'V(MFZY1DCFL-A""#6VGK#M#<;*CE;7$VZ([E M%I7S]?9?_SM$$R;UW]:W8`4BAO^28&6M_:I'F^>XPJRBM0\W\3+/8`'H&?/J M@%5#:P]^!A[&L]A']J<*\^Y'K@TEB6@X&R'M/D^N[AB2DEQNQ.OIF#$WA2\R M%H+C.TDHJ%_>"\1NY^BL_T=Q-C*7JD!%YWQ60O5S$H/USU[Z=Y!=YW$`F;A2 M"NODKW)G;).12NZ?ME^TB!SJ6V]\L:UQ,I#)G,#$*4@B(;::B3NQ@-:M'5U% ML?4:0YJ/3.Z^N!-"+&)D[65P+Z1$C]L->FZ>B9Z9D[H%IVLB]&5)YO^V[F?R M.E`3.1JKM_6BTV`'-$/LS]BZGY=?NW^]#*,P"[NU#.R)Y*#0:MMR(6"7`0AM`C6=EG2NC_YRQ MG59+GGA-;BV]8=IJE%*`9=TUXD>4PS?ZAI6X="U5/R\S6Y`592M@&_>(`(THP0RILW!QMN M.@IN-2UI[1(D53Q'6URTOH%H1T1'4+E?,OVEN-5,,/:.;W)WYMPQDLGUW#S$ M,LHI^8@6G#!SJ3+`,M$.ER\-J83R6VL1VO&C.`DWR)IC$2I$N!! MH[K&T4K;8O#M83HOWI+B&O5!OATEZ^1KBN-9TL0'(("8.Q:G M4^RW3Z.:*A$7CWPC2F3G?:7`Q"HKP?>7&,'UCG1!#-K6=;*] M#]VC89U%45*$=]./]ZY-*>E'=436"L7E/NEC%%0IPWT,B.X/Y#(JO\SG.`,R MFZKIY_>$V_NZC'O9R#I3/-GX4#O`TS9T6W%Q5Y,CIW*F[,5;6,].':P]86UL M\C6L=KE+B?+^/1\@`=9GJXM9%\RH-G];G=-K[>[Y+9M=3)])3C6+S&._-$L/Q$;VIV@)V:I?" MU75"[9J1:GSLTIR4;5F=7K`\G2[W[WH'7F,W795`YO:SQFOB[)]ZZUXC-''B MS_67J)&:+L$7]Q*KT7(LOX.O5@W?="F^O!M?C=ITB7]GEX?:CCT))6#:85VB MH%"NBJT-IQ+%A;\B)QKD%!9&4;@-+-R[Z%470.\(,5>[$I_=O3%7=3S5PD76ORUM.;$TXBUX:B<:-^A M]X)-!]CJGJ>8V5*&F%_/18Z6//YGD+TE0?VD%\U1G59:R1R]]=XA:O[26WAS M@*A?N!M\22MU^/%1%$1^]KZ'BWS18(_G>3`'N_.=75:-)&&,6\?GF1=7#[A= M>,LP\Z+JS3>B3/Q:6IZ6+L5BORC=*J/G_:-WS`4Q>V;DH]@MI5E2ICJW7T[) MW+Q+LO+B(DR"ZR3%]O@PKK*R;)4QTO04JZA_R8A(:V:&OFJ M"^V":&J M^OMT&R(Z$I0^GL4/2&D&I.AJZ>IJHH'3$"GQ2R]B).1F%-2![R,.'6"<-O7O MVJ1CGMK-$DK&\!'XR1RM<1#@Z]X8`EBM[.=DNP.CW>H)I"NT4>/D7]BZ2[82 M=FY+"];)&LF\QGFZ8NIZVBFD)>X6G8U(GVNO;';>;$8--1',Y0#6[N;\&%5> M%45RX;MWM,=5H4`EK2"+0RQI9#8"6HS3_<9+HW`NQG;4DH#09H7R[VA#ZX7? MBQ=^+W8<-AX!)NR(B6T8?.Y%F##3S&LZ)%&S2GI.A+\"F.%;-L;J4OL%/=D. MT*Z$Y6K>T#%X`[V\S@!*^CUDR[&$=<+43B1V.M_8^X=$JJX-L.T%&MQ];'6O;":ONFI[5(;>=L!2TR%H=A-L; M.*J9V.K(VTZP]?/GLCI`5Q9/B3OW7F&Y2)=[2:Q$3HL.;G4(<#>ZJ%B/MSIF MN/,N0?,>L3J"N"M:NS9UJR.#>VV?:@V^5D<1=U,,!=QYK(XE[FB!(%^@6!U3 MW`DI";<*J\.,.X%'\H.T.KRXZU$AX,5N=5RQ8MRV_O)6AQ5W6I)T1WZKHXB[ M3C`QUS-;\[/V,/^I]L*T.E>KFMG)M#MA0!=P&"XC M&[#<3*+&?FP@.IL\1/SPX`U6GQU6XL?DF.D[]*#&BR?G3:YVK+?MAY]HM'N= M!ID<[5!3*#L-%](X4?*UU#C9I7.[QU!V'`TA8.D\((6!-+'8BN^MY8=?%C+`;/B&1=[SI8DC*MJ?\!8+? MGQG[2B:C(7X<;/!878+3?-['#D1RJ:SN97 M>&+B"Q1ZE$^'5C2BW1:S855F8T^O9DMF'5,RQ!@;MS6F].W->\_(ORL\K;@! MLK,CE(EE#9`:L;`RTTH9(SG[ZG5I>Z=O$R4.> M^F\>!)SD-,SRY@9@,AB>K5$BLL"0*+BM$1_.V':X"K(F@#B4BOL25DM5L#4" M5P8M@>/'UN!;:9BZ:-JV1MN*4NZ63P61XDYLSYJVLY(H*%P-PUJ/)6F$)NBH MU',6W4[!CT101^Q%_NA%VTW('CN MP1#M0#/?3_+";4ON9DJ-9:?^^D,2A<7[1FPK(*."#LO4/HADL??+N3L,H^\P MN/;__8):Y65:H-N%=.[<_/5.9$N6*Q_.M$8SK3%M1H3-UWHC$7&]3U4V23OZJ-0,?O#5&;A8'E>MP(Q=3[=CTC`0ZC[!Y41]%E!:5R1^E6W-T MS42Z5HTBW`RC%_'T!U8-1SCM(9R.4NT?PW$.01*$P-.Y.QF'D\I4.B`<=!'0>U]EAT'%0!!Y79 MC1SM=+33T4X^[:PI99%K89L9>)-/-($9W$L,#+6:185%;J:"YS&OGHWJ(`-] MAZXG$)16G;G81%7$$=UASQ\U>](4*:!3%3IQX=Z;OR/(CB`[@CPX0>YKGW4T MV9'#\:R\F^?)JN<8*8_&1(4L('W$JF5/)G$KF5#)% MUQ/*C]')*&N"`'<_::U/$M`9R3YGM/79`YPQP1D3%!@3BG7UED0("%@^\HK+ M*@TW,$M1[DXW2W@XYHB=0DZAGZ!J,:JX3Y]$FD6OQD%G]BI?(987Z]AUAML\6 M[RBEHY2=*.4`VY>CG(YR.LK)IYS77I@6#W;7+%.%W[\M!),$#X=N,JN8T@>> M#8M=Y_`IM".4AT`H15:?HY>.7@I:+#D;H:.,CC(ZRLBGC%=>&H?Q'#Z`M/`K MT1HFNBL,SQ9(*Z[%>DD%4DQX%X[IZ.&4Z2%O[3MJZ*BA(#5D;,6.%CI:Z&AA M#UJH+SA2/SET]&J4M'5(D"",T)Q=@2?@YVF1+.KJNQ_E:,I?H_6-`PCRK(K# MD.7=`WQ(\85_ZZOXV0!_%@>76%`0[`DA<='?HUU'N!WA=H3;$6[V57^?C6LR MQ)RIN0QQ"DXF?,ZI/$[EZ>NON_%+LLYKPC)M84KWY#CTZ*;SF7`TW1B:KN&K8"S-CH:8Q"-&5/.G67`T7RHQ4V0 MG>MV0BWO^)!)1QF3#S$&W5$?1WV,HCZ:<.%LZ68HGT1:^.,)EA!G%D?_\?]0 M2P,$%`````@`2U^J0L.F0%4N#P```L``00E#@``!#D!``#M'=MRX[;NO3/]!QX_G+.= M6<>Y=+?=S*8=Y[([GLG&&OHX+"%"/.X3]GDK/7UKMV]N^CU6K_^ M\OUW'__5;J/!`%URQD@0D"?TNT<"(K`B:(@?.>.S)W3G3:GG<[#P\,!\2=8M#D+*",''I]U4+N=C/!;Q,LI>G]P?`AX MRR<#'C+_%)U8MRX$P0J@D0]&YO,G M02=3A=YX/P`P0&H,-#@8'%AB_1O=<28!>C;'[`EU@P`--)9$`R*)N"?^04Q4 M&FD13"&39RU+P(>3`RXF'1CBJ//[E^MH5EK??X`9D7/LD0U4`*_\C##U MB8O9)1GC4.OQKQ`'=$R)WT)8*4%'H2(I@)`M07[15#YBQK@R[Z[YK>_,YY2- M>?P3;F@#/14\($/0"](77P>]M4I`+#A,>?3*FC!I9C@[!8Z$$W;X$4BBBA2QB'SM9"EGB(3C2/OO% M7'LX\,+`(%[#[Q@YAG`AS@5X+J8VP%QRMAHOOINHZADT>`>L&[/KCS]1!IZ1 MXN"62\/718"EC*U/ZW``"'^41'"K$E8:M""$]/K!?,+TP@97D@=4KSH^.L>! M]M7H;DJ(DHU&=ZC16RR(I@1$<%!9O09[C8Y_W$3'Z$V*L1\:G5?5>0]BS!GI M!HH(!O+H_>JO M$%:W+O/[&E^'S_`(9A_4%NG1TK%'VQM3<9O`^[P)%"A>Z_UBBMF$2%B.(;#W M"43HHX!H>-@.*:JO;P49$R$,(O?^1,!5=!7S^A_T!D(RB:66JM@N;7\LXZPJ?0"+D-!X( M\&UM8CF[X)QAE899-5(.2*`]ZP672IIU_5RG`D&[!JN:;6P[AM-&C@ZS-F*6 M]K:AA>SA&EO9TE;LF"F*DS3LIAZC/#6W_H^R^@>=SSB+8[UO6`C,FOW\ULK_ MA*GX#0>AI:&*;L!-P:WDXZR2-3%DJ.DP83$:[`*D$B95UZA\6Y5?8<$@>).W M1!CW7$W=J['=JC[)JOJ:2XF`"C)D&JWNPHLG;G$#EYU'=>OS1Z=_UOGTF")L MW6";#B9C;@Z(/LXDZ&X.P6.C]"V5KN>QF)+?AY'** MJ]("C0&]>'Z@@JE4I>DVBEP^L3!7T%C$L^\@*UC`.AI.C1_GLH/IW62CZHHU M6(NIC,]X[`.:KN\;!G&0K\BJCN?6:R[K5WADI..%!7&[8$N?^"I,FYJ/RGJ/ MXZ\D_,JJ-_O8K<5<6B\?W35ZVDQ/9DDST8X=[,3S&@=:0QZM?P:V/S?%,]:= M`9%*4,]$9(N;9J^_^)4LF5DS>.'1W5:6RRBN#`5C!E',(5(\'2'$7+Y-W7V+ MEJSFDULK(HS&K#(_7'LB#]K;YI4C.^4HMM<5"\EBV$SIY?Q MT"@>N[&D32TI'QJL6AHM[LRH\@RIEJ26A-)Y;S;GL87$8URP& MN]:[Y9$7N2"KIJ.4#6Q$PVT/N<1AB?J3QCJ>PRO,PTB0_OB2!B$LES=$Z9Q> MDAXL<`AK49RZ/\FE$"V26ODQ4014<]G%1M&;*=K,*;TG9AKEMRGUIA<\#/RK M1RK5;2AD"/YWR*\>B?"HU.%;J/2WUKH6P/AH^WUGOB'PC0ARPU6/>4'H$[_' M+I;SG+6:%Q_?;8*Y;&?"7V1G$ID!D&$1&1Y1PJ0./!,V3;"Y9#1>S6R79N?#*%3U5CG@T)NJTOEZ7= MH(*K60R?Q8[B$JE4@11HW)1'6=51I#4FM/O<6Z9LJUS6 MK122VQ@*\JN9NJ]&VW!;_Z/;P0S(&)E.+Z>ZN9T$" MHJC2H]@AA"8$[SX.@E:GOI*GU5A"<$`H$/QR069/Y`[PB`0E10;8`I&O-84] MD3;[FI<0&E`*A$[5'Q3(_K%CM\B!7^D6.A]!="X48H7-?5;TET)1"ZMK[AE" M#A3]JYW@M?6M]M%Q^^3HX%'Z,8M5.%C.=#4.$KRJ'!1V;2H[=H*@!WU7:CAG M&ZQ5PYHA"_MN=4B@Y()6>TFK^NSG&EV5FH0LEIZ)#WKZC]YOPX+5HZLB&YS= M;,:)JZ_9%HK1=ZKJ95UK,"<[17C)CZT8R70;*\5$@J,OMAH\W[6LU/@66GR] M@HNX>YEAXZREBX9(E.!;=@"Q&H`L^G^8#6L4SFI/_D=5Q&AQ,EW_3F$##&&H M>.HI,M.16POAD50">^JL-<:!67P,("Q*E/M#@^J'(@ZIHV>CJ!\1/"`C"HZ, MT2#0/)RUE`BU4X6H&):54.-\%CR<)Z-3&'7U9(0ZNZ0(+$3J"YF-B,C(7/`\ M$BUJR7?J\QFFK$BRB"V78+L3X8[,<42U.Q'$`.3E*`3:6D_1`JER:@)S\7>D MIX(Z2`@6B&936F*ZP6Q!=0D2F[R:T@H8-:6U;EEBD!>6PU>G4\`47C@R,UDL MD6XC$Q`IETE>NU)MF6FSU54!9Q^<2=1;J<>L$[58`%MF!]#S";G#5]&TFNL. M'WBBG)S37`E1)[=IF#QWRY![7#L!%L;3%Z9=[]7CG$9C7&)%KAZ5;B+&V:UA M(BM>163;.A-)-K3.YQ*_)V6HZ7ZC:GJ%O>D->3!'/N;#J23KOVX:2A))>6%S MKK39HKF+N>":!,^L[+IQ,Q;>%/SH);DG`9_KN\,I5M]@R'/R*60^21G%5F2> M+8S8H8->_1%V4311#KQ&486#X6QTL1ZTGE$&AQT5TURGWL;N(\TH;C74R\OE MTUGD22O+=?ZD1[TT"\UZ^=+0M5JKS"Y1FKUC_FOGU*<-*3$K8.U#@'A)[ZE/ MF*\_S;S'@7:NIL>^)?-JD"W7FYWJLTS+\&[,DRU<);0:.=9+$4[T`1P'>WRZ M%7PB\"P7,KJ`ZO0R+L.\*+*#ERM9ZVU+=(/5*QA<4\-8M+B71ZF1':YA.KO( MEP.OY4(/"%+&Y0SRD^`S$Y6#/TZOZ(5IA0UP]V'U6"=%5-QFS4-9A#JM+$N> MH_X%":\]=J'_5HVG29F-F7F:5%`52UV1PG[90"+6K:`>29?S9J9A!62\),%Z M-(_OU4'KBWYIO,?\T"-V#&BZ'L1M3UT;7^Z4/(;8BT3B-7Z0\`I> MXAF>D(L`TYDE6M'#?5#:%_Q(9^',RI2+7<S0[`*./O@ MTR%P@JW3'`=1P)S;^*]X7J<]O[T;LOL[+#8#R1&L3,E5'FDO]!B.`NHE$?\- M4:MBYW6`6X;.NWP]!\3C$WC7EDV$%OUB%IX8G,X=$?<@@OZ(3V?:4L<^FY/8 M!Z7K/T/JAP$I2B$7Y85*PM3B.)L1*@%;RW30DN_4%ZJZ1L;3!Y/11Z56 M\[MX/=7OIEO+6]&KI154EVBUE6Q,Z__#BI8291H\;S9-A>1288)*[K]>G+R4 MJKB;Z*)11*JY6-+#H\1D[8)L[28-"!-YWF>9*MA:Q5`O;;HRR[6J0YE MVC%,#-SY4Z[1=?;#=<4%!2IO38C=>"JM.+D^,SEV);!5'/Q)GC MKR`NQ2D`J%V>)IS/HQLX2,YG99^5^?RY.NH^'(]\96"!#P(`A/499OH`K`\" M=H.`F\]%9L.JI0,4J\X;=89,NNR@#7*+):Q6ZDAVZH MIESHT[\2$N91:K3NNIFV8N+2@J9P]D#2LH:ZJRK!%_CP_RL31%>+$?\SIDPW MC.VQ2S)2RS![4>2>$KP"UEX42RXJ+E8DJU<\WRI%O4N333ZQ921W>I!_5*?S M@G5UUGM071VS..2WH?"FL#DH+F-S@]7(_26,/O!5MF0]>D5;^MB)VOC`Y?\` M4$L!`AX#%`````@`2U^J0L1(7WD7;@```9T$`!$`&````````0```*2!```` M`&=A;'0M,C`Q,S`S,S$N>&UL550%``,>&8U1=7@+``$$)0X```0Y`0``4$L! M`AX#%`````@`2U^J0LJJ`Q0````(`$M?JD+((QON=RH``+1!`P`5`!@```````$```"D@0MZ``!G M86QT+3(P,3,P,S,Q7V1E9BYX;6Q55`4``QX9C5%U>`L``00E#@``!#D!``!0 M2P$"'@,4````"`!+7ZI"=$G(E\)2``"WF@0`%0`8```````!````I('1I``` M9V%L="TR,#$S,#,S,5]L86(N>&UL550%``,>&8U1=7@+``$$)0X```0Y`0`` M4$L!`AX#%`````@`2U^J0G"EH6A[+```/M<#`!4`&````````0```*2!XO<` M`&=A;'0M,C`Q,S`S,S%?<')E+GAM;%54!0`#'AF-475X"P`!!"4.```$.0$` M`%!+`0(>`Q0````(`$M?JD+#ID!5+@\``'.8```1`!@```````$```"D@:PD M`0!G86QT+3(P,3,P,S,Q+GAS9%54!0`#'AF-475X"P`!!"4.```$.0$``%!+ 4!08`````!@`&`!H"```E-`$````` ` end XML 16 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; word-wrap: break-word; } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 17 R25.htm IDEA: XBRL DOCUMENT v2.4.0.6

Weighted Average Assumptions Used to Determine Fair Value of Options Granted (Detail)
3 Months Ended 153 Months Ended

Mar. 31, 2013

Mar. 31, 2013

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Risk-free interest rate 0.80% 1.76%

Expected life of the options 5 years 5 years 2 months 12 days

Expected volatility of the underlying stock 117.00% 119.00%

Expected dividend rate 0.00% 0.00%

X

- Definition

The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (f)(2)(iii)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 123R

-Paragraph A240

-Subparagraph e(2)(c)

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition

Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 14.D.2)

-URI http://asc.fasb.org/extlink&oid=6793087&loc=d3e301413-122809

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (f)(2)(i)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 14

-Section D

-Subsection 2

+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition

The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (f)(2)(ii)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 123R

-Paragraph A240

-Subparagraph e(2)(b)

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition

The risk-free interest rate assumption that is used in valuing an option on its own shares.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (f)(2)(iv)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 123R

-Paragraph A240

-Subparagraph e(2)(d)

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 18 R9.htm IDEA: XBRL DOCUMENT v2.4.0.6

Stock-Based Compensation
3 Months Ended

Mar. 31, 2013

Stock-Based Compensation

3. Stock-Based Compensation

Following is the stock-based compensation expense related to common stock options, common stock, restricted common stock and common stock warrants:

 Three Months Ended
March 31,

 2013 2012

Research and development
 $ 319 $ 149

General and administrative
 533 324





Total stock-based compensation expense
 $ 852 $ 473





The following table summarizes the stock option activity in the Company’s equity incentive plans, including non-plan grants to Company executives, from December 31, 2012 through March 31, 2013:



 Shares
 Weighted Average
Exercise Price

Outstanding, December 31, 2012
 3,539,961 $ 5.66

Granted
 200,426 3.36

Exercised
 (39,762) 2.77

Options forfeited/cancelled
 (44,408) 9.50





Outstanding, March 31, 2013
 3,656,217 $ 5.52





As of March 31, 2013, there was $5,427,000 of unrecognized compensation related to 1,466,586 unvested options, which is expected to be recognized over a weighted–average period of approximately 3.9 years. The weighted-average grant date fair value for options granted during the three months ended March 31, 2013 was $2.73. There were no grants during the three months ended March 31, 2012.

The fair value of all other options granted is determined using the Black-Scholes option-pricing model. The following weighted average assumptions were used (there were no option grants to employees or consultants during the three months ended March 31, 2013):

 Three
 Months Ended
March 31,
Cumulative

Period from

Inception

(July 10, 2000) to
March 31,

 2013

 2013

Risk-free interest rate
 0.80% 1.76%

Expected life of the options
 5.0 years 5.2 years

Expected volatility of the underlying stock
 117% 119%

Expected dividend rate
 0% 0%

X

- Definition

The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 14

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 50

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6406099&loc=d3e25284-112666

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Statement of Position (SOP)

-Number 93-6

-Paragraph 53

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 40

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6418621&loc=d3e17540-113929

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 123R

-Paragraph 64, 65, A240

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5444-113901

+ Details

Name: us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

EXCEL 19 Financial_Report.xls IDEA: XBRL DOCUMENT begin 644 Financial_Report.xls M[[N_34E-12U697)S:6]N.B`Q+C`-"E@M1&]C=6UE;G0M5'EP93H@5V]R:V)O M;VL-"D-O;G1E;G0M5'EP93H@;75L=&EP87)T+W)E;&%T960[(&)O=6YD87)Y M/2(M+2TM/5].97AT4&%R=%]F-C0P9#5E8U\S,34T7S1C,69?8F(U8E\S8C$Y M,F-C,#-E-S(B#0H-"E1H:7,@9&]C=6UE;G0@:7,@82!3:6YG;&4@1FEL92!7 M96(@4&%G92P@86QS;R!K;F]W;B!A'!L;W)E&UL;G,Z=CTS1")U&UL;G,Z;STS1")U&UL/@T*(#QX.D5X8V5L5V]R:V)O;VL^#0H@(#QX M.D5X8V5L5V]R:W-H965T5]);F9O#I%>&-E;%=O#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/D-O;G-O;&ED871E9%]3=&%T96UE;G1?3V9?0VAA M;CPO>#I.86UE/@T*("`@(#QX.E=O#I7;W)K#I%>&-E;%=O M#I7;W)K M#I7;W)K#I.86UE/@T*("`@(#QX.E=O M#I%>&-E;%=O#I.86UE/D-O;6UO;E]3=&]C:U]A;F1?5V%R#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/D-O M;6UI=&UE;G1S7T-O;G1I;F=E;F-I97-?86YD7SPO>#I.86UE/@T*("`@(#QX M.E=O#I%>&-E;%=O M#I.86UE/E-U8G-E<75E;G1?179E;G1S/"]X.DYA M;64^#0H@("`@/'@Z5V]R:W-H965T4V]U#I%>&-E;%=O'!E M;G-E#I7;W)K#I7;W)K#I% M>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O M'!E;G-E#I7;W)K M'!E M;G,\+W@Z3F%M93X-"B`@("`\>#I7;W)K#I7 M;W)K#I7;W)K#I7;W)K5\\+W@Z3F%M93X-"B`@("`\>#I7;W)K#I% M>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I. M86UE/@T*("`@(#QX.E=O#I7;W)K#I3='EL97-H965T($A2 M968],T0B5V]R:W-H965T3X-"CPO:'1M;#X- M"@T*+2TM+2TM/5].97AT4&%R=%]F-C0P9#5E8U\S,34T7S1C,69?8F(U8E\S M8C$Y,F-C,#-E-S(-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO9C8T M,&0U96-?,S$U-%\T8S%F7V)B-6)?,V(Q.3)C8S`S93'0O:'1M;#L@8VAA2`P.2P@,C`Q,SQB'0^,3`M43QS<&%N/CPO'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@("`@/'1R(&-L87-S/3-$'0^1T%,5#QS<&%N/CPO'0^1T%,14-424X@5$A%4D%0 M155424-3($E.0SQS<&%N/CPO'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@("`@/'1R(&-L87-S/3-$2!#;VUM;VX@4W1O8VLL(%-H87)E'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S7!E.B!T M97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE M860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT M96YT/3-$)W1E>'0O:'1M;#L@8VAA'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S M/3-$'!E;G-E2!A;F0@97%U:7!M96YT+"!N970\+W1D/@T*("`@("`@("`\=&0@8VQA'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$6%B;&4\+W1D/@T* M("`@("`@("`\=&0@8VQA'0^)FYB'0^)FYB'0^)FYB'0^)FYB3PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]F-C0P9#5E8U\S,34T M7S1C,69?8F(U8E\S8C$Y,F-C,#-E-S(-"D-O;G1E;G0M3&]C871I;VXZ(&9I M;&4Z+R\O0SHO9C8T,&0U96-?,S$U-%\T8S%F7V)B-6)?,V(Q.3)C8S`S93'0O M:'1M;#L@8VAAF5D/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU+#`P,"PP,#`\'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$F5D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$ M;G5M<#XY,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$F5D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR+#$P M,"PP,#`\'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X- M"@T*+2TM+2TM/5].97AT4&%R=%]F-C0P9#5E8U\S,34T7S1C,69?8F(U8E\S M8C$Y,F-C,#-E-S(-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO9C8T M,&0U96-?,S$U-%\T8S%F7V)B-6)?,V(Q.3)C8S`S93'0O:'1M;#L@8VAA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'!E;G-E7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\ M:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E M;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA&-E<'0@4VAA M'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0O:F%V87-C3X-"B`@ M("`\=&%B;&4@8VQA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$'!E;G-E/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XX-3(L,#`P/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S2`H=7-E9"!I;BD@:6YV97-T:6YG(&%C=&EV:71I97,\+W1D/@T* M("`@("`@("`\=&0@8VQA'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M2!W87)R86YT'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S M/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0O:F%V87-C3X- M"B`@("`\=&%B;&4@8VQA'0^/&1I M=CX-"CQT86)L92!S='EL93TS1"="3U)$15(M0T],3$%04T4Z(&-O;&QA<'-E M)R!B;W)D97(],T0P(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@ M=VED=&@],T0Q,#`E/@T*/'1R/@T*/'1D('9A;&EG;CTS1'1O<"!W:61T:#TS M1#0E(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@ M5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CX\8CXQ+CPO8CX\+V9O;G0^/"]T M9#X-"CQT9"!V86QI9VX],T1T;W`@86QI9VX],T1L969T/CQF;VYT('-T>6QE M/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/CQB M/D)A6QE/3-$)TU!4D=)3BU43U`Z(#9P>#L@5$58 M5"U)3D1%3E0Z(#0E.R!-05)'24XM0D]45$]-.B`P<'@G/@T*/&9O;G0@6EN9R!I=',@;&5A9&5R"<^#0H\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@ M5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY4:&4@=6YA=61I=&5D#0IC;VYD M96YS960@8V]N2!297!O2!T;R!P2!T:&4-"F9I;F%N8VEA;"!P;W-I=&EO;B!O9B!T:&4@0V]M<&%N>2!A M$$P.S,Q+"`R,#$S(&%N9"!T:&4-"G)E2`Q,"P-"C(P,#`I('1H2`Q,"P@,C`P,"D@=&\@36%R8V@F(WA!,#LS,2P@ M,C`Q,RX@06QL#0IA9&IU2!O=&AE65A#L@5$585"U)3D1%3E0Z(#0E.R!-05)'24XM0D]45$]-.B`P<'@G/@T* M/&9O;G0@$$P.S,Q+"`R,#$S+"!T:&4@0V]M<&%N>2!H860-"B0W M+#`Q."PP,#`@;V8@=6YR97-T2!B96QI979E28C>#(P,3D[2!T;R!F=6YD(&]P97)A=&EO;G,@869T97(@:71S(&-U&AA=7-T960@9&5P96YD2!T;R!O8G1A:6X@861D:71I;VYA;"!F:6YA;F-I;F<@;W(-"F%C:&EE=F4@ M<')O9FET86)L92!O<&5R871I;VYS+"!A2P@8F%S960@;VX@ M=&AE(&9O2!I;F-L=61E M(&%N>2!A9&IU2!I9@T* M=&AE($-O;7!A;GD@:7,@=6YA8FQE('1O(&-O;G1I;G5E(&%S(&$@9V]I;F<@ M8V]N8V5R;BX\+V9O;G0^/"]P/@T*/'`@#L@5$585"U)3D1%3E0Z(#0E.R!-05)'24XM0D]45$]-.B`P<'@G/@T* M/&9O;G0@2!I;F-U$$P.S,Q+"`R,#$S+B!4:&4@0V]M<&%N>28C>#(P M,3D[$$P.W1H90T*0V]M<&%N>28C M>#(P,3D[6UE;G1S+"!A;F0@=&AE(&-O2P@9&5V96QO<&UE;G0-"F%N9"!C;VUM97)C:6%L M:7IA=&EO;B!A8W1I=FET:65S(&%N9"!P;W1E;G1I86P@;&5G86P@8V]S="!T M;PT*<')O=&5C="!I=',@:6YT96QL96-T=6%L('!R;W!E2!E>'!E8W1S('1O(&EN8W5R#0IA9&1I=&EO;F%L(&QO$$P.S,Q+"`R,#$S+"!T:&4@0V]M<&%N>2!U6QE/3-$)TU!4D=)3BU43U`Z(#$R<'@[(%1%6%0M24Y$14Y4.B`T M)3L@34%21TE.+4)/5%1/33H@,'!X)SX-"CQF;VYT('-T>6QE/3-$)T9/3E0M M1D%-24Q9.B!4:6UEF4],T0R/E1H92!#;VUP86YY M('=A2`R,#`Q('5N9&5R M('1H92!N86UE("8C>#(P,4,[4')O+5!H87)M86-E=71I8V%L$$P.TUA2!B96=A;B!T6UB;VP@1T%,5"X@26UM961I871E;'D@ M<')I;W(@=&\@36%R8V@F(WA!,#LR,RP@,C`Q,BP@=&AE($-O;7!A;GD-"G=A M6UB;VP@ M1T%,5"Y/0BX\+V9O;G0^/"]P/@T*/'`@#L@5$585"U)3D1%3E0Z(#0E.R!-05)'24XM0D]45$]-.B`P<'@G/@T* M/&9O;G0@2!O9B!P3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R M=%]F-C0P9#5E8U\S,34T7S1C,69?8F(U8E\S8C$Y,F-C,#-E-S(-"D-O;G1E M;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO9C8T,&0U96-?,S$U-%\T8S%F7V)B M-6)?,V(Q.3)C8S`S93'0O:'1M;#L@8VAA'!E;G-E'0^ M/&1I=CX-"CQT86)L92!S='EL93TS1"="3U)$15(M0T],3$%04T4Z(&-O;&QA M<'-E)R!B;W)D97(],T0P(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS M1#`@=VED=&@],T0Q,#`E/@T*/'1R/@T*/'1D('9A;&EG;CTS1'1O<"!W:61T M:#TS1#0E(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E, M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CX\8CXR+CPO8CX\+V9O;G0^ M/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@86QI9VX],T1L969T/CQF;VYT('-T M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R M/CQB/D%C8W)U960-"D5X<&5N"<^#0H\9F]N="!S='EL M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CX\ M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S M:7IE/3-$,CY!8V-R=65D(&5X<&5N#L@1D].5"U325I%.B`Q,G!X M)SX-"CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C>$$P.SPO9F]N=#X\+W`^#0H\<"!S='EL93TS1"=- M05)'24XM5$]0.B`V<'@[(%1%6%0M24Y$14Y4.B`T)3L@34%21TE.+4)/5%1/ M33H@,'!X)SX-"CPO<#X-"CQT86)L92!S='EL93TS1"="3U)$15(M0T],3$%0 M4T4Z(&-O;&QA<'-E)R!B;W)D97(],T0P(&-E;&QS<&%C:6YG/3-$,"!C96QL M<&%D9&EN9STS1#`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`],T1N M;W=R87`^/&9O;G0@6QE/3-$)U1%6%0M M24Y$14Y4.B`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`],T1N M;W=R87`^/&9O;G0@F4],T0Q/B8C>$$P.SPO9F]N=#X\ M+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4 M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O M;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\ M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S M:7IE/3-$,CXT,B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O M='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@6QE/3-$)U1%6%0M24Y$14Y4.B`M,65M M.R!-05)'24XM3$5&5#H@,65M)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E, M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY3979E6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG M;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M M1D%-24Q9.B!4:6UEF4],T0R/C$L,#`P)B-X03`[ M/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO M=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O M;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V M86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M M1D%-24Q9.B!4:6UEF4],T0R/B8C>$$P.SPO9F]N M=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF M;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/C$L,#`P)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$ M8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49! M34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\ M+V9O;G0^/"]T9#X-"CPO='(^#0H\='(^#0H\=&0@=F%L:6=N/3-$=&]P/@T* M/'`@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/D]T:&5R/"]F;VYT/CPO<#X-"CPO=&0^#0H\=&0@=F%L M:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D M/@T*/'1D('9A;&EG;CTS1'1O<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O M;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI M9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^ M/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%- M24Q9.B!4:6UEF4],T0R/B8C>$$P.R8C>$$P.SPO M9F]N=#X\+W1D/@T*/"]T"<^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H\=&0@=F%L:6=N/3-$ M8F]T=&]M/B8C>$$P.SPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^ M#0H\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H\=&0@=F%L:6=N M/3-$8F]T=&]M/@T*/'`@$$P.SPO<#X-"CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T M=&]M/@T*/'`@$$P.SPO<#X-"CPO=&0^#0H\=&0^)B-X03`[/"]T9#X-"CQT9"!V M86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T M;VT^#0H\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI M9"<^)B-X03`[/"]P/@T*/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^#0H\ M<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X M03`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`[/"]F M;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A M<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N M)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"CPO='(^#0H\ M='(@6QE/3-$ M)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T* M/"]T9#X-"CQT9#XF(WA!,#L\+W1D/@T*/"]T7!E.B!T97AT+VAT;6P[(&-H87)S M970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@ M:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M M;#L@8VAA6QE/3-$)T)/4D1%4BU#3TQ,05!313H@8V]L;&%P6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/CQB/C,N/"]B/CPO9F]N=#X\+W1D/@T*/'1D M('9A;&EG;CTS1'1O<"!A;&EG;CTS1&QE9G0^/&9O;G0@#L@5$585"U) M3D1%3E0Z(#0E.R!-05)'24XM0D]45$]-.B`P<'@G/@T*/&9O;G0@#L@ M1D].5"U325I%.B`Q,'!X)SX-"CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UEF4],T0R/B8C>$$P.SPO9F]N=#X\+W`^ M#0H\<"!S='EL93TS1"=-05)'24XM5$]0.B`V<'@[(%1%6%0M24Y$14Y4.B`T M)3L@34%21TE.+4)/5%1/33H@,'!X)SX-"CPO<#X-"CQT86)L92!S='EL93TS M1"="3U)$15(M0T],3$%04T4Z(&-O;&QA<'-E)R!B;W)D97(],T0P(&-E;&QS M<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`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`P,#`@,7!X('-O;&ED)R!V M86QI9VX],T1B;W1T;VT@8V]L$$P.R8C>$$P.R8C>$$P.R8C>$$P.R8C>$$P.R8C>$$P.SPO8CX\ M+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T M>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`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`],T1N;W=R87`^/&9O;G0@6QE/3-$)U1%6%0M24Y$14Y4.B`M,65M.R!-05)' M24XM3$5&5#H@,65M)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY'96YE6QE/3-$)T9/3E0M1D%-24Q9.B!4 M:6UEF4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T* M/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE M/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/C4S M,R8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R M87`],T1N;W=R87`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`@$$P.SPO<#X-"CPO=&0^#0H\=&0@=F%L:6=N/3-$ M8F]T=&]M/@T*/'`@$$P.SPO<#X-"CPO=&0^#0H\=&0^)B-X03`[/"]T9#X-"CQT M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"CQT9"!V86QI M9VX],T1B;W1T;VT^#0H\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P M(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*/"]T9#X-"CQT9"!V86QI9VX],T1B M;W1T;VT^#0H\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S M;VQI9"<^)B-X03`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`Z M(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*/"]T9#X-"CQT9#XF M(WA!,#L\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\ M+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3X-"CQP('-T>6QE/3-$)T)/4D1% M4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*/"]T9#X- M"CQT9"!V86QI9VX],T1B;W1T;VT^#0H\<"!S='EL93TS1"="3U)$15(M5$]0 M.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"CPO=&0^#0H\=&0^ M)B-X03`[/"]T9#X-"CPO='(^#0H\(2TM($5N9"!486)L92!";V1Y("TM/CPO M=&%B;&4^#0H\<"!S='EL93TS1"=-05)'24XM5$]0.B`V<'@[(%1%6%0M24Y$ M14Y4.B`T)3L@34%21TE.+4)/5%1/33H@,'!X)SX-"B8C>$$P.SPO<#X-"CQP M('-T>6QE/3-$)TU!4D=)3BU43U`Z(#9P>#L@5$585"U)3D1%3E0Z(#0E.R!- M05)'24XM0D]45$]-.B`P<'@G/@T*/&9O;G0@0T*:6YC96YT M:79E('!L86YS+"!I;F-L=61I;F<@;F]N+7!L86X@9W)A;G1S('1O($-O;7!A M;GD@97AE8W5T:79E"<^#0H\+W`^#0H\=&%B;&4@F4],T0Q/B8C M>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU" M3U143TTZ(",P,#`P,#`@,7!X('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L M#L@1D].5"U325I%.B`Q,G!X)SX-"B8C>$$P.SPO<#X- M"CQP('-T>6QE/3-$)TU!4D=)3BU43U`Z(#!P>#L@34%21TE.+4)/5%1/33H@ M,7!X)R!A;&EG;CTS1&-E;G1E6QE/3-$)T9/3E0M1D%- M24Q9.B!4:6UEF4],T0R/B8C>$$P.R8C>$$P.R8C M>$$P.R8C>$$P.R8C>$$P.R8C>$$P.R8C>$$P.R8C>$$P.R8C>$$P.R8C>$$P M.U-H87)E$$P.R8C>$$P.R8C>$$P.R8C>$$P.R8C>$$P.R8C>$$P.R8C M>$$P.R8C>$$P.R8C>$$P.R8C>$$P.SPO9F]N=#X\+W`^#0H\+W1D/@T*/'1D M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^ M/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@$$P.T%V97)A9V4F(WA!,#LF(WA!,#L\8G(@+SX-"D5X97)C M:7-E(%!R:6-E/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/CQF M;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*/"]T6QE/3-$)U1%6%0M24Y$14Y4.B`M,65M.R!-05)'24XM3$5&5#H@,65M M)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N M)R!S:7IE/3-$,CY/=71S=&%N9&EN9RP-"D1E8V5M8F5R)B-X03`[,S$L(#(P M,3(\+V9O;G0^/"]P/@T*/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^/&9O M;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE MF4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D M('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$ M)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/C,L-3,Y M+#DV,3PO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`] M,T1N;W=R87`^/&9O;G0@F4],T0Q/B8C>$$P.R8C>$$P M.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF M(WA!,#LD/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N M/3-$$$P.R8C>$$P.R8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T* M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@6QE/3-$)U1%6%0M24Y$14Y4.B`M,65M.R!- M05)'24XM3$5&5#H@,V5M)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@ M5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY'F4],T0Q/B8C M>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3X\ M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S M:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T M;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@ M5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXR,#`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`],T1N;W=R87`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`F M(WA!,#LF(WA!,#LF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI M9VX],T1B;W1T;VT@;F]W6QE/3-$)T9/ M3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C>$$P.R8C M>$$P.SPO9F]N=#X\+W1D/@T*/"]T"<^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H\=&0@=F%L M:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H\=&0@=F%L:6=N/3-$ M8F]T=&]M/@T*/'`@$$P.SPO<#X-"CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M M/@T*/'`@$$P.SPO<#X-"CPO=&0^#0H\=&0^)B-X03`[/"]T9#X-"CQT9"!V86QI M9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"CQT9"!V86QI9VX],T1B M;W1T;VT^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"CQT9"!V M86QI9VX],T1B;W1T;VT^/"]T9#X-"CPO='(^#0H\='(@8F=C;VQO6QE/3-$ M)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/D]U='-T M86YD:6YG+"!-87)C:"8C>$$P.S,Q+`T*,C`Q,SPO9F]N=#X\+W`^#0H\+W1D M/@T*/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF M(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@ M6QE/3-$)T9/3E0M1D%-24Q9.B!4 M:6UEF4],T0R/B8C>$$P.R0\+V9O;G0^/"]T9#X- M"CQT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXU M+C4R)B-X03`[)B-X03`[)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@ M=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA! M,#LF(WA!,#L\+V9O;G0^/"]T9#X-"CPO='(^#0H\='(@6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@ M,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*/"]T9#X-"CQT9"!V86QI9VX],T1B M;W1T;VT^#0H\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D M;W5B;&4G/B8C>$$P.SPO<#X-"CPO=&0^#0H\=&0^)B-X03`[/"]T9#X-"CQT M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"CQT9"!V86QI M9VX],T1B;W1T;VT^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X- M"CQT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"CPO='(^#0H\(2TM($5N9"!4 M86)L92!";V1Y("TM/CPO=&%B;&4^#0H\<"!S='EL93TS1"=-05)'24XM5$]0 M.B`V<'@[(%1%6%0M24Y$14Y4.B`T)3L@34%21TE.+4)/5%1/33H@,'!X)SX- M"CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/D%S(&]F#0I-87)C:"8C>$$P.S,Q+"`R,#$S+"!T:&5R92!W M87,@)#4L-#(W+#`P,"!O9B!U;G)E8V]G;FEZ960-"F-O;7!E;G-A=&EO;B!R M96QA=&5D('1O(#$L-#8V+#4X-B!U;G9E6QE M/3-$)TU!4D=)3BU43U`Z(#$P<'@[(%1%6%0M24Y$14Y4.B`T)3L@34%21TE. M+4)/5%1/33H@,'!X)SX-"CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4 M:6UEF4],T0R/CQF;VYT('-T>6QE/3-$)T9/3E0M M1D%-24Q9.B!4:6UEF4],T0R/E1H92!F86ER('9A M;'5E(&]F(&%L;"!O=&AE<@T*;W!T:6]N65E$$P.SPO9F]N M=#X\+V9O;G0^/"]P/@T*/'`@#L@ M5$585"U)3D1%3E0Z(#0E.R!-05)'24XM0D]45$]-.B`P<'@G/@T*/"]P/@T* M/'1A8FQE('-T>6QE/3-$)T)/4D1%4BU#3TQ,05!313H@8V]L;&%PF4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D M('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED)R!V M86QI9VX],T1B;W1T;VT@;F]W6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/E1H$$P.R8C>$$P.R8C>$$P.SQBF4],T0Q/B8C>$$P.SPO M9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$ M,3XF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^/&9O M;G0@6QE/3-$)TU!4D=)3BU43U`Z(#!P>#L@34%21TE.+4)/5%1/33H@ M,'!X)R!A;&EG;CTS1&-E;G1E6QE/3-$)T9/3E0M1D%- M24Q9.B!4:6UEF4],T0R/D-U;75L871I=F4\+V9O M;G0^/"]P/@T*/'`@"<@86QI9VX],T1C96YT97(^#0H\ M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S M:7IE/3-$,CY);F-E<'1I;VX\+V9O;G0^/"]P/@T*/'`@$$P.W1O)B-X03`[)B-X03`[)B-X03`[/&)R("\^#0I-87)C:"`S,2P\ M+V9O;G0^/"]P/@T*/"]T9#X-"CPO='(^#0H\='(^#0H\=&0@=F%L:6=N/3-$ M8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\ M+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P M,#`P(#%P>"!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$8V5N=&5R M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/C(P,3,\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T M;VT^/&9O;G0@$$P.SPO<#X-"CPO=&0^#0H\=&0@=F%L:6=N M/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\ M+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X M('-O;&ED)R!V86QI9VX],T1B;W1T;VT@86QI9VX],T1C96YT97(^/&9O;G0@ M6QE/3-$)U1% M6%0M24Y$14Y4.B`M,65M.R!-05)'24XM3$5&5#H@,65M)SX\9F]N="!S='EL M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY2 M:7-K+69R964@:6YT97)E6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/C`N.#`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`M,65M.R!-05)' M24XM3$5&5#H@,65M)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY%>'!E8W1E9"!V;VQA=&EL:71Y(&]F M('1H90T*=6YD97)L>6EN9R!S=&]C:SPO9F]N=#X\+W`^#0H\+W1D/@T*/'1D M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\ M+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1C96YT M97(^/&9O;G0@6QE/3-$)T9/ M3E0M1D%-24Q9.B!4:6UEF4],T0R/C$Q.24\+V9O M;G0^/"]T9#X-"CPO='(^#0H\='(^#0H\=&0@=F%L:6=N/3-$=&]P/@T*/'`@ M6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/D5X<&5C=&5D(&1I=FED96YD#0IR871E/"]F;VYT/CPO<#X- M"CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C M>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!A M;&EG;CTS1&-E;G1E6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R M/C`E/"]F;VYT/CPO=&0^#0H\+W1R/@T*/"$M+2!%;F0@5&%B;&4@0F]D>2`M M+3X\+W1A8FQE/@T*/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM M+2TM/5].97AT4&%R=%]F-C0P9#5E8U\S,34T7S1C,69?8F(U8E\S8C$Y,F-C M,#-E-S(-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO9C8T,&0U96-? M,S$U-%\T8S%F7V)B-6)?,V(Q.3)C8S`S93'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R M"<^#0H\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@ M5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CX\9F]N="!S='EL93TS1"=&3TY4 M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY4:&4@9F]L;&]W M:6YG('1A8FQE#0IS=6UM87)I>F5S('1H92!C;VUM;VX@6QE/3-$)TU!4D=)3BU43U`Z(#!P>#L@34%21TE.+4)/5%1/33H@,'!X M.R!&3TY4+5-)6D4Z(#$P<'@G/@T*/&9O;G0@6QE/3-$)TU!4D=)3BU43U`Z(#9P>#L@5$585"U)3D1%3E0Z M(#0E.R!-05)'24XM0D]45$]-.B`P<'@G/@T*/"]P/@T*/'1A8FQE('-T>6QE M/3-$)T)/4D1%4BU#3TQ,05!313H@8V]L;&%PF4],T0Q/B8C>$$P.SPO9F]N M=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF M(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O M;'-P86X],T0R/@T*/'`@$$P.SPO<#X- M"CQP('-T>6QE/3-$)TU!4D=)3BU43U`Z(#9P>#L@34%21TE.+4)/5%1/33H@ M,7!X)R!A;&EG;CTS1&-E;G1E6QE/3-$)T9/3E0M1D%- M24Q9.B!4:6UEF4],T0R/B8C>$$P.R8C>$$P.R8C M>$$P.R8C>$$P.R8C>$$P.R8C>$$P.R8C>$$P.R8C>$$P.R8C>$$P.R8C>$$P M.U-H87)E$$P.R8C>$$P.R8C>$$P.R8C>$$P.R8C>$$P.R8C>$$P.R8C M>$$P.R8C>$$P.R8C>$$P.R8C>$$P.SPO9F]N=#X\+W`^#0H\+W1D/@T*/'1D M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^ M/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@$$P.T%V97)A9V4F(WA!,#LF(WA!,#L\8G(@+SX-"D5X97)C M:7-E(%!R:6-E/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/CQF M;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*/"]T6QE/3-$)U1%6%0M24Y$14Y4.B`M,65M.R!-05)'24XM3$5&5#H@,65M M)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N M)R!S:7IE/3-$,CY/=71S=&%N9&EN9RP-"D1E8V5M8F5R)B-X03`[,S$L(#(P M,3(\+V9O;G0^/"]P/@T*/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^/&9O M;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE MF4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D M('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$ M)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/C$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!N M;W=R87`],T1N;W=R87`^/&9O;G0@F4],T0Q/B8C>$$P M.R8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE M/3-$,CXF(WA!,#LD/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M M(&%L:6=N/3-$$$P.R8C>$$P.R8C>$$P M.R8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R M87`],T1N;W=R87`^/&9O;G0@6QE/3-$ M)U1%6%0M24Y$14Y4.B`M,65M.R!-05)'24XM3$5&5#H@,V5M)SX\9F]N="!S M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$ M,CY'F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T* M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E, M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T M9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$ M,CXU+#`P,"8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O M;2!N;W=R87`],T1N;W=R87`^/&9O;G0@F4],T0Q/B8C M>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3X\ M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S M:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T M;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@ M5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXR+C8U)B-X03`[)B-X03`[)B-X M03`[)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&YO M=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T M9#X-"CPO='(^#0H\='(@8F=C;VQO6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE MF4],T0R/D5X97)C:7-E9#PO9F]N=#X\+W`^#0H\ M+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA! M,#LF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^/&9O M;G0@F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG M;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@ M3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V M86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=& M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXM)B-X03`[ M)B-X03`[)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$ M8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49! M34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\ M+V9O;G0^/"]T9#X-"CPO='(^#0H\='(^#0H\=&0@=F%L:6=N/3-$=&]P/@T* M/'`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`],T1N;W=R87`^/&9O;G0@6QE/3-$)T9/3E0M4TE:13H@ M,7!X)SX-"CQT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"CQT9"!V86QI9VX] M,T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T M;VT^#0H\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI M9"<^)B-X03`[/"]P/@T*/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^#0H\ M<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X M03`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`@6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P M,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*/"]T9#X-"CQT9#XF(WA!,#L\ M+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T* M/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O M;3X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*/"]T6QE/3-$)TU! M4D=)3BU43U`Z(#$V<'@[($U!4D=)3BU"3U143TTZ(#!P>"<^/&9O;G0@6QE M/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/DEN M($IA;G5A2!O9B`X-R4L(')I MF5R;R!D:79I M9&5N9',N(%1H92!#;VUP86YY(')E8V]G;FEZ960@86X@97AP96YS92!O9@T* M)#7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI M(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS M1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA7!E/3-$=&5X="]J879A'0^ M/&1I=CX-"CQT86)L92!S='EL93TS1"="3U)$15(M0T],3$%04T4Z(&-O;&QA M<'-E)R!B;W)D97(],T0P(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS M1#`@=VED=&@],T0Q,#`E/@T*/'1R/@T*/'1D('9A;&EG;CTS1'1O<"!W:61T M:#TS1#0E(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E, M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CX\8CXU+CPO8CX\+V9O;G0^ M/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@86QI9VX],T1L969T/CQF;VYT('-T M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R M/CQB/D9A:7(@5F%L=64@;V8@1FEN86YC:6%L#0I);G-T"<^#0H\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W M(%)O;6%N)R!S:7IE/3-$,CY4:&4@0V]M<&%N>2!H87,-"F-E0T*3&5V96P@,B!I;G!U=',@=71I;&EZ92!D871A('!O:6YTF4@=6YO8G-E'!E M;G-E3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]F-C0P M9#5E8U\S,34T7S1C,69?8F(U8E\S8C$Y,F-C,#-E-S(-"D-O;G1E;G0M3&]C M871I;VXZ(&9I;&4Z+R\O0SHO9C8T,&0U96-?,S$U-%\T8S%F7V)B-6)?,V(Q M.3)C8S`S93'0O:'1M;#L@8VAA6QE/3-$)T)/4D1%4BU#3TQ,05!313H@8V]L;&%P6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/CQB/C8N/"]B/CPO9F]N=#X\+W1D/@T*/'1D M('9A;&EG;CTS1'1O<"!A;&EG;CTS1&QE9G0^/&9O;G0@6QE/3-$)T9/3E0M1D%- M24Q9.B!4:6UEF4],T0R/D)A6QE/3-$)TU!4D=) M3BU43U`Z(#!P>#L@34%21TE.+4)/5%1/33H@,'!X.R!&3TY4+5-)6D4Z(#$R M<'@G/@T*/&9O;G0@6QE/3-$ M)TU!4D=)3BU43U`Z(#9P>#L@5$585"U)3D1%3E0Z(#0E.R!-05)'24XM0D]4 M5$]-.B`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`[86UO=6YT6QE/3-$ M)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/D)A6QE/3-$)U1%6%0M24Y$14Y4.B`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`T*3PO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`] M,T1N;W=R87`^/&9O;G0@6QE/3-$)U1%6%0M24Y$14Y4.B`M,65M.R!-05)'24XM3$5& M5#H@,F5M)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W M(%)O;6%N)R!S:7IE/3-$,CY796EG:'1E9"!A=F5R86=E(&-O;6UO;@T*F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS M1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W M(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI M9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4 M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXQ-BPP-SD\+V9O M;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@;F]W6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG M;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^ M/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/DYE="!L;W-S('!E#(P,3,[ M(&)AF4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N M=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=& M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\ M+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H M=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N M)R!S:7IE/3-$,CXD)B-X03`[)B-X03`[*#`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`Z(#$P<'@[($U!4D=)3BU" M3U143TTZ(#!P>#L@1D].5"U325I%.B`Q<'@G/@T*/&9O;G0@6QE/3-$)TU!4D=)3BU43U`Z(#!P>#L@5$58 M5"U)3D1%3E0Z(#0E.R!-05)'24XM0D]45$]-.B`P<'@G/@T*/&9O;G0@&ES="!P M=7)S=6%N="!T;R!T:&4@97AE"<^#0H\9F]N="!S='EL M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF M(WA!,#L\+V9O;G0^/"]P/@T*/'`@"<^#0H\+W`^ M#0H\=&%B;&4@F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O M;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI M9VX],T1B;W1T;VT^/&9O;G0@F4],T0Q/B8C>$$P.SPO M9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P M,#`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`],T1N;W=R87`^/&9O;G0@6QE/3-$)U1%6%0M24Y$14Y4.B`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`],T1N;W=R87`^/&9O;G0@6QE/3-$)U1% M6%0M24Y$14Y4.B`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`],T1N;W=R87`^ M/&9O;G0@6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"CQT9"!V86QI9VX],T1B;W1T M;VT^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"CQT M9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^ M)B-X03`[/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^#0H\<"!S='EL93TS M1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T* M/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8V]LF4],T0Q M/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE M/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@ M86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXQ,RPW,#0L,C,P)B-X03`[)B-X03`[ M)B-X03`[)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$ M8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49! M34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\ M+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS M1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%- M24Q9.B!4:6UEF4],T0R/C$S+#`T."PX,3DF(WA! M,#LF(WA!,#LF(WA!,#LF(WA!,#LF(WA!,#LF(WA!,#LF(WA!,#LF(WA!,#LF M(WA!,#LF(WA!,#LF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI M9VX],T1B;W1T;VT@;F]W6QE/3-$)T9/ M3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C>$$P.R8C M>$$P.SPO9F]N=#X\+W1D/@T*/"]T"<^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H\=&0@=F%L M:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M M(&-O;'-P86X],T0X/@T*/'`@$$P.SPO M=&0^#0H\+W1R/@T*/"$M+2!%;F0@5&%B;&4@0F]D>2`M+3X\+W1A8FQE/@T* M/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO M=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R M=%]F-C0P9#5E8U\S,34T7S1C,69?8F(U8E\S8C$Y,F-C,#-E-S(-"D-O;G1E M;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO9C8T,&0U96-?,S$U-%\T8S%F7V)B M-6)?,V(Q.3)C8S`S93'0O:'1M;#L@8VAA6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/D]N#0I-87)C:"8C>$$P.S(R+"`R,#$R+"!T:&4@0V]M M<&%N>2!E;G1E#(P,40[*2!O9B!T:&4@0V]M M<&%N>2P@96%C:"!U;FET(&-O;G-I2!O<'1I;VX@=&\@<'5R8VAA$$P M.S(V+"`R,#$R+B!4:&4@<'5B;&EC(&]F9F5R:6YG('!R:6-E(&9O<@T*96%C M:"!5;FET('=A'!I M6QE/3-$)TU!4D=)3BU43U`Z(#$R<'@[(%1%6%0M24Y$14Y4.B`T)3L@34%2 M1TE.+4)/5%1/33H@,'!X)SX-"CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UEF4],T0R/D]N#0I-87)C:"8C>$$P.S(X M+"`R,#$R+"!T:&4@0V]M<&%N>2!S;VQD(&%N9"!I$$P.S(X+"`R,#$R+"!U#(P M,4,[1&5R:79A=&EV97,@86YD($AE9&=I;F"<^#0H\9F]N="!S M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$ M,CY/;@T*36%R8V@F(WA!,#LR."P@,C`Q,BP@:6X@8V]N;F5C=&EO;B!W:71H M('1H:7,@=6YD97)W2!I28C>$$P.S(L(#(P,38L(&AA=F4@86X@97AE&5R8VES86)L92!B96=I;FYI;F<@ M,2!Y96%R(&9R;VT@36%R8V@F(WA!,#LR,BP-"C(P,3(@*'1H92!D871E(&]F M('1H92!U;F1E65A#(P,4,[1&5R:79A=&EV97,@86YD($AE9&=I;F#L@5$585"U)3D1%3E0Z(#0E.R!-05)'24XM0D]45$]-.B`P M<'@G/@T*/&9O;G0@$$P.S(S M+"`R,#$R+"!A;F0@:6X@8V]N;F5C=&EO;B!W:71H('1H92!P7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T* M#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O M;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA6QE/3-$ M)T)/4D1%4BU#3TQ,05!313H@8V]L;&%P6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/CQB/C@N/"]B/CPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1'1O M<"!A;&EG;CTS1&QE9G0^/&9O;G0@6QE/3-$)T9/3E0M M1D%-24Q9.B!4:6UEF4],T0R/CQI/D%G6QE/3-$)TU!4D=)3BU43U`Z(#9P>#L@5$585"U) M3D1%3E0Z(#0E.R!-05)'24XM0D]45$]-.B`P<'@G/@T*/&9O;G0@2`Q+"`R,#$S+"!T:&4@0V]M<&%N>2!E;G1E$$P.RAI;F1I M=FED=6%L;'D@86YD#0IC;VQL96-T:79E;'DL("8C>#(P,4,[0U1))B-X,C`Q M1#LI+"!W:&5R96)Y($-422!I2!#5$D@=VET:"!R97-P M96-T('1O(&%N>2!P87)T:6-U;&%R(&-L:6YI8V%L(')E2!S<&]N$$P M.U5N;&5S28C>$$P M.S,Q+`T*,C`Q."X\+V9O;G0^/"]P/@T*/'`@#L@5$585"U)3D1%3E0Z(#0E.R!-05)'24XM0D]45$]-.B`P<'@G M/@T*/&9O;G0@28C>#(P,3D[#(P M,4,[3D%32"8C>#(P,40[*0T*=VET:"!A9'9A;F-E9"!H97!A=&EC(&9I8G)O M$$P.T-422!I$$P.W=I=&@@2!A;F0@28C>#(P,3D[2!O9B!T:&4@:6YV97-T:6=A=&EO;F%L#0ID$$P.SPO<#X-"CQP('-T M>6QE/3-$)TU!4D=)3BU43U`Z(#!P>#L@5$585"U)3D1%3E0Z(#0E.R!-05)' M24XM0D]45$]-.B`P<'@G/@T*/&9O;G0@$$P.S,Q+"`R,#$T+B8C>$$P.U1H92!E2P@=VET:"!P M87EM96YT6QE/3-$)TU!4D=) M3BU43U`Z(#$R<'@[(%1%6%0M24Y$14Y4.B`T)3L@34%21TE.+4)/5%1/33H@ M,'!X)SX-"CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/E1H92!!9W)E96UE;G0-"F]R(&%N>2!W;W)K(&]R M9&5R(&UA>2!B92!T97)M:6YA=&5D(&9O2!P M87)T>0T*=7!O;B!N:6YE='D@*#DP*28C>$$P.V1A>7,@<')I;W(@=W)I='1E M;B!N;W1I8V4@=&\@=&AE(&]T:&5R('!A2!I9B!T:&4@;W1H97(@<&%R='D@8F5C;VUE2`H.3`I M)B-X03`[9&%Y2!B92!T97)M:6YA=&5D(&EM;65D:6%T96QY(&)Y('=R:71T96X@ M;F]T:6-E(&9R;VT@=&AE#0I#;VUP86YY+"!I;B!T:&4@9F]L;&]W:6YG(&-I M$$P.W1H92!&1$$@=VET:&1R87=S#0IA=71H M;W)I>F%T:6]N(&%N9"!A<'!R;W9A;"!T;R!C;VYD=6-T(&$@$$P.W1H90T*0V]M<&%N>2!R96%S;VYA8FQY(&1E=&5R;6EN97,@ M=&AA="!F;W(@;65D:6-A;"P@8VQI;FEC86P@;W(@<&%T:65N=`T*2X@26X@861D:71I;VXL#0IE:71H97(@<&%R='D@;6%Y('1E2!W;W)K(&]R9&5R(&9O<@T*;6%T97)I86P@ M8G)E86-H('5P;VX@=&AI$$P.V1A>0T*<&5R M:6]D+CPO9F]N=#X\+W`^#0H\<"!S='EL93TS1"=-05)'24XM5$]0.B`Q.'!X M.R!-05)'24XM0D]45$]-.B`P<'@G/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%- M24Q9.B!4:6UEF4],T0R/CQI/D1R=6<@1&ES8V]V M97)Y(%!R;V=R86T-"G=I=&@@=&AE(%5N:79E"<^#0H\9F]N="!S M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$ M,CY);B!&96)R=6%R>0T*,C`Q,RP@=&AE($-O;7!A;GD@97-T86)L:7-H960@ M82!C;VQL86)O$$P.T-O;7!L97@@0V%R8F]H>61R871E(%)E$$P.V%T#0IT:&4F(WA!,#M5;FEV97)S:71Y(&]F($=E;W)G:6$N(%1H:7,@ M<')O9W)A;2!I0T*96ET:&5R('!A6QE/3-$)TU!4D=)3BU43U`Z(#$X<'@[ M($U!4D=)3BU"3U143TTZ(#!P>"<^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/DEN($9E8G)U87)Y#0HR,#`Y+"!T:&4@0V]M<&%N>2!E M;G1E#(P,40[*2!F;W(@86YY(&1R=6<@8V%N M9&ED871E(&]R(&1R=6<-"F1E;&EV97)Y(&-A;F1I9&%T92!B87-E9"!O;B!T M:&4@0V]M<&%N>28C>#(P,3D[&5R8VES92!S M=&]C:R!O<'1I;VX@=&\@<'5R8VAA0T*:6YV97-T;65N M="!O$$P.U!L871T(&ES(&%L$$P.W1H92!R96YE=V5D(&QIF%T:6]N(&]F("0Q,#`@;6EL;&EO;BX@4&%Y M;65N="!U<&]N('1H92!E=F5N=',-"BAI*28C>$$P.V%N9"`H:6EI*28C>$$P M.VUA>2!B92!D969E2!F:6QE2!O0T*<&5T:71I;VX@9F]R(&)A;FMR=7!T8WDL('=H971H97(@;W(@ M;F]T(&$@;6EL97-T;VYE(&5V96YT(&AA&-H86YG M92!A;F0@979E;G1U86QL>2!R96%C:"!A(&UA2!R96-O9VYI>F5D('1H M92`D,2XP(&UI;&QI;VX@6QE/3-$)TU!4D=)3BU4 M3U`Z(#$R<'@[(%1%6%0M24Y$14Y4.B`T)3L@34%21TE.+4)/5%1/33H@,'!X M)SX-"CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/D]N($UA>28C>$$P.S(L#0HR,#$R+"!$$$P.S(R+"`R,#$R+`T*=&AE($-O;7!A;GDF(W@R M,#$Y.W,@8V]M;6]N('-T;V-K('=A$$P.U!L871T)B-X,C`Q.3MS(&1E;6%N9"!I;B!A;&P@$$P.U!L871T('5P;VX@=&AE(&]C8W5R'!E;G-E('!A>6%B;&4@:68-"F%N9"!W:&5N M('1H92!M:6QE"<^#0H\9F]N="!S='EL93TS1"=&3TY4+49!34E, M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY/;@T*3V-T;V)E$$P M.S$R+"`R,#$R+"!$$$P.U1R86)E$$P.TUC1V%U;&5Y('=H;R!I;B!T M:&5I&5C=71I=F4@3V9F:6-E6UE;G0-"F]F('=A M9V5S+B!4:&4@;&%W6UE;G0@;V8@=&AE("0Q+C`@;6EL;&EO;@T*$$P.TUC1V%U;&5Y)B-X,C`Q.3MS(&UO=&EO;B!T;R!D:7-M M:7-S+CPO9F]N=#X\+W`^#0H\<"!S='EL93TS1"=-05)'24XM5$]0.B`Q,G!X M.R!-05)'24XM0D]45$]-.B`P<'@[($9/3E0M4TE:13H@,7!X)SX-"B8C>$$P M.SPO<#X-"CQP('-T>6QE/3-$)TU!4D=)3BU43U`Z(#!P>#L@5$585"U)3D1% M3E0Z(#0E.R!-05)'24XM0D]45$]-.B`P<'@G/@T*/&9O;G0@2!T;R!E;G1E2!T M;R!T:&4@0V]M<&%N>2P-"F%N9"!W87,@=6YD=6QY(&5N6UE;G0@;V8@86QL('-E<&%R871I;VX-"F)E;F5F:71S('!A M:60@=&\@1'(N)B-X03`[4&QA='0@=&\@9&%T92X@1&5P96YD:6YG(&]N('1H M92!O=71C;VUE#0IO9B!T:&4@87)B:71R871I;VXL('1H92!P6QE/3-$)TU!4D=) M3BU43U`Z(#$X<'@[($U!4D=)3BU"3U143TTZ(#!P>"<^/&9O;G0@6QE/3-$)TU!4D=)3BU43U`Z(#9P>#L@5$58 M5"U)3D1%3E0Z(#0E.R!-05)'24XM0D]45$]-.B`P<'@G/@T*/&9O;G0@2`R,#$S#0HU('-H87)E28C>#(P M,3D[#(P,4,[1&EV:61E M;F0@4FEG:'1S)B-X,C`Q1#LI+@T*56YD97(@=&AE('1E6%B;&4@;VX@;W5T$$P.S,Q+"`R,#$S+"!T:&4@1&EV:61E;F0@4FEG M:'1S(&AA9"!A#0IL:7%U:61A=&EO;B!V86QU92!O9B`D,C0Q+#`P,"X\+V9O M;G0^/"]P/@T*/'`@#L@34%21TE. M+4)/5%1/33H@,'!X)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CX\:3Y/=&AE6QE/3-$)TU!4D=)3BU43U`Z M(#9P>#L@5$585"U)3D1%3E0Z(#0E.R!-05)'24XM0D]45$]-.B`P<'@G/@T* M/&9O;G0@65A$$P.S,Q+"`R,#$R+CPO9F]N=#X\+W`^#0H\+V1I=CX\'0O M:F%V87-C3X-"B`@("`\ M=&%B;&4@8VQA6QE/3-$)TU!4D=)3BU43U`Z(#9P>#L@5$585"U)3D1%3E0Z(#0E.R!-05)' M24XM0D]45$]-.B`P<'@G/@T*/&9O;G0@#L@ M5$585"U)3D1%3E0Z(#0E.R!-05)'24XM0D]45$]-.B`P<'@G/@T*/&9O;G0@ M$$P.T$M,B!W87)R86YT'1E;F1E9"!B>2!A;B!A9&1I=&EO;F%L(&9I=F4@>65A M&-H86YG92!F;W(@=&AE2!W:6QL(&YO(&QO;F=E3X-"CPO:'1M;#X-"@T*+2TM+2TM/5]. M97AT4&%R=%]F-C0P9#5E8U\S,34T7S1C,69?8F(U8E\S8C$Y,F-C,#-E-S(- M"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO9C8T,&0U96-?,S$U-%\T M8S%F7V)B-6)?,V(Q.3)C8S`S93'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R'!E;G-E'0^/&1I=CX-"CQP('-T>6QE/3-$)TU!4D=)3BU43U`Z M(#$P<'@[(%1%6%0M24Y$14Y4.B`T)3L@34%21TE.+4)/5%1/33H@,'!X)SX- M"CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/D%C8W)U960@97AP96YS97,@8V]N6QE M/3-$)TU!4D=)3BU43U`Z(#!P>#L@34%21TE.+4)/5%1/33H@,'!X.R!&3TY4 M+5-)6D4Z(#$R<'@G/@T*/&9O;G0@6QE/3-$)TU!4D=)3BU43U`Z(#9P>#L@5$585"U)3D1%3E0Z(#0E.R!- M05)'24XM0D]45$]-.B`P<'@G/@T*/"]P/@T*/'1A8FQE('-T>6QE/3-$)T)/ M4D1%4BU#3TQ,05!313H@8V]L;&%PF4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O M;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL M93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9"<@=F%L:6=N M/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQF;VYT('-T M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R M/B8C>$$P.R8C>$$P.R8C>$$P.R8C>$$P.TUAF4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O M;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL M93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9"<@=F%L:6=N M/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQF;VYT('-T M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R M/B8C>$$P.T1E8V5M8F5R)B-X03`[,S$L)B-X03`[/&)R("\^#0HR,#$R/"]F M;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q M/B8C>$$P.SPO9F]N=#X\+W1D/@T*/"]TF4],T0Q/B8C>$$P.SPO9F]N M=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF M(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@ M6QE/3-$ M)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/BAI;B!T M:&]UF4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*/"]T6QE/3-$)U1%6%0M24Y$14Y4.B`M,65M.R!-05)'24XM3$5&5#H@,65M M)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N M)R!S:7IE/3-$,CY,96=A;"!A;F0@86-C;W5N=&EN9PT*9F5E6QE/3-$ M)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C>$$P M.R8C>$$P.R8C>$$P.R8C>$$P.R0\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX] M,T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49! M34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXX,"8C>$$P.SPO9F]N M=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^ M/&9O;G0@F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T* M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E, M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LD/"]F;VYT/CPO M=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/D%C8W)U960-"F-O;7!E;G-A=&EO;CPO9F]N=#X\+W`^#0H\+W1D M/@T*/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\ M+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1T;W`^/"]T9#X-"CQT9"!V86QI M9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%- M24Q9.B!4:6UEF4],T0R/B8C>$$P.SPO9F]N=#X\ M+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4] M,T0R/C8Q)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@ M5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^ M/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R M/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG M;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/C0R)B-X03`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`],T1N;W=R87`^/&9O;G0@F4],T0Q/B8C M>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$ M,CXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@86QI M9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@ M3F5W(%)O;6%N)R!S:7IE/3-$,CXQ,"8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D M('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@6QE/3-$)T9/ M3E0M4TE:13H@,7!X)SX-"CQT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"CQT M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"CQT9"!V86QI9VX],T1B M;W1T;VT^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X- M"CQT9"!V86QI9VX],T1B;W1T;VT^#0H\<"!S='EL93TS1"="3U)$15(M5$]0 M.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*/"]T9#X-"CQT9"!V M86QI9VX],T1B;W1T;VT^#0H\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P M,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*/"]T9#X-"CQT9#XF(WA!,#L\ M+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*/'1D('9A M;&EG;CTS1&)O='1O;3X-"CQP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P M,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H\+W1D/@T*/'1D('9A;&EG;CTS M1&)O='1O;3X-"CQP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X M('-O;&ED)SXF(WA!,#L\+W`^#0H\+W1D/@T*/'1D/B8C>$$P.SPO=&0^#0H\ M+W1R/@T*/'1R(&)G8V]L;W(],T0C0T-%149&/@T*/'1D('9A;&EG;CTS1'1O M<#X-"CQP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`M,65M.R!-05)'24XM3$5& M5#H@,65M)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W M(%)O;6%N)R!S:7IE/3-$,CY4;W1A;#PO9F]N=#X\+W`^#0H\+W1D/@T*/'1D M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^ M/"]T9#X-"CQT9"!V86QI9VX],T1T;W`^/"]T9#X-"CQT9"!V86QI9VX],T1B M;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4 M:6UEF4],T0R/B8C>$$P.R8C>$$P.R8C>$$P.R8C M>$$P.R0\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@86QI9VX] M,T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W M(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#LF(WA!,#LF(WA!,#LF(WA! M,#LF(WA!,#LF(WA!,#LF(WA!,#LQ+#$U,B8C>$$P.SPO9F]N=#X\+W1D/@T* M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG M;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@ M3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LD/"]F;VYT/CPO=&0^#0H\=&0@ M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE MF4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D M/@T*/"]T"<^#0H\=&0@ M=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/B8C M>$$P.SPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0X/@T* M/'`@$$P.SPO=&0^#0H\+W1R/@T*/"$M M+2!%;F0@5&%B;&4@0F]D>2`M+3X\+W1A8FQE/@T*/"]D:78^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D M>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]F-C0P9#5E8U\S,34T M7S1C,69?8F(U8E\S8C$Y,F-C,#-E-S(-"D-O;G1E;G0M3&]C871I;VXZ(&9I M;&4Z+R\O0SHO9C8T,&0U96-?,S$U-%\T8S%F7V)B-6)?,V(Q.3)C8S`S93'0O M:'1M;#L@8VAA"<^#0H\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@ M3F5W(%)O;6%N)R!S:7IE/3-$,CX\9F]N="!S='EL93TS1"=&3TY4+49!34E, M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY&;VQL;W=I;F<@:7,@=&AE M#0IS=&]C:RUB87-E9"!C;VUP96YS871I;VX@97AP96YS92!R96QA=&5D('1O M(&-O;6UO;B!S=&]C:R!O<'1I;VYS+`T*8V]M;6]N('-T;V-K+"!R97-T6QE/3-$)TU!4D=)3BU43U`Z(#!P M>#L@34%21TE.+4)/5%1/33H@,'!X.R!&3TY4+5-)6D4Z(#$P<'@G/@T*/&9O M;G0@6QE/3-$)TU!4D=)3BU4 M3U`Z(#9P>#L@5$585"U)3D1%3E0Z(#0E.R!-05)'24XM0D]45$]-.B`P<'@G M/@T*/"]P/@T*/'1A8FQE('-T>6QE/3-$)T)/4D1%4BU#3TQ,05!313H@8V]L M;&%PF4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O M='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X- M"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI M9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0V(&%L:6=N/3-$8V5N=&5R M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/CQB/E1H2`M+3X-"CQT6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/C,Q.28C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O M='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@F4],T0Q M/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O M;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N M)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#LF(WA!,#LD/"]F;VYT/CPO=&0^#0H\ M=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R M/D=E;F5R86P@86YD#0IA9&UI;FES=')A=&EV93PO9F]N=#X\+W`^#0H\+W1D M/@T*/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF M(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@ M6QE/3-$)T9/3E0M1D%-24Q9.B!4 M:6UEF4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T* M/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE M/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/C,R M-"8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R M87`],T1N;W=R87`^/&9O;G0@6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"CQT9"!V M86QI9VX],T1B;W1T;VT^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^)B-X M03`[)B-X03`[/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^#0H\<"!S='EL M93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P M/@T*/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^#0H\<"!S='EL93TS1"=" M3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*/"]T M9#X-"CQT9#XF(WA!,#L\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3XF(WA! M,#LF(WA!,#L\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3X-"CQP('-T>6QE M/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^ M#0H\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3X-"CQP('-T>6QE/3-$)T)/ M4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H\+W1D M/@T*/'1D/B8C>$$P.SPO=&0^#0H\+W1R/@T*/'1R(&)G8V]L;W(],T0C0T-% M149&/@T*/'1D('9A;&EG;CTS1'1O<#X-"CQP('-T>6QE/3-$)U1%6%0M24Y$ M14Y4.B`M,65M.R!-05)'24XM3$5&5#H@,V5M)SX\9F]N="!S='EL93TS1"=& M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY4;W1A;"!S M=&]C:RUB87-E9`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`],T1N;W=R87`^/&9O;G0@6QE/3-$)T9/3E0M4TE:13H@ M,7!X)SX-"CQT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"CQT9"!V86QI9VX] M,T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T M;VT^#0H\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B M;&4G/B8C>$$P.SPO<#X-"CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/@T* M/'`@$$P.SPO=&0^#0H\=&0@=F%L:6=N M/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T M=&]M/@T*/'`@6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^ M)B-X03`[/"]P/@T*/"]T9#X-"CQT9#XF(WA!,#L\+W1D/@T*/"]T2!O9B!3=&]C:R!/<'1I;VX@06-T:79I='D\+W1D/@T*("`@("`@("`\=&0@ M8VQA"<^#0H\ M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S M:7IE/3-$,CX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W M(%)O;6%N)R!S:7IE/3-$,CY4:&4@9F]L;&]W:6YG('1A8FQE#0IS=6UM87)I M>F5S('1H92!S=&]C:R!O<'1I;VX@86-T:79I='D@:6X@=&AE($-O;7!A;GDF M(W@R,#$Y.W,@97%U:71Y#0II;F-E;G1I=F4@<&QA;G,L(&EN8VQU9&EN9R!N M;VXM<&QA;B!G2!E>&5C=71I=F5S+`T*9G)O;2!$ M96-E;6)E$$P.S,Q+"`R,#$R('1H"<^#0H\+W`^#0H\=&%B;&4@F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D M/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O M;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L#L@1D].5"U3 M25I%.B`Q,G!X)SX-"B8C>$$P.SPO<#X-"CQP('-T>6QE/3-$)TU!4D=)3BU4 M3U`Z(#!P>#L@34%21TE.+4)/5%1/33H@,7!X)R!A;&EG;CTS1&-E;G1E6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C>$$P.R8C>$$P.R8C>$$P.R8C>$$P.R8C>$$P.R8C>$$P M.R8C>$$P.R8C>$$P.R8C>$$P.R8C>$$P.U-H87)E$$P.R8C>$$P.R8C M>$$P.R8C>$$P.R8C>$$P.R8C>$$P.R8C>$$P.R8C>$$P.R8C>$$P.R8C>$$P M.SPO9F]N=#X\+W`^#0H\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N M="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B M;W1T;VT^/&9O;G0@$$P.T%V97)A9V4F M(WA!,#LF(WA!,#L\8G(@+SX-"D5X97)C:7-E(%!R:6-E/"]F;VYT/CPO=&0^ M#0H\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO M9F]N=#X\+W1D/@T*/"]T6QE/3-$)U1%6%0M24Y$14Y4 M.B`M,65M.R!-05)'24XM3$5&5#H@,65M)SX\9F]N="!S='EL93TS1"=&3TY4 M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY/=71S=&%N9&EN M9RP-"D1E8V5M8F5R)B-X03`[,S$L(#(P,3(\+V9O;G0^/"]P/@T*/"]T9#X- M"CQT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R M/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG M;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/C,L-3,Y+#DV,3PO9F]N=#X\+W1D/@T*/'1D M('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A M;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LD/"]F;VYT/CPO=&0^#0H\ M=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P.R8C M>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!N M;W=R87`],T1N;W=R87`^/&9O;G0@6QE M/3-$)U1%6%0M24Y$14Y4.B`M,65M.R!-05)'24XM3$5&5#H@,V5M)SX\9F]N M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE M/3-$,CY'F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D M/@T*/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49! M34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^ M/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE M/3-$,CXR,#`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`],T1N;W=R87`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`F(WA!,#LF(WA!,#LF(WA!,#LF(WA! M,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@;F]W6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*/"]T M"<^#0H\=&0@=F%L:6=N M/3-$8F]T=&]M/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C M>$$P.SPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/@T*/'`@$$P.SPO<#X-"CPO M=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/@T*/'`@$$P.SPO<#X-"CPO=&0^#0H\ M=&0^)B-X03`[/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X M03`[/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"CQT9"!V86QI M9VX],T1B;W1T;VT^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X- M"CPO='(^#0H\='(@8F=C;VQO6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/D]U='-T86YD:6YG+"!-87)C:"8C>$$P.S,Q M+`T*,C`Q,SPO9F]N=#X\+W`^#0H\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O M;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"CQT M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4] M,T0R/B8C>$$P.R0\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@ M86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXU+C4R)B-X03`[)B-X03`[)B-X03`[ M)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A M<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@ M3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X- M"CPO='(^#0H\='(@6QE M/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P M/@T*/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^#0H\<"!S='EL93TS1"=" M3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"CPO M=&0^#0H\=&0^)B-X03`[/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^)B-X M03`[)B-X03`[/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"CQT M9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^ M/"]T9#X-"CPO='(^#0H\(2TM($5N9"!486)L92!";V1Y("TM/CPO=&%B;&4^ M#0H\+V1I=CX\"<^#0H\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CX\9F]N="!S='EL93TS1"=&3TY4+49! M34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY4:&4@9F%I6QE/3-$)TU!4D=)3BU43U`Z(#!P>#L@34%21TE.+4)/ M5%1/33H@,'!X.R!&3TY4+5-)6D4Z(#$X<'@G/@T*/&9O;G0@6QE/3-$)TU!4D=)3BU43U`Z(#$R<'@[(%1% M6%0M24Y$14Y4.B`T)3L@34%21TE.+4)/5%1/33H@,'!X)SX-"CPO<#X-"CQT M86)L92!S='EL93TS1"="3U)$15(M0T],3$%04T4Z(&-O;&QA<'-E)R!B;W)D M97(],T0P(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`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`C,#`P,#`P(#%P>"!S;VQI9"<@=F%L M:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1&-E;G1E6QE/3-$)T9/ M3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C>$$P.R8C M>$$P.R8C>$$P.R8C>$$P.TUO;G1H$$P.T5N9&5D)B-X03`[#0HF(WA! M,#LF(WA!,#LF(WA!,#L\8G(@+SX-"DUAF4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`@86QI9VX],T1C96YT97(^#0H\ M<"!S='EL93TS1"=-05)'24XM5$]0.B`P<'@[($U!4D=)3BU"3U143TTZ(#!P M>"<@86QI9VX],T1C96YT97(^#0H\9F]N="!S='EL93TS1"=&3TY4+49!34E, M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY#=6UU;&%T:79E/"]F;VYT M/CPO<#X-"CQP('-T>6QE/3-$)TU!4D=)3BU43U`Z(#!P>#L@34%21TE.+4)/ M5%1/33H@,'!X)R!A;&EG;CTS1&-E;G1E6QE/3-$)T9/ M3E0M1D%-24Q9.B!4:6UEF4],T0R/E!E$$P.V9R;VT\+V9O;G0^/"]P/@T*/'`@6QE/3-$)TU!4D=) M3BU43U`Z(#!P>#L@34%21TE.+4)/5%1/33H@,7!X)R!A;&EG;CTS1&-E;G1E M6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C>$$P.RA*=6QY)B-X03`[,3`L)B-X03`[,C`P,"DF M(WA!,#MT;R8C>$$P.R8C>$$P.R8C>$$P.SQBF4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG M;CTS1&)O='1O;3X-"CQP('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P M,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H\+W1D/@T*/'1D('9A;&EG;CTS M1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T M9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S M;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$8V5N=&5R/CQF;VYT('-T M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R M/C(P,3,\+V9O;G0^/"]T9#X-"CPO='(^#0H\(2TM($5N9"!486)L92!(96%D M("TM/CPA+2T@0F5G:6X@5&%B;&4@0F]D>2`M+3X-"CQTF4],T0Q/B8C>$$P.R8C>$$P.SPO M9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1&-E;G1E M6QE/3-$)T9/ M3E0M1D%-24Q9.B!4:6UEF4],T0R/C$N-S8E/"]F M;VYT/CPO=&0^#0H\+W1R/@T*/'1R/@T*/'1D('9A;&EG;CTS1'1O<#X-"CQP M('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`M,65M.R!-05)'24XM3$5&5#H@,65M M)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N M)R!S:7IE/3-$,CY%>'!E8W1E9"!L:69E(&]F('1H90T*;W!T:6]N65AF4],T0Q/B8C>$$P M.R8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG M;CTS1&-E;G1E6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/C$Q-R4\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T M;VT^/&9O;G0@F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG M;CTS1&)O='1O;2!A;&EG;CTS1&-E;G1E6QE/3-$)U1%6%0M24Y$14Y4.B`M,65M.R!-05)'24XM3$5&5#H@,65M)SX\ M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S M:7IE/3-$,CY%>'!E8W1E9"!D:79I9&5N9`T*F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T* M/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1&-E;G1E7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S M8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I M=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA7!E/3-$=&5X="]J879A"<^#0H\9F]N="!S='EL93TS1"=&3TY4+49! M34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CX\9F]N="!S='EL93TS M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY4:&4@ M9F]L;&]W:6YG('1A8FQE#0IS=6UM87)I>F5S('1H92!C;VUM;VX@2!F6QE/3-$)TU!4D=)3BU43U`Z(#!P>#L@34%21TE.+4)/5%1/ M33H@,'!X.R!&3TY4+5-)6D4Z(#$P<'@G/@T*/&9O;G0@6QE/3-$)TU!4D=)3BU43U`Z(#9P>#L@5$585"U) M3D1%3E0Z(#0E.R!-05)'24XM0D]45$]-.B`P<'@G/@T*/"]P/@T*/'1A8FQE M('-T>6QE/3-$)T)/4D1%4BU#3TQ,05!313H@8V]L;&%PF4],T0Q/B8C>$$P M.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE M/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=" M3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9"<@=F%L:6=N/3-$8F]T M=&]M(&-O;'-P86X],T0R/@T*/'`@$$P M.SPO<#X-"CQP('-T>6QE/3-$)TU!4D=)3BU43U`Z(#9P>#L@34%21TE.+4)/ M5%1/33H@,7!X)R!A;&EG;CTS1&-E;G1E6QE/3-$)T9/ M3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C>$$P.R8C M>$$P.R8C>$$P.R8C>$$P.R8C>$$P.R8C>$$P.R8C>$$P.R8C>$$P.R8C>$$P M.R8C>$$P.U-H87)E$$P.R8C>$$P.R8C>$$P.R8C>$$P.R8C>$$P.R8C M>$$P.R8C>$$P.R8C>$$P.R8C>$$P.R8C>$$P.SPO9F]N=#X\+W`^#0H\+W1D M/@T*/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\ M+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@$$P.T%V97)A9V4F(WA!,#LF(WA!,#L\8G(@+SX- M"D5X97)C:7-E(%!R:6-E/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T M=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*/"]T6QE/3-$)U1%6%0M24Y$14Y4.B`M,65M.R!-05)'24XM3$5& M5#H@,65M)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W M(%)O;6%N)R!S:7IE/3-$,CY/=71S=&%N9&EN9RP-"D1E8V5M8F5R)B-X03`[ M,S$L(#(P,3(\+V9O;G0^/"]P/@T*/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T M;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UEF4],T0R/B8C>$$P.SPO9F]N=#X\+W1D M/@T*/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R M/C$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O M='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@F4],T0Q M/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O M;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N M)R!S:7IE/3-$,CXF(WA!,#LD/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$ M8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P M.R8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O M;2!N;W=R87`],T1N;W=R87`^/&9O;G0@6QE/3-$)U1%6%0M24Y$14Y4.B`M,65M.R!-05)'24XM3$5&5#H@,V5M)SX\ M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S M:7IE/3-$,CY'F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\ M+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4 M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O M;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\ M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S M:7IE/3-$,CXU+#`P,"8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS M1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@F4] M,T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O M='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O M;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX] M,T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49! M34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXR+C8U)B-X03`[)B-X M03`[)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T M=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E, M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O M;G0^/"]T9#X-"CPO='(^#0H\='(@8F=C;VQO6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UEF4],T0R/D5X97)C:7-E9#PO9F]N=#X\ M+W`^#0H\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$ M,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T M;VT^/&9O;G0@F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@ M5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X- M"CQT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXM M)B-X03`[)B-X03`[)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L M:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=& M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF M(WA!,#L\+V9O;G0^/"]T9#X-"CPO='(^#0H\='(^#0H\=&0@=F%L:6=N/3-$ M=&]P/@T*/'`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`],T1N;W=R87`^/&9O;G0@6QE/3-$)T9/3E0M M4TE:13H@,7!X)SX-"CQT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"CQT9"!V M86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"CQT9"!V86QI9VX] M,T1B;W1T;VT^#0H\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P M>"!S;VQI9"<^)B-X03`[/"]P/@T*/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T M;VT^#0H\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI M9"<^)B-X03`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`Z M(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*/"]T9#X-"CQT9#XF M(WA!,#L\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\ M+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*/'1D('9A;&EG;CTS M1&)O='1O;3X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*/"]T M7!E M.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@ M/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C M;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA"<^#0H\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@ M5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY4:&4@8V]M<'5T871I;VX-"F]F M(&1I;'5T960@;F5T(&QO6QE/3-$)TU!4D=)3BU43U`Z(#!P>#L@34%21TE. M+4)/5%1/33H@,'!X.R!&3TY4+5-)6D4Z(#$R<'@G/@T*/&9O;G0@6QE/3-$)TU!4D=)3BU43U`Z(#9P>#L@ M5$585"U)3D1%3E0Z(#0E.R!-05)'24XM0D]45$]-.B`P<'@G/@T*/"]P/@T* M/'1A8FQE('-T>6QE/3-$)T)/4D1%4BU#3TQ,05!313H@8V]L;&%PF4],T0Q/B8C>$$P M.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE M/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B M;W1T;VT@8V]L6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/C(P,3(\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^ M/&9O;G0@6QE/3-$ M)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/BAI;B8C M>$$P.W1H;W5S86YD&-E<'0F(WA!,#MS:&%R93QB2`M+3X-"CQTF4] M,T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O M='1O;3X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*/'1D('9A M;&EG;CTS1&)O='1O;3X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N M="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI M9VX],T1B;W1T;VT^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X- M"CQT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"CPO='(^#0H\='(^#0H\=&0@ M=F%L:6=N/3-$=&]P/@T*/'`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`W.3PO9F]N M=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^ M/&9O;G0@F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\ M+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4 M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O M;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\ M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S M:7IE/3-$,CXQ,RPP,3`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`],T1N;W=R87`^/&9O;G0@2`M+3X\+W1A M8FQE/@T*/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@("`@/'1R(&-L87-S/3-$"<^#0H\9F]N="!S='EL93TS1"=&3TY4 M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CX\9F]N="!S='EL M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY$ M:6QU=&EV92!S:&%R97,@=VAI8V@@8V]U;&0-"F5X:7-T('!U&5R8VES92!O9B!O=71S=&%N9&EN9R!S=&]C:R!I;G-T#L@1D].5"U325I%.B`Q,G!X)SX-"CQF;VYT('-T>6QE/3-$)T9/3E0M M1D%-24Q9.B!4:6UEF4],T0R/B8C>$$P.SPO9F]N M=#X\+W`^#0H\<"!S='EL93TS1"=-05)'24XM5$]0.B`P<'@[(%1%6%0M24Y$ M14Y4.B`T)3L@34%21TE.+4)/5%1/33H@,'!X)SX-"CPO<#X-"CQT86)L92!S M='EL93TS1"="3U)$15(M0T],3$%04T4Z(&-O;&QA<'-E)R!B;W)D97(],T0P M(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`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`C,#`P,#`P(#%P>"!S;VQI M9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C>$$P.R8C>$$P.R8C>$$P.R8C>$$P.R8C>$$P.R8C>$$P M.TUA$$P.R8C>$$P.R8C>$$P.R8C M>$$P.R8C>$$P.R8C>$$P.SQB2`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`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H\+W1D/@T*/'1D M('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$-3X-"CQP('-T>6QE/3-$)T)/ M4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H\+W1D M/@T*/'1D/B8C>$$P.SPO=&0^#0H\+W1R/@T*/'1R/@T*/'1D('9A;&EG;CTS M1'1O<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$ M,3XF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1T;W`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`],T1N;W=R87`^/&9O;G0@6QE/3-$)T9/3E0M4TE:13H@,7!X)SX- M"CQT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T M;VT^)B-X03`[/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8V]L'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T* M#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O M;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S M8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I M=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA7!E/3-$=&5X="]J879A'!E;G-E(%)E;&%T960@=&\@0V]M M;6]N(%-T;V-K($]P=&EO;G,L($-O;6UO;B!3=&]C:RP@4F5S=')I8W1E9"!# M;VUM;VX@4W1O8VL@86YD($-O;6UO;B!3=&]C:R!787)R86YTF5D(%!E'!E;G-E M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS,3DL,#`P/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%SF5D(%!E7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S M+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE M<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA M&5R8VES92!0'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$3X-"CPO:'1M;#X-"@T*+2TM M+2TM/5].97AT4&%R=%]F-C0P9#5E8U\S,34T7S1C,69?8F(U8E\S8C$Y,F-C M,#-E-S(-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO9C8T,&0U96-? M,S$U-%\T8S%F7V)B-6)?,V(Q.3)C8S`S93'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R M6UE;G0@07=A'0^ M,R!Y96%R3X- M"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]F-C0P9#5E8U\S,34T7S1C M,69?8F(U8E\S8C$Y,F-C,#-E-S(-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z M+R\O0SHO9C8T,&0U96-?,S$U-%\T8S%F7V)B-6)?,V(Q.3)C8S`S93'0O:'1M M;#L@8VAA2!3:&%R92UB87-E9"!087EM96YT($%W M87)D(%M,:6YE($ET96US73PO'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@("`@/'1R(&-L87-S/3-$'0^-2!Y96%R65A2!O9B!T:&4@=6YD97)L>6EN9R!S=&]C:SPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$&5R8VES960\+W1D/@T*("`@("`@("`\=&0@ M8VQA'0^)FYB7!E.B!T97AT+VAT;6P[(&-H87)S970] M(G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T M<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@ M8VAA6UE;G0@ M07=A&5R8VES92!P'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^-2!Y96%R65A65A'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@("`@/'1R(&-L87-S/3-$'!E8W1E9"!D:79I9&5N9"!R871E/"]T9#X-"B`@ M("`@("`@/'1D(&-L87-S/3-$;G5M<#XP+C`P)3QS<&%N/CPO'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'!E;G-E/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$;G5M<#XD(#@U,BPP,#`\'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO M=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R M=%]F-C0P9#5E8U\S,34T7S1C,69?8F(U8E\S8C$Y,F-C,#-E-S(-"D-O;G1E M;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO9C8T,&0U96-?,S$U-%\T8S%F7V)B M-6)?,V(Q.3)C8S`S93'0O:'1M;#L@8VAA2!M87)K970@9G5N9',L($9A:7(@5F%L=64L M($EN<'5T2!M M87)K970@9G5N9',\+W1D/@T*("`@("`@("`\=&0@8VQA7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S M8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I M=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA7!E/3-$=&5X="]J879A&-E<'0@4&5R(%-H87)E M(&1A=&$L('5N;&5S7!E.B!T97AT+VAT;6P[ M(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@ M/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E M>'0O:'1M;#L@8VAA&ES M="!0=7)S=6%N="!T;R!%>&5R8VES92!O9B!/=71S=&%N9&EN9R!3=&]C:R!) M;G-T'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$&-L=61E9"!F7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA2!;3&EN92!)=&5M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$&5R8VES92!P'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S M/3-$'!I'0^36%R(#(X+`T*"0DR,#$W/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$'!E8W1E9"!L:69E/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$=&5X=#X\'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$&5R8VES92!P'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'!I'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^36%Y(#(L#0H)"3(P,38\'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S65A7,\'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@ M(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]F-C0P9#5E M8U\S,34T7S1C,69?8F(U8E\S8C$Y,F-C,#-E-S(-"D-O;G1E;G0M3&]C871I M;VXZ(&9I;&4Z+R\O0SHO9C8T,&0U96-?,S$U-%\T8S%F7V)B-6)?,V(Q.3)C M8S`S93'0O:'1M;#L@8VAA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^2F%N(#,Q+`T*"0DR,#$X/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M'!E;G-E M'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M'0^.3`@9&%Y7,\6%L M='D@'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%SF%T:6]N/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$=&5X=#X\6UE M;G0@<&5R:6]D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$6UE;G0\ M+W1D/@T*("`@("`@("`\=&0@8VQA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S7,\'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M'0O M:F%V87-C3X-"B`@("`\ M=&%B;&4@8VQA2`P-BP@,C`Q,SQB'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$&5R M8VES86)L92!L:69E(&5X=&5N9&5D('!E'0^-2!Y96%R7!E.B!T97AT+VAT;6P[(&-H87)S970] M(G5S+6%S8VEI(@T*#0H\>&UL('AM;&YS.F\],T0B=7)N.G-C:&5M87,M;6EC M&UL/@T*+2TM+2TM/5].97AT4&%R J=%]F-C0P9#5E8U\S,34T7S1C,69?8F(U8E\S8C$Y,F-C,#-E-S(M+0T* ` end XML 20 R29.htm IDEA: XBRL DOCUMENT v2.4.0.6

Computation of Diluted Net Loss Per Share (Detail) (USD $)
In Thousands, except Per Share data, unless otherwise specified
3 Months Ended 153 Months Ended

Mar. 31, 2013

Mar. 31, 2012

Mar. 31, 2013

Basic and diluted net loss per common share:

Net loss applicable to common stockholders $ (3,472) $ (2,204) $ (83,744)

Weighted average common shares outstanding - basic and diluted 16,079 13,010

Net loss per common share - basic and diluted $ (0.22) $ (0.17)

X

- Definition

The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.

+ References

No definition available.

+ Details

Name: us-gaap_EarningsPerShareBasicAndDiluted

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_EarningsPerShareBasicAndDilutedAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Net income after adjustments for dividends on preferred stock (declared in the period) and/or cumulative preferred stock (accumulated for the period).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 11

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1377-109256

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 128

-Paragraph 9

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).

+ References

No definition available.

+ Details

Name: us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

XML 21 R28.htm IDEA: XBRL DOCUMENT v2.4.0.6

Fair Value of Financial Instruments - Additional Information (Detail) (Money market funds, Fair Value, Inputs, Level 2, USD $)

Mar. 31, 2013

Dec. 31, 2012

Money market funds | Fair Value, Inputs, Level 2

Fair Value of Financial Instruments [Line Items]

Fair value of cash and cash equivalents invested in money market funds $ 192,000 $ 583,000

X

- Details

Name: galt_FairValueOfFinancialInstrumentsLineItems

Namespace Prefix: galt_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

This element represents the aggregate of the assets reported on the balance sheet at period end measured at fair value by the entity. This element is intended to be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=7578670&loc=d3e19207-110258

+ Details

Name: us-gaap_AssetsFairValueDisclosure

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

XML 22 R30.htm IDEA: XBRL DOCUMENT v2.4.0.6

Dilutive Shares Which Could Exist Pursuant to Exercise of Outstanding Stock Instruments and Which were not Included in Calculation (Detail)
3 Months Ended

Mar. 31, 2013

Mar. 31, 2012

Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]

Dilutive shares not included in calculation 13,704,230 13,048,819

Warrant

Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]

Dilutive shares not included in calculation 7,429,241 7,424,241

Stock Options

Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]

Dilutive shares not included in calculation 3,656,217 2,997,468

Contingently Issuable Shares

Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]

Dilutive shares not included in calculation 2,618,772 2,627,110

X

- Definition

Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Emerging Issues Task Force (EITF)

-Number 07-4

-Paragraph 4

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Diluted Earnings Per Share

-URI http://asc.fasb.org/extlink&oid=6510752

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Contingent Stock Agreement

-URI http://asc.fasb.org/extlink&oid=6508534

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Antidilution

-URI http://asc.fasb.org/extlink&oid=6505113

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 128

-Paragraph 171

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 128

-Paragraph 40

-Subparagraph c

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 128

-Paragraph 13, 14

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 23 R31.htm IDEA: XBRL DOCUMENT v2.4.0.6

Common Stock and Warrant Offering and Reverse Split - Additional Information (Detail) (USD $)
1 Months Ended

Mar. 22, 2012

Mar. 23, 2012

Mar. 28, 2012

Mar. 31, 2013

Dec. 31, 2012

Stockholders Equity [Line Items]

Stock issued, shares 1,159,445 1,333,361

Common share issued 2 16,190,429 16,060,853

Warrant to purchase common stock 1

Option to purchase additional units to cover over-allotments 45 days

Additional units authorize for issuance 173,916

Public Offering price $ 9.00

Exercise price of warrant 5.63

Expiration date of warrant Mar. 28, 2017

Issuance of common stock and warrants 2,666,722

Gross proceeds from issuance of stock and warrants $ 12,000,000

Net proceeds from issuance of stock and warrants 10,403,000

Reverse stock split ratio 0.1667

Warrant one

Stockholders Equity [Line Items]

Price per share of warrants $ 5.63

Warrants to purchase shares of common stock 1,333,361

Value of warrants 4,445,000

Closing price of warrant issued $ 4.20

Warrant, expected life 5 years

Warrant, volatility rate 119.00%

Warrant, risk free interest rate 1.05%

Warrant two

Stockholders Equity [Line Items]

Exercise price of warrant 5.63

Expiration date of warrant May 02, 2016

Warrants to purchase shares of common stock 46,378

Value of warrants $ 143,000

Closing price of warrant issued $ 4.20

Warrant, expected life 4 years 1 month 6 days

Warrant, volatility rate 117.00%

Warrant, risk free interest rate 0.78%

X

- Definition

Class Of Warrant Or Right Issuable With Each New Share Of Common Stock

+ References

No definition available.

+ Details

Name: galt_ClassOfWarrantOrRightIssuableWithEachNewShareOfCommonStock

Namespace Prefix: galt_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Expiration Period of Agreements

+ References

No definition available.

+ Details

Name: galt_ExpirationPeriodOfAgreements

Namespace Prefix: galt_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition

Gross Proceeds from Issuance of Common Stock and Warrants

+ References

No definition available.

+ Details

Name: galt_GrossProceedsFromIssuanceOfCommonStockAndWarrants

Namespace Prefix: galt_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Issuance Of Common Stock And Warrants, Shares

+ References

No definition available.

+ Details

Name: galt_IssuanceOfCommonStockAndWarrantsShares

Namespace Prefix: galt_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Issuance Of Warrants Price Per Share

+ References

No definition available.

+ Details

Name: galt_IssuanceOfWarrantsPricePerShare

Namespace Prefix: galt_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition

Issuance Of Warrants, Value

+ References

No definition available.

+ Details

Name: galt_IssuanceOfWarrantsValue

Namespace Prefix: galt_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Public offering, net price per share

+ References

No definition available.

+ Details

Name: galt_PublicOfferingNetPricePerShare

Namespace Prefix: galt_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Details

Name: galt_StockholdersEquityLineItems

Namespace Prefix: galt_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Underwriters Exercise of Public Offering Over-Allotment, Shares

+ References

No definition available.

+ Details

Name: galt_UnderwritersExerciseOfPublicOfferingOverAllotmentShares

Namespace Prefix: galt_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Warrant, Expiration Date

+ References

No definition available.

+ Details

Name: galt_WarrantExpirationDate

Namespace Prefix: galt_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: instant

X

- Definition

WarrantsPricePerShare

+ References

No definition available.

+ Details

Name: galt_WarrantsPricePerShare

Namespace Prefix: galt_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition

The exercise price of each class of warrants or rights outstanding.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(i)(4))

-URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph i

-Subparagraph 4

-Article 4

+ Details

Name: us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights

Namespace Prefix: us-gaap_

Data Type: us-types:perUnitItemType

Balance Type: na

Period Type: instant

X

- Definition

The specified number of securities that each class of warrants or rights outstanding give the holder the right but not the obligation to purchase from the issuer at a specific price, on or before a certain date.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(i)(2))

-URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph i

-Subparagraph 2

-Article 4

+ Details

Name: us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Period the instrument, asset or liability is expected to be outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (e)

-URI http://asc.fasb.org/extlink&oid=7578670&loc=d3e19207-110258

+ Details

Name: us-gaap_FairValueAssumptionsExpectedTerm

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition

Risk-free interest rate assumption used in valuing an instrument.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (e)

-URI http://asc.fasb.org/extlink&oid=7578670&loc=d3e19207-110258

+ Details

Name: us-gaap_FairValueAssumptionsRiskFreeInterestRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition

Weighted average expected volatility of stock price.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (e)

-URI http://asc.fasb.org/extlink&oid=7578670&loc=d3e19207-110258

+ Details

Name: us-gaap_FairValueAssumptionsWeightedAverageVolatilityRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition

The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 19

-Subparagraph a

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 18

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 14

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3255-108585

+ Details

Name: us-gaap_ProceedsFromIssuanceOrSaleOfEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

This item represents the conversion ratio used in the calculation of a stock split.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Stock Split

-URI http://asc.fasb.org/extlink&oid=6525746

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 4

-Subparagraph (SAB TOPIC 4.C)

-URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187143-122770

+ Details

Name: us-gaap_StockholdersEquityNoteStockSplitConversionRatio

Namespace Prefix: us-gaap_

Data Type: xbrli:decimalItemType

Balance Type: na

Period Type: duration

X

- Definition

Number of new stock issued during the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187085-122770

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Principles Board Opinion (APB)

-Number 12

-Paragraph 10

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

XML 24 R8.htm IDEA: XBRL DOCUMENT v2.4.0.6

Accrued Expenses
3 Months Ended

Mar. 31, 2013

Accrued Expenses

2. Accrued Expenses

Accrued expenses consist of the following:

 March 31,
2013 December 31,
2012

(in thousands)

Legal and accounting fees
 $ 80 $ 109

Accrued compensation
61 42

Severance agreement (Note 8)
1,000 1,000

Other
11 10

Total
 $ 1,152 $ 1,161

X

- Definition

The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 19

-Subparagraph a

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19(a),20,24)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 20, 24

-Article 5

+ Details

Name: us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 25 R32.htm IDEA: XBRL DOCUMENT v2.4.0.6

Commitments, Contingencies and Legal Proceedings - Additional Information (Detail) (USD $)
1 Months Ended 3 Months Ended

Feb. 01, 2013

Jan. 31, 2013

Oct. 31, 2012

Feb. 28, 2009

Mar. 31, 2013

Right

Dec. 31, 2012

Commitments and Contingencies [Line Items]

Service agreement expiration date Jan. 31, 2018

Estimated budget for work order $ 2,155,000

Recognized expenses related to agreement for services performed 728,000

Agreement termination notice period 90 days

Breach of contract termination notice period 30 days

Severance payment due to Dr. Platt 1,000,000 61,000 42,000

Number of options vested 83,334

Royalty revenue 50,000,000

Market capitalization 100,000,000

Severance payment period 6 months

Separation based payments 1,000,000

Lawsuit payment 1,000,000

Dividend rights issued 5

Rate of dividend 6.00%

Outstanding Dividend Rights 10

Liquidation value of dividend rights 241,000

Drug Discovery Program with the University of Georgia

Commitments and Contingencies [Line Items]

Agreement termination notice period 90 days

Collaborative funding agreement 154,000

Series C super dividend convertible preferred stock

Commitments and Contingencies [Line Items]

Series C prefer stock converted to common stock 5

Common Stock

Commitments and Contingencies [Line Items]

Conversion of share, common stock issued 8,475

Common Stock | Principal shares

Commitments and Contingencies [Line Items]

Conversion of share, common stock issued 8,334

Common Stock | Accrued Interest

Commitments and Contingencies [Line Items]

Conversion of share, common stock issued 141

Minimum

Commitments and Contingencies [Line Items]

Cashless stock option exercisable period 10 years

Equity investment $ 10,000,000

Cashless stock option exercisable 50,000

X

- Definition

Collaboration Agreement, Research And Development That Will Be Funded

+ References

No definition available.

+ Details

Name: galt_CollaborationAgreementResearchAndDevelopmentThatWillBeFunded

Namespace Prefix: galt_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: galt_CommitmentsAndContingenciesLineItems

Namespace Prefix: galt_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Dividend Equivalent Rights

+ References

No definition available.

+ Details

Name: galt_DividendEquivalentRights

Namespace Prefix: galt_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Lawsuit Damage Claim

+ References

No definition available.

+ Details

Name: galt_LawsuitDamageClaim

Namespace Prefix: galt_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Maximum Development Budget

+ References

No definition available.

+ Details

Name: galt_MaximumDevelopmentBudget

Namespace Prefix: galt_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Minimum Company Market Capitalization

+ References

No definition available.

+ Details

Name: galt_MinimumCompanyMarketCapitalization

Namespace Prefix: galt_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Notice Period For Termination Of Agreement

+ References

No definition available.

+ Details

Name: galt_NoticePeriodForTerminationOfAgreement

Namespace Prefix: galt_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition

Notice Period To Cure Breach Of Agreement

+ References

No definition available.

+ Details

Name: galt_NoticePeriodToCureBreachOfAgreement

Namespace Prefix: galt_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition

Number Of Right Declared As Dividend Distribution For Each Outstanding Share Of Common Stock

+ References

No definition available.

+ Details

Name: galt_NumberOfRightDeclaredAsDividendDistributionForEachOutstandingShareOfCommonStock

Namespace Prefix: galt_

Data Type: xbrli:integerItemType

Balance Type: na

Period Type: instant

X

- Definition

Organizational and Separation Related Charges

+ References

No definition available.

+ Details

Name: galt_OrganizationalAndSeparationRelatedCharges

Namespace Prefix: galt_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Recognized Expenses Related To Agreement For Services Performed

+ References

No definition available.

+ Details

Name: galt_RecognizedExpensesRelatedToAgreementForServicesPerformed

Namespace Prefix: galt_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Service Agreements, Expiration Date

+ References

No definition available.

+ Details

Name: galt_ServiceAgreementsExpirationDate

Namespace Prefix: galt_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition

Severance Payment Period

+ References

No definition available.

+ Details

Name: galt_SeverancePaymentPeriod

Namespace Prefix: galt_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition

Share Based Compensation Arrangement by Share Based Payment Award, Options, Vested in Period

+ References

No definition available.

+ Details

Name: galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriod

Namespace Prefix: galt_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4332-108586

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4313-108586

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4304-108586

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 32

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_ConversionOfStockSharesConverted1

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4332-108586

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4313-108586

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4304-108586

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 32

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_ConversionOfStockSharesIssued1

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 20

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_EmployeeRelatedLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.12)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 323

-SubTopic 10

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=16385135&loc=d3e33749-111570

+ Details

Name: us-gaap_EquityMethodInvestments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

The percentage rate used to calculate dividend payments on preferred stock.

+ References

No definition available.

+ Details

Name: us-gaap_PreferredStockDividendRatePercentage

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition

Value of the difference between preference in liquidation and the par or stated values of the preferred shares.

+ References

No definition available.

+ Details

Name: us-gaap_PreferredStockLiquidationPreferenceValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Revenue earned during the period from the leasing or otherwise lending to a third party the entity's rights or title to certain property. Royalty revenue is derived from a percentage or stated amount of sales proceeds or revenue generated by the third party using the entity's property. Examples of property from which royalties may be derived include patents and oil and mineral rights.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.1(e))

-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 1

-Article 5

+ Details

Name: us-gaap_RoyaltyRevenue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(iii)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 123R

-Paragraph A240

-Subparagraph b(1)(c), d(2)

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

XML 26 R2.htm IDEA: XBRL DOCUMENT v2.4.0.6

Condensed Consolidated Balance Sheets (USD $)
In Thousands, unless otherwise specified

Mar. 31, 2013

Dec. 31, 2012

Current assets:

Cash and cash equivalents $ 7,018 $ 9,364

Prepaid expenses and other current assets 137 153

Total current assets 7,155 9,517

Property and equipment, net 7 8

Other long term assets 6 6

Intangible assets, net 28 30

Total assets 7,196 9,561

Current liabilities:

Accounts payable 316 397

Accrued expenses 1,152 1,161

Accrued dividends payable 80

Total current liabilities 1,468 1,638

Other long-term liabilities 5 6

Total liabilities 1,473 1,644

Commitments and contingencies (Note 8)

Stockholders' equity (deficit):

Undesignated stock, $0.01 par value; 20,000,000 shares authorized, 8,001,000 designated at March 31, 2013 and December 31, 2012

Series A 12% convertible preferred stock; 5,000,000 shares authorized, 1,562,500 issued and outstanding at March 31, 2013 and December 31, 2012 632 632

Common stock, $0.001 par value; 50,000,000 shares authorized at March 31, 2013 and December 31, 2012, 16,190,429 and 16,060,853 issued and outstanding at March 31, 2013 and December 31, 2012, respectively 16 16

Additional paid-in capital 81,806 80,535

Deficit accumulated during the development stage (83,490) (80,018)

Total stockholders' (deficit) equity (1,036) 1,165

Total liabilities, redeemable convertible preferred stock and stockholders' (deficit) equity 7,196 9,561

Series B-1 12% redeemable convertible preferred stock

Current liabilities:

Convertible preferred stock, value 1,702 1,698

Series B-2 12% redeemable convertible preferred stock

Current liabilities:

Convertible preferred stock, value 2,952 2,900

Series C super dividend convertible preferred stock

Current liabilities:

Convertible preferred stock, value $ 2,105 $ 2,154

X

- Definition

Undesignated Capital Stock, Value

+ References

No definition available.

+ Details

Name: galt_UndesignatedCapitalStockValue

Namespace Prefix: galt_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19(a))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 19

-Subparagraph a

-Article 5

+ Details

Name: us-gaap_AccountsPayableCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 20

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_AccruedLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 31

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.30(a)(1))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_AdditionalPaidInCapital

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 12

-Article 7

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Concepts (CON)

-Number 6

-Paragraph 25

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 18

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.18)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_Assets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 9

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.9)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6361293&loc=d3e6801-107765

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6361293&loc=d3e6676-107765

+ Details

Name: us-gaap_AssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_AssetsCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6361293&loc=d3e6676-107765

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash Equivalents

-URI http://asc.fasb.org/extlink&oid=6507016

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 8, 9

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 7, 26

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash

-URI http://asc.fasb.org/extlink&oid=6506951

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3044-108585

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 7

-Footnote 1

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.1)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 1

-Article 5

+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-03.(a),19)

-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.25)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 25

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 450

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6952336&loc=d3e14326-108349

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 5

-Paragraph 8, 9

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 17

-Article 9

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 19

-Article 7

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-03.17)

-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

+ Details

Name: us-gaap_CommitmentsAndContingencies

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Cumulative net losses reported during the development stage.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 915

-SubTopic 210

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6472335&loc=d3e37729-110921

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 7

-Paragraph 11

-Subparagraph a

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 43

-Section A

-Paragraph 7

-Chapter 3

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 20

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=6361293&loc=d3e6935-107765

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Current Liabilities

-URI http://asc.fasb.org/extlink&oid=6509677

+ Details

Name: us-gaap_DividendsPayableCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 2

-Subparagraph ((a)(1),(b))

-URI http://asc.fasb.org/extlink&oid=7658586&loc=d3e16323-109275

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 142

-Paragraph 42, 45

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_IntangibleAssetsNetExcludingGoodwill

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19-26)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_Liabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Total of all Liabilities and Stockholders' Equity items (or Partners' Capital, as applicable), including the portion of equity attributable to noncontrolling interests, if any.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.32)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 25

-Article 7

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 32

-Article 5

+ Details

Name: us-gaap_LiabilitiesAndStockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.21)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 21

-Article 5

+ Details

Name: us-gaap_LiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_LiabilitiesCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Aggregate carrying amount, as of the balance sheet date, of noncurrent assets not separately disclosed in the balance sheet. Noncurrent assets are expected to be realized or consumed after one year (or the normal operating cycle, if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.17)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 17

-Article 5

+ Details

Name: us-gaap_OtherAssetsNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Aggregate carrying amount, as of the balance sheet date, of noncurrent obligations not separately disclosed in the balance sheet. Noncurrent liabilities are expected to be paid after one year (or the normal operating cycle, if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.24)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 24

-Article 5

+ Details

Name: us-gaap_OtherLiabilitiesNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Principles Board Opinion (APB)

-Number 12

-Paragraph 10

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 129

-Paragraph 2, 3, 4, 5, 6, 7, 8

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187085-122770

+ Details

Name: us-gaap_PreferredStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

The total of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer, and the aggregate carrying amount of current assets, as of the balance sheet date, not separately presented elsewhere in the balance sheet. Current assets are expected to be realized or consumed within one year (or the normal operating cycle, if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 8

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6361293&loc=d3e6676-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 43

-Section A

-Paragraph 4

-Chapter 3

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_PrepaidExpenseAndOtherAssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Amount, net of accumulated depreciation, depletion and amortization, of long-lived physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 8

-Article 7

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 12

-Paragraph 5

-Subparagraph b, c

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.13)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 13

-Subparagraph a

-Article 5

+ Details

Name: us-gaap_PropertyPlantAndEquipmentNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29-31)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30, 31

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph A3

-Appendix A

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB TOPIC 4.E)

-URI http://asc.fasb.org/extlink&oid=6228006&loc=d3e74512-122707

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section E

+ Details

Name: us-gaap_StockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_StockholdersEquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.

+ References

No definition available.

+ Details

Name: us-gaap_TemporaryEquityCarryingAmountAttributableToParent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

XML 27 R6.htm IDEA: XBRL DOCUMENT v2.4.0.6

Condensed Consolidated Statements Of Cash Flows (USD $)
3 Months Ended 153 Months Ended

Mar. 31, 2013

Mar. 31, 2012

Mar. 31, 2013

CASH FLOWS FROM OPERATING ACTIVITIES:

Net loss $ (3,203,000) $ (1,950,000) $ (75,195,000)

Adjustments to reconcile net loss to net cash used in operating activities:

Depreciation and amortization 3,000 2,000 558,000

Stock-based compensation expense 852,000 473,000 13,226,000

Non-cash interest expense 4,279,000

Change in fair value of convertible debt instrument 3,426,000

Change in fair value of warrant liabilities (9,022,000)

Write off of intangible assets 351,000

Changes in operating assets and liabilities:

Prepaid expenses and other assets 16,000 (11,000) (140,000)

Accounts payable and accrued expenses (90,000) 1,536,000

Other long-term liabilities (1,000) 5,000

Net cash used in operating activities (2,423,000) (1,486,000) (60,976,000)

CASH FLOWS FROM INVESTING ACTIVITIES:

Purchases of property and equipment (431,000)

Increase in patents costs and other assets (404,000)

Net cash provided by (used in) investing activities (835,000)

CASH FLOWS FROM FINANCING ACTIVITIES:

Net proceeds from issuance of common stock and warrants 10,403,000 39,093,000

Net proceeds from issuance of convertible debt instruments 10,621,000

Repayment of convertible debt instruments (1,641,000)

Proceeds from exercise of common stock warrants and options 77,000 11,370,000

Proceeds from shareholder advances 9,000

Net cash provided by financing activities 77,000 10,403,000 68,829,000

NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS (2,346,000) 8,917,000 7,018,000

CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD 9,364,000 6,397,000

CASH AND CASH EQUIVALENTS, END OF PERIOD 7,018,000 15,314,000 7,018,000

SUPPLEMENTAL DISCLOSURE - Cash paid for interest 114,000

NONCASH FINANCING ACTIVITIES:

Issuance of equity warrants in connection with equity offerings 4,445,000 9,482,000

Conversion of accrued expenses into common stock 329,000

Cashless exercise of common stock options and warrants 38,000 8,000 712,000

Conversion and redemption of convertible notes and accrued interest into common stock 12,243,000

Conversion of extension costs related to convertible notes into common stock 171,000

Payment of preferred stock dividends in common stock 293,000 277,000 4,448,000

Issuance of warrants to induce conversion of notes payable 503,000

Issuance of stock to acquire Pro-Pharmaceuticals-NV 107,000

Series A 12% convertible preferred stock

CASH FLOWS FROM FINANCING ACTIVITIES:

Net proceeds from issuance of convertible preferred stock and related warrants 1,691,000

Series B-1 12% redeemable convertible preferred stock

CASH FLOWS FROM FINANCING ACTIVITIES:

Net proceeds from issuance of redeemable convertible preferred stock and related warrants 1,548,000

Series B-2 12% redeemable convertible preferred stock

CASH FLOWS FROM FINANCING ACTIVITIES:

Net proceeds from issuance of redeemable convertible preferred stock and related warrants 3,935,000

Series C super dividend convertible preferred stock

CASH FLOWS FROM FINANCING ACTIVITIES:

Net proceeds from issuance of convertible preferred stock and related warrants $ 2,203,000

X

- Definition

Cashless Exercise of Stock Options and Warrants

+ References

No definition available.

+ Details

Name: galt_CashlessExerciseOfStockOptionsAndWarrants

Namespace Prefix: galt_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Change in fair value of warrant

+ References

No definition available.

+ Details

Name: galt_ChangeInFairValueOfWarrant

Namespace Prefix: galt_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Conversion Of Accrued Liabilities To Common Stock

+ References

No definition available.

+ Details

Name: galt_ConversionOfAccruedLiabilitiesToCommonStock

Namespace Prefix: galt_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Issuance of equity warrants in connection with equity offerings

+ References

No definition available.

+ Details

Name: galt_IssuanceOfEquityWarrantsInConnectionWithEquityOfferings

Namespace Prefix: galt_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Issuance of warrants to induce conversion of notes payable

+ References

No definition available.

+ Details

Name: galt_IssuanceOfWarrantsToInduceConversionOfNotesPayable

Namespace Prefix: galt_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The cash inflow associated with the amount received from holders exercising their stock options and warrants.

+ References

No definition available.

+ Details

Name: galt_ProceedsFromStockOptionAndWarrantExercises

Namespace Prefix: galt_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Supplemental Dividends on ESOP convertible preferred stock

+ References

No definition available.

+ Details

Name: galt_SupplementalDividendsOnConvertiblePreferredStock

Namespace Prefix: galt_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Unrealized Gain (Loss) In Debt Instrument Fair Value

+ References

No definition available.

+ Details

Name: galt_UnrealizedGainLossInDebtInstrumentFairValue

Namespace Prefix: galt_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6361293&loc=d3e6676-107765

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash Equivalents

-URI http://asc.fasb.org/extlink&oid=6507016

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 8, 9

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 7, 26

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash

-URI http://asc.fasb.org/extlink&oid=6506951

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3044-108585

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 7

-Footnote 1

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.1)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 1

-Article 5

+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 26

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4304-108586

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 32

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4332-108586

+ Details

Name: us-gaap_DebtConversionConvertedInstrumentAmount1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The amount of the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4304-108586

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 32

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4332-108586

+ Details

Name: us-gaap_DebtConversionOriginalDebtAmount1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 28

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Principles Board Opinion (APB)

-Number 12

-Paragraph 5

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_DepreciationAndAmortization

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 3

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=7658586&loc=d3e16373-109275

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 142

-Paragraph 46

-Subparagraph b

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 28

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_IncreaseDecreaseInOperatingCapitalAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period in other noncurrent operating liabilities not separately disclosed in the statement of cash flows.

+ References

No definition available.

+ Details

Name: us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period in the value of prepaid expenses and other assets not separately disclosed in the statement of cash flows, for example, deferred expenses, intangible assets, or income taxes.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 28

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The amount of cash paid for interest during the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4297-108586

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 29

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 25

-Subparagraph (e)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3536-108585

+ Details

Name: us-gaap_InterestPaid

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The net cash inflow or outflow from financing activity for the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 26

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3574-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 26

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The net cash inflow or outflow from investing activity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 26

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3574-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 26

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The net cash from (used in) all of the entity's operating activities, including those of discontinued operations, of the reporting entity. Operating activities generally involve producing and delivering goods and providing services. Operating activity cash flows include transactions, adjustments, and changes in value that are not defined as investing or financing activities. While for technical reasons this element has no balance attribute, the default assumption is a debit balance consistent with its label.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 26

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 25

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3536-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 28

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3521-108585

+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 19

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.22)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=6519514

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.18)

-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 130

-Paragraph 10, 15

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 20

-Article 9

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=6518256

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Emerging Issues Task Force (EITF)

-Number 87-21

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 28, 29, 30

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 13: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=20435746&loc=d3e565-108580

Reference 14: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph A7

-Appendix A

Reference 15: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph 38

-Subparagraph a

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 16: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph 38

-Subparagraph d

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Interest paid other than in cash for example by issuing additional debt securities. As a noncash item, it is added to net income when calculating cash provided by or used in operations using the indirect method.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

+ Details

Name: us-gaap_PaidInKindInterest

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 15

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Investing Activities

-URI http://asc.fasb.org/extlink&oid=6516133

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 13

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3213-108585

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 17

-Subparagraph c

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_PaymentsToAcquireProductiveAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 15

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Investing Activities

-URI http://asc.fasb.org/extlink&oid=6516133

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 13

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3213-108585

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 17

-Subparagraph c

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_PaymentsToAcquirePropertyPlantAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 19

-Subparagraph b

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 18

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 14

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3255-108585

+ Details

Name: us-gaap_ProceedsFromConvertibleDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The cash inflow from the additional capital contribution to the entity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 19

-Subparagraph a

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 18

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 14

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3255-108585

+ Details

Name: us-gaap_ProceedsFromIssuanceOfCommonStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 19

-Subparagraph a

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 18

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 14

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3255-108585

+ Details

Name: us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The cash inflow from issuance of callable preferred stock which is identified as being convertible to another type of financial security at the option of the issuer or the holder.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 19

-Subparagraph a

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 18

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 14

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3255-108585

+ Details

Name: us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The net cash inflow or outflow from other financing activities. This element is used when there is not a more specific and appropriate element in the taxonomy.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 18, 19, 20

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3095-108585

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 9

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3098-108585

+ Details

Name: us-gaap_ProceedsFromPaymentsForOtherFinancingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 18

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 15

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3291-108585

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 20

-Subparagraph b

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_RepaymentsOfConvertibleDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 28

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

+ Details

Name: us-gaap_ShareBasedCompensation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The fair value of stock issued in noncash financing activities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4332-108586

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4313-108586

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4304-108586

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 32

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_StockIssued1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

XML 28 R22.htm IDEA: XBRL DOCUMENT v2.4.0.6

Stock-Based Compensation Expense Related to Common Stock Options, Common Stock, Restricted Common Stock and Common Stock Warrants (Detail) (USD $)
3 Months Ended 153 Months Ended

Mar. 31, 2013

Mar. 31, 2012

Mar. 31, 2013

Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]

Stock-based compensation expense $ 852,000 $ 473,000 $ 13,226,000

Research and development

Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]

Stock-based compensation expense 319,000 149,000

General and administrative

Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]

Stock-based compensation expense $ 533,000 $ 324,000

X

- Details

Name: us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 28

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

+ Details

Name: us-gaap_ShareBasedCompensation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

XML 29 R24.htm IDEA: XBRL DOCUMENT v2.4.0.6

Stock-Based Compensation - Additional Information (Detail) (USD $)
3 Months Ended

Mar. 31, 2013

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Unrecognized compensation cost $ 5,427,000

Unvested option 1,466,586

Unrecognized compensation cost, recognition period 3 years 10 months 24 days

Weighted-average grant-date fair values of options granted $ 2.73

X

- Definition

Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number

+ References

No definition available.

+ Details

Name: galt_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumber

Namespace Prefix: galt_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

As of the balance sheet date, the aggregate unrecognized cost of equity-based awards made to employees under equity-based compensation awards that have yet to vest.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (i)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 123R

-Paragraph A240

-Subparagraph h

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Weighted average period over which unrecognized compensation is expected to be recognized for equity-based compensation plans, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (i)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 123R

-Paragraph A240

-Subparagraph c(1)

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (d)(1)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

XML 30 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.1.0.1 * */ var moreDialog = null; var Show = { Default:'raw', more:function( obj ){ var bClosed = false; if( moreDialog != null ) { try { bClosed = moreDialog.closed; } catch(e) { //Per article at http://support.microsoft.com/kb/244375 there is a problem with the WebBrowser control // that somtimes causes it to throw when checking the closed property on a child window that has been //closed. So if the exception occurs we assume the window is closed and move on from there. bClosed = true; } if( !bClosed ){ moreDialog.close(); } } obj = obj.parentNode.getElementsByTagName( 'pre' )[0]; var hasHtmlTag = false; var objHtml = ''; var raw = ''; //Check for raw HTML var nodes = obj.getElementsByTagName( '*' ); if( nodes.length ){ objHtml = obj.innerHTML; }else{ if( obj.innerText ){ raw = obj.innerText; }else{ raw = obj.textContent; } var matches = raw.match( /<\/?[a-zA-Z]{1}\w*[^>]*>/g ); if( matches && matches.length ){ objHtml = raw; //If there is an html node it will be 1st or 2nd, // but we can check a little further. var n = Math.min( 5, matches.length ); for( var i = 0; i < n; i++ ){ var el = matches[ i ].toString().toLowerCase(); if( el.indexOf( '= 0 ){ hasHtmlTag = true; break; } } } } if( objHtml.length ){ var html = ''; if( hasHtmlTag ){ html = objHtml; }else{ html = ''+ "\n"+''+ "\n"+' Report Preview Details'+ "\n"+' '+ "\n"+''+ "\n"+''+ objHtml + "\n"+''+ "\n"+''; } moreDialog = window.open("","More","width=700,height=650,status=0,resizable=yes,menubar=no,toolbar=no,scrollbars=yes"); moreDialog.document.write( html ); moreDialog.document.close(); if( !hasHtmlTag ){ moreDialog.document.body.style.margin = '0.5em'; } } else { //default view logic var lines = raw.split( "\n" ); var longest = 0; if( lines.length > 0 ){ for( var p = 0; p < lines.length; p++ ){ longest = Math.max( longest, lines[p].length ); } } //Decide on the default view this.Default = longest < 120 ? 'raw' : 'formatted'; //Build formatted view var text = raw.split( "\n\n" ) >= raw.split( "\r\n\r\n" ) ? raw.split( "\n\n" ) : raw.split( "\r\n\r\n" ) ; var formatted = ''; if( text.length > 0 ){ if( text.length == 1 ){ text = raw.split( "\n" ) >= raw.split( "\r\n" ) ? raw.split( "\n" ) : raw.split( "\r\n" ) ; formatted = "
"+ text.join( "

\n" ) +"
"; }else{ for( var p = 0; p < text.length; p++ ){ formatted += "
" + text[p] + "
\n"; } } }else{ formatted = '
' + raw + '
'; } html = ''+ "\n"+''+ "\n"+' Report Preview Details'+ "\n"+' '+ "\n"+''+ "\n"+''+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+'
'+ "\n"+' formatted: '+ ( this.Default == 'raw' ? 'as Filed' : 'with Text Wrapped' ) +''+ "\n"+'
'+ "\n"+'
'+formatted+'
'+ "\n"+'
'+ "\n"+'
'+raw+'
'+ "\n"+'
'+ "\n"+''+ "\n"+''; moreDialog = window.open("","More","width=700,height=650,status=0,resizable=yes,menubar=no,toolbar=no,scrollbars=yes"); moreDialog.document.write(html); moreDialog.document.close(); this.toggle( moreDialog ); } moreDialog.document.title = 'Report Preview Details'; }, toggle:function( win, domLink ){ var domId = this.Default; var doc = win.document; var domEl = doc.getElementById( domId ); domEl.style.display = 'block'; this.Default = domId == 'raw' ? 'formatted' : 'raw'; if( domLink ){ domLink.innerHTML = this.Default == 'raw' ? 'with Text Wrapped' : 'as Filed'; } var domElOpposite = doc.getElementById( this.Default ); domElOpposite.style.display = 'none'; }, LastAR : null, showAR : function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }, toggleNext : function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }, hideAR : function(){ Show.LastAR.style.display = 'none'; } } XML 31 R7.htm IDEA: XBRL DOCUMENT v2.4.0.6

Basis of Presentation
3 Months Ended

Mar. 31, 2013

Basis of Presentation

1. Basis of Presentation

Galectin Therapeutics Inc. (the “Company”) is a development-stage company that is applying its leadership in galectin science and drug development to create new therapies for fibrotic disease and cancer. These candidates are based on the Company’s targeting of galectin proteins which are key mediators of biologic and pathologic function. These compounds also may have application for drugs to treat other diseases and chronic health conditions.

The unaudited condensed consolidated financial statements as reported in this Quarterly Report on Form 10-Q reflect all adjustments which are, in the opinion of management, necessary to present fairly the financial position of the Company as of March 31, 2013 and the results of its operations for the three months ended March 31, 2013 and 2012 and the cumulative period from inception (July 10, 2000) through March 31, 2013 and its cash flows for the three months ended March 31, 2013 and 2012, and for the cumulative period from inception (July 10, 2000) to March 31, 2013. All adjustments made to the interim financial statements include all those of a normal and recurring nature. The Company considers events or transactions that occur after the balance sheet date but before the financial statements are issued to provide additional evidence relative to certain estimates or to identify matters that require additional disclosure. Subsequent events have been evaluated through the date these financial statements are available to be issued. The results for interim periods are not necessarily indicative of results which may be expected for any other interim period or for the full year. The unaudited condensed consolidated financial statements of the Company should be read in conjunction with its Annual Report on Form 10-K for the year ended December 31, 2012.

The Company has operated at a loss since its inception and has had no significant revenues. The Company anticipates that losses will continue for the foreseeable future. At March 31, 2013, the Company had $7,018,000 of unrestricted cash and cash equivalents available to fund future operations. The Company believes that with the cash on hand at March 31, 2013, there is sufficient cash to fund operations through the first quarter of 2014. The Company’s ability to fund operations after its current cash resources are exhausted depends on its ability to obtain additional financing or achieve profitable operations, as to which no assurances can be given. The Company has developed several plans, including cost containment efforts and potential strategic alternatives in the event that such financing cannot be realized by the Company. Accordingly, based on the forecasts and estimates underlying the Company’s current operating plan, the financial statements do not currently include any adjustments that might be necessary if the Company is unable to continue as a going concern.

As shown in the condensed consolidated financial statements, the Company incurred cumulative net losses applicable to common stockholders of $83.7 million for the cumulative period from inception (July 10, 2000) through March 31, 2013. The Company’s net losses have resulted principally from costs associated with (i) research and development expenses, including clinical trial costs, (ii) general and administrative activities and (iii) the Company’s financing transactions including interest, dividend payments, and the costs related to fair value accounting for the Company’s convertible debt instruments. As a result of planned expenditures for future research, discovery, development and commercialization activities and potential legal cost to protect its intellectual property, the Company expects to incur additional losses and use additional cash in its operations for the foreseeable future. Through March 31, 2013, the Company had raised a net total of $68.8 million in capital through sale and issuance of common stock, common stock purchase warrants, convertible preferred stock and debt securities in public and private offerings. From inception (July 10, 2000) through March 31, 2013, the Company used cash of $61.0 million in its operations.

The Company was founded in July 2000, was incorporated in the State of Nevada in January 2001 under the name “Pro-Pharmaceuticals, Inc.,” and changed its name to “Galectin Therapeutics Inc.” on May 26, 2011. On March 23, 2012, the Company began trading on The NASDAQ Capital Market under the symbol GALT. Immediately prior to March 23, 2012, the Company was traded on the Over-the Counter Bulletin Board (“OTCBB”) under the symbol GALT.OB.

The Company is subject to a number of risks similar to those of other development-stage companies, including dependence on key individuals, uncertainty of product development and generation of revenues, dependence on outside sources of capital, risks associated with clinical trials of products, dependence on third-party collaborators for research operations, need for regulatory approval of products, risks associated with protection of intellectual property, and competition with larger, better-capitalized companies. Successful completion of the Company’s development program and, ultimately, the attainment of profitable operations is dependent upon future events, including obtaining adequate financing to fulfill its development activities and achieving a level of revenues adequate to support the Company’s cost structure. There are no assurances that the Company will be able to obtain additional financing on favorable terms, or at all, or successfully market its products.

X

- Definition

The entire disclosure for the basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).

+ References

No definition available.

+ Details

Name: us-gaap_BasisOfAccounting

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 32 R3.htm IDEA: XBRL DOCUMENT v2.4.0.6

Condensed Consolidated Balance Sheets (Parenthetical) (USD $)

Mar. 31, 2013

Dec. 31, 2012

Undesignated stock, par value $ 0.01 $ 0.01

Undesignated stock, shares authorized 20,000,000 20,000,000

Undesignated stock, shares designated 8,001,000 8,001,000

Series A 12% convertible preferred stock, shares authorized 5,000,000 5,000,000

Series A 12% convertible preferred stock, issued 1,562,500 1,562,500

Series A 12% convertible preferred stock, outstanding 1,562,500 1,562,500

Common stock, par value $ 0.001 $ 0.001

Common stock, shares authorized 50,000,000 50,000,000

Common stock, issued 16,190,429 16,060,853

Common stock, outstanding 16,190,429 16,060,853

Series B-1 12% redeemable convertible preferred stock

Convertible preferred stock, shares authorized 900,000 900,000

Convertible preferred stock, issued 900,000 900,000

Convertible preferred stock, outstanding 900,000 900,000

Convertible preferred stock, redemption value $ 1,800,000

Convertible preferred stock, liquidation value 1,800,000

Series B-2 12% redeemable convertible preferred stock

Convertible preferred stock, shares authorized 2,100,000 2,100,000

Convertible preferred stock, issued 2,100,000 2,100,000

Convertible preferred stock, outstanding 2,100,000 2,100,000

Convertible preferred stock, redemption value 4,200,000

Convertible preferred stock, liquidation value 4,200,000

Series C super dividend convertible preferred stock

Convertible preferred stock, shares authorized 1,000 1,000

Convertible preferred stock, issued 215 220

Convertible preferred stock, outstanding 215 220

Convertible preferred stock, redemption value 5,078,000

Convertible preferred stock, liquidation value $ 2,150,000

X

- Definition

Undesignated Capital Stock, No Par Value

+ References

No definition available.

+ Details

Name: galt_UndesignatedCapitalStockNoParValue

Namespace Prefix: galt_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition

Undesignated Capital Stock, Shares Authorized

+ References

No definition available.

+ Details

Name: galt_UndesignatedCapitalStockSharesAuthorized

Namespace Prefix: galt_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Undesignated Capital Stock, Shares, Outstanding

+ References

No definition available.

+ Details

Name: galt_UndesignatedCapitalStockSharesOutstanding

Namespace Prefix: galt_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Face amount or stated value of common stock per share; generally not indicative of the fair market value per share.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 129

-Paragraph 4

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition

The maximum number of common shares permitted to be issued by an entity's charter and bylaws.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187085-122770

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Principles Board Opinion (APB)

-Number 12

-Paragraph 10

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

+ Details

Name: us-gaap_CommonStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 129

-Paragraph 2, 3, 4, 5, 6, 7, 8

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_PreferredStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_PreferredStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_PreferredStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

The aggregate liquidation preference (or restrictions) of stock classified as temporary equity that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 129

-Paragraph 4

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_TemporaryEquityLiquidationPreference

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

The aggregate amount to be paid by the entity upon redemption of the security that is classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.27(b))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 28

-Subparagraph b

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Emerging Issues Task Force (EITF)

-Number 00-19

-Paragraph 12

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_TemporaryEquityRedemptionValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 129

-Paragraph 2, 3, 4, 5, 6, 7, 8

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.27(b))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 28

-Subparagraph b

-Article 5

+ Details

Name: us-gaap_TemporaryEquitySharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.27(b))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 28

-Subparagraph b

-Article 5

+ Details

Name: us-gaap_TemporaryEquitySharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.27(b))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 28

-Subparagraph b

-Article 5

+ Details

Name: us-gaap_TemporaryEquitySharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

XML 33 R17.htm IDEA: XBRL DOCUMENT v2.4.0.6

Stock-Based Compensation (Tables)
3 Months Ended

Mar. 31, 2013

Stock-Based Compensation Expense Related to Common Stock Options, Common Stock, Restricted Common Stock and Common Stock Warrants

Following is the stock-based compensation expense related to common stock options, common stock, restricted common stock and common stock warrants:

 Three Months Ended
March 31,

 2013 2012

Research and development
 $ 319 $ 149

General and administrative
 533 324





Total stock-based compensation expense
 $ 852 $ 473





Summary of Stock Option Activity

The following table summarizes the stock option activity in the Company’s equity incentive plans, including non-plan grants to Company executives, from December 31, 2012 through March 31, 2013:



 Shares
 Weighted Average
Exercise Price

Outstanding, December 31, 2012
 3,539,961 $ 5.66

Granted
 200,426 3.36

Exercised
 (39,762) 2.77

Options forfeited/cancelled
 (44,408) 9.50





Outstanding, March 31, 2013
 3,656,217 $ 5.52





Weighted Average Assumptions Used to Determine Fair Value of Options Granted

The fair value of all other options granted is determined using the Black-Scholes option-pricing model. The following weighted average assumptions were used (there were no option grants to employees or consultants during the three months ended March 31, 2013):

 Three
 Months Ended
March 31,
Cumulative

Period from

Inception

(July 10, 2000) to
March 31,

 2013

 2013

Risk-free interest rate
 0.80% 1.76%

Expected life of the options
 5.0 years 5.2 years

Expected volatility of the underlying stock
 117% 119%

Expected dividend rate
 0% 0%

X

- Definition

Tabular disclosure of the allocation of equity-based compensation costs to a given line item on the balance sheet and income statement for the period. This may include the reporting line for the costs and the amount capitalized and expensed.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 123R

-Paragraph A240

-Subparagraph g(1)

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 14

-Section F

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (h)(1)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 123R

-Paragraph 64

-Subparagraph b

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 14.F)

-URI http://asc.fasb.org/extlink&oid=6793087&loc=d3e301413-122809

+ Details

Name: us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Tabular disclosure of the number and weighted-average exercise prices (or conversion ratios) for share options (or share units) that were outstanding at the beginning and end of the year, vested and expected to vest, exercisable or convertible at the end of the year, and the number of share options or share units that were granted, exercised or converted, forfeited, and expired during the year.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (f)(2)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 34 R1.htm IDEA: XBRL DOCUMENT v2.4.0.6

Document and Entity Information
3 Months Ended

Mar. 31, 2013

May 09, 2013

Document Information [Line Items]

Document Type 10-Q

Amendment Flag false

Document Period End Date Mar. 31, 2013

Document Fiscal Year Focus 2013

Document Fiscal Period Focus Q1

Trading Symbol GALT

Entity Registrant Name GALECTIN THERAPEUTICS INC

Entity Central Index Key 0001133416

Current Fiscal Year End Date --12-31

Entity Filer Category Smaller Reporting Company

Entity Common Stock, Shares Outstanding 16,251,469

X

- Definition

If the value is true, then the document is an amendment to previously-filed/accepted document.

+ References

No definition available.

+ Details

Name: dei_AmendmentFlag

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition

End date of current fiscal year in the format --MM-DD.

+ References

No definition available.

+ Details

Name: dei_CurrentFiscalYearEndDate

Namespace Prefix: dei_

Data Type: xbrli:gMonthDayItemType

Balance Type: na

Period Type: duration

X

- Definition

This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.

+ References

No definition available.

+ Details

Name: dei_DocumentFiscalPeriodFocus

Namespace Prefix: dei_

Data Type: dei:fiscalPeriodItemType

Balance Type: na

Period Type: duration

X

- Definition

This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.

+ References

No definition available.

+ Details

Name: dei_DocumentFiscalYearFocus

Namespace Prefix: dei_

Data Type: xbrli:gYearItemType

Balance Type: na

Period Type: duration

X

- Details

Name: dei_DocumentInformationLineItems

Namespace Prefix: dei_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.

+ References

No definition available.

+ Details

Name: dei_DocumentPeriodEndDate

Namespace Prefix: dei_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".

+ References

No definition available.

+ Details

Name: dei_DocumentType

Namespace Prefix: dei_

Data Type: dei:submissionTypeItemType

Balance Type: na

Period Type: duration

X

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation 12B

-Number 240

-Section 12b

-Subsection 1

+ Details

Name: dei_EntityCentralIndexKey

Namespace Prefix: dei_

Data Type: dei:centralIndexKeyItemType

Balance Type: na

Period Type: duration

X

- Definition

Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.

+ References

No definition available.

+ Details

Name: dei_EntityCommonStockSharesOutstanding

Namespace Prefix: dei_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.

+ References

No definition available.

+ Details

Name: dei_EntityFilerCategory

Namespace Prefix: dei_

Data Type: dei:filerCategoryItemType

Balance Type: na

Period Type: duration

X

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation 12B

-Number 240

-Section 12b

-Subsection 1

+ Details

Name: dei_EntityRegistrantName

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name: dei_TradingSymbol

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

XML 35 R18.htm IDEA: XBRL DOCUMENT v2.4.0.6

Common Stock Warrants (Tables)
3 Months Ended

Mar. 31, 2013

Common Stock Warrant Activity

The following table summarizes the common stock warrant activity from December 31, 2012 through March 31, 2013:



 Shares
 Weighted Average
Exercise Price

Outstanding, December 31, 2012
 7,424,241 $ 3.71

Granted
 5,000 2.65

Exercised
 - -

Forfeited/cancelled
 - -





Outstanding, March 31, 2013
 7,429,241 $ 3.71





X

- Definition

Schedule of Stockholders' Equity Note, Warrants and Common Stock Activity

+ References

No definition available.

+ Details

Name: galt_ScheduleOfStockholdersEquityNoteWarrantsAndCommonStockActivityTableTextBlock

Namespace Prefix: galt_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 36 R4.htm IDEA: XBRL DOCUMENT v2.4.0.6

Condensed Consolidated Statements Of Operations (USD $)
In Thousands, except Per Share data, unless otherwise specified
3 Months Ended 153 Months Ended

Mar. 31, 2013

Mar. 31, 2012

Mar. 31, 2013

Operating expenses:

Research and development $ 1,752 $ 901 $ 29,362

General and administrative 1,456 1,052 48,492

Total operating expenses 3,208 1,953 77,854

Total operating loss (3,208) (1,953) (77,854)

Other income (expense):

Interest income 5 3 823

Interest expense (4,451)

Change in fair value of convertible debt instrument (3,426)

Change in fair value of warrant liabilities 9,022

Other income 691

Total other income (expense) 5 3 2,659

Net loss (3,203) (1,950) (75,195)

Preferred stock dividends (213) (197) (4,448)

Preferred stock accretion (56) (57) (4,101)

Net loss applicable to common stockholders $ (3,472) $ (2,204) $ (83,744)

Net loss per common share - basic and diluted $ (0.22) $ (0.17)

Weighted average common shares outstanding - basic and diluted 16,079 13,010

X

- Definition

Change in fair value of warrant

+ References

No definition available.

+ Details

Name: galt_ChangeInFairValueOfWarrant

Namespace Prefix: galt_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Unrealized Gain (Loss) In Debt Instrument Fair Value

+ References

No definition available.

+ Details

Name: galt_UnrealizedGainLossInDebtInstrumentFairValue

Namespace Prefix: galt_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.

+ References

No definition available.

+ Details

Name: us-gaap_EarningsPerShareBasicAndDiluted

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition

The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.4)

-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

+ Details

Name: us-gaap_GeneralAndAdministrativeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The cost of borrowed funds accounted for as interest that was charged against earnings during the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 9

-Article 9

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher OTS

-Name Federal Regulation (FR)

-Number Title 12

-Section 563c.102

-Paragraph 9

-Chapter V

-Subsection II

-LegacyDoc This is a non-GAAP reference that was included in the 2009 taxonomy. It will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 34

-Paragraph 21

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 835

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-04.9)

-URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882

+ Details

Name: us-gaap_InterestExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Income derived from investments in debt securities and on cash and cash equivalents the earnings of which reflect the time value of money or transactions in which the payments are for the use or forbearance of money.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 115

-Paragraph 14

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 7

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.7(b))

-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

+ Details

Name: us-gaap_InvestmentIncomeInterest

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 19

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.22)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=6519514

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.18)

-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 130

-Paragraph 10, 15

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 20

-Article 9

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=6518256

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Emerging Issues Task Force (EITF)

-Number 87-21

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 28, 29, 30

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 13: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=20435746&loc=d3e565-108580

Reference 14: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph A7

-Appendix A

Reference 15: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph 38

-Subparagraph a

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 16: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph 38

-Subparagraph d

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Net income after adjustments for dividends on preferred stock (declared in the period) and/or cumulative preferred stock (accumulated for the period).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 11

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1377-109256

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 128

-Paragraph 9

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.7)

-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 7

-Article 5

+ Details

Name: us-gaap_NonoperatingIncomeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_NonoperatingIncomeExpenseAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.

+ References

No definition available.

+ Details

Name: us-gaap_OperatingExpenses

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_OperatingExpensesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The net result for the period of deducting operating expenses from operating revenues.

+ References

No definition available.

+ Details

Name: us-gaap_OperatingIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The aggregate amount of other income amounts, the components of which are not separately disclosed on the income statement, resulting from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business) also known as other nonoperating income recognized for the period. Such amounts may include: (a) dividends, (b) interest on securities, (c) profits on securities (net of losses), and (d) miscellaneous other income items.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.7)

-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 7

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Audit and Accounting Guide (AAG)

-Number AAG-BRD

-Paragraph 80

-Subparagraph Exhibit 4-4

-IssueDate 2006-05-01

-Chapter 4

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_OtherNonoperatingIncome

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The amount of accretion of the preferred stock redemption discount during the period.

+ References

No definition available.

+ Details

Name: us-gaap_PreferredStockAccretionOfRedemptionDiscount

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The amount of preferred stock dividends that is an adjustment to net income apportioned to common stockholders.

+ References

No definition available.

+ Details

Name: us-gaap_PreferredStockDividendsIncomeStatementImpact

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 141

-Paragraph 51

-Subparagraph g

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 86

-Paragraph 11, 12

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 985

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 730

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 2

-Paragraph 12, 13

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_ResearchAndDevelopmentExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).

+ References

No definition available.

+ Details

Name: us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

XML 37 R12.htm IDEA: XBRL DOCUMENT v2.4.0.6

Loss Per Share
3 Months Ended

Mar. 31, 2013

Loss Per Share

6. Loss Per Share

Basic net loss per common share is computed by dividing the net loss available to common stockholders by the weighted average number of common shares outstanding during the period. Diluted net loss per common share is computed by dividing the net loss available to common stockholders by the weighted average number of common shares and other potential common shares then outstanding. Potential common shares consist of common shares issuable upon the assumed exercise of in-the-money stock options and warrants and potential common shares related to the conversion of the preferred stock. The computation of diluted net loss per share does not assume the issuance of common shares that have an anti-dilutive effect on net loss per share.

 Three Months Ended
March 31,

 2013 2012

 (in thousands, except share
and per share amounts)

Basic and diluted net loss per common share:


Net loss applicable to common stockholders
 $(3,472) $(2,204)

Weighted average common shares outstanding – basic and diluted
 16,079 13,010

Net loss per common share – basic and diluted
 $ (0.22) $ (0.17)

Dilutive shares which could exist pursuant to the exercise of outstanding stock instruments and which were not included in the calculation because their affect would have been anti-dilutive are as follows:

 March 31, 2013
(shares) March 31, 2012
(shares)

Warrants to purchase shares of common stock
7,429,241 7,424,241

Options to purchase shares of common stock
3,656,217 2,997,468

Shares of common stock issuable upon conversion of preferred stock
2,618,772 2,627,110

13,704,230 13,048,819

X

- Definition

The entire disclosure for earnings per share.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1252-109256

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 55

-Paragraph 52

-URI http://asc.fasb.org/extlink&oid=16381557&loc=d3e4984-109258

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1278-109256

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 128

-Paragraph 40

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.21)

-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

+ Details

Name: us-gaap_EarningsPerShareTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 38 R11.htm IDEA: XBRL DOCUMENT v2.4.0.6

Fair Value of Financial Instruments
3 Months Ended

Mar. 31, 2013

Fair Value of Financial Instruments

5. Fair Value of Financial Instruments

The Company has certain financial assets and liabilities recorded at fair value. Fair values determined by Level 1 inputs utilize observable data such as quoted prices in active markets. Fair values determined by Level 2 inputs utilize data points other than quoted prices in active markets that are observable either directly or indirectly. Fair values determined by Level 3 inputs utilize unobservable data points in which there is little or no market data, which require the reporting entity to develop its own assumptions. The carrying amounts reflected in the consolidated balance sheets for cash equivalents, accounts payable and accrued expenses approximates their carrying value due to their short-term nature. Included in cash and cash equivalents, as of March 31, 2013 and December 31, 2012, the Company had $192,000 and $583,000, respectively invested in money market funds which had calculated net asset values and were therefore classified as Level 2. There were no level 3 assets held at fair value at March 31, 2013 or December 31, 2012.

X

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 16

-URI http://asc.fasb.org/extlink&oid=7491637&loc=d3e13504-108611

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 107

-Paragraph 15C, 15D

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 133

-Paragraph 44A, 44B

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 107

-Paragraph 15A

-Subparagraph a-d

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 107

-Paragraph 3, 10, 14, 15

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 10

-URI http://asc.fasb.org/extlink&oid=7491637&loc=d3e13433-108611

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 159

-Paragraph 17-22, 27, 28

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 21

-URI http://asc.fasb.org/extlink&oid=7491637&loc=d3e13537-108611

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 107

-Paragraph 15B

-Subparagraph a, b

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 157

-Paragraph 32, 33, 34

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=7578670&loc=d3e19207-110258

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=6957238&loc=d3e14064-108612

Reference 13: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 30

-URI http://asc.fasb.org/extlink&oid=6957238&loc=d3e14172-108612

+ Details

Name: us-gaap_FairValueDisclosuresTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 39 R23.htm IDEA: XBRL DOCUMENT v2.4.0.6

Summary of Stock Option Activity (Detail) (USD $)
3 Months Ended

Mar. 31, 2013

Shares

Beginning Balance 3,539,961

Granted 200,426

Exercised (39,762)

Options forfeited/cancelled (44,408)

Ending Balance 3,656,217

Weighted Average Exercise Price

Beginning Balance $ 5.66

Granted $ 3.36

Exercised $ 2.77

Options forfeited/cancelled $ 9.50

Ending Balance $ 5.52

X

- Definition

The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(iv)(3)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 123R

-Paragraph A240

-Subparagraph b(1)(f)

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Gross number of share options (or share units) granted during the period.

+ References

No definition available.

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

The number of shares reserved for issuance under stock option agreements awarded under the plan that validly exist and are outstanding as of the balance sheet date, including vested options.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 123R

-Paragraph A240

-Subparagraph b(1)(b)

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(i)-(ii)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 123R

-Paragraph A240

-Subparagraph b(1)(a)

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(i)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 123R

-Paragraph A240

-Subparagraph b(1)(a)

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Weighted average price at which option holders acquired shares when converting their stock options into shares.

+ References

No definition available.

+ Details

Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition

Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.

+ References

No definition available.

+ Details

Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition

Weighted average price at which grantees can acquire the shares reserved for issuance on stock options awarded.

+ References

No definition available.

+ Details

Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition

Number of share options (or share units) exercised during the current period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28,29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(iv)(2)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30

-Article 5

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187085-122770

+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

XML 40 R19.htm IDEA: XBRL DOCUMENT v2.4.0.6

Loss Per Share (Tables)
3 Months Ended

Mar. 31, 2013

Computation of Diluted Net Loss Per Share does not Assume Issuance of Common Shares that have an Anti-dilutive Effect on Net Loss Per Share

The computation of diluted net loss per share does not assume the issuance of common shares that have an anti-dilutive effect on net loss per share.

 Three Months Ended
March 31,

 2013 2012

 (in thousands, except share
and per share amounts)

Basic and diluted net loss per common share:


Net loss applicable to common stockholders
 $(3,472) $(2,204)

Weighted average common shares outstanding – basic and diluted
 16,079 13,010

Net loss per common share – basic and diluted
 $ (0.22) $ (0.17)

Dilutive Shares Which Could Exist Pursuant to Exercise of Outstanding Stock Instruments and Which Were Not Included in Calculation

Dilutive shares which could exist pursuant to the exercise of outstanding stock instruments and which were not included in the calculation because their affect would have been anti-dilutive are as follows:

 March 31, 2013
(shares) March 31, 2012
(shares)

Warrants to purchase shares of common stock
7,429,241 7,424,241

Options to purchase shares of common stock
3,656,217 2,997,468

Shares of common stock issuable upon conversion of preferred stock
2,618,772 2,627,110

13,704,230 13,048,819

X

- Definition

Schedule Of Computation Of Basic And Diluted Earnings Per Share Table

+ References

No definition available.

+ Details

Name: galt_ScheduleOfComputationOfBasicAndDilutedEarningsPerShareTableTextBlock

Namespace Prefix: galt_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 128

-Paragraph 40

-Subparagraph c

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 41 R15.htm IDEA: XBRL DOCUMENT v2.4.0.6

Subsequent Events
3 Months Ended

Mar. 31, 2013

Subsequent Events

9. Subsequent Events

The Company has evaluated all events or transactions that occurred through the date on which the financial statements were issued, noting the following:

On May 6, 2013, the Company modified the terms of the Class A-2 and Class B warrants that were originally issued with the Series B Preferred Stock offering. The Class B warrants were modified to allow for the cashless exercise of all 4,000,000 outstanding Class B warrants. Previously, only half of the Class B warrants allowed for cashless exercise. The Class A-2 warrants for the purchase of 1,000,000 shares of common and all of the Class B warrants had their exercisable life extended by an additional five years. In exchange for these modifications, the 10X Fund agreed that the Series B Preferred Stock will no longer be mandatorily redeemable, if and when the Company will no longer be required to issue Dr. Platt a promissory note as may currently be required under the separation agreement (see Note 8).

X

- Definition

The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.

+ References

No definition available.

+ Details

Name: us-gaap_SubsequentEventsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 42 R13.htm IDEA: XBRL DOCUMENT v2.4.0.6

Common Stock and Warrant Offering and Reverse Split
3 Months Ended

Mar. 31, 2013

Common Stock and Warrant Offering and Reverse Split

7. Common Stock and Warrant Offering and Reverse Split

On March 22, 2012, the Company entered into an underwriting agreement, relating to the offer and sale of 1,159,445 units (the “Units”) of the Company, each unit consisted of two shares of Common Stock and one warrant to purchase one share of Common Stock. Pursuant to the underwriting agreement, the Company granted the underwriters a 45-day option to purchase up to an additional 173,916 Units to cover over-allotments, which they exercised on March 26, 2012. The public offering price for each Unit was $9.00. Each warrant has an initial exercise price of $5.63 per share, is exercisable upon separation of the Units and expires on March 28, 2017.

On March 28, 2012, the Company sold and issued 1,333,361 Units (2,666,722 shares of common stock and related $5.63 warrants to purchase 1,333,361 shares of common stock) for gross proceeds of $12.0 million (net cash proceeds of $10,403,000 after the underwriting discount and offering costs). The warrants were valued at $4,445,000 as of the issuance date of March 28, 2012, using the closing price of $4.20, a life of 5 years, a volatility of 119% and a risk free interest rate of 1.05%. Based upon the Company’s analysis of the criteria contained in ASC Topic 815-40, “Derivatives and Hedging—Contracts in Entity’s Own Equity” the Company has determined that warrants issued in connection with this financing transaction were not derivative liabilities and therefore, were recorded as additional paid-in capital.

On March 28, 2012, in connection with this underwritten financing as per the underwriting agreement, the Company issued a total of 46,378 common stock purchase warrants to the underwriters. These warrants expire May 2, 2016, have an exercise price of $5.63 per share, and are exercisable beginning 1 year from March 22, 2012 (the date of the underwriting agreement). These warrants were valued at $143,000 as of the date of issuance (March 28, 2012), using the closing price of $4.20, life of 4.1 years, volatility of 117% and risk free interest rate of 0.78. Based upon the Company’s analysis of the criteria contained in ASC Topic 815-40, “Derivatives and Hedging—Contracts in Entity’s Own Equity”, the Company has determined that these warrants issued in connection with this financing transaction were not derivative liabilities and therefore, were recorded as additional paid-in capital.

Effective as of March 23, 2012, and in connection with the pricing of the offering of Units, the Company effected a one-for-six reverse split of its Common Stock. Per the terms of the reverse split, all fractional shares were rounded up.

X

- Definition

Stock Warrants

+ References

No definition available.

+ Details

Name: galt_StockWarrantsTextBlock

Namespace Prefix: galt_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 43 R14.htm IDEA: XBRL DOCUMENT v2.4.0.6

Commitments, Contingencies and Legal Proceedings
3 Months Ended

Mar. 31, 2013

Commitments, Contingencies and Legal Proceedings

8. Commitments, Contingencies and Legal Proceedings

Agreement with CTI for Phase I Clinical Trial

On February 1, 2013, the Company entered into an Amended and Restated Master Services Agreement (the “Agreement”) with CTI Clinical Trial Services, Inc. and CTI Clinical Consulting Services, Inc. (individually and collectively, “CTI”), whereby CTI is assisting the Company in the design, development and conduct of one or more clinical research studies from time to time. All work performed by CTI for the Company is being conducted pursuant to the terms of work orders that describe the specific obligations undertaken by CTI with respect to any particular clinical research study sponsored or conducted by the Company. Unless otherwise terminated sooner in accordance with the terms of the Agreement, the Agreement will be effective until January 31, 2018.

On February 1, 2013, the Company entered into a work order (the “Work Order”) with CTI in accordance with the terms of the Agreement. The Work Order provides that CTI will provide services with respect to the Company’s Phase I Clinical Trial to evaluate the safety of the Company’s drug GR-MD-02 in subjects with Non-Alcoholic Steatohepatitis (“NASH”) with advanced hepatic fibrosis. CTI is providing the following services, amongst others, with respect to the Work Order: reviewing and providing notices regarding IND safety reports, selecting investigators and monitors for the study, informing investigators of new observations, monitoring the progress of the study and reviewing ongoing investigations, keeping certain records, inspecting the Company’s records and reports, and disposing of any unused supply of the investigational drug.

The Work Order provides for CTI’s anticipated involvement in the study from February 1, 2013 until March 31, 2014. The estimated budget for the Work Order is $2,155,000, which is subject to change as necessary, with payments made throughout the term of the project as the work is performed. During the three months ended March 31, 2013, the Company recognized $728,000 of expenses related to this agreement for services performed during the period.

The Agreement or any work order may be terminated for any reason by any party upon ninety (90) days prior written notice to the other party. In addition, the Agreement may be terminated by either party immediately if the other party becomes insolvent, is dissolved or liquidated, makes a general assignment for the benefit of its creditors, files or has filed against it (and does not obtain a dismissal within ninety (90) days) a petition of bankruptcy, or has a receiver appointed for it or a substantial part of its assets, among other reasons. Further, the Agreement or any relevant work order may be terminated immediately by written notice from the Company, in the following circumstances: (1) the FDA withdraws authorization and approval to conduct a study; or (2) the Company reasonably determines that for medical, clinical or patient safety reasons, a study should terminate immediately. In addition, either party may terminate the Agreement or any work order for material breach upon thirty (30) days’ written notice specifying the nature of the breach, if such breach has not been substantially cured within the thirty (30) day period.

Drug Discovery Program with the University of Georgia

In February 2013, the Company established a collaborative drug discovery program at the Complex Carbohydrate Research Center at the University of Georgia. This program is focused on the discovery of new carbohydrate molecules that can be used in the therapy of diseases where galectin proteins play a major role, including cancer and inflammatory and fibrotic disorders. The term of the agreement is effective through December 31, 2013, for which the Company will provide funding of $154,000 during the period as work is performed. This agreement may be terminated by either party upon 90 days notice.

Separation Agreement

In February 2009, the Company entered into a Separation Agreement in connection with the resignation of David Platt, Ph.D., the Company’s former Chief Executive Officer and Chairman of the Board of Directors. The Separation Agreement provides for the deferral of a $1.0 million separation payment due to Dr. Platt upon the earlier occurrence of any of the following milestone events: (i) the approval by the Food and Drug Administration for a new drug application (“NDA”) for any drug candidate or drug delivery candidate based on the Company’s GM-CT-01 technology (whether or not such technology is patented), in which case Dr. Platt is also entitled to a fully vested 10-year cashless-exercise stock option to purchase at least 83,334 shares of common stock at an exercise price not less than the fair market value of the common stock determined as of the date of grant; (ii) consummation of a transaction with a pharmaceutical company expected to result in at least $10.0 million of equity investment or $50 million of royalty revenue to the Company, in which case Dr. Platt is also entitled to stock options on the same terms to purchase at least 50,000 shares of common stock; or (iii) the renewed listing of the Company’s securities on a national securities exchange and the achievement of a market capitalization of $100 million. Payment upon the events (i) and (iii) may be deferred up to six months, and if the Company has insufficient cash at the time of any of such events, it may issue Dr. Platt a secured promissory note for such amount. If the Company files a voluntary or involuntary petition for bankruptcy, whether or not a milestone event has occurred, such event shall trigger the obligation to pay the $1.0 million with the result that Dr. Platt may assert a claim for such obligation against the bankruptcy estate. During 2011, when it became probable that the Company could be relisted on a national securities exchange and eventually reach a market capitalization of $100 million, the Company recognized the $1.0 million severance payment due to Dr. Platt and it is included in accrued expenses at March 31, 2013 and December 31, 2012.

On May 2, 2012, Dr. Platt instituted arbitration before the American Arbitration Association, seeking a $1.0 million separation payment based on a claim that a milestone event in the Separation Agreement has occurred (see clause (iii) above). On March 22, 2012, the Company’s common stock was listed on the NASDAQ Capital Markets, but since that date, the stock has not achieved the required market capitalization. Therefore, it is the Company’s position that a milestone event has not yet occurred. The arbitration hearing was held on October 16 - 17, 2012 and on November 1, 2012, the arbitrator denied Dr. Platt’s demand in all respects. Insofar as the Company does not dispute its obligations under the Separation Agreement to pay Dr. Platt upon the occurrence of a milestone event, it has recorded the payment as an accrued expense payable if and when the milestone event occurs.

On October 12, 2012, Dr. Platt commenced a lawsuit under the Massachusetts Wage Act against Dr. Traber and Mr. McGauley who in their capacities as the Company’s Chief Executive Officer and Chief Financial Officer respectively can be held individually liable under the Wage Act for non-payment of wages. The lawsuit is based on the facts and issues raised in the arbitration regarding the payment of the $1.0 million separation payment under the Separation Agreement, and other unspecified “wages”. The statute provides that a successful claimant may be entitled to multiple damages, interest and attorneys fees. Although the Company is not a party to the lawsuit, it plans to indemnify Dr. Traber and Mr. McGauley consistent with its obligations under the by-laws and applicable law, believes the lawsuit is without merit, and intends a vigorous defense on their behalf. On April 29, 2013, the Court allowed Dr. Traber’s and Mr. McGauley’s motion to dismiss.

On March 29, 2013, the Company instituted arbitration before the American Arbitration Association, seeking to rescind or reform the Separation Agreement discussed above. The Company claims that Dr. Platt fraudulently induced the Company to enter into the Separation Agreement, breached his fiduciary duty to the Company, and was unduly enriched from his conduct. Along with removal of the $1.0 million milestone payment provided for under the Separation Agreement, the Company is seeking repayment of all separation benefits paid to Dr. Platt to date. Depending on the outcome of the arbitration, the previously accrued $1.0 million could be reversed. The timing and ultimate outcome of this arbitration, though, is uncertain and there is no guarantee that the Company will be successful in this demand.

Series C Post Conversion Dividend Rights

In January 2013 5 shares of the Company’s Series C Super Dividend Convertible Preferred Stock (“Series C”) were converted into 8,475 shares of common stock (consisting of 8,334 shares of common stock for principal and 141 shares for accrued interest at the time of the conversion) which also resulted in the issuance of 5 Series C post-conversion dividend rights (“Dividend Rights”). Under the terms of the Series C, the Dividend Rights entitle the holder only to dividend payments based on actual sales of GM-CT-01 and will not participate in the 6% dividend payable on outstanding shares of Series C following a conversion to common stock. At March 31, 2013, there are a total of 10 outstanding Dividend Rights which were determined to have a de minimis value, because payment of a dividend for the Dividend Rights is considered improbable at this time and the Company has not recorded a liability related to the Dividend Rights. The Company will continue to evaluate and assess the Dividend Rights for each reporting period. At March 31, 2013, the Dividend Rights had a liquidation value of $241,000.

Other Legal Proceedings

The Company records accruals for such contingencies to the extent that the Company concludes that their occurrence is probable and the related damages are estimable, except as noted above. There has been no change in the matters reported in our Annual Report on Form 10-K for the year ended December 31, 2012.

X

- Definition

The entire disclosure for commitments and contingencies.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 460

-SubTopic 10

-Section 50

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=6398077&loc=d3e12565-110249

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 450

-SubTopic 20

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6952336&loc=d3e14435-108349

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name FASB Interpretation (FIN)

-Number 14

-Paragraph 3

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 440

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6394976&loc=d3e25287-109308

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.25)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6449706&loc=d3e16207-108621

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 5

-Paragraph 9, 10, 11, 12

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 44 R16.htm IDEA: XBRL DOCUMENT v2.4.0.6

Accrued Expenses (Tables)
3 Months Ended

Mar. 31, 2013

Accrued Expenses

Accrued expenses consist of the following:

 March 31,
2013 December 31,
2012

(in thousands)

Legal and accounting fees
 $ 80 $ 109

Accrued compensation
61 42

Severance agreement (Note 8)
1,000 1,000

Other
11 10

Total
 $ 1,152 $ 1,161

X

- Definition

Tabular disclosure of the components of accrued liabilities.

+ References

No definition available.

+ Details

Name: us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 45 R21.htm IDEA: XBRL DOCUMENT v2.4.0.6

Accrued Expenses (Detail) (USD $)
In Thousands, unless otherwise specified

Mar. 31, 2013

Dec. 31, 2012

Feb. 28, 2009

Schedule of Accrued Liabilities [Line Items]

Legal and accounting fees $ 80 $ 109

Accrued compensation 61 42 1,000

Severance agreement (Note 8) 1,000 1,000

Other 11 10

Total $ 1,152 $ 1,161

X

- Definition

Accrued Separation Agreement

+ References

No definition available.

+ Details

Name: galt_AccruedSeparationAgreement

Namespace Prefix: galt_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: galt_ScheduleOfAccruedLiabilitiesLineItems

Namespace Prefix: galt_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 20

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_AccruedLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 43

-Section A

-Paragraph 7

-Chapter 3

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 20

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6361293&loc=d3e6911-107765

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=6361293&loc=d3e6935-107765

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Current Liabilities

-URI http://asc.fasb.org/extlink&oid=6509677

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 43

-Section A

-Paragraph 8

-Chapter 3

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_AccruedProfessionalFeesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 20

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_EmployeeRelatedLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Carrying value as of the balance sheet date of obligations incurred through that date and payable arising from transactions not otherwise specified in the taxonomy. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 43

-Section A

-Paragraph 7

-Chapter 3

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 20

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6361293&loc=d3e6911-107765

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=6361293&loc=d3e6935-107765

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Current Liabilities

-URI http://asc.fasb.org/extlink&oid=6509677

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 9

-URI http://asc.fasb.org/extlink&oid=6361293&loc=d3e7018-107765

+ Details

Name: us-gaap_OtherAccruedLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

XML 46 R26.htm IDEA: XBRL DOCUMENT v2.4.0.6

Common Stock Warrant Activity (Detail) (USD $)
3 Months Ended

Mar. 31, 2013

Shares

Outstanding, December 31, 2012 7,424,241

Granted 5,000

Exercised

Forfeited/cancelled

Outstanding, March 31, 2013 7,429,241

Weighted Average Exercise Price

Outstanding, December 31, 2012 $ 3.71

Granted $ 2.65

Exercised

Forfeited/cancelled

Outstanding, March 31, 2013 $ 3.71

X

- Definition

Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Exercises in Period

+ References

No definition available.

+ Details

Name: galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesInPeriod

Namespace Prefix: galt_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Exercises in Period, Weighted Average Exercise Price

+ References

No definition available.

+ Details

Name: galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesInPeriodWeightedAverageExercisePrice

Namespace Prefix: galt_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition

Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures in Period, Weighted Average Exercise Price

+ References

No definition available.

+ Details

Name: galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresInPeriodWeightedAverageExercisePrice

Namespace Prefix: galt_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition

Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Exercise Price

+ References

No definition available.

+ Details

Name: galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageExercisePrice

Namespace Prefix: galt_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition

Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Exercise Price

+ References

No definition available.

+ Details

Name: galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice

Namespace Prefix: galt_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Details

Name: galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceAbstract

Namespace Prefix: galt_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(iv)(3)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 123R

-Paragraph A240

-Subparagraph b(2)(e)

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(2)(iii)(1)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 123R

-Paragraph A240

-Subparagraph b(2)(c)

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(2)(i)-(ii)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 123R

-Paragraph A240

-Subparagraph b(2)(b)

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 123R

-Paragraph A240

-Subparagraph b(2)(a)

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 47 R5.htm IDEA: XBRL DOCUMENT v2.4.0.6

Consolidated Statement Of Changes In Redeemable Convertible Preferred Stock And Stockholders' (Deficit) Equity (USD $)
In Thousands, except Share data

Total

USD ($)

Series A 12% convertible preferred stock

USD ($)

Series C super dividend convertible preferred stock

USD ($)

Series B-1 12% redeemable convertible preferred stock

USD ($)

Series B-2 12% redeemable convertible preferred stock

USD ($)

Series C super dividend convertible preferred stock

USD ($)

Series A 12% convertible preferred stock

USD ($)

Common Stock

USD ($)

Common Stock

Series A 12% convertible preferred stock

Common Stock

Series B-1 12% redeemable convertible preferred stock

Common Stock

Series B-2 12% redeemable convertible preferred stock

Common Stock

Series C super dividend convertible preferred stock

Additional Paid-In Capital

USD ($)

Additional Paid-In Capital

Series A 12% convertible preferred stock

USD ($)

Additional Paid-In Capital

Series B-1 12% redeemable convertible preferred stock

USD ($)

Additional Paid-In Capital

Series B-2 12% redeemable convertible preferred stock

USD ($)

Additional Paid-In Capital

Series C super dividend convertible preferred stock

USD ($)

Deficit Accumulated During the Development Stage

USD ($)

Deficit Accumulated During the Development Stage

Series A 12% convertible preferred stock

USD ($)

Deficit Accumulated During the Development Stage

Series B-1 12% redeemable convertible preferred stock

USD ($)

Deficit Accumulated During the Development Stage

Series B-2 12% redeemable convertible preferred stock

USD ($)

Deficit Accumulated During the Development Stage

Series C super dividend convertible preferred stock

USD ($)

Beginning Balance at Dec. 31, 2012 $ 1,165 $ 1,698 $ 2,900 $ 2,154 $ 632 $ 16 $ 80,535 $ (80,018)

Beginning Balance (in shares) at Dec. 31, 2012 900,000 2,100,000 220 1,562,500 16,060,853

Accretion of Series B redeemable convertible preferred stock (43) 4 39 (43)

Accretion of beneficial conversion feature for Series B-2 (13) 13 (13)

Convertible preferred stock dividend (in shares) 15,625 14,580 34,020 17,114

Convertible preferred stock dividend 47 33 57 52 122 62 (10) (52) (122) (29)

Conversion of Series C to common stock (in shares) (5) 8,475

Conversion of Series C to common stock 49 (49) 49

Issuance of common stock upon exercise of options (in shares) 39,762 39,762

Issuance of common stock upon exercise of options 77 77

Stock-based compensation expense 852 852

Net loss (3,203) (3,203)

Ending Balance at Mar. 31, 2013 $ (1,036) $ 1,702 $ 2,952 $ 2,105 $ 632 $ 16 $ 81,806 $ (83,490)

Ending Balance (in shares) at Mar. 31, 2013 900,000 2,100,000 215 1,562,500 16,190,429

X

- Definition

Accretion on redeemable convertible preferred stock.

+ References

No definition available.

+ Details

Name: galt_AccretionOfRedeemableConvertiblePreferredStock

Namespace Prefix: galt_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

This element represents the amount of recognized equity-based compensation during the period, that is, the amount recognized as expense in the income statement (or as asset if compensation is capitalized). Alternate captions include the words "stock-based compensation".

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 20

-Section 55

-Paragraph 13

-URI http://asc.fasb.org/extlink&oid=6576910&loc=d3e11178-113907

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 123R

-Paragraph 64

-Subparagraph b

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 35

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6415241&loc=d3e4534-113899

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 123R

-Paragraph A91

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 20

-Section 55

-Paragraph 12

-URI http://asc.fasb.org/extlink&oid=6576910&loc=d3e11149-113907

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 123R

-Paragraph 39

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Equity impact of aggregate cash, stock, and paid-in-kind dividends declared for preferred shareholders during the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Statement of Position (SOP)

-Number 01-6

-Paragraph 14

-Subparagraph l

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187085-122770

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 405

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6957935&loc=d3e64057-112817

+ Details

Name: us-gaap_DividendsPreferredStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 19

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.22)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=6519514

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.18)

-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 130

-Paragraph 10, 15

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 20

-Article 9

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=6518256

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Emerging Issues Task Force (EITF)

-Number 87-21

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 28, 29, 30

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 13: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=20435746&loc=d3e565-108580

Reference 14: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph A7

-Appendix A

Reference 15: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph 38

-Subparagraph a

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 16: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph 38

-Subparagraph d

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Number of shares of preferred stock issued as dividends during the period. Excludes stock splits.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

+ Details

Name: us-gaap_PreferredStockDividendsShares

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Number of shares issued and outstanding as of the balance sheet date.

+ References

No definition available.

+ Details

Name: us-gaap_SharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29-31)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30, 31

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph A3

-Appendix A

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB TOPIC 4.E)

-URI http://asc.fasb.org/extlink&oid=6228006&loc=d3e74512-122707

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section E

+ Details

Name: us-gaap_StockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Number of shares issued during the period as a result of the conversion of convertible securities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Principles Board Opinion (APB)

-Number 12

-Paragraph 10

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29-30)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 129

-Paragraph 4, 5

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187085-122770

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Number of share options (or share units) exercised during the current period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28,29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(iv)(2)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30

-Article 5

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187085-122770

+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

The gross value of stock issued during the period upon the conversion of convertible securities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187085-122770

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 129

-Paragraph 4, 5

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Principles Board Opinion (APB)

-Number 12

-Paragraph 10

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29-31)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30, 31

-Article 5

+ Details

Name: us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Value of stock issued as a result of the exercise of stock options.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187085-122770

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29-31)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Principles Board Opinion (APB)

-Number 12

-Paragraph 10

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30, 31

-Article 5

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

+ Details

Name: us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Value of accretion of temporary equity to its redemption value during the period. This item is an adjustment to net income necessary to derive net income apportioned to common stockholders and is to be distinguished from Temporary Equity, Accretion to Redemption Value (TemporaryEquityAccretionToRedemptionValue).

+ References

No definition available.

+ Details

Name: us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

XML 48 R10.htm IDEA: XBRL DOCUMENT v2.4.0.6

Common Stock Warrants
3 Months Ended

Mar. 31, 2013

Common Stock Warrants

4. Common Stock Warrants

The following table summarizes the common stock warrant activity from December 31, 2012 through March 31, 2013:



 Shares
 Weighted Average
Exercise Price

Outstanding, December 31, 2012
 7,424,241 $ 3.71

Granted
 5,000 2.65

Exercised
 - -

Forfeited/cancelled
 - -





Outstanding, March 31, 2013
 7,429,241 $ 3.71





Consultant Warrants

In January 2013, the Company entered into an agreement with a consultant that provided for the grant of warrants for the purchase of 5,000 shares of common stock at an exercise price of $2.65 per share. The following assumptions were used to value the warrants: an expected life of 3 years, volatility of 87%, risk free interest rate of 0.42% and zero dividends. The Company recognized an expense of $7,000 related to these warrants during the three months ended March 31, 2013.

X

- Definition

The entire disclosure for shareholders' equity, comprised of portions attributable to the parent entity and noncontrolling interest, if any, including other comprehensive income (as applicable). Including, but not limited to: (1) balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings; (2) accumulated balance for each classification of other comprehensive income and total amount of comprehensive income; (3) amount and nature of changes in separate accounts, including the number of shares authorized and outstanding, number of shares issued upon exercise and conversion, and for other comprehensive income, the adjustments for reclassifications to net income; (4) rights and privileges of each class of stock authorized; (5) basis of treasury stock, if other than cost, and amounts paid and accounting treatment for treasury stock purchased significantly in excess of market; (6) dividends paid or payable per share and in the aggregate for each class of stock for each period presented; (7) dividend restrictions and accumulated preferred dividends in arrears (in aggregate and per share amount); (8) retained earnings appropriations or restrictions, such as dividend restrictions; (9) impact of change in accounting principle, initial adoption of new accounting principle and correction of an error in previously issued financial statements; (10) shares held in trust for Employee Stock Ownership Plan (ESOP); (11) deferred compensation related to issuance of capital stock; (12) note received for issuance of stock; (13) unamortized discount on shares; (14) description, terms, and number of warrants or rights outstanding; (15) shares under subscription and subscription receivables, effective date of new retained earnings after quasi-reorganization and deficit eliminated by quasi-reorganization and, for a period of at least ten years after the effective date, the point in time from which the new retained dates; and (16) retroactive effective of subsequent change in capital structure.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30, 31

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section E

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Preferred Stock

-URI http://asc.fasb.org/extlink&oid=6521494

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 11

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 4

-Subparagraph (SAB TOPIC 4.C)

-URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187143-122770

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 30

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 43

-Section B

-Paragraph 7, 11A

-Chapter 1

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 13: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section C

Reference 14: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 15: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph d

-Article 4

Reference 16: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29-31)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 17: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB TOPIC 4.E)

-URI http://asc.fasb.org/extlink&oid=6228006&loc=d3e74512-122707

Reference 18: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 5

-Paragraph 15

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 19: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187085-122770

Reference 20: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 129

-Paragraph 2, 3, 4, 5, 6, 7, 8

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 21: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Principles Board Opinion (APB)

-Number 12

-Paragraph 10

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 22: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(d),(e))

-URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690

Reference 23: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Article 4

+ Details

Name: us-gaap_StockholdersEquityNoteDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 49 R27.htm IDEA: XBRL DOCUMENT v2.4.0.6

Common Stock Warrants - Additional Information (Detail) (USD $)
3 Months Ended 153 Months Ended 3 Months Ended

Mar. 31, 2013

Mar. 31, 2012

Mar. 31, 2013

Mar. 22, 2012

Mar. 31, 2013

Warrant

Jan. 31, 2013

Warrant

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Warrants to purchase shares of common stock 5,000

Exercise price of warrant 5.63 2.65

Expected life 5 years 5 years 2 months 12 days 3 years

Expected volatility of the underlying stock 117.00% 119.00% 87.00%

Risk-free interest rate 0.80% 1.76% 0.42%

Expected dividend rate 0.00% 0.00% 0.00%

Stock-based compensation expense $ 852,000 $ 473,000 $ 13,226,000 $ 7,000

X

- Definition

The exercise price of each class of warrants or rights outstanding.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(i)(4))

-URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph i

-Subparagraph 4

-Article 4

+ Details

Name: us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights

Namespace Prefix: us-gaap_

Data Type: us-types:perUnitItemType

Balance Type: na

Period Type: instant

X

- Definition

The specified number of securities that each class of warrants or rights outstanding give the holder the right but not the obligation to purchase from the issuer at a specific price, on or before a certain date.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(i)(2))

-URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph i

-Subparagraph 2

-Article 4

+ Details

Name: us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 28

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

+ Details

Name: us-gaap_ShareBasedCompensation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (f)(2)(iii)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 123R

-Paragraph A240

-Subparagraph e(2)(c)

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition

Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 14.D.2)

-URI http://asc.fasb.org/extlink&oid=6793087&loc=d3e301413-122809

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (f)(2)(i)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 14

-Section D

-Subsection 2

+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition

The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (f)(2)(ii)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 123R

-Paragraph A240

-Subparagraph e(2)(b)

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition

The risk-free interest rate assumption that is used in valuing an option on its own shares.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (f)(2)(iv)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 123R

-Paragraph A240

-Subparagraph e(2)(d)

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 50 FilingSummary.xml IDEA: XBRL DOCUMENT 2.4.0.6 Html 91 191 1 false 29 0 false 6 false false R1.htm 101 - Document - Document and Entity Information Sheet http://www.galectintherapeutics.com/taxonomy/role/DocumentDocumentandEntityInformation Document and Entity Information true false R2.htm 103 - Statement - Condensed Consolidated Balance Sheets Sheet http://www.galectintherapeutics.com/taxonomy/role/StatementOfFinancialPositionClassified Condensed Consolidated Balance Sheets false false R3.htm 104 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://www.galectintherapeutics.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical Condensed Consolidated Balance Sheets (Parenthetical) false false R4.htm 105 - Statement - Condensed Consolidated Statements Of Operations Sheet http://www.galectintherapeutics.com/taxonomy/role/StatementOfIncomeAlternative Condensed Consolidated Statements Of Operations false false R5.htm 106 - Statement - Consolidated Statement Of Changes In Redeemable Convertible Preferred Stock And Stockholders' (Deficit) Equity Sheet http://www.galectintherapeutics.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncome Consolidated Statement Of Changes In Redeemable Convertible Preferred Stock And Stockholders' (Deficit) Equity false false R6.htm 107 - Statement - Condensed Consolidated Statements Of Cash Flows Sheet http://www.galectintherapeutics.com/taxonomy/role/StatementOfCashFlowsIndirect Condensed Consolidated Statements Of Cash Flows false false R7.htm 108 - Disclosure - Basis of Presentation Sheet http://www.galectintherapeutics.com/taxonomy/role/NotesToFinancialStatementsBasisOfAccounting Basis of Presentation false false R8.htm 109 - Disclosure - Accrued Expenses Sheet http://www.galectintherapeutics.com/taxonomy/role/NotesToFinancialStatementsAccountsPayableAndAccruedLiabilitiesDisclosureTextBlock Accrued Expenses false false R9.htm 110 - Disclosure - Stock-Based Compensation Sheet http://www.galectintherapeutics.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock Stock-Based Compensation false false R10.htm 111 - Disclosure - Common Stock Warrants Sheet http://www.galectintherapeutics.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock Common Stock Warrants false false R11.htm 112 - Disclosure - Fair Value of Financial Instruments Sheet http://www.galectintherapeutics.com/taxonomy/role/NotesToFinancialStatementsFairValueDisclosuresTextBlock Fair Value of Financial Instruments false false R12.htm 113 - Disclosure - Loss Per Share Sheet http://www.galectintherapeutics.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlock Loss Per Share false false R13.htm 114 - Disclosure - Common Stock and Warrant Offering and Reverse Split Sheet http://www.galectintherapeutics.com/taxonomy/role/NotesToFinancialStatementsStockWarrantsTextBlock Common Stock and Warrant Offering and Reverse Split false false R14.htm 115 - Disclosure - Commitments, Contingencies and Legal Proceedings Sheet http://www.galectintherapeutics.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock Commitments, Contingencies and Legal Proceedings false false R15.htm 116 - Disclosure - Subsequent Events Sheet http://www.galectintherapeutics.com/taxonomy/role/NotesToFinancialStatementsSubsequentEventsTextBlock Subsequent Events false false R16.htm 117 - Disclosure - Accrued Expenses (Tables) Sheet http://www.galectintherapeutics.com/taxonomy/role/NotesToFinancialStatementsAccountsPayableAndAccruedLiabilitiesDisclosureTextBlockTables Accrued Expenses (Tables) false false R17.htm 118 - Disclosure - Stock-Based Compensation (Tables) Sheet http://www.galectintherapeutics.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables Stock-Based Compensation (Tables) false false R18.htm 119 - Disclosure - Common Stock Warrants (Tables) Sheet http://www.galectintherapeutics.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlockTables Common Stock Warrants (Tables) false false R19.htm 120 - Disclosure - Loss Per Share (Tables) Sheet http://www.galectintherapeutics.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlockTables Loss Per Share (Tables) false false R20.htm 121 - Disclosure - Basis of Presentation - Additional Information (Detail) Sheet http://www.galectintherapeutics.com/taxonomy/role/DisclosureBasisOfPresentationAdditionalInformation Basis of Presentation - Additional Information (Detail) false false R21.htm 122 - Disclosure - Accrued Expenses (Detail) Sheet http://www.galectintherapeutics.com/taxonomy/role/DisclosureAccruedExpenses Accrued Expenses (Detail) false false R22.htm 123 - Disclosure - Stock-Based Compensation Expense Related to Common Stock Options, Common Stock, Restricted Common Stock and Common Stock Warrants (Detail) Sheet http://www.galectintherapeutics.com/taxonomy/role/DisclosureStockBasedCompensationExpenseRelatedToCommonStockOptionsCommonStockRestrictedCommonStockAndCommonStockWarrants Stock-Based Compensation Expense Related to Common Stock Options, Common Stock, Restricted Common Stock and Common Stock Warrants (Detail) false false R23.htm 124 - Disclosure - Summary of Stock Option Activity (Detail) Sheet http://www.galectintherapeutics.com/taxonomy/role/DisclosureSummaryOfStockOptionActivity Summary of Stock Option Activity (Detail) false false R24.htm 125 - Disclosure - Stock-Based Compensation - Additional Information (Detail) Sheet http://www.galectintherapeutics.com/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformation Stock-Based Compensation - Additional Information (Detail) false false R25.htm 126 - Disclosure - Weighted Average Assumptions Used to Determine Fair Value of Options Granted (Detail) Sheet http://www.galectintherapeutics.com/taxonomy/role/DisclosureWeightedAverageAssumptionsUsedToDetermineFairValueOfOptionsGranted Weighted Average Assumptions Used to Determine Fair Value of Options Granted (Detail) false false R26.htm 127 - Disclosure - Common Stock Warrant Activity (Detail) Sheet http://www.galectintherapeutics.com/taxonomy/role/DisclosureCommonStockWarrantActivity Common Stock Warrant Activity (Detail) false false R27.htm 128 - Disclosure - Common Stock Warrants - Additional Information (Detail) Sheet http://www.galectintherapeutics.com/taxonomy/role/DisclosureCommonStockWarrantsAdditionalInformation Common Stock Warrants - Additional Information (Detail) false false R28.htm 129 - Disclosure - Fair Value of Financial Instruments - Additional Information (Detail) Sheet http://www.galectintherapeutics.com/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsAdditionalInformation Fair Value of Financial Instruments - Additional Information (Detail) false false R29.htm 130 - Disclosure - Computation of Diluted Net Loss Per Share (Detail) Sheet http://www.galectintherapeutics.com/taxonomy/role/DisclosureComputationOfDilutedNetLossPerShare Computation of Diluted Net Loss Per Share (Detail) false false R30.htm 131 - Disclosure - Dilutive Shares Which Could Exist Pursuant to Exercise of Outstanding Stock Instruments and Which were not Included in Calculation (Detail) Sheet http://www.galectintherapeutics.com/taxonomy/role/DisclosureDilutiveSharesWhichCouldExistPursuantToExerciseOfOutstandingStockInstrumentsAndWhichWereNotIncludedInCalculation Dilutive Shares Which Could Exist Pursuant to Exercise of Outstanding Stock Instruments and Which were not Included in Calculation (Detail) false false R31.htm 132 - Disclosure - Common Stock and Warrant Offering and Reverse Split - Additional Information (Detail) Sheet http://www.galectintherapeutics.com/taxonomy/role/DisclosureCommonStockAndWarrantOfferingAndReverseSplitAdditionalInformation Common Stock and Warrant Offering and Reverse Split - Additional Information (Detail) false false R32.htm 133 - Disclosure - Commitments, Contingencies and Legal Proceedings - Additional Information (Detail) Sheet http://www.galectintherapeutics.com/taxonomy/role/DisclosureCommitmentsContingenciesAndLegalProceedingsAdditionalInformation Commitments, Contingencies and Legal Proceedings - Additional Information (Detail) false false R33.htm 134 - Disclosure - Subsequent Events - Additional Information (Detail) Sheet http://www.galectintherapeutics.com/taxonomy/role/DisclosureSubsequentEventsAdditionalInformation Subsequent Events - Additional Information (Detail) false false All Reports Book All Reports Element us-gaap_EmployeeRelatedLiabilitiesCurrent had a mix of decimals attribute values: -5 -3. Element us-gaap_ShareBasedCompensation had a mix of decimals attribute values: -3 0. 'Monetary' elements on report '107 - Statement - Condensed Consolidated Statements Of Cash Flows' had a mix of different decimal attribute values. 'Monetary' elements on report '121 - Disclosure - Basis of Presentation - Additional Information (Detail)' had a mix of different decimal attribute values. 'Monetary' elements on report '132 - Disclosure - Common Stock and Warrant Offering and Reverse Split - Additional Information (Detail)' had a mix of different decimal attribute values. Process Flow-Through: 103 - Statement - Condensed Consolidated Balance Sheets Process Flow-Through: Removing column 'Mar. 31, 2012' Process Flow-Through: Removing column 'Dec. 31, 2011' Process Flow-Through: 104 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Process Flow-Through: Removing column 'Mar. 22, 2012' Process Flow-Through: 105 - Statement - Condensed Consolidated Statements Of Operations Process Flow-Through: 107 - Statement - Condensed Consolidated Statements Of Cash Flows galt-20130331.xml galt-20130331.xsd galt-20130331_cal.xml galt-20130331_def.xml galt-20130331_lab.xml galt-20130331_pre.xml true true XML 51 R20.htm IDEA: XBRL DOCUMENT v2.4.0.6

Basis of Presentation - Additional Information (Detail) (USD $)
3 Months Ended 153 Months Ended

Mar. 31, 2013

Mar. 31, 2012

Mar. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Basis of Presentation [Line Items]

Unrestricted cash and cash equivalents $ 7,018,000 $ 15,314,000 $ 7,018,000 $ 9,364,000 $ 6,397,000

Net losses applicable to common stockholders (3,472,000) (2,204,000) (83,744,000)

Net total capital through sale and issuance of common stock and warrants 68,800,000

Net cash used in operating activities $ (2,423,000) $ (1,486,000) $ (60,976,000)

X

- Details

Name: galt_BasisOfPresentationLineItems

Namespace Prefix: galt_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6361293&loc=d3e6676-107765

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash Equivalents

-URI http://asc.fasb.org/extlink&oid=6507016

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 8, 9

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 7, 26

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash

-URI http://asc.fasb.org/extlink&oid=6506951

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3044-108585

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 7

-Footnote 1

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.1)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 1

-Article 5

+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

The net cash from (used in) all of the entity's operating activities, including those of discontinued operations, of the reporting entity. Operating activities generally involve producing and delivering goods and providing services. Operating activity cash flows include transactions, adjustments, and changes in value that are not defined as investing or financing activities. While for technical reasons this element has no balance attribute, the default assumption is a debit balance consistent with its label.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 26

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 25

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3536-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 28

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3521-108585

+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: na

Period Type: duration

X

- Definition

Net income after adjustments for dividends on preferred stock (declared in the period) and/or cumulative preferred stock (accumulated for the period).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 11

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1377-109256

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 128

-Paragraph 9

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187085-122770

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30, 31

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Principles Board Opinion (APB)

-Number 12

-Paragraph 10

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

+ Details

Name: us-gaap_StockIssuedDuringPeriodValueNewIssues

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

Date: May 10, 2013

/s/ Peter G. Traber

Peter G. Traber, M.D.

Chief Executive Officer and President

(principal executive officer)

Weighted Average Assumptions Used to Determine Fair Value of Options Granted (Detail)	3 Months Ended	153 Months Ended
	Mar. 31, 2013	Mar. 31, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk-free interest rate	0.80%	1.76%
Expected life of the options	5 years	5 years 2 months 12 days
Expected volatility of the underlying stock	117.00%	119.00%
Expected dividend rate	0.00%	0.00%

Computation of Diluted Net Loss Per Share (Detail) (USD $) In Thousands, except Per Share data, unless otherwise specified	3 Months Ended		153 Months Ended
	Mar. 31, 2013	Mar. 31, 2012	Mar. 31, 2013
Basic and diluted net loss per common share:
Net loss applicable to common stockholders	$ (3,472)	$ (2,204)	$ (83,744)
Weighted average common shares outstanding - basic and diluted	16,079	13,010
Net loss per common share - basic and diluted	$ (0.22)	$ (0.17)

Fair Value of Financial Instruments - Additional Information (Detail) (Money market funds, Fair Value, Inputs, Level 2, USD $)	Mar. 31, 2013	Dec. 31, 2012
Money market funds \| Fair Value, Inputs, Level 2
Fair Value of Financial Instruments [Line Items]
Fair value of cash and cash equivalents invested in money market funds	$ 192,000	$ 583,000

Dilutive Shares Which Could Exist Pursuant to Exercise of Outstanding Stock Instruments and Which were not Included in Calculation (Detail)	3 Months Ended
	Mar. 31, 2013	Mar. 31, 2012
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Dilutive shares not included in calculation	13,704,230	13,048,819
Warrant
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Dilutive shares not included in calculation	7,429,241	7,424,241
Stock Options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Dilutive shares not included in calculation	3,656,217	2,997,468
Contingently Issuable Shares
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Dilutive shares not included in calculation	2,618,772	2,627,110

Common Stock and Warrant Offering and Reverse Split - Additional Information (Detail) (USD $)	1 Months Ended
	Mar. 22, 2012	Mar. 23, 2012	Mar. 28, 2012	Mar. 31, 2013	Dec. 31, 2012
Stockholders Equity [Line Items]
Stock issued, shares	1,159,445		1,333,361
Common share issued	2			16,190,429	16,060,853
Warrant to purchase common stock	1
Option to purchase additional units to cover over-allotments	45 days
Additional units authorize for issuance	173,916
Public Offering price	$ 9.00
Exercise price of warrant	5.63
Expiration date of warrant	Mar. 28, 2017
Issuance of common stock and warrants			2,666,722
Gross proceeds from issuance of stock and warrants			$ 12,000,000
Net proceeds from issuance of stock and warrants			10,403,000
Reverse stock split ratio		0.1667
Warrant one
Stockholders Equity [Line Items]
Price per share of warrants			$ 5.63
Warrants to purchase shares of common stock			1,333,361
Value of warrants			4,445,000
Closing price of warrant issued			$ 4.20
Warrant, expected life			5 years
Warrant, volatility rate			119.00%
Warrant, risk free interest rate			1.05%
Warrant two
Stockholders Equity [Line Items]
Exercise price of warrant			5.63
Expiration date of warrant			May 02, 2016
Warrants to purchase shares of common stock			46,378
Value of warrants			$ 143,000
Closing price of warrant issued			$ 4.20
Warrant, expected life			4 years 1 month 6 days
Warrant, volatility rate			117.00%
Warrant, risk free interest rate			0.78%

Commitments, Contingencies and Legal Proceedings - Additional Information (Detail) (USD $)	1 Months Ended				3 Months Ended
	Feb. 01, 2013	Jan. 31, 2013	Oct. 31, 2012	Feb. 28, 2009	Mar. 31, 2013 Right	Dec. 31, 2012
Commitments and Contingencies [Line Items]
Service agreement expiration date					Jan. 31, 2018
Estimated budget for work order	$ 2,155,000
Recognized expenses related to agreement for services performed					728,000
Agreement termination notice period	90 days
Breach of contract termination notice period	30 days
Severance payment due to Dr. Platt				1,000,000	61,000	42,000
Number of options vested				83,334
Royalty revenue				50,000,000
Market capitalization				100,000,000
Severance payment period				6 months
Separation based payments			1,000,000
Lawsuit payment			1,000,000
Dividend rights issued		5
Rate of dividend		6.00%
Outstanding Dividend Rights					10
Liquidation value of dividend rights					241,000
Drug Discovery Program with the University of Georgia
Commitments and Contingencies [Line Items]
Agreement termination notice period	90 days
Collaborative funding agreement	154,000
Series C super dividend convertible preferred stock
Commitments and Contingencies [Line Items]
Series C prefer stock converted to common stock		5
Common Stock
Commitments and Contingencies [Line Items]
Conversion of share, common stock issued		8,475
Common Stock \| Principal shares
Commitments and Contingencies [Line Items]
Conversion of share, common stock issued		8,334
Common Stock \| Accrued Interest
Commitments and Contingencies [Line Items]
Conversion of share, common stock issued		141
Minimum
Commitments and Contingencies [Line Items]
Cashless stock option exercisable period				10 years
Equity investment				$ 10,000,000
Cashless stock option exercisable				50,000

Condensed Consolidated Balance Sheets (USD $) In Thousands, unless otherwise specified	Mar. 31, 2013	Dec. 31, 2012
Current assets:
Cash and cash equivalents	$ 7,018	$ 9,364
Prepaid expenses and other current assets	137	153
Total current assets	7,155	9,517
Property and equipment, net	7	8
Other long term assets	6	6
Intangible assets, net	28	30
Total assets	7,196	9,561
Current liabilities:
Accounts payable	316	397
Accrued expenses	1,152	1,161
Accrued dividends payable		80
Total current liabilities	1,468	1,638
Other long-term liabilities	5	6
Total liabilities	1,473	1,644
Commitments and contingencies (Note 8)
Stockholders' equity (deficit):
Undesignated stock, $0.01 par value; 20,000,000 shares authorized, 8,001,000 designated at March 31, 2013 and December 31, 2012
Series A 12% convertible preferred stock; 5,000,000 shares authorized, 1,562,500 issued and outstanding at March 31, 2013 and December 31, 2012	632	632
Common stock, $0.001 par value; 50,000,000 shares authorized at March 31, 2013 and December 31, 2012, 16,190,429 and 16,060,853 issued and outstanding at March 31, 2013 and December 31, 2012, respectively	16	16
Additional paid-in capital	81,806	80,535
Deficit accumulated during the development stage	(83,490)	(80,018)
Total stockholders' (deficit) equity	(1,036)	1,165
Total liabilities, redeemable convertible preferred stock and stockholders' (deficit) equity	7,196	9,561
Series B-1 12% redeemable convertible preferred stock
Current liabilities:
Convertible preferred stock, value	1,702	1,698
Series B-2 12% redeemable convertible preferred stock
Current liabilities:
Convertible preferred stock, value	2,952	2,900
Series C super dividend convertible preferred stock
Current liabilities:
Convertible preferred stock, value	$ 2,105	$ 2,154

Stock-Based Compensation - Additional Information (Detail) (USD $)	3 Months Ended
	Mar. 31, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation cost	$ 5,427,000
Unvested option	1,466,586
Unrecognized compensation cost, recognition period	3 years 10 months 24 days
Weighted-average grant-date fair values of options granted	$ 2.73

Condensed Consolidated Balance Sheets (Parenthetical) (USD $)	Mar. 31, 2013	Dec. 31, 2012
Undesignated stock, par value	$ 0.01	$ 0.01
Undesignated stock, shares authorized	20,000,000	20,000,000
Undesignated stock, shares designated	8,001,000	8,001,000
Series A 12% convertible preferred stock, shares authorized	5,000,000	5,000,000
Series A 12% convertible preferred stock, issued	1,562,500	1,562,500
Series A 12% convertible preferred stock, outstanding	1,562,500	1,562,500
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	50,000,000	50,000,000
Common stock, issued	16,190,429	16,060,853
Common stock, outstanding	16,190,429	16,060,853
Series B-1 12% redeemable convertible preferred stock
Convertible preferred stock, shares authorized	900,000	900,000
Convertible preferred stock, issued	900,000	900,000
Convertible preferred stock, outstanding	900,000	900,000
Convertible preferred stock, redemption value	$ 1,800,000
Convertible preferred stock, liquidation value	1,800,000
Series B-2 12% redeemable convertible preferred stock
Convertible preferred stock, shares authorized	2,100,000	2,100,000
Convertible preferred stock, issued	2,100,000	2,100,000
Convertible preferred stock, outstanding	2,100,000	2,100,000
Convertible preferred stock, redemption value	4,200,000
Convertible preferred stock, liquidation value	4,200,000
Series C super dividend convertible preferred stock
Convertible preferred stock, shares authorized	1,000	1,000
Convertible preferred stock, issued	215	220
Convertible preferred stock, outstanding	215	220
Convertible preferred stock, redemption value	5,078,000
Convertible preferred stock, liquidation value	$ 2,150,000

Document and Entity Information	3 Months Ended
Document and Entity Information	Mar. 31, 2013	May 09, 2013
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Mar. 31, 2013
Document Fiscal Year Focus	2013
Document Fiscal Period Focus	Q1
Trading Symbol	GALT
Entity Registrant Name	GALECTIN THERAPEUTICS INC
Entity Central Index Key	0001133416
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		16,251,469

Summary of Stock Option Activity (Detail) (USD $)	3 Months Ended
Summary of Stock Option Activity (Detail) (USD $)	Mar. 31, 2013
Shares
Beginning Balance	3,539,961
Granted	200,426
Exercised	(39,762)
Options forfeited/cancelled	(44,408)
Ending Balance	3,656,217
Weighted Average Exercise Price
Beginning Balance	$ 5.66
Granted	$ 3.36
Exercised	$ 2.77
Options forfeited/cancelled	$ 9.50
Ending Balance	$ 5.52

Accrued Expenses (Detail) (USD $) In Thousands, unless otherwise specified	Mar. 31, 2013	Dec. 31, 2012	Feb. 28, 2009
Schedule of Accrued Liabilities [Line Items]
Legal and accounting fees	$ 80	$ 109
Accrued compensation	61	42	1,000
Severance agreement (Note 8)	1,000	1,000
Other	11	10
Total	$ 1,152	$ 1,161

Common Stock Warrant Activity (Detail) (USD $)	3 Months Ended
Common Stock Warrant Activity (Detail) (USD $)	Mar. 31, 2013
Shares
Outstanding, December 31, 2012	7,424,241
Granted	5,000
Exercised
Forfeited/cancelled
Outstanding, March 31, 2013	7,429,241
Weighted Average Exercise Price
Outstanding, December 31, 2012	$ 3.71
Granted	$ 2.65
Exercised
Forfeited/cancelled
Outstanding, March 31, 2013	$ 3.71

Consolidated Statement Of Changes In Redeemable Convertible Preferred Stock And Stockholders' (Deficit) Equity (USD $) In Thousands, except Share data	Total USD ($)	Series A 12% convertible preferred stock USD ($)	Series C super dividend convertible preferred stock USD ($)	Series B-1 12% redeemable convertible preferred stock USD ($)	Series B-2 12% redeemable convertible preferred stock USD ($)	Series C super dividend convertible preferred stock USD ($)	Series A 12% convertible preferred stock USD ($)	Common Stock USD ($)	Common Stock Series A 12% convertible preferred stock	Common Stock Series B-1 12% redeemable convertible preferred stock	Common Stock Series B-2 12% redeemable convertible preferred stock	Common Stock Series C super dividend convertible preferred stock	Additional Paid-In Capital USD ($)	Additional Paid-In Capital Series A 12% convertible preferred stock USD ($)	Additional Paid-In Capital Series B-1 12% redeemable convertible preferred stock USD ($)	Additional Paid-In Capital Series B-2 12% redeemable convertible preferred stock USD ($)	Additional Paid-In Capital Series C super dividend convertible preferred stock USD ($)	Deficit Accumulated During the Development Stage USD ($)	Deficit Accumulated During the Development Stage Series A 12% convertible preferred stock USD ($)	Deficit Accumulated During the Development Stage Series B-1 12% redeemable convertible preferred stock USD ($)	Deficit Accumulated During the Development Stage Series B-2 12% redeemable convertible preferred stock USD ($)	Deficit Accumulated During the Development Stage Series C super dividend convertible preferred stock USD ($)
Beginning Balance at Dec. 31, 2012	$ 1,165			$ 1,698	$ 2,900	$ 2,154	$ 632	$ 16					$ 80,535					$ (80,018)
Beginning Balance (in shares) at Dec. 31, 2012				900,000	2,100,000	220	1,562,500	16,060,853
Accretion of Series B redeemable convertible preferred stock	(43)			4	39													(43)
Accretion of beneficial conversion feature for Series B-2	(13)				13													(13)
Convertible preferred stock dividend (in shares)									15,625	14,580	34,020	17,114
Convertible preferred stock dividend		47	33											57	52	122	62		(10)	(52)	(122)	(29)
Conversion of Series C to common stock (in shares)						(5)		8,475
Conversion of Series C to common stock	49					(49)							49
Issuance of common stock upon exercise of options (in shares)	39,762							39,762
Issuance of common stock upon exercise of options	77												77
Stock-based compensation expense	852												852
Net loss	(3,203)																	(3,203)
Ending Balance at Mar. 31, 2013	$ (1,036)			$ 1,702	$ 2,952	$ 2,105	$ 632	$ 16					$ 81,806					$ (83,490)
Ending Balance (in shares) at Mar. 31, 2013				900,000	2,100,000	215	1,562,500	16,190,429